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Background: For people with localised prostate cancer, active treatments are effective but have significant
side effects. Minimally invasive treatments that destroy (or ablate) either the entire gland or the part of the
prostate with cancer may be as effective and cause less side effects at an acceptable cost. Such therapies
include cryotherapy, high-intensity focused ultrasound (HIFU) and brachytherapy, among others.
Objectives: This study aimed to determine the relative clinical effectiveness and cost-effectiveness of
ablative therapies compared with radical prostatectomy (RP), external beam radiotherapy (EBRT) and active
surveillance (AS) for primary treatment of localised prostate cancer, and compared with RP for salvage
treatment of localised prostate cancer which has recurred after initial treatment with EBRT.
Data sources: MEDLINE (1946 to March week 3, 2013), MEDLINE In-Process & Other Non-Indexed
Citations (29 March 2013), EMBASE (1974 to week 13, 2013), Bioscience Information Service (BIOSIS)
(1956 to 1 April 2013), Science Citation Index (1970 to 1 April 2013), Cochrane Central Register of
Controlled Trials (CENTRAL) (issue 3, 2013), Cochrane Database of Systematic Reviews (CDSR) (issue 3,
2013), Database of Abstracts of Reviews of Effects (DARE) (inception to March 2013) and Health
Technology Assessment (HTA) (inception to March 2013) databases were searched. Costs were obtained
from NHS sources.
Review methods: Evidence was drawn from randomised controlled trials (RCTs) and non-RCTs, and from
case series for the ablative procedures only, in people with localised prostate cancer. For primary therapy,
the ablative therapies were cryotherapy, HIFU, brachytherapy and other ablative therapies. The
comparators were AS, RP and EBRT. For salvage therapy, the ablative therapies were cryotherapy and HIFU.
The comparator was RP. Outcomes were cancer related, adverse effects (functional and procedural) and
quality of life. Two reviewers extracted data and carried out quality assessment. Meta-analysis used a
Bayesian indirect mixed-treatment comparison. Data were incorporated into an individual simulation
Markov model to estimate cost-effectiveness.
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Results: The searches identified 121 studies for inclusion in the review of patients undergoing primary
treatment and nine studies for the review of salvage treatment. Cryotherapy [3995 patients; 14 case series,
1 RCT and 4 non-randomised comparative studies (NRCSs)], HIFU (4000 patients; 20 case series, 1 NRCS)
and brachytherapy (26,129 patients; 2 RCTs, 38 NRCSs) studies provided limited data for meta-analyses.
All studies were considered at high risk of bias. There was no robust evidence that mortality (4-year
survival 93% for cryotherapy, 99% for HIFU, 91% for EBRT) or other cancer-specific outcomes differed
between treatments. For functional and quality-of-life outcomes, the paucity of data prevented any
definitive conclusions from being made, although data on incontinence rates and erectile dysfunction for
all ablative procedures were generally numerically lower than for non-ablative procedures. The safety
profiles were comparable with existing treatments. Studies reporting the use of focal cryotherapy
suggested that incontinence rates may be better than for whole-gland treatment. Data on AS, salvage
treatment and other ablative therapies were too limited. The cost-effectiveness analysis confirmed the
uncertainty from the clinical review and that there is no technology which appears superior, on the basis of
current evidence, in terms of average cost-effectiveness. The probabilistic sensitivity analyses suggest that a
number of ablative techniques are worthy of further research.
Limitations: The main limitations were the quantity and quality of the data available on cancer-related
outcomes and dysfunction.
Conclusions: The findings indicate that there is insufficient evidence to form any clear recommendations
on the use of ablative therapies in order to influence current clinical practice. Research efforts in the use of
ablative therapies in the management of prostate cancer should now be concentrated on the performance
of RCTs and the generation of standardised outcomes.
Study registration: This study is registered as PROSPERO CRD42012002461.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Ablative therapies are relatively new procedures for the treatment of localised prostate cancer. Thesetherapies are promising because they may be as effective as either surgery or radiotherapy (i.e. standard
treatments), while causing fewer side effects (e.g. incontinence or erection difficulties). They may also be
better than active surveillance (whereby patients are monitored and only treated if there is cancer
progression) because they actively treat cancer at diagnosis. They involve the application of different types
of energy to either the entire prostate or specific areas with cancer, to achieve tissue destruction. Examples
include cryotherapy (using rapid freezing and thawing), high-intensity focused ultrasound (HIFU, using heat
generated from sound waves) and brachytherapy (using radioactive seeds implanted into the prostate).
These procedures are generally carried out on a day-patient basis with patients allowed home the following
day. The results from our study suggested that cryotherapy, HIFU and brachytherapy may have potential
clinical benefits for many patients in terms of reduced incontinence and erection difficulties, while
possessing similar benefits in terms of cancer control compared with either surgery or radiotherapy.
However, the overall quality of the available evidence was very poor owing to the low quality of identified
studies, and it remained impossible to determine if the benefits were real. In terms of balancing the cost of
the ablative treatments against the benefits and harms produced, no technology appears better.
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxiii

Scientific summary
Background
People diagnosed with cancer of the prostate, a sex gland in the pelvis, have a choice of treatment options
depending on the severity of disease. For people whose cancer is at medium and low risk of spread,
the main options are surgical removal of the prostate, radical prostatectomy (RP), use of external beam
radiotherapy (EBRT) to destroy the cancer or delaying treatment until there are signs that the cancer is
getting worse [active surveillance (AS)]. RP and radiotherapy are effective at curing the cancer but may also
cause long-term urinary incontinence and sexual problems. AS, on the other hand, may be quite difficult
for people to cope with as they know that the cancer is still present. Newer treatments aim to target the
disease more precisely so that surrounding normal tissues can be preserved, reducing the risk of side
effects but still effectively destroying the cancer. These more targeted ablative therapies include cryotherapy,
high-intensity focused ultrasound (HIFU), brachytherapy, photodynamic therapy (PDT), radiofrequency
interstitial tumour ablation (RITA) and laser therapy, among others.
Aims
This study aimed to
l develop clinical care pathways relevant to a UK NHS context
l review systematically the evidence of the clinical effectiveness and safety of each newer ablative
therapy concerning primary and salvage treatment of localised prostate cancer
l determine which therapies are most likely to be cost-effective for implementation in the UK NHS
l identify and prioritise future research needs.
Methods
Clinical effectiveness review
We conducted two discrete systematic reviews:
(a) primary ablative treatment of localised prostate cancer compared with AS, RP or EBRT
(b) salvage ablative treatment for local prostate cancer relapse after primary EBRT compared with salvage RP.
MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Bioscience Information Service
(BIOSIS), Science Citation Index, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane
Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and the Health
Technology Assessment (HTA) databases were searched to the end of March 2013. Reference lists of all
included studies were scanned and experts on our advisory panel were contacted for details of additional
reports. Evidence came from randomised controlled trials (RCTs), non-randomised comparative studies
(NRCSs) (if no RCT evidence was identified) and single-arm cohort studies (case series) with greater than
10 participants for the ablative procedures only. Conference abstracts or non-English-language reports
were excluded. For the primary therapy systematic review, the ablative therapies considered were
cryotherapy, HIFU, PDT, RITA, laser ablation and brachytherapy. The comparators were AS, RP and EBRT.
For the salvage therapy systematic review, the ablative therapies considered were cryotherapy and HIFU.
The comparator was RP. Outcomes were cancer related, adverse effects (functional and procedural)
and quality of life. Two reviewers extracted data and carried out quality assessment. For meta-analysis,
a Bayesian indirect mixed-treatment comparison was used.
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Cost-effectiveness
The cost-effectiveness of the different treatments and their subsequent care pathways was assessed using
a modified Markov individual simulation model, applied to a UK NHS setting. The perspective for the
model was a health services perspective. Parameter estimates were derived from the systematic review of
clinical effectiveness, a micro-costing exercise, other literature, the expert advisory group and other UK
sources. The outputs of the model were costs and quality-adjusted life-years (QALYs) for each procedure,
incremental costs and QALYs and incremental cost per QALY over the remaining lifetime. Both costs
and QALYs were discounted at 3.5%. An elasticity analysis, together with probabilistic and deterministic
sensitivity analyses, were performed to explore the uncertainty surrounding parameter estimates.
Results
Clinical effectiveness
Cryotherapy
Data from 3995 patients who received cryotherapy across 19 studies (1 RCT, 4 NRCSs and 14 case series)
were included, with most studies considered to be at high risk of bias. In the short term, there was
conflicting evidence relating to cancer-specific outcomes when cryotherapy was compared with either
EBRT or surgery. The only finding that reached statistical significance was 1-year disease-free survival,
which was worse for cryotherapy than for either EBRT or RP. However, none of the other cancer-specific
outcomes, such as biochemical failure or overall survival, showed any significant differences between them.
The findings in relation to cancer-specific outcomes are best regarded as inconclusive.
There was evidence that the rate of urinary incontinence at 1 year was lower for people undergoing
cryotherapy than for those undergoing RP [3% vs. 66%; odds ratio (OR) 0.02, 95% credible interval (CrI)
< 0.01 to 0.34], but the size of the difference decreased with longer follow-up. There was a general trend
for cryotherapy to have fewer procedural complications, apart from urinary retention. The only difference
that reached statistical significance was for urethral stricture, which was less frequent after cryotherapy
than after RP (1% vs. 8%; OR 0.24, 95% CrI 0.09 to 0.54).
High-intensity focused ultrasound
Data from 4000 patients who received HIFU across 21 studies (1 NRCS and 20 case series) were included,
with all studies considered to be at high risk of bias.
There was some evidence that biochemical failure rates were higher at 1 year when using HIFU than when
using EBRT, and this was statistically significant. However, the difference was no longer statistically
significant at 5 years. Similar findings were observed with regard to disease-free survival at 1 year, with
worse outcomes for HIFU than for EBRT, which were statistically significant. The differences were no longer
significant at 3 years. The biochemical result was in contrast to overall survival at 4 years, which was higher
when using HIFU.
There were insufficient data on any urinary incontinence, erectile dysfunction or bowel problems to
draw any robust conclusions, although at 1 year HIFU had lower incontinence rates than RP (10% vs.
66%; OR 0.06, 95% CrI 0.01 to 0.48). The safety profile for HIFU was generally good, apart from a
potential numerical increase in rates of urinary retention and dysuria. However, HIFU appeared to have
a slightly higher incidence of urethral stricture than EBRT, and the difference was statistically significant
(8% vs. 1%; OR 5.8, 95% CrI 1.2 to 24.5).
Brachytherapy
This review considered data from 26,129 patients who received brachytherapy across 40 studies (2 RCTs
and 38 NRCSs), with most studies considered to be at high risk of bias. The data for brachytherapy were
generally more robust than for other ablative therapies.
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In the short term, there was some evidence at 5-year follow-up that the rate of biochemical failure
was lower for brachytherapy (7%) than for EBRT (13%; OR 0.46, 95% CrI 0.32 to 0.67) or
RP (11%; OR 0.35, 95% CrI 0.21 to 0.56). There was also some evidence that disease-free survival
was better for brachytherapy at 3-year follow-up.
There was evidence that the rate of urinary incontinence up to 5 years after treatment was lower for
people undergoing brachytherapy than for RP, but the size of the difference decreased with longer
follow-up. There was also a trend towards lower erectile dysfunction rates for brachytherapy than for EBRT
or RP and this reached statistical significance at 3 years after treatment (60% vs. 81% for EBRT and 88%
for RP). There were insufficient data to draw any conclusions on bowel problems.
The findings regarding procedural complications were mixed. Dysuria rates were higher for brachytherapy
and this reached statistical significance when compared with RP. Urinary retention was also statistically
significantly higher for brachytherapy than for EBRT. Stricture rates for brachytherapy were higher than
those for EBRT, but lower than those for RP. The differences for stricture reached statistical significance
when compared with RP. For rectal pain, there was evidence that rates were significantly lower for
brachytherapy than for EBRT. Acute genitourinary toxicity, though rare, had statistically higher rates for
brachytherapy than for EBRT, but acute gastrointestinal toxicity was lower for brachytherapy.
Other ablative therapies
Only two other ablative therapies were identified in the review: focal laser ablative therapy and PDT. Data
were too scarce (a total of 35 participants for these two procedures) for any conclusions.
Salvage therapy
Data from 400 participants who were treated with salvage therapy following primary EBRT across nine
case series were included. Six studies involved salvage RP, two involved salvage cryotherapy and one
involved salvage HIFU. In six studies, data were not collected prospectively, and only short-term outcomes
were reported. As such, all of the studies were considered as having a high risk of bias. There was no
robust evidence that mortality or other cancer-specific outcomes differed between salvage cryotherapy and
salvage RP in the short term. There were no data on cancer-specific outcomes for salvage HIFU. In regard
to functional and quality of life outcomes, lack of data prevented any conclusions. In terms of adverse
event outcomes, salvage cryotherapy had numerically fewer periprocedural complications (especially for
bladder neck stenosis) than salvage HIFU or salvage RP, but there was a high level of uncertainty with
this observation.
Focal ablation
Descriptive subgroup assessment within studies reporting the use of focal ablation was limited, but
suggested that cancer-specific outcomes were at least comparable with those seen in full-gland therapy
studies. Urinary incontinence rates may be lower following focal ablation, but the evidence is weak in light
of the poor quality and quantity of the data.
Active surveillance
Lack of outcome data prevented comparison of the efficacy of ablative therapies with a programme of AS,
apart from the rate of erectile dysfunction at 12 months, where there was no statistically significant difference.
Cost-effectiveness
Assuming equal recurrence in line with the lack of statistical differences from the effectiveness review,
EBRT was the least costly (£19,363 per patient) and least effective (3.63 QALYs), whereas HIFU was
more costly (£19,860 per patient) and more effective (3.86 QALYs). HIFU was more effective and less costly
than the other newer ablative interventions. The lifetime incremental cost per QALY for HIFU compared
with EBRT was £2915. There was a 75% chance that HIFU would be considered cost-effective at a
£30,000-per-QALY threshold. In a plausible best-and-worst-case analysis, the probability that HIFU would
be considered cost-effective varied between 60% and 70%.
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Strengths and limitations
The main strength of the study was the systematic approach taken to review the literature and the
inclusion of a relatively large quantity of studies, giving a high total number of participants. The main
limitations were the low quantity and poor quality of the data available on cancer-related outcomes and
long-term adverse events of urinary incontinence, sexual and bowel dysfunction, and the changing
technology over the review period. Many published studies were poorly reported or lacked sufficient detail.
Inconsistency in outcome definition, measurement and reporting was also a significant problem, and much
of the information available was unsuitable for meta-analysis. Another major limitation resulted from the
majority of comparisons being made using case series, with few head-to-head comparisons of ablative
therapies against current practice. The estimates were therefore generated using indirect comparisons.
Like all analyses, they require assumptions to be made that may or may not be reasonable. Accordingly,
the results should be interpreted with a large degree of caution. Despite the considerable efforts to
construct a model and seek the best data available, the lack of effectiveness data had implications for the
economic evaluation. The limited data meant that there was insufficient evidence to assume that there
was any difference between interventions for a number of parameters, a particular issue for biochemical
recurrence, which was a key parameter in the evaluation. The impact of these assumptions was explored in
sensitivity analyses.
Conclusions
Implications for health care
For primary ablative therapy, neither cryotherapy nor HIFU had sufficiently robust data to enable any
definitive conclusions to be made. The effectiveness data on brachytherapy were more robust and there
was some evidence that cancer-specific outcomes in the short term were either better or equivalent to
either EBRT or RP, with comparable adverse effect profiles apart from a possible increased risk of dysuria
and urinary retention. The findings on focal ablative therapy were mostly derived from data on focal
cryotherapy, which suggested that cancer-specific outcomes were at least comparable with those of
full-gland cryotherapy, and there was a suggestion that the urinary incontinence outcome may be better
following focal cryotherapy than whole-gland cryotherapy. The cost-effectiveness analysis confirmed the
uncertainty from the clinical review and that there is no technology which appears superior, on the basis of
current evidence, in terms of average cost-effectiveness. The probabilistic sensitivity analyses suggest that a
number of ablative techniques are worthy of further research.
For salvage ablative therapy following primary EBRT, a lack of reliable and robust data prevented any
meaningful conclusions from being made, in comparison with salvage RP.
The findings from the review indicate that there is insufficient evidence to help inform recommendations
on the use of ablative therapies in the UK NHS.
Need for further research
The main gaps in the evidence base are the lack of direct comparative studies of ablative therapies; the
consequent lack of robust data to inform calculations of cost-effectiveness and the role of focal ablative
therapies; and the lack of longer-term data on cancer control, such as overall and cancer-specific mortality.
The key research recommendations, in order of importance, are as follows:
1. HIFU and brachytherapy seem the most promising newer interventions but they lack high-quality
evaluation. Such evaluation should ideally be by multicentre RCT with long-term follow-up, and would
include predefined assessment of cancer-specific, dysfunction and health-related quality-of-life
measures. Such studies should incorporate economic evaluations and also inform economic modelling.
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2. The role of focal therapies in the management of people with localised prostate cancer should be
investigated. It may be desirable to incorporate the focal approach into the design described above.
It is noted, however, that the use of focal therapies is dependent on prior precise localisation of the
cancer, for which the technology remains developmental.
3. AS is an increasingly used strategy for people with localised prostate cancer that is deemed to be at low
initial risk of spread. The results of ongoing studies are required to assess its safety, acceptability to
people with prostate cancer and cost-effectiveness.
4. Agreed definitions of outcomes in urology and agreed measures for recording them are urgently
needed. Partnership between governing bodies and international initiatives such as Core Outcome
Measures in Effectiveness Trials (COMET) may be desirable.
Study registration
This study is registered as PROSPERO CRD42012002461.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the underlying health problem
The management of an individual diagnosed with prostate cancer is highly complex and fraught with
difficulties, especially in relation to localised prostate cancer. This is due to many factors which influence
decision-making: the array of available interventions, each with different treatment characteristics and
associated adverse effects; uncertainties regarding the most accurate ways of determining the grade and
stage of the disease and making predictions regarding prognosis; and controversies regarding the natural
history of the disease. The relative clinical effectiveness of standard and widely accepted interventions
for localised prostate cancer, such as radical prostatectomy (RP) and external beam radiotherapy (EBRT),
have been the subject of various health technology assessments (HTAs) around the world. The present
assessment is tasked with determining the relative clinical effectiveness and cost-effectiveness of ablative
therapy, which is a relatively new intervention, for the treatment of people diagnosed with localised
prostate cancer, in comparison with other standard interventions from the perspective of the UK NHS.
Importance of prostate cancer as a health problem
Prostate cancer is the commonest cancer diagnosed in people in the UK and is the second commonest
cause of cancer deaths.1 In 2011, 41,736 people in the UK were diagnosed with prostate cancer (Figure 1).2
It accounts for approximately 7% of cancer-related deaths in people in the UK, with an age-standardised
mortality rate of 35 in 100,000, amounting to 10,837 people in 2012.2 In 2006, the 10-year prevalence in
the UK was estimated to be 181,463.3 The disease also incurs significant economic costs to health-care
providers. In 1997 the annual cost to the NHS was estimated at £55M.4 An economic analysis published in
2012 reported that the total cost of prostate cancer in the UK in 2009 – encompassing treatment costs for
surgery, radiotherapy, hospital and community care, premature deaths, time off work and unpaid care
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FIGURE 1 Age-specific incidence rates for prostate cancer in the UK, 2009–11.3
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given to patients by family and friends – was estimated at around £800M per annum.5 This ties in with a
recent estimate from the USA that a diagnosis of prostate cancer incurs an average health-care and
personal cost of US$20,000 (£13,000) over the individual’s remaining lifetime.6,7
Since the advent in the mid-1980s of testing for prostate-specific antigen (PSA), an organ-specific serum
marker of prostate cancer, there has been a substantial increase in the number of people diagnosed with
prostate cancer.8 The largest rise in incidence is among relatively younger people as a consequence of
case-finding and screening for asymptomatic disease using serum PSA and multiple transrectal ultrasound
(TRUS)-guided needle biopsies of the prostate.9,10 By the same token, the use of PSA testing has resulted in
a gradual stage migration towards the earlier stages of the disease in terms of diagnosis. Indeed, presently
the majority of people (i.e. up to 80%) with prostate cancer are diagnosed in the localised stages of the
disease,11,12 and a large proportion of them often have favourable pathological characteristics.13,14
Standard curative treatment options for localised prostate cancer
The decision to treat and the choice of treatment are influenced heavily by four major factors:
i. the patient’s life expectancy, as determined by his chronological age, comorbidities and fitness in terms
of activities of daily living (called performance status)
ii. tumour characteristics, determined by the PSA level at diagnosis; the aggressiveness of the tumour, as
determined by histological examination using a microscope [or tumour grade, categorised by Gleason
sum score (2–10)]; other histological parameters, including volume of the cancer and length of
involvement of the biopsy strands of tissue with cancer; and the stage (or extent of spread) of the
disease on clinical examination and imaging, all of which can be used for risk stratification to predict
behaviour or outcomes using nomograms15,16
iii. clinician or patient preference linked to risk of adverse effects
iv. availability of resources underpinning each treatment option.
A standard clinical treatment care pathway for people with localised prostate cancer is given in MacLennan
and colleagues,17 and this is further described in Chapter 2. As the majority of people present with
asymptomatic, early and localised disease, most of them can be cured by way of radical (or curative)
treatment options, which include either RP or radical EBRT. However, it is also clear that prostate cancer
has a wide spectrum in terms of the risk and time course of disease progression,18 and in spite of the use
of nomograms, the disease course for some patients can be unpredictable.
Radical prostatectomy
Radical prostatectomy involves removing the prostate and seminal vesicles, with or without removal
of adjacent lymph nodes depending on tumour grade and PSA level.19,20 The aims of the operation
are to achieve cancer cure, to minimise perioperative morbidity and to preserve continence and sexual
function. This can be achieved by the traditional open technique through a lower abdominal incision,
by laparoscopic (keyhole) surgery through several small incisions and, most recently, by robotic-assisted
laparoscopic prostatectomy, where the surgeon controls the instruments remotely, giving a more
comfortable and precise surgical technique.21 Contemporary high-volume units record very low
perioperative morbidity, whichever technique is used. The main concerns are to minimise the risk of
recurrence by maintaining a low positive margin rate and maximise recovery of continence and erectile
function by preserving the pelvic neurovascular bundles. Recent literature reviews suggest a median
positive margin rate of 22% with RP.22
Radical external beam radiotherapy
Radical EBRT typically involves delivery of a minimum dose of 74 Gy of radiation to the prostate at no more
than 2 Gy per fraction.9 There are, however, variations in terms of radiation dose, treatment schedules
and whether or not the treatment is combined with a 3- to 6-month course of chemical androgen
ablation, as neo-adjuvant or adjuvant therapy. Recent developments in radiation and imaging technology
have facilitated the emergence of newer techniques including three-dimensional conformal radiotherapy
BACKGROUND
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(3D-CRT), whereby the delivery of the radiation beam conforms to the three-dimensional structure of the
prostate gland, and intensity-modulated radiotherapy (IMRT), which is a further development of 3D-CRT
but with more precise control of the radiation beam and improved optimisation of treatment planning.23
Another relatively new form of radiotherapy is proton beam radiation therapy (PBT),24 in which protons
rather than photons are delivered in a conformal manner to the prostate. PBT has the potential to improve
the therapeutic ratio of prostate radiation by allowing for an increase in dose without a substantial
increase in side effects. There are variations in each EBRT treatment modality, in terms of radiation dose,
treatment schedules and whether the treatment is combined with hormonal therapy or otherwise, in either
a neo-adjuvant or adjuvant fashion, or combined with other EBRT modalities (e.g. PBT may be combined
with 3D-CRT). EBRT is also increasingly being used in combination with high-dose-rate brachytherapy
boost.25,26 The main complications from radiotherapy include bowel disturbance, urethral stricture
formation, lower urinary tract symptoms, erectile and ejaculatory dysfunction and skin irritation.
Radical interstitial brachytherapy, which is often considered as a form of radical radiotherapy technique,
will be considered under ablative therapies for the purposes of this review, in accordance with the HTA
commissioning brief for this review.
In summary, both RP and radical EBRT are widely accepted as the current standard curative treatment
options for the treatment of localised prostate cancer. Both are associated with a relatively high cure rate.27
However, both procedures are associated with a significant risk of adverse effects which impair function,
including erectile dysfunction in between 24% and 90% of patients, urinary incontinence in 2–72% and
bowel-related problems in 2–15%.27–30 These adverse events can significantly impair quality of life.27,31
There is increasing recognition that a large proportion of people with early, localised disease will
neither develop progressive disease nor die from it.32,33 As such, it is possible that the harms of radical
interventions, which are highly invasive, may outweigh the benefits for some people. In spite of this, there
is evidence to indicate that the use of radical treatment for early, localised prostate cancer is increasing.34
In this regard, there is a risk of overtreatment. It has been estimated that more than 40% of people with
early localised prostate cancer have been overtreated,35 and this has important repercussions for the
people concerned and for the NHS.
Active surveillance
The strategy of active surveillance (AS) for low- and intermediate-risk localised prostate cancer36 is based
on the premise that such cancers are unlikely to cause ill health during an individual’s lifespan and will not
contribute to early death. It involves an active decision not to begin treatment immediately but to monitor
the cancer by regular PSA checks, digital rectal examination (DRE) and planned rebiopsy to detect disease
advancement. If subsequent disease changes pass defined thresholds, then appropriate interventions such
as radical or newer ablative treatment options are suggested. Trends in population-based cohort studies on
the incidence and mortality rates of prostate cancer detected by PSA screening,13 and in retrospective
cohort studies of people with clinically localised prostate cancer identified in both the pre-PSA32 and the
post-PSA37 eras, appear to support such a strategy. However, there is no consensus on the definition of
disease progression, such as thresholds for absolute or time-dependent PSA rise, and degree of change in
microscopic disease appearance on biopsy (Gleason sum score or other histological parameters such as
volume of cancer) or on imaging, such as multiparametric magnetic resonance imaging (MRI). The
disadvantages of AS as a cancer management strategy include patient and clinician anxiety in leaving a
deliberately detected cancer untreated, uncertainty regarding when to initiate treatment and risk of more
rapid disease progression precluding cure.
In summary, deciding between treatment options is complex for both clinicians and patients because of a
lack of reliable predictors of disease progression and of risk of suffering cancer-related morbidity during an
individual’s natural lifespan. The basic problem is differentiating between indolent tumours that are not a
threat to health and aggressive cancers that are likely to cause symptomatic disease or early death.38
As a result of this uncertainty, most otherwise healthy people younger than 70 years diagnosed with
localised prostate cancer currently choose to undergo immediate curative treatment rather than AS,39
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although there is little high-quality evidence to guide this choice.27 In addition to this uncertainty for the
population at risk, any potential oncological benefit of curative treatment (e.g. cancer-specific survival) may
take at least 10 years to accrue.40 The recent decrease in disease-specific mortality from prostate cancer
seen in communities with high rates of radical treatment, such as the USA, is seen by some as evidence
of success for the strategy of early intervention,41 whereas others consider it more likely to be due to a
combination of lead-time and length-time bias resulting from earlier detection of less aggressive disease.42
It is against the backdrop of the apparent tension between extremely invasive radical treatment options
on one hand, versus a conservative approach inherent in a policy of AS on the other, that alternative,
minimally invasive ablative therapies were developed.
Description of the interventions
Evolution of ablative therapies for localised prostate cancer
Ablative therapies refers to a group of interventions which aim for either total, subtotal or focal ablation
(or destruction) of the prostate gland in order to treat localised prostate cancer. These therapies have some
common characteristics, including (i) a minimally invasive nature, that is they are performed percutaneously
through the perineum, transurethrally or transrectally; (ii) being technically simple and easy to master;
(iii) allowing repeat treatments; and (iv) allowing salvage radical treatment for treatment failure (i.e. failure
to eradicate disease) or disease recurrence following initial cure. These therapies destroy the cancer in
the prostate gland in a minimally invasive manner using a range of energy sources, while simultaneously
minimising damage to adjacent structures such as the urinary sphincter, urethra, bladder, rectum and
nerves for erectile function, hence potentially reducing the risk of adverse effects.
The technology was first described in the mid-1990s, with cryotherapy, high-intensity focused ultrasound
(HIFU) and interstitial brachytherapy being used to treat localised and locally advanced prostate cancer in a
non-focused manner, whereby the entire prostate gland was subjected to treatment. Over the past two
decades, advances in imaging by ultrasound (US) or MRI, together with template biopsy protocols and
improvement to the treatment technologies, have all driven the possibility that these therapies can be used
in a more precise way, whereby the part of the prostate harbouring the most aggressive cancer can be
preferentially targeted for destruction.43,44 This is achieved in several ways, including lesion-targeted
therapy, hemi-ablative therapy (where one half of the gland is targeted) and subtotal ablative therapy. This
approach enables preservation of areas of the gland without cancer, together with surrounding structures
such as the nerves and blood vessels for erectile function, and the urinary sphincter muscle, bowel and
bladder, hence potentially reducing the risk of adverse effects. The approach is also potentially applicable
to the common finding of multifocal disease, where the dominant foci with less favourable pathological
characteristics are treated, while other, smaller, low-risk foci are left and AS continued.44 Although
primarily undertaken using general anaesthetic, ablative therapies may also be performed under local
anaesthetic or sedation in the outpatient setting. Other advantages include the ability to repeat the
ablative procedure if required, and if the procedure fails to achieve cancer control, then salvage treatment
by way of surgery or radiotherapy can be undertaken.
In addition, ablative therapies have also been used in treating people with local relapse after radical EBRT.
Although radical EBRT is considered a curative treatment option for localised prostate cancer, a relatively
high proportion of people, estimated at approximately 30%,45 will develop recurrent disease signalled by a
rising PSA and a positive rebiopsy. This recurrence rate is, to some extent, inflated by the higher proportion
of people being treated for more advanced disease compared with RP. If left untreated, at least 75% of
these people will develop localised prostate cancer recurrence within 5 years46 and hence require further
treatment, although the timing of second-line treatment remains controversial. Subsequent treatment
options include palliative hormonal therapy and potentially curative salvage procedures. The currently
recommended option, salvage prostatectomy, carries a high risk of morbidity including urinary
incontinence and rectal injury.
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The ablative technologies considered in this review are (1) brachytherapy; (2) cryotherapy; (3) HIFU;
(4) vascular-targeted photodynamic therapy (PDT); (5) transperineal radiofrequency interstitial tumour
ablation (RITA) therapy; and (6) laser ablation therapy (encompassing procedures such as photothermal
therapy, laser interstitial tumour therapy and laser photocoagulation).
Technical description of the interventions
Brachytherapy
Interstitial brachytherapy involves the ultrasound and template-guided insertion of radioactive seeds into
the prostate gland. It is an established curative treatment option for low-risk, early-stage prostate cancer.9,47
Owing to its more localised effects of radiation, the procedure offers the potential advantage of
delivering a higher radiation dose to the prostate than would be possible with conventional EBRT.
Brachytherapy is thought to be at least equivalent to the other curative treatment options for localised
prostate cancer in terms of cancer control.47–49 There are various brachytherapy protocols, each with subtle
differences in technique, including variations in radiation dosages and scheduling. It can be used either
singly or in combination with EBRT (especially IMRT). Two types of radioactive implants are available:
permanent seeds [with either iodine (I)-125 or palladium (Pd)-103] or temporary implants [iridium (Ir)-192].
The recommended prescription doses for permanent seed brachytherapy (as monotherapy) are 145Gy for
125I and 120–125 Gy for 103Pd.48 For temporary brachytherapy, the radiation dose is delivered at a higher
dose rate than for a permanent implant, because the implant can be removed after the treatment
session. As such, temporary brachytherapy is termed high-dose-rate brachytherapy. High-dose-rate
brachytherapy is commonly delivered in two or more fractions of 810 Gy or more. The commonest adverse
effects associated with brachytherapy include urinary, bowel and sexual dysfunction. Since it was first
introduced, brachytherapy has been used to treat the entire prostate gland. However, the ability to target
discrete lesions within the prostate, by virtue of improved imaging techniques, has made it possible to use
brachytherapy as an intraprostatic targeted treatment option for early, localised prostate cancer.44
Cryotherapy
Cryotherapy is the ablation of tissue using localised application of extreme cold. It achieves tissue
destruction by three processes: (i) direct cell damage from the freeze–thaw cycle; (ii) coagulative necrosis
within a few days after treatment; and (iii) apoptosis. The efficiency of tissue ablation is influenced by
various factors, including velocity of cooling and thawing, nadir temperature, duration of freezing, number
of freeze–thaw cycles and the presence of large blood vessels, which can act as heat sinks. A minimum
freezing cycle of –40 °C for 3 minutes is required for tumour eradication.50 The procedure involves the
placement of needle probes transperineally using a template under TRUS guidance. The probes are then
cooled to generate an ice ball within the prostate. Cryotherapy has been in use for prostate cancer
whole-gland treatment for more than 20 years but the technology has evolved considerably recently.
TRUS guidance and urethral warmers were introduced, resulting in more accurate probe placement and
enabling monitoring of the ice ball in real time, while the urethral warmers decreased the risk of urethral
sloughing.51 Current third-generation devices utilise probes in which pressurised gas is used to freeze
(argon gas) and thaw (helium gas). This enables the use of finer-calibre probes, which further enhance
the precision of probe placement and improve the efficiency of tumour cell killing while reducing damage
to surrounding structures.52 The main adverse effects of cryotherapy are erectile dysfunction, urinary
incontinence, urethral sloughing, rectal injury and rectourethral fistula formation.53
High-intensity focused ultrasound
High-intensity focused ultrasound uses high-energy ultrasound waves (0.8–3.5MHz) focused to a specific
point within the target organ in order to ablate tissue. Cellular damage occurs by two mechanisms:
(i) conversion of mechanical energy into heat and (ii) a process termed inertial cavitation. Once tissue
temperature exceeds 56 °C, irreversible cell death occurs from coagulative necrosis. Inertial cavitation results
from the alternating cycles of compression and rarefaction of the sound waves. At the time of rarefaction,
gas can be drawn out of solution to form bubbles, which then collapse rapidly, causing acoustic shock
waves which induce mechanical stress. The procedure involves the placement of an ultrasound probe
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transrectally. HIFU is also able to deliver its ablative energy more precisely than cryotherapy, with minimal
effect on surrounding tissues outside the target zone. However, unlike cryotherapy, there is no ‘ice ball’
equivalent, and hence it can be difficult to monitor the ablative effects of HIFU during treatment, although
the process is guided by ultrasound. To minimise the thermal effects on the rectal wall, the rectum is
irrigated with degassed, cooled water, which also eliminates acoustic interference between the transducer
and the rectal mucosa. HIFU has been widely used in Europe for whole-gland therapy, and two systems are
currently marketed. Both work by generating and focusing high-energy ultrasound waves at the target to
generate temperatures above 60 °C. The major adverse effects of HIFU include acute urinary retention,
erectile dysfunction, urethral stricture, rectourethral fistula and pelvic pain.54 Disadvantages of HIFU include
difficulty in achieving complete ablation of the prostate, especially in glands larger than 40ml, and in
targeting cancers in the anterior zone of the prostate.55
Vascular-targeted photodynamic therapy
Photodynamic therapy is a technology which achieves destruction of targeted tissues using a light-sensitive
agent (photosensitiser) and laser light of a specific wavelength in the presence of oxygen. The photosensitiser
absorbs light of specific wavelength and transfers the energy to adjacent oxygen molecules, to create reactive
oxygen species that trigger cell destruction.56 To treat prostate cancer, the photosensitiser [Tookad® WST09 and
WST11 (STEBA Biotech S.A., Luxembourg City, Luxembourg)] is administered intravenously and accumulates
preferentially in the tumour blood vessels. The photosensitiser is activated by laser light of specific wavelength,
which is delivered transperineally using optical fibres. Alternative photosensitisers are also under investigation.
Complications of vascular-targeted PDT include phototoxicity, skin photosensitisation, erectile dysfunction,
urethral damage and rectourethral fistula formation.55
Radiofrequency interstitial tumour ablation
Radiofrequency interstitial tumour ablation is a procedure that utilises low-level radiofrequency energy
(approximately 460 kHz) to heat and ablate tissue in a focused manner. Tissue destruction is achieved by
coagulative necrosis resulting from heating tissues to 100 °C for 5 minutes. The procedure has been shown
to be effective and safe in the treatment of primary and secondary liver tumours57 and in renal cancer as an
alternative to nephron-sparing surgery.58 For the treatment of localised prostate cancer, the radiofrequency
energy is delivered through needle probes which are inserted transperineally into the prostate, and
treatment is conducted under TRUS guidance. Temperature in the rectal wall is monitored and both the
urethra and rectum are irrigated with cooling solutions to avoid heat damage. The procedure is conducted
under sedation on an outpatient basis. Patients are usually catheterised urethrally for a day. Adverse effects
include frank haematuria, bladder spasms and dysuria, all of which appear to be transient.59
Laser ablation therapy
Laser ablation is a generic term implying thermal destruction of tissue by laser energy. It encompasses a
number of technologies that have been used to treat prostate cancer and are therefore relevant to
this review, including photothermal therapy, laser interstitial tumour therapy and laser interstitial
photocoagulation. Tissue destruction occurs by local coagulative necrosis, with temperatures ranging from
42 °C to more than 60 °C. However, laser energy has a localised effect, resulting in minimal damage
outside the targeted ablation zone. Experience with laser ablation for solid tumours comes from the focal
treatment of liver metastases from colorectal cancer.60 The Nd-YAG laser, with a wavelength of 1064 nm,
was initially used for prostate cancer ablation but it is being superseded by more compact and less
expensive infrared diode lasers (wavelength 800–980 nm). The laser is delivered transperineally through
flexible quartz fibres within a flexible fibre-optic device which also allows the use of water-cooled laser
application sheaths, which prevent overheating close to the fibre tip.61 Targeting of the lesion and
real-time monitoring of the ablation can be performed using either magnetic resonance (MR) thermometry
or contrast-enhanced ultrasound. The use of MR thermometry is particularly advantageous as it allows
for individually adjusted heat dosing application, thereby ensuring adequate tumour ablation while
simultaneously avoiding damage to adjacent normal tissues. Reported adverse effects include transient
perineal discomfort and haematuria.62 Laser ablation therapy has the theoretical advantages of accurate,
predictable and reproducible delivery of energy. Real-time monitoring by either MR or contrast-enhanced
ultrasound is also more easily performed.
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Current use of ablative therapies in the UK NHS
The ablative technologies described in the previous section are currently not recommended for routine use
in people with localised prostate cancer in UK NHS hospitals. The last National Institute for Health and
Care Excellence (NICE) clinical guideline9 suggested that HIFU and cryotherapy should only be used within
controlled clinical trials comparing their use with standard interventions. Since the publication of this
guideline, ablative technology has evolved, such that focal ablative therapies are increasingly being
considered as a feasible and valid minimally invasive option in the treatment of people with localised
prostate cancer.43,44 Apart from cryotherapy and HIFU, which are currently being investigated within the
context of clinical trials, none of the other techniques are available in the UK. However, newer ablative
techniques such as vascular-targeted PDT and transperineal RITA are being assessed elsewhere around the
world. Further options currently being tested in early-phase clinical studies include interstitial hyperthermia
using magnetic nanoparticles, and electroporation.43,63
Although promising, newer ablative therapies for localised prostate cancer are still relatively untested in
comparison with other, established treatment modalities such as surgery or radiotherapy, and are likely to
evolve as new technologies emerge. The most important challenges for the effectiveness of minimally
invasive ablative therapy include the need for accurate imaging modalities to target treatment; identification
and localisation of areas of higher-risk aggressive cancer using precise biopsy templates with reproducible
pathological categorisation; defining disease persistence and disease recurrence; and finally determining the
most appropriate salvage treatment options for treatment failure.
Projected rise in the number of people in the UK requiring treatment for
localised prostate cancer
At present in the UK, localised prostate cancer is detected by case finding among asymptomatic people
who request a PSA test and during the assessment of people complaining of unrelated urinary symptoms.
In 2010, almost 41,000 people were diagnosed with prostate cancer in the UK,1 with 18,408 (45%) aged
younger than 70 years.3 The majority of these people will have localised-stage disease, and are hence
suitable for curative treatment.1 Previous annual estimates of treatment suggest that over a 12-month
period, 3922 people underwent RP,64 while approximately 4000 underwent EBRT and 1455 underwent
brachytherapy.64 The corresponding figure for AS was approximately 800.65 There is evidence from the USA
to suggest that the use of RP as a primary treatment option for localised prostate cancer is increasing.34
The results from a PSA screening trial, the European Randomised Study of Screening for Prostate Cancer
(ERSPC), showed a doubling of cancer detection rate among people in the target age group (55–69 years)
accompanied by a similar increase in the number of people going on to have potentially curative treatment.66
Overall, 3% of people screened and 1% of controls underwent RP during the 9 years of follow-up.
Findings from the US-based Prostate, Lung, Colon and Ovarian Cancer Screening Study (PLCO) were similar,
with 3% of people screened and 2% of controls having RP during the 10-year study duration.67 Translating
these figures to the UK 2011 population of 5.05 million people aged 55–69 years, the annual number of
RPs would rise to approximately 7000 with increased case finding and to 11,000 if a screening programme
was instituted.
Recent evidence from the HTA-funded UK trial of treatment for localised prostate cancer, Prostate Testing
for Cancer and Treatment (ProtecT), suggests that the incidence of disease in younger people aged under
55 years is also significant, further increasing the population potentially requiring consideration towards
treatment.68 Evidence from the USA suggests that increasing incidence of low-risk cancer is accompanied
by increased use of AS and newer ablative therapies such as cryotherapy, with AS being selected by
10.2% and newer ablative therapies by 4.4% of affected people between 2004 and 2006.34 In NHS
hospitals in England, the numbers of people with prostate cancer treated with newer ablative options
remains small, with 66 recorded as undergoing cryotherapy and 168 HIFU,64 although discussion
with relevant clinicians suggests that the numbers are increasing.
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Summary
In summary, increasing incidence of low- and medium-risk localised prostate cancer makes it likely that
demand for alternative, non-radical treatment options for prostate cancer in the UK will increase
substantially over the next decade, requiring appropriate service provision and the need for policy decisions
regarding the cost-effectiveness of available treatment options. As such, policy-makers within the NHS
are faced with the need to plan service provision for such alternative treatment options, in particular
ablative therapies. This assessment has therefore been designed to help inform decisions regarding the
commissioning and use of ablative therapy for people with localised prostate cancer in the NHS.
Aims of the assessment
This assessment aims to systematically review and meta-analyse evidence on the clinical effectiveness and
harms of ablative therapies, including those recently developed for localised prostate cancer within the UK
NHS, and to model the cost-effectiveness of these therapies. The specific objectives of this assessment
are to:
1. develop clinical care pathways for the treatment of localised prostate cancer in a UK NHS context
(objective 1)
2. review systematically the evidence of the clinical effectiveness and safety of each ablative therapy
(objective 2), concerning:
i. primary treatment of localised low-/intermediate-risk prostate cancer compared with AS,
RP and EBRT
ii. primary treatment of localised high-risk prostate cancer compared with RP and EBRT
iii. salvage treatment for local prostate cancer relapse after EBRT compared with salvage RP
3. determine which therapies are most likely to be cost-effective for implementation in the UK NHS
(objective 3)
4. identify and prioritise future research needs (objective 4).
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Chapter 2 Description of care pathways
Patient group
Introduction
The population of patients considered for this review are people with localised prostate cancer who are
considered suitable for active treatment or AS and are managed within the UK NHS. The patient
characteristics that define this population include age and comorbidity that collectively determine an
estimated life expectancy of at least 10 years.
Disease factors provide the estimated risk of developing recurrent disease, either from distant metastases
not identified at pre-operative assessment, or because of failure to completely remove localised disease.
The approximate magnitude of this risk for an individual diagnosed with prostate cancer can be calculated
using a nomogram. The most commonly used version is hosted by the Memorial Sloan Kettering (MSK)
Cancer Institute in web-based form.69 These models use the pre-operative disease variables of age, PSA,
clinical tumour stage, Gleason grade and number of needle biopsy cores positive for cancer.
The described care pathway was constructed using available evidence, previous care pathways (Figure 2)
developed by the Aberdeen Academic Urology group in conjunction with a national and international
panel of experts, and consensus-building through several meetings of the expert panel convened for this
review. Although it is primarily constructed as the basis of the modelling of cost-effectiveness reported in
Chapters 9 and 10, the pathway is consistent with previously published clinical pathways of care.9,70–73 The
complete care pathway developed for the review is shown in Chapter 9 (see Figure 16, with Figures 17–20
illustrating how the care pathway varies for alternative interventions under investigation).
Pretreatment level of prostate-specific antigen
The pretreatment PSA level is an independent statistically significant predictor of future recurrence, but on
its own is limited in reliability and predictive value. For prognostic purposes the value is defined in risk
groupings corresponding to low (< 10 ng/ml), intermediate (10–20 ng/ml) and high (> 20 ng/ml) risk of
disease progression following radical treatment.36
Staging of prostate cancer
The stage of an individual’s cancer is categorised according to the Union for International Cancer Control
(UICC) 2009 tumour node metastasis (TNM) classification.74 Pre-operatively, this is determined by clinical
assessment using DRE and imaging and is given the prefix ‘c’. Following removal and pathological
examination of the prostate and, in some cases, adjacent lymph nodes, the staging is adjusted accordingly
and given the prefix ‘p’.
Gleason grading
The qualitative low-magnification microscopic histological description of prostate cancer first suggested by
Gleason in 196675 remains an essential aspect of prognostic categorisation, although there have been
substantial modifications over the years.76 Standard practice consists of identifying the first and second
most prevalent patterns within a set of biopsy cores which give the primary and secondary Gleason grades
(each rated 1–5). These are then added together to give the overall Gleason sum score (2–10). Recent
consensus tends to limit the use of grades 1 and 2 and therefore scores generally range between 6 and
10.77 Higher individual grade and total score indicate more aggressive disease, with primary grade being
more predictive. An individual whose tumour is categorised as Gleason score 4+ 3= 7 will therefore tend
to have a worse prognosis than if the Gleason score was 3+ 4= 7, for example.78
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Cancer volume
There is some evidence that cancer volume is also an independent prognostic factor for progression of
the cancer following initial management. For this reason, pathologists examining biopsy cores will estimate
cancer volume by stating the number of cores that contain cancer and estimating the proportion of each
core that is affected by the cancer.79
Summary
Pretreatment information including age, serum PSA, tumour stage, Gleason sum score and tumour
volume predicts the risk of disease recurrence. It is therefore important that studies comparing treatments,
such as this current assessment, include an evaluation of whether or not the patient groups undergoing
each procedure are balanced for these variables. For the purposes of the current assessment, people
with localised prostate cancer will be stratified into three groups according to D’Amico risk of recurrence
following curative treatment36 (Table 1): low, intermediate and high risk. The system utilises pretreatment
variables of serum PSA level, Gleason sum score and T stage of the TNM staging system.
Treatment characteristics
Introduction
This study includes a cost-effectiveness analysis of ablative therapies compared with other standard
interventions (see Chapters 9 and 10 for more details). For the economic modelling, it is assumed that the
procedures being considered will be carried out in hospitals that have the necessary resources in terms of
staff, facilities and NHS cancer plan approval to carry out the various interventions on a routine basis.
For surgical procedures (i.e. RP, HIFU or cryotherapy), this will comprise operating theatre and recovery
facilities, including critical care and standard urology wards; the required clinical and technical expertise,
including surgeons, anaesthetists, theatre nursing team, pathologists and technicians; and continued
care, including outpatient review, repeat imaging and facilities for further treatment for adverse events or
cancer progression. For EBRT, the resource estimates were modelled after IMRT, because in most cancer units
around the UK, IMRT has superseded 3D-CRT as the standard for EBRT. The resource estimation includes
costs associated with radiotherapy planning visits, treatment sessions, staff time, consumables, etc. For
brachytherapy, the resource estimates were modelled after low-dose brachytherapy (i.e. involving permanent
seed implantation), and resource estimation includes costs for seed implantation under general anaesthetic,
incorporating costs for a radiologist, urologist, oncologist, anaesthetist, theatre staff, consumables, etc.
A detailed description of the various interventions are provided in Chapter 1, and a more detailed description
of the treatment care pathways for each intervention in terms of resource use is provided in Chapter 9.
TABLE 1 D’Amico risk of biochemical recurrence after radical treatment stratified according to tumour
characteristics36
Group PSA (ng/ml) Gleason score (0–10) Clinical stage
Low risk < 10 and ≤ 6 and T1–T2a
Intermediate risk 10–20 or 7 or T2b–T2c
High risk > 20 or 8–10 or T3–T4
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Learning curve of procedures
For safe conduct of all interventions, it is essential that all members of staff involved in delivering the
therapy have had specific training and are competent to undertake the procedure. In the UK, all of
the surgical procedures (including RP, cryotherapy and HIFU) are normally performed by consultants
who have received specific training. As such, for the economic modelling, it is assumed that such
procedures are undertaken by a trained consultant. Non-surgical procedures such as EBRT and
brachytherapy are less susceptible to learning curve effects of individuals. The review assumes that
such procedures are undertaken by experienced teams led by a consultant oncologist.
Hospital stay
For surgical procedures, people are generally admitted to hospital either on the day of surgery or the
evening before. For RP, a rectal enema is administered to clear the lower bowel. Immediately prior to the
procedure, prophylactic antibiotics are given according to local policy and venous thrombosis/embolism
prophylaxis is commenced as required. After surgery, the patient is routinely nursed on a standard ward
although specific comorbidities or intraoperative complications may require a period in a critical care bed.
For RP performed laparoscopically, people are typically discharged home after 3 days with an indwelling
catheter, although this may be variable (e.g. hospitalisation time can be reduced by managed care
programmes). They then return to the ward as a day patient after a further 7–14 days, according to local
protocol, for urinary catheter removal and voiding check. For cryotherapy, people stay up to 2 nights in
hospital after their procedure, whereas for HIFU they stay for 0–1 night. In both instances, they return to
the ward after a further 7–14 days as a day patient for urinary catheter removal and voiding check.
Perioperative complications
Although people undergoing surgery for localised prostate cancer (including RP, cryotherapy and HIFU)
generally do not have concurrent comorbidity that is a persistent threat to their health, a proportion will be
expected to suffer adverse events associated with surgery, and anaesthetic-related problems such as cardiac
ischaemia and pulmonary embolism. In addition, specific complications include urinary and blood stream
infection, inadvertent injury to adjacent organs (e.g. rectal injury), excessive blood loss requiring transfusion,
prolonged urinary or lymphatic leakage from abdominal drains, development of urethral stricture or fistula,
etc. The adverse effect of these complications in terms of their severity and requirement for additional
interventions and hospital stay can be summarised according to the Clavien system (Table 2).80,81
TABLE 2 Abbreviated Clavien–Dindo classification of surgical complications80
Grade Definition Exclusions
0 No deviation from planned postoperative course considering procedure and
pre-existing comorbidity
I Any deviation from the normal postoperative course without the need for specific
pharmacological treatment or surgical, endoscopic and radiological interventions
II Requiring pharmacological treatment with drugs other than those allowed for grade I
complications. Includes blood transfusions and total parenteral nutrition
Treatments listed
under grade I
IIIa Requiring surgical, endoscopic or radiological intervention not under general anaesthesia
IIIb Requiring surgical, endoscopic or radiological intervention under general anaesthesia
IVa Life-threatening complication affecting single organ system requiring IC/ICU management TIAs
IVb Life-threatening complication affecting more than one organ system requiring IC/ICU
management
TIAs
V Death of a patient
IC, intensive care; ICU, intensive care unit; TIA, transient ischaemic attack.
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For RP, an additional specific short-term complication is narrowing (bladder neck stenosis) of the sutured
join between the top of the urethra and bladder outlet (vesicourethral anastomosis). This will become
noticeable after removal of the draining catheter and will result in voiding problems reported by the
patient at the 6-week outpatient review. It is treated with endoscopic incision of the narrowed area, which
requires an additional short hospital stay and a 7-day period of catheterisation. For most people the
problem is cured by a single incision, although for some this may need to be repeated once or twice.82
For non-surgical interventions (e.g. EBRT and brachytherapy), the management of adverse events depends
on the severity, graded according to common acute and late toxicity grading systems [e.g. Radiation
Therapy Oncology Group (RTOG) Common Toxicity Criteria].83 In this assessment, for the estimation of
resource use, expected duration of hospital stay based on the severity of adverse events was graded based
on clinical judgement from members of the study team.
Histopathological examination of prostate biopsies and radical
prostatectomy specimen
For RP, careful and thorough microscopic examination of the removed prostate by an experienced
pathologist is required to determine the true extent of the disease, to decide whether or not the surgery
may have been unable to remove all the contained cancer (positive margin) and whether or not the cancer
had spread outside the prostate (extracapsular extension), and, if lymphadenectomy has been performed,
to detect the presence of lymph node metastatic disease. In addition, a more comprehensive description of
the distribution of Gleason patterns within the cancer is possible. This examination will recategorise the
disease according to stage [pathological tumour (pT) and pathological node (pN)] and postoperative
Gleason score, which will allow more accurate estimation of prognosis according to available post-RP
prognostic nomogram69 and inform whether or not early additional (adjuvant) treatment should be
advised. The crucial nature of this examination has led to consensus meetings of expert pathologists who
have set out a specified protocol of specimen collection, processing, examination and analysis.77,84
For interventions whereby repeat prostate biopsies are necessary as part of the follow-up protocol (e.g. AS,
cryotherapy and HIFU), or triggered by a suspicion of biochemical recurrence, the economic model assumes
that the biopsies are performed using the TRUS approach, and where appropriate, this may be augmented
by MRI-directed or guided strategies. The biopsy specimens are reviewed and reported by an experienced
pathologist within a urological cancer multidisciplinary team setting.
Surveillance following initial treatment
Follow-up schedule
People who have undergone RP are generally seen by the operating team as outpatients 6 weeks after
their surgery, then 3-monthly for the first year and 6-monthly for the next 4 years. At each follow-up,
serum PSA is checked for tumour recurrence and a qualitative assessment made for continence and
desired sexual function. If further assessment or treatment is required for any of these aspects, then the
pathway of care will be changed accordingly.
For EBRT and brachytherapy, patients were assumed to have follow-up as part of post-treatment
surveillance for up to 5 years, assuming that there were no changes in the patient’s condition, nor any
evidence of biochemical recurrence such that they had to leave the surveillance state. In the first year of
surveillance, patients would attend four nurse-led urology outpatient appointments, with PSA tests
conducted in each of these. For the second year through to the fifth it was assumed that patients would
attend two nurse-led urology outpatient appointments with PSA testing at each. After the first 5 years,
it was assumed that patients would receive an annual PSA test conducted by a practice nurse in a primary
care setting. Patients would also have an annual DRE each year for the first 5 years.
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For cryotherapy and HIFU, similar assumptions were made. Where repeat prostate biopsies were
mandatory within the first year of treatment, this was regarded as a part of the ‘package of treatment’
rather than as a part of follow-up. The economic model also made allowance for imaging of the prostate
using multiparametric MRI during the follow-up period.
For AS, the following assumptions were made based on a standard protocol. In the first year of follow-up,
patients would attend four nurse-led urology outpatient appointments with PSA tests conducted at
each appointment. At 12 months, a multidisciplinary team cancer meeting would take place to review each
patient. Patients in year 2 would attend two nurse-led urology outpatient appointments, again with PSA
tests performed at each appointment. In addition, patients would undergo a standard 12-core TRUS-guided
biopsy. Year 4 of AS was assumed to be identical to this, and years 3 and 5 were assumed to be the
same with the exception of the TRUS-guided biopsy. Patients would also have an annual DRE in years 1–5.
After the first 5 years, it was assumed that patients would receive an annual PSA test conducted by a
practice nurse in a general practice setting.
Detection of persistent or recurrent disease
The risk of disease recurrence is higher if one or more of the disease factors, including pre-operative
PSA > 20 ng/ml, Gleason score of > 7, extracapsular disease (T3/T4), positive margin or positive lymph
nodes (N stages N1/N2 of the TNM staging system), are present as determined by lymphadenectomy. If the
likelihood of disease persistence or recurrence is deemed to be very high, then immediate adjunctive
treatment may be offered. For the majority of people, PSA surveillance is started according to the above
schedule. There are multiple definitions of the threshold of PSA rise that signifies biochemical recurrence
between interventions, and within an intervention. For RP, because the prostate gland and prostate cancer
(which are the only sources of PSA in the blood) have been removed, if cure has been achieved, the
expectation is a complete absence of serum PSA 3 weeks after treatment. However, laboratories have
different sensitivity and specificity thresholds. The commonest baseline is 0.2 ng/ml. As such, for a
definition of cure, the patient should have reached a nadir (i.e. lowest PSA reading) which is below
0.2 ng/ml after 3 weeks following treatment. The most common definition for biochemical recurrence is
two successive serum PSA readings > 0.2 ng/ml.85
For EBRT and brachytherapy, several definitions are in existence, the commonest of which is the Phoenix
definition.86 This defines recurrence as ‘a rise by 2 ng/ml or more above the nadir PSA’.
For cryotherapy and HIFU, there is no consensus regarding what should constitute biochemical recurrence.
Although the Phoenix criterion is often reported, it has not been validated for either intervention.
For AS, because the cancer remains untreated but merely monitored, definitions for biochemical recurrence
do not apply. The main immediate cancer-related outcome of relevance for AS is disease progression or
upgrading of cancer grade (often collectively termed ‘reclassification of disease’). However, there is
controversy regarding what constitutes progression or reclassification, with AS protocols adopting different
definitions.87
For all interventions except AS, the occurrence of biochemical recurrence does not automatically
trigger salvage treatment; in some instances, the patient may continue to be monitored until a point
where salvage treatment is deemed necessary. However, most patients will undergo salvage treatment
once biochemical recurrence occurs. The decision whether to institute immediate salvage treatment
or further monitoring will be informed by tests such as MRI and/or a radionuclide bone scan designed to
demonstrate the site of recurrence as being in the prostatic bed (i.e. localised recurrence), or as lymph
node or bone metastases (i.e. systemic recurrence).
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Salvage treatment
Following localised recurrence, the salvage treatment options are salvage RP, salvage EBRT, savage
brachytherapy and salvage ablative therapy (HIFU or cryotherapy) (see Figure 16 in Chapter 9).
The assumption for the model is that salvage treatment should differ from the primary treatment
(i.e. patients who have had primary RP would be ineligible for salvage RP). With the exception
of salvage RP, the model allows for the addition of androgen deprivation therapy for a duration of up
to 2 years following salvage treatment.
For people with likely systemic recurrence, long-term androgen deprivation therapy (medical castration),
most commonly achieved with a luteinising hormone-releasing hormone (LHRH) agonist, is recommended.
This consists of 3-monthly injections of a depot preparation of the chosen drug. For people whose disease
progresses despite local and systemic adjuvant treatment, palliative symptom control will be instituted.
Urinary incontinence
Urinary incontinence is one of the most important long-term adverse effects of treatment for localised
prostate cancer. Recovery of continence following some interventions, such as RP, can take up to 12 months,
although most people will regain continence by 6 months. Therefore, people suffering urinary incontinence
will be advised to use containment devices such as absorbent pads or penile sheath drainage for the initial
12 months. For the majority of interventions, the expectation is for urinary incontinence to improve within the
first year, beyond which further improvement is unlikely. As such, if bothersome leakage persists beyond this
time, then the main treatment options will be surgical implantation of an artificial urinary sphincter (AUS) or
continued use of containment devices.
Erectile dysfunction
Of people who were sexually active prior to treatment, a large proportion will experience worsening of
their sexual function, and in particular difficulty initiating and sustaining penile erection sufficient for
intercourse. This is particularly dependent on preservation of one or both neurovascular bundles during
treatment. For these people, treatment options will include drug treatment taken as required, vacuum
constriction device or penile implant surgery. Most people will first trial the oral phosphodiesterase
inhibitors sildenafil, tadalafil (Cialis®, Lilly) or vardenafil (Levitra®, Bayer) which, under NHS prescribing rules,
are limited to one tablet weekly. The next option will be alprostadil given as an intraurethral pellet or an
intracavernosal injection with NHS supply, again limited to once-weekly doses. For people who achieve
satisfactory restoration of sexual activity with these drugs, it is assumed that their use will continue long
term. If drug treatments are unsuccessful, people may trial a vacuum constriction device, or consider
surgical implantation of a penile prosthesis. The proportion of people pursuing the last two options is
small, as most will accept their loss of sexual function in the longer term.
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Chapter 3 Methods of, and studies included in,
the systematic reviews of clinical effectiveness
Search methods
Comprehensive electronic searches were conducted to identify reports of published studies. Highly
sensitive search strategies were designed, including appropriate subject headings and text word terms,
interventions under consideration and included study designs. Given the anticipated large number of
studies requiring full-paper assessment, only English-language reports were included, with the exception
of randomised controlled trial (RCT) evidence that involved an ablative procedure, where no language
restriction was applied. Searches were not restricted by year of publication. MEDLINE, MEDLINE In-Process
& Other Non-Indexed Citations, EMBASE, Bioscience Information Service (BIOSIS), Science Citation Index,
Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews
(CDSR), Database of Abstracts of Reviews of Effects (DARE) and the HTA databases were searched. All
databases were searched up to March 2013. Reference lists of all included studies were scanned and we
asked our expert panel for details of additional reports. All database search strategies and details of dates
of searches for clinical effectiveness are detailed in Appendix 1.
Identification of other relevant information, including unpublished data
The World Health Organization (WHO) International Clinical Trials Registry, EU Clinical Trials Register,
Current Controlled Trials, ClinicalTrials.gov and National Institute for Health Research (NIHR) Portfolio were
searched for ongoing studies. Websites of manufacturers, professional organisations, HTA organisations
and regulatory bodies were also checked for additional reports (see Appendix 1, Websites consulted).
Inclusion and exclusion criteria
Types of study
For all three reviews, we considered evidence from RCTs and non-randomised comparative studies (NRCSs)
(if no RCT evidence was identified), and from single-arm cohort studies (case series) (greater than
10 participants) for the ablative procedures only. Had comparative studies of the ablative procedures been
identified, consideration would have been given to removing single-arm cohort studies from the reviews.
Studies comparing only multiple treatments of the same non-ablative therapy within the same comparative
study (e.g. comparing different dosages of radiotherapy, or open vs. laparoscopic prostatectomy) were
excluded. Conference abstracts were excluded, as were non-English-language reports with the exception
of RCTs incorporating an ablative procedure comparison, for which no language restriction was applied.
Types of participants
The types of participant considered were people with localised prostate cancer, defined as cancer
confined to the prostate gland. Eligible patients had clinical stage T1 or T2 disease at presentation
(not pathological staging).
We planned to stratify people into localised low/intermediate risk and localised high risk of progression,
based on the criteria shown in Table 3 (adapted from D’Amico risk stratification).69
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
The criteria for assessing the patient’s risk of recurrent disease were the same for primary or salvage
treatment. For studies with patients of mixed clinical stages (i.e. T1 to T4), studies were included if greater
than 80% of the patients were stage T1 or T2. Additionally, for the salvage therapy review the patients
must have received EBRT prior to salvage therapy being considered. Studies of people with locally
advanced prostate cancer (considered as stage T3/T4) were excluded.
Although the systematic reviews of primary treatment of localised low-/intermediate-/high-risk prostate
cancer and salvage therapy relate to subsets of T1 and T2 disease, we included any studies that reported
comparative data on T1 and/or T2 disease. This reflects the observation during scoping (and our experience
of conducting such reviews in prostate cancer) that many studies do not report outcomes by the substages
of T1 or T2 disease. Given the difficulty in attributing studies to subsets of T1 and T2 disease, it was not
possible to undertake analyses of subsets on risk.
For the primary review, studies were included if patients were fit for surgery. Where studies enrolled
patients for both primary and salvage procedures and reported combined results, the study was eligible if
5% or less of the study population were salvage patients.
For the salvage review, studies were included if at least 80% of all salvage patients had received prior
treatment with EBRT.
Types of interventions and comparators
For the primary therapy systematic review on low-/intermediate-risk localised prostate cancer, the ablative
therapies considered were cryotherapy, HIFU, PDT, RITA, laser ablation and brachytherapy. The comparators
were AS, RP and EBRT.
For the primary therapy systematic review on high-risk localised prostate cancer, the ablative therapies
considered were cryotherapy, HIFU, PDT, RITA, laser ablation and brachytherapy. The comparators
were RP and EBRT.
For the salvage therapy systematic review, the ablative therapies considered were cryotherapy and HIFU.
The comparator was RP.
Types of outcome measures
In addition to contacting content experts to identify outcomes of importance, we also elicited the views of
a group of people living with prostate cancer. The group consisted of seven male participants who had
undergone ablative therapy (HIFU), robotic, laparoscopic and open RP, and radiotherapy. The participants
were invited to join a group discussion and express their own opinions on the choice of relevant outcomes
following treatment for localised prostate cancer. They were recruited through a local Urological Cancer
Charity (UCAN) and were not aware of the views of the content experts.
On the whole, the participants were in agreement with the content experts as to the key outcomes of
importance. For example, clear primary importance was placed on survival and recurrence (cancer-specific
outcomes). Several people commented that other outcomes were irrelevant in the event of death. Survival
TABLE 3 Risk stratification for people with localised prostate cancer69
Group PSA (ng/ml) Gleason score (0–10) Clinical stage
Low risk < 10 and ≤ 6 and T1–T2a
Intermediate risk 10–20 or 7 or T2b–T2c
High risk > 20 or 8–10 and T2c or lower
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was deemed the most important outcome, but some noted that, in the context of localised disease, they
assume that they will survive the cancer and so other outcomes then take on more importance. The
interaction between survival, recurrence, progression and treatment success was also considered important
in treatment decision-making.
Other outcomes that were highlighted as being meaningful to all of the participants were urinary
incontinence and erectile dysfunction, followed by quality of life. Outcomes that were mentioned by some
of the participants were catheterisation, urethral stricture, Peyronie’s disease, length of hospital stay, faecal
incontinence, rectal itching and bleeding, emptying the bladder when ejaculating, having to travel for
treatment, getting ‘back to normal’ and recovery times. Financial cost to the NHS was not deemed to be of
high importance.
The outcomes considered in this assessment were categorised as follows:
l cancer related
¢ biochemical (PSA) recurrence (primary cancer-related outcome)43
¢ disease-free survival, defined as the absence of clinically detectable disease in a surviving patient
¢ overall survival
¢ further prostate cancer treatment
l adverse effects: functional outcomes
¢ sexual (penile erection) function, defined by validated score [such as the International Index of
Erectile Function-5 (IIEF-5)], or as defined by the triallists
¢ urinary continence, defined, for example, as ≤ 1 thin pad per day and/or by validated symptom
score [such as the International Consultation on Incontinence Modular Questionnaire – Urinary
Incontinence (ICIQ-UI)], or as defined by the triallists
l quality of life
¢ generic and disease-specific quality of life [validated quality of life score such as the Short Form
questionnaire-36 items (SF-36)]88
l procedural
¢ length of hospital stay (if applicable)
¢ abandonment of the procedure
l adverse events: procedural complications and early death
¢ including, but not restricted to, urethral sloughing, rectourethral fistula formation, urethral stricture
formation, acute urinary retention, dysuria, pelvic pain, rectal injury, perioperative death, and
periprocedural death and Clavien score (if applicable).
Exclusion criteria
The following types of report were excluded:
l reports focusing on people with metastatic disease
l non-English-language reports of non-randomised studies
l conference abstracts
l reports of retrospective studies of AS.
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Data extraction strategy
Two reviewers independently screened titles and abstracts of all citations identified by the search
strategies. Full-text copies of all potentially relevant reports were obtained and independently assessed by
two reviewers to determine whether or not they met the predefined inclusion criteria. Any disagreements
were resolved by consensus or arbitration by a third person. A data extraction form was developed
specifically for the purpose of this assessment to collect information on study design, characteristics of
participants, characteristics of interventions and outcome measures. For studies reporting adverse events,
surgeons categorised each complication using the Clavien–Dindo Classification of Surgical Complications,80
with a third surgeon acting as arbiter in cases of disagreement about classification.
Quality assessment strategy
Risk of bias
Experience has demonstrated that multiple quality assessment tools are required for systematic reviews
where multiple study designs are considered. One reviewer assessed the quality of included studies using
one of three prespecified checklists, depending on study design. The standard Cochrane risk-of-bias tool89
was used to assess the risk of bias in randomised trials, and the risk-of-bias tool recommended by the
Cochrane Non-Randomised Studies Methods Group was used for NRCSs.89 For NRCSs, the main
confounders were identified a priori by the expert panel (by outcome). A study was considered to be
at high risk of bias if any of the confounders were imbalanced (e.g. age or D’Amico risk). We developed a
case series tool for assessing risk of bias through our partnership in the Review Body for Interventional
Procedures for NICE.90–93 The case series tool rates bias and generalisability, sample definition and selection,
description of the intervention, outcome assessment, adequacy of follow-up and performance of the
analysis. Discrepancies were resolved by discussion or referred to a third party. Copies of the risk-of-bias
tools are given in Appendices 3–5.
Data analysis
Data from each study were tabulated and summarised for each procedure in a form appropriate for the
data and the meta-analysis. If data were only available from Kaplan–Meier graphs, they were extracted
from the graphs using Engauge Digitizer version 4.1 (http://digitizer.sourceforge.net/) and transformed into
outcomes using methods proposed by Tierney and colleagues.94 The lack of RCT evidence precluded
undertaking any standard two-group meta-analyses; therefore, an indirect comparison (cross-design)
approach allowing inclusion of non-randomised comparative data and case series was adopted.95 The main
parameters in the models for dichotomous outcomes are the logarithm of the odds ratios (log-ORs) of each
ablative procedure compared with the reference comparative procedures. Models were run in a pairwise
fashion for each ablative procedure against each comparative procedure; this was repeated for each
outcome where studies had reported data that facilitated meta-analysis. Odds ratios (ORs) and associated
95% central credible intervals (CrIs) were estimated between each ablative comparative procedure where
possible. An estimate of the probability of each outcome was also modelled within each ablative and
comparative procedure using a single-arm meta-analysis. This is summarised as the probability of the
outcome and 95% CrI. The CrIs reflect the degree of uncertainty around these estimated model
parameters. In the tables, for a positive outcome (i.e. overall survival), an OR of > 1 favours the ablative
procedure; for a negative outcome (i.e. biochemical failure), an OR of < 1 favours the ablative procedure.
We calculated, for each comparison made, the probability that the ablative procedure was better, denoted
by ‘p (ablative> comparator)’ in the results tables.
Vague prior distributions were used on the log-ORs of ablative procedures compared with comparative
procedures. Owing to a paucity of data, models would often not converge with a vague prior on the
between-study (random-effects) standard deviation. To ameliorate this we used an informative prior
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for the between-study standard deviation that reflected moderate between-study heterogeneity [a uniform
(0, 2) distribution]. For most outcomes, a burn-in period of 10,000 iterations was adequate to achieve
convergence and a further 10,000 samples were taken. The model parameters were estimated with Bayesian
methodology with the use of WinBUGS software version 1.4.396 (MRC Biostatistics Unit, Cambridge, UK),
using the winbugs from stata package97 in Stata 13 (StataCorp LP, College Station, TX, USA).
Pre-planned subgroup analyses
After discussion at the first expert advisory group meeting for this assessment, three subgroup analyses
were identified to be undertaken. The subgroups were:
l low risk of bias studies only
l focal ablative therapy versus EBRT or RP
l low-risk disease treated with ablative therapy versus AS.
Clinical effectiveness: overview of included studies
Number of studies identified
Title and abstract searches identified 7134 potentially relevant citations, from which 548 reports were
retrieved for full-text screening. Of these, 121 were included and 427 were excluded, with reasons given in
Figure 3. Of the 121 included reports, 113 reports (88 studies) were eligible for inclusion in the review of
patients undergoing primary treatment for localised prostate cancer,36,49,52,98–207 and eight additional reports
(nine studies) were included in the review of patients undergoing salvage treatment for recurrence of local
prostate cancer following EBRT failure.208–215 In one report,120 two studies were reported, each eligible for
primary and salvage reviews; another121 reported data separately for a subset of participants who were
Abstracts identified (n = 7134)
Primary review searches, n = 6605
Supplementary searches for salvage
review, n = 529
Selected from screening
(n = 548)
Primary search, n = 508
Supplementary search,
n = 40
Excluded (n = 427)
• Inadequate sample size, n = 10
• Ineligible population, n = 136
• Unknown clinical stage, n = 51
• Ineligible intervention, n = 19
• Ineligible comparator(s), n = 49
• Pre-salvage therapy not
   EBRT or unknown, n = 17
• No useable outcome/data, n = 54
• Non-RCT non-English, n = 12
• Not a primary study, n = 59
• Non-RCT abstract, n = 9
• Discussion paper, n = 9
• Not obtained, n = 2
Included reports (n = 121a)
Primary review 113 (88 studies)
Salvage review 9 (9 studies)
FIGURE 3 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of potentially
relevant reports of identified studies and the numbers subsequently included and excluded from the clinical
effectiveness review. a, one included in both reviews.
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randomised and also for all randomised and non-randomised participants. These reports were treated as
contributing two studies each to this review. Uchida and colleagues195 was found to be related to five
other reports;183,190,192–194 Ferrer and colleagues130 was related to two reports;137,167 Shah and colleagues182
was related to Mohammed and colleagues164 and Vicini and colleagues;201 Bul and colleagues111 was
related to van den Bergh and colleagues;197 Klotz 2010146 was related to three reports;147,148,157 Selvadurai
and colleagues181 was related to van As and colleagues;196 Caso and colleagues114 was related to a
secondary report with the same lead author115 and to Polascik and colleagues;175 Truesdale and colleagues188
was related to Lambert and colleagues;152 Donnelly and colleagues125 was related to Robinson and
colleagues;179 another study by Donnelly and colleagues124 was related to three reports;177,178,180 and Paulson
and colleagues168 also published their report in German.169 Appendix 6 details the references of the included
reports and shows the linked reports, and Appendix 7 details the excluded reports.
Primary review (quantity and quality of included studies)
Number and types of studies included
Of the 88 studies, four RCTs were included in the primary review, one each comparing cryotherapy with
EBRT125 and EBRT with RP,168 and two comparing brachytherapy with RP.49,121 Forty NRCSs,36,100,101,103,105,108–110,
113,117,119,121,123,126,128,130,131,135,136,144,145,149,151,153,156,160,163,170–172,176,182,184,186,189,198,203,205–207 including 25 prospective
studies,100,101,103,108–110,113,117,121,123,128,130,144,145,149,153,156,160,163,172,176,182,184,186,198 were included in the primary review.
The method of data collection could not be determined for the study by Beyer and colleagues.105 Thirteen
studies compared brachytherapy versus EBRT,105,119,126,135,136,170–172,182,189,205–207 one brachytherapy versus
cryotherapy,203 nine brachytherapy versus RP,101,108–110,113,121,123,145,149 one AS versus EBRT versus RP,198 one
brachytherapy versus cryotherapy versus RP,160 one brachytherapy versus cryotherapy versus EBRT versus RP,128
13 brachytherapy versus EBRT versus RP36,100,117,130,131,144,151,153,156,163,176,184,186 and one brachytherapy versus
cryotherapy versus HIFU versus PDT.103 Forty-four case series,52,98,99,102,104,106,107,111,114,116,120,122,124,127,129,132–134,138–143,
146,150,154,155,158,159,161,162,166,173,174,181,185,187,188,191,195,199,202,204 including 20 prospective52,98,99,104,111,114,124,134,139–141,143,146,150,
155,161,181,187,199,202 and 13 retrospective studies,102,106,107,127,132,133,138,154,162,166,173,185,188 were included in the primary
review. Fourteen studies were case series of cryotherapy,52,102,114,122,124,129,138,139,154,158,166,188,202,204 20 of HIFU,98,99,
106,107,116,120,127,132,133,142,143,150,159,161,162,173,174,185,191,195 one of laser therapy155 and nine of AS.104,111,134,140,141,146,181,187,199
Table 4 summarises the number and types of included studies.
To further summarise the network of studies in the primary review, Table 5 is a matrix of the number of
studies in the primary review by comparison/intervention.
Two studies were considered to include potential patient overlap: Ganzer and colleagues133 derived data
from the multicentre-based @-Registry for 804 participants who were recruited between February 1993 and
July 2009 and treated with HIFU in Lyon (France), Regensburg (Germany), Como (Italy) and Montpellier
(France), while Blana and colleagues107 reported 356 HIFU participants recruited between February 1993
and October 2010 from the same registry, from nine centres. These studies were treated separately because
Blana and colleagues, in addition to similar inclusion criteria reported by Ganzer and colleagues, also
selected participants with anteroposterior prostate height of ≤ 24mm and a treated volume of > 120% of
the prostate volume, while Ganzer and colleagues also selected participants with a minimum follow-up
of 3 years. Similarly, Uchida and colleagues191 reported the results of 72 consecutive participants treated
with HIFU in different centres within an unspecified period of time. The same authors also reported data
related to 517 participants recruited between January 1999 and December 2007 from a single clinical
centre.195 These data sets were treated as two separate studies because if any patient overlap existed it was
likely to have a minor impact on meta-analyses, as the study sample sizes were significantly different.
Malcolm and colleagues160 and Hubosky and colleagues52 were, respectively, a NRCS and a case series
conducted in the same centre around the same time period. The same number of participants enrolled by
Hubosky and colleagues52 was enrolled into the cryotherapy arm of the study by Malcolm and colleagues.160
METHODS OF, AND STUDIES INCLUDED IN, THE SYSTEMATIC REVIEWS OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
TA
B
LE
4
N
u
m
b
er
an
d
ty
p
es
o
f
in
cl
u
d
ed
st
u
d
ie
s
A
S
EB
R
T
R
P
B
T
C
R
Y
O
H
IF
U
La
se
r
th
er
ap
y
PD
T
R
C
T
Pr
o
sp
ec
ti
ve
N
R
C
S
R
et
ro
sp
ec
ti
ve
N
R
C
S
N
R
C
S:
u
n
kn
o
w
n
d
at
a
co
lle
ct
io
n
Pr
o
sp
ec
ti
ve
C
S
R
et
ro
sp
ec
ti
ve
C
S
C
S:
u
n
kn
o
w
n
d
at
a
co
lle
ct
io
n
To
ta
l
✗
5
5
4
14
✗
5
8
7
20
✗
1
1
✗
9
9
✗
✗
2
9
11
✗
✗
1
1
✗
✗
1
1
✗
✗
2
10
1
13
✗
✗
1
1
✗
✗
✗
1
1
✗
✗
✗
10
3
13
✗
✗
✗
1
1
✗
✗
✗
✗
1
1
✗
✗
✗
✗
1
1 88
BT
,
br
ac
hy
th
er
ap
y;
C
RY
O
,
cr
yo
th
er
ap
y;
C
S,
ca
se
se
rie
s.
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
TA
B
LE
5
M
at
ri
x
o
f
st
u
d
ie
s
in
cl
u
d
ed
in
th
e
p
ri
m
ar
y
re
vi
ew
b
y
co
m
p
ar
is
o
n
/in
te
rv
en
ti
o
n
C
R
Y
O
B
T
H
IF
U
La
se
r
th
er
ap
y
PD
T
A
S
EB
R
T
R
P
C
RY
O
14
C
S
1
N
RC
S
(R
P*
)
1
N
RC
S
(R
P,
EB
RT
*)
1
N
RC
S
1
N
RC
S
(B
T,
H
IF
U
*)
1
RC
T
BT
1
N
RC
S
(R
P*
)
1
N
RC
S
(R
P,
EB
RT
*)
1
N
RC
S
✗
13
N
RC
Ss
13
N
RC
Ss
(R
P*
)
9
N
RC
Ss
2
RC
Ts
H
IF
U
20
C
S
La
se
r
th
er
ap
y
1
C
S
PD
T
1
N
RC
S
(B
T,
H
IF
U
*)
0
C
S
A
S
9
C
S
1
N
RC
S
(R
P*
)
EB
RT
1
RC
T
13
N
RC
Ss
13
N
RC
Ss
(R
P*
)
1
N
RC
S
(R
Pb
)
✗
1
RC
T
RP
9
N
RC
Ss
2
RC
Ts
1
RC
T
✗
BT
,
br
ac
hy
th
er
ap
y;
C
RY
O
,
cr
yo
th
er
ap
y;
C
S,
ca
se
se
rie
s.
1
N
RC
S
(R
P*
)=
1
N
RC
S
of
BT
vs
.
C
RY
O
vs
.
RP
.
1
N
RC
S
(R
P,
EB
RT
*)
=
1
N
RC
S
of
BT
vs
.
C
RY
O
vs
.
EB
RT
vs
.
RP
.
1
N
RC
S
(R
P*
)=
1
N
RC
S
of
A
S
vs
.
EB
RT
vs
.
RP
.
13
N
RC
Ss
(R
P*
)=
13
N
RC
Ss
of
BT
vs
.
EB
RT
vs
.
RP
.
1
N
RC
S
(B
T,
H
IF
U
*)
=
1
N
RC
S
of
BT
vs
.
C
RY
O
vs
.
PD
T
vs
.
H
IF
U
.
To
ta
ln
um
be
r
of
st
ud
ie
s
=
88
(4
RC
Ts
,
40
N
RC
Ss
,
44
C
S)
.
METHODS OF, AND STUDIES INCLUDED IN, THE SYSTEMATIC REVIEWS OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
However, the baseline characteristics of the patient groups were different and therefore the data sets were
considered as separate studies.
The RCTs of brachytherapy versus RP by Giberti and colleagues49 and Crook and colleagues121 were
conducted in Italy and Canada respectively; Donnelly and colleagues125 conducted a study of cryotherapy
versus EBRT in Canada, and Paulson and colleagues168 conducted a study of EBRT versus RP in the USA.
The NRCS of brachytherapy versus cryotherapy conducted by Williams and colleagues203 was set in the
USA. About two-thirds of the NRCSs of brachytherapy versus EBRT were set in the USA, while one172 was
conducted in Germany, two in Canada171,189 and two in both the Netherlands and Austria.135,136 Of nine
non-randomised studies of brachytherapy versus RP, there were three each from the USA101,110,123 and
Germany,108,109,145 and one each from France,113 Canada121 and Japan.149 The non-randomised study
of AS versus EBRT versus RP198 was conducted in the Netherlands. Both non-randomised studies of
brachytherapy versus cryotherapy versus RP were from the USA.128,160 Of 13 studies of brachytherapy
versus EBRT versus RP, 11 were conducted in the USA36,100,117,131,144,151,153,156,163,176,186 and one each in
Spain and Australia.130,184
Characteristics of study participants
A total of 72,259 study participants from 88 studies were enrolled; 26,129 had brachytherapy, 3995 had
cryotherapy, 4000 had HIFU, 12 had laser therapy, 23 had PDT, 12,547 had EBRT, 19,961 had RP and
5592 had AS. Of these, 70,804 (99%), including 25,805 brachytherapy, 3964 cryotherapy, 3997 HIFU,
12 laser therapy, 23 PDT, 5437 AS, 12,426 EBRT and 19,140 RP participants, were included in the
analyses. Table 6 shows the demographic and disease characteristics of the study participants.
Most studies reported either the mean or median age; 12 studies did not report this information.36,100,103,128,
133,150,163,168,182,203,205,207 The average age was similar across interventions.
At least half of the participants in all interventions were clinical stage T1, except in cryotherapy, where
T1 participants constituted one-fifth. T2 participants made up about one- to two-fifths across all
intervention groups.
About 20–25% of brachytherapy, cryotherapy, EBRT, RP and HIFU participants were Gleason 6, as were
the majority of AS, laser therapy and PDT participants. The proportion of participants with a Gleason score
of 7 ranged from 2.1% in AS to 22.1% in cryotherapy.
The average PSA ranged from 5.55 ng/ml in AS to 8.43 ng/ml in cryotherapy. Of those reporting PSA,
18 studies did not report it as a mean or median.36,102,103,105,108,117,123,126,129,138–140,146,187,202,203,205,206
Thirty studies reported prostate size;49,99,106,107,111,113,116,120,122,123,125–127,130,132,133,139,142,143,155,159,161,162,172–174,185,188,191,195
most studies on HIFU and laser therapy and almost half the studies on AS reported the prostate size,
whereas most of the studies on other interventions did not. The average prostate size reported ranged
from 26.5ml in HIFU to 45.0ml in RP.
Categorising studies into low-, medium- and high-risk localised disease
As the results in Table 6 illustrate, the variety of differences in reporting of clinical stage, Gleason score
and PSA made it impossible to categorise the studies according to the criteria described in Table 3.
Although the inability to categorise studies according to the risk strata had no significant effect on
comparisons including EBRT and RP, the inability to identify studies of people with low-risk localised
disease meant that no comparison with AS would have been possible. After discussion with the expert
advisory group, a pragmatic decision was made to categorise as studies of low-risk localised disease all
those in which the Gleason scores of two-thirds of the patients were Gleason 6 or less in the
ablative studies.
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Thirty-four studies36,49,101,103,105,107,109,110,116,117,119,123,126,129,135,138,151,153,155,156,160,162,170–172,174,184,186,189,198,202,205–207
met this criterion and were compared with the AS participants in a subgroup analysis. This subset of
participants included 9069 brachytherapy, 1377 cryotherapy, 5628 EBRT, 994 HIFU, 12 laser therapy,
23 PDT and 7840 RP participants at enrolment.
Focal ablative therapies
Each included ablative study was categorised depending on whether or not a focal approach was the
primary intervention.
Focal cryotherapy
Of the 19 studies on primary cryotherapy,52,102,103,114,122,124,125,128,129,138,139,154,158,160,188,202–204,216 six used a focal
ablative approach.103,129,138,166,188,202 These studies included 1394 participants at enrolment.
Focal high-intensity focused ultrasound
Of the 21 studies on primary HIFU,98,99,103,106,107,116,120,127,132,133,142,143,150,159,161,162,173,174,185,191,195 four, comprising
two studies by Ahmed and colleagues,98,99 Barret and colleagues103 and El Fegoun and colleagues,127 used
a focal ablative approach. These studies included 94 participants at enrolment.
Focal photodynamic therapy
The only study identified for PDT, Barret and colleagues,103 reported using a focal technique and included
23 participants at enrolment.
Focal brachytherapy
Of the 41 studies on brachytherapy,36,49,100,101,103,105,108–110,113,117,119,121,123,126,128,130,131,135,136,144,145,149,151,153,156,160,163,
170–172,176,182,184,186,189,203,205–207 only Barret and colleagues103 reported a focal technique and included
12 participants at enrolment.
Overview of type of outcomes reported
Efficacy
Fifty-four studies (61%) reported the rate of biochemical failure49,106,114,119,125,127,135,138,143,149,154,159,162,168,173,184,188
or control36,52,102,105,107,109,116,120,122–124,126,129,132,133,136,139,144,149–151,155,158,161,166,170,171,174,182,185,189,191,195,202,205–207 using
varying definitions and time points.
Twelve studies (14%) reported data on both overall survival and prostate cancer-specific mortality,111,125,134,
140,143,144,146,158,162,173,181,187 while an additional 10 (11%) reported either overall survival103,105,124,127,154,182 or
prostate cancer-specific mortality.101,123,171,195
Functional outcomes
Thirty-seven studies (42%) reported data on postoperative urinary incontinence status.49,52,99,102,109,110,113,114,
116,117,120,121,124,125,127,129–131,138,139,145,154,158,159,166,172,174,176,182,184–186,188,191,202–204 Twenty-seven studies (31%)
provided data on the status of urinary function or dysfunction49,52,99,103,108,114,116,121,125,127,130,131,149,150,153,155,
159–161,163,172,184–186,189,195,199 and six (7%) on unspecified urinary symptoms,49,98,145,161,189,191 while some
reported specific urinary symptoms such as frequency,114,189 nocturia,189 urgency,108,113,114,143,145,159,174,189
weak stream and incomplete emptying,121,189 and splayed stream.114 Ten studies (11%) provided data on
the status of postoperative bowel function,52,121,125,130,131,149,153,156,160,172 four studies (5%) reported faecal
incontinence109,113,182,191 and four (5%) reported bowel symptoms/problems.49,110,186,189
Thirty-three studies (38%) provided data on erectile dysfunction or the status of sexual potency.49,98–100,110,
113,114,116,117,120,121,124,125,129,138,139,141,143,154,158,159,166,174,184,185,189,191,195,198,202,203,206,207 Of these, nine studies in
eight reports also reported the status of sexual function,98,99,114,121,141,159,184,195 with an additional 14 (16%)
also providing this information.52,103,121,130,131,149,155,160,161,163,172,186,188,199
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Adverse events
Forty-three studies (49%) reported one or more adverse events as a result of the intervention.49,52,98,99,102,103,
113,114,116,120,121,124–129,138,139,142,143,150,154,155,158,159,161,166,171,172,174,182,185,188,189,191,195,202–207 The main adverse outcomes
reported were dysuria, urinary retention, urethral sloughing, infection, urethral stricture, bladder neck
stenosis, bladder contracture, bladder spasm, rectal pain, rectal bleeding and acute radiation toxicities.
Quality of life
Twenty-two studies reported quality-of-life outcomes using one or more validated tools.49,98,99,104,109,110,116,121,
124,125,130,145,149,153,159,172,176,184,191,195,198,199
Risk-of-bias/quality assessment
Forty-three studies, comprising 39 NRCSs36,100,101,103,105,108–110,113,117,119,121,123,126,130,131,135,136,144,145,149,151,153,156,160,163,
170–172,176,182,184,186,189,198,203,205–207 and 4 RCTs,49,121,125,168 were assessed for risk of bias for the primary
outcomes of this review using the Cochrane risk-of-bias tool.89 Forty-four case series were assessed for
methodological quality using the Review Body for Interventional Procedures (ReBIP) checklist.52,98,99,102,104,106,
107,111,114,116,120,122,124,127,129,132–134,138–143,146,150,154,155,158,159,161,162,166,173,174,181,185,187,188,191,195,199,202,204 One study which
reported exclusively adverse events, but not other relevant outcomes, was not assessed for risk of bias.128
Randomised controlled studies
The results of the risk-of-bias assessments for individual studies are shown in Appendix 9. The assessments
are summarised in Figures 4–8.
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FIGURE 4 Summary of risk-of-bias assessments for RCTs reporting efficacy (n= 3).
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FIGURE 5 Summary of risk-of-bias assessments for RCTs reporting urinary function (n= 2).
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FIGURE 6 Summary of risk-of-bias assessments for RCTs reporting sexual function (n= 2).
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FIGURE 8 Summary of risk-of-bias assessments for RCTs reporting quality of life (n= 2).
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FIGURE 7 Summary of risk-of-bias assessments for RCTs reporting bowel function (n= 1).
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Efficacy
Three studies were assessed for risk of bias of efficacy outcomes.49,125,168 Of these, only the study by Giberti
and colleagues49 was considered to be at low risk for sequence generation and others were unclear.
None provided adequate information for the assessment of allocation concealment.
Urinary function
Two studies were assessed for risk of bias of urinary function outcomes.49,121 The study by Giberti and
colleagues49 was considered low risk of bias for sequence generation whereas this was unclear in the study
by Crook and colleagues,121 and both were judged as unclear risk of bias for allocation concealment.
Sexual function
Two studies were assessed for risk of bias of sexual function outcomes.49,121 The study by Giberti and
colleagues49 was considered to be at low risk for sequence generation, whereas there was insufficient
information to assess sequence generation in that by Crook and colleagues121 or allocation concealment in
either study.49,121
Bowel function
Only one study49 was assessed for risk of bias of bowel function outcomes; it was considered to be at low
risk of bias for sequence generation and unclear for allocation concealment.
Quality of life
Two studies were assessed for risk of bias of quality of life outcomes.49,121 The study by Giberti and
colleagues49 was considered to be at low risk for sequence generation whereas that by Crook
and colleagues121 was unclear. Both studies were judged as unclear for allocation concealment.49,121
Non-randomised controlled studies
The results of the risk-of-bias assessments for individual studies are shown in Appendix 9. The assessments
are summarised in Figures 9–13.
Efficacy
Twenty-one studies were assessed for risk of bias of efficacy outcomes.36,101,103,105,109,119,123,126,135,136,144,149,151,
170,171,182,184,189,205–207 Of these, nine103,105,109,119,135,144,184,205,206 were considered to be at low risk of bias for
confounding and one182 was unclear.
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FIGURE 9 Summary of risk-of-bias assessments for NRCSs reporting efficacy (n= 21).
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FIGURE 10 Summary of risk-of-bias assessments for NRCSs reporting urinary function (n= 23).
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FIGURE 11 Summary of risk-of-bias assessments for NRCSs reporting sexual function (n= 21).
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FIGURE 12 Summary of risk-of-bias assessments for NRCSs reporting bowel function (n= 16).
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Urinary function
Twenty-three studies were assessed for risk of bias of urinary function outcomes.103,108–110,113,117,121,126,130,131,
145,149,153,160,163,172,176,182,184,186,189,203,206 Of these, 11109,121,130,149,153,172,176,184,186,203,206 were considered to be at
low risk of bias for confounding. The studies by Frank and colleagues131 and Shah and colleagues182
were unclear.
Sexual function
Twenty-one studies were assessed for risk of bias of sexual function outcomes.100,103,109,110,113,117,121,126,130,131,
149,160,163,172,182,186,189,198,203,206,207 Of these, seven109,130,172,184,186,189,203 were considered to be at low risk of bias
for confounding. The studies by Barret and colleagues103 and Frank and colleagues131 were unclear.
Bowel function
Sixteen studies were assessed for risk of bias of bowel function outcomes.109,110,113,117,126,130,131,149,156,160,172,184,
186,189,203,206 Of these, seven109,130,156,184,186,189,206 were considered to be at low risk of bias for confounding.
The studies by Williams and colleagues203 and Frank and colleagues131 were unclear.
Quality of life
Thirteen studies were assessed for risk of bias of quality of life outcomes.109,110,121,130,131,145,149,153,160,172,176,184,198
Of these, seven were considered to be at low risk of bias for confounding.109,121,131,149,153,172,184 The study by
Reeve176 was unclear.
Case series
The ReBIP checklist was used to assess the methodological quality of the case series. Studies with all items
scored as ‘no’ or ‘unclear’ were considered at high risk of bias. All case series included in this review were
judged as having a high risk of bias. The results of the quality assessment are summarised in Figure 14 and
further details are provided in Appendix 9.
Summary of risk-of-bias assessment in the primary review
The risk-of-bias assessment and the quality of the case series in the primary review suggested that the
included studies were generally at a high or very high risk of bias. No subgroup analysis of studies at low
risk of bias was therefore undertaken.
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FIGURE 13 Summary of risk-of-bias assessments for NRCSs reporting quality of life (n= 13).
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Salvage review (quantity and quality of included studies)
Number and types of studies included
All included studies were case series; six were studies of salvage RP,209–211,213–215 two of salvage
cryotherapy208,212 and one of salvage HIFU.120 Data were collected prospectively in three of the included
studies212,213,215 and retrospectively in a further three,120,208,211 and in the remaining studies patient enrolment
was unclear. Table 7 summarises the number and types of included studies.
The study by Chin and colleagues208 and that by Robinson and colleagues212 were conducted in Canada;
those by Gheiler and colleagues,210 Neerhut and colleagues211 and Tefilli and colleagues214 were conducted
in the USA; and those by Darras and colleagues,209 Seabra and colleagues213 and van der Poel and
colleagues215 were conducted in Belgium, Brazil and the Netherlands respectively.
Pre-operative identification of prognostic factors
Dropouts similar to completers
Information on dropouts
Adequate follow-up period
Objective (valid and reliable) outcome measures
Important outcomes considered
Adequate and appropriate facilities
Procedure carried out by experienced doctor
Clear definition of intervention
Prospective data collection
Consecutive patient selection
Similarity in disease severity
Description of eligibility criteria
Spectrum representative
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FIGURE 14 Summary of quality assessments of the case series in the primary review.
TABLE 7 Characteristics of studies included in the salvage review
Intervention Study design Data collection Number of studies
Salvage RP Single-arm cohort Prospective 2
Retrospective 3
Not reported 1
Salvage CRYO Single-arm cohort Prospective 1
Not reported 1
Salvage HIFU Single-arm cohort Not reported 1
Total 9
CRYO, cryotherapy.
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Characteristics of study participants
A total of 400 participants were enrolled in nine studies; 164 had salvage cryotherapy, 71 had salvage
HIFU and 165 had salvage RP. Three hundred and eighty-eight (388) (97%) participants, encompassing
164 salvage cryotherapy, 71 salvage HIFU and 153 salvage RP patients, were included in the final outcome
analyses. Table 8 summarises the baseline characteristics of the study participants.
The mean age of salvage cryotherapy participants was comparable with that of salvage RP participants.
All interventions were comparable in terms of participants with clinical stage T2 or less. The Gleason
scores of enrolled participants were not comparable, as the proportion of participants with Gleason scores
of 6 or less who underwent salvage RP was double that of those who underwent salvage cryotherapy,
and vice versa for participants with Gleason scores of 8 or more. There was no information on Gleason
score for participants who underwent salvage HIFU. It was not possible to comment on the PSA and
prostate size because data were limited.
TABLE 8 Summary of the characteristics of the study participants included in the salvage review, where data were
combinable, from the information reported by the study authors
Variable Salvage CRYO Salvage HIFU Salvage RP
n enrolled 164 71 165
Mean age (years) 70 63.4
n (%) 46 (28.0) 165 (100.0)
Missing/unknown, n (%) 118 (72.0) 71 (100.0)
Clinical stage, n (%)
T1 16 (9.8) 40 (24.2)
T2 134 (81.7) 111 (67.3)
≤ T2a 71 (100.0)
T3 14 (8.5) 14 (8.5)
PSA, n (%)
≤ 10 ng/ml 65 (39.6)
> 10 ng/ml 98 (59.8)
Missing/unknown 71 (100.0) 165 (100.0)
Gleason score, n (%)
≤ 6 23 (14.0) 53 (32.1)
7 23 (13.9)
8–10 24 (14.6) 9 (5.5)
Missing/unknown 117 (71.3) 71 (100.0) 80 (48.5)
Prostate size (ml) 21
n (%) 71 (100.0)
Missing/unknown, n (%) 164 (100.0) 165 (100.0)
CRYO, cryotherapy.
a Clinical stage for all patients as reported by Colombel 2006.120 This group could not be included in any other category.
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Overview of studies reporting the main outcomes of the review
Efficacy
Eight studies reported biochemical disease-free survival or treatment success using PSA level as an
indicator,120,179,208–210,213–215 two179,209 reported both the overall and prostate cancer-specific mortality and
three210,211,215 reported the prostate cancer-specific mortality only.
Functional outcomes
Five studies reported data on erectile dysfunction or potency,179,209,213–215 one reported sexual function,179
seven reported data on urinary continence or incontinence,120,208–210,213–215 one reported the urinary function
status179 and one reported the bowel function status.179
Adverse events
Seven studies presented data on adverse events;120,208–211,213,215 two reported urinary obstruction,208,213 one
reported debris sloughing,208 one reported epididymitis,210 three reported strictures,209,211,215 four reported
bladder neck contracture and stenosis,120,208–210 five reported rectourethral/rectovesical fistula,120,208,210,211,213
and one each reported rectal injury,211 vesicourethral fistula,208 ureteral fistula,210 ureteral transection,211
deep-vein thrombosis,210 prolonged postoperative ileus,211 anastomotic stone formation,211 mild acute
tubular necrosis,211 ureterovesical junction stricture and hydronephrosis,211 grade 3 rectal complaints,215
grade 4 rectal complaints,215 intraoperative complications209 and operative death.211
Quality of life
Two studies presented data on quality of life using validated tools.212,214
Quality assessment
All case series included in the salvage review were judged at high risk of bias as all methodological items
were scored as ‘no’ or ‘unclear’ on the ReBIP checklist. The results of the quality assessment are
summarised in Figure 15 and further details are provided in Appendix 9.
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FIGURE 15 Summary of quality assessments of the case series in the salvage review.
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Chapter 4 The comparative effectiveness
of cryotherapy
Included studies
The characteristics of the included studies were described in Chapter 3, and are detailed in Appendix 8 and
summarised here.
There were 3995 enrolled and 3964 analysed patients undergoing cryotherapy from 19 studies included in
the review.52,102,103,114,122,124,125,128,129,138,139,154,158,160,188,202–204,216 The studies were mainly case series,52,102,114,122,124,
129,138,139,154,158,188,202,204,216 but with one RCT of cryotherapy versus EBRT125 and one NRCS each on cryotherapy
versus brachytherapy versus EBRT versus RP,128 cryotherapy versus EBRT versus RP,160 cryotherapy versus
brachytherapy203 and cryotherapy versus brachytherapy versus HIFU versus PDT.103
Assessment of effectiveness
Details of all outcomes, including those which were used in meta-analyses, are tabulated in Appendix 10.
Cancer-related efficacy outcomes
Biochemical failure
Four studies125,138,175,188 provided data on biochemical failure following cryotherapy that could be used for
meta-analysis (Table 9). Meta-analysis of these data showed a numerically increased risk of biochemical
failure for cryotherapy compared with EBRT at all follow-up points, but this was not statistically significant
(the probability that cryotherapy was superior to EBRT for this outcome was 0.07, 0.07 and 0.38 for
years 1, 3 and 5 respectively). For the comparison with RP, cryotherapy showed a numerically decreased
risk of biochemical failure at 1 year, but an increased risk thereafter. None of the differences were
statistically significant (the probability that cryotherapy was superior to RP for this outcome was 0.60, 0.04
and 0.24 for years 1, 3 and 5 respectively). The 3-year time point had a higher number of studies
contributing to the meta-analysis and the predicted rate of biochemical failure in the mixed-treatment
comparison model at 3 years was 19% for cryotherapy, 5% for EBRT and 7% for RP.
Overall survival
Only two cryotherapy studies124,125 provided information on overall survival that could be used for
meta-analysis (Table 10). Meta-analysis of these data showed no evidence of a difference in survival
for cryotherapy compared with EBRT at 4 years (the probability that cryotherapy was superior to EBRT was
0.73). The predicted rate of survival in the mixed-treatment comparison model at 4 years was 93% for
cryotherapy and 91% for EBRT. There were no data available to estimate survival from the RP studies
at 4 years.
Disease-free survival
Seven studies involving people undergoing cryotherapy52,122,129,139,180,188,202 provided information on
disease-free survival that could be used for meta-analysis (Table 11). Meta-analysis of these data showed
a numerically lower rate of disease-free survival for people undergoing cryotherapy than for those treated
with EBRT and RP at 1 year, and this was statistically significant (the probability that cryotherapy was
superior to EBRT/RP was < 0.01). Findings for the 3-year time point were numerically similar to the 1-year
results but the comparisons were no longer statistically significant. The 1-year time point had the greater
number of studies contributing to the meta-analysis and the predicted rate of disease-free survival in the
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mixed-treatment comparison model at 1 year was 80% for cryotherapy, 99% for EBRT and 95% for RP.
These results from the meta-analysis were potentially conflicting with 4-year overall survival figures, which
demonstrated no evidence of a difference between treatment by cryotherapy and EBRT (see Table 10).
Adverse effects
Urinary function: urinary incontinence
Six studies involving people treated with cryotherapy52,114,124,138,139,202 provided information on urinary
incontinence that could be used for meta-analysis (Table 12). Meta-analysis of these data showed a
numerically decreased risk of incontinence for cryotherapy compared with EBRT at 1 year but this was not
statistically significant (the probability that the outcome favoured cryotherapy was 0.67). For comparison
with RP, cryotherapy showed a statistically significant decrease in risk of incontinence at 1 year (the
probability that cryotherapy was superior to RP was > 0.99). By 5 years, the risk of incontinence was still
numerically lower for people treated with cryotherapy, but was no longer statistically significant (the
probability that the outcome favoured cryotherapy was 0.81). The predicted rate of incontinence in the
mixed-treatment comparison model at 1 year was 3% for cryotherapy, 5% for EBRT and 66% for RP.
Sexual function: erectile dysfunction
As described in Chapter 3, Overview of type of outcomes reported, a total of 33 studies provided data
on sexual function.49,98–100,110,113,114,116,117,120,121,124,125,129,138,139,141,143,154,158,159,166,174,184,185,189,191,195,198,202,203,206,207
The time point following intervention when the outcome was assessed and the measure used to quantify
the outcome showed wide variation across the studies. Given the diversity of definitions and types of
data (continuous or dichotomous), it was not possible to collate all the data from individual studies into a
form suitable for meta-analysis. However, five studies involving people treated with cryotherapy129,138,139,175,202
provided information on erectile dysfunction that could be used for meta-analysis (Table 13). Meta-analysis
of these data showed a numerically lower rate of erectile dysfunction for people treated with cryotherapy
than for those receiving RP at 1 year, but the difference was not statistically significant (the probability that
cryotherapy was superior to RP was 0.58). The predicted rate of erectile dysfunction in the mixed-treatment
comparison model at 1 year was 18% for cryotherapy and 33% for RP. There were no data available to
estimate the rate of erectile dysfunction at 1 year in people treated with EBRT.
Bowel function
Disturbance in bowel function among people treated with cryotherapy was rarely measured as an outcome.
In the single comparative study that compared cryotherapy with EBRT,125 people treated with cryotherapy
reported a lower rate of moderate or severe bowel problems, as measured by the University of California
at Los Angeles – Prostate Cancer Index (UCLA-PCI),217 than those receiving EBRT at 1-year follow-up
(5% vs. 17%).
Procedural complications
Data on short-term adverse events related to the use of cryotherapy, including dysuria, urinary retention,
urethral sloughing, infection, stricture, bladder neck contracture, bladder spasm, rectal pain/bleeding and
fistula, are presented below. Abstracted data concerning other specific adverse events not included below
are detailed in Appendix 10. Given the variety of definitions and periods of follow-up between studies,
a degree of caution should be used in interpretation of these results.
Dysuria
One study114 provided information on the occurrence of dysuria that could be used for meta-analysis
(Table 14). Meta-analysis of these data showed a decrease in risk of dysuria for cryotherapy compared
with EBRT and RP, but this was not statistically significant (the probabilities that cryotherapy was superior
were 0.92 and 0.79 for EBRT and RP respectively). The predicted rate of dysuria in the mixed-treatment
comparison model was 2% for cryotherapy, 14% for EBRT and 6% for RP.
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Urinary retention
Eight cryotherapy studies52,103,114,138,154,188,202,203 provided information on urinary retention that could be used
for meta-analysis (Table 15). Meta-analysis of the data reporting urinary retention showed a small increase
in risk of urinary retention for cryotherapy compared with EBRT, but this was not statistically significant
(the probability that the outcome favoured cryotherapy was 0.26 for EBRT). The predicted rate of urinary
retention in the mixed-treatment comparison model was 4% for cryotherapy and 2% for EBRT. It was not
possible to estimate the rate of urinary retention after RP.
Urethral sloughing
Urethral sloughing was reported by seven studies involving people undergoing cryotherapy.52,114,125,138,139,154,204
The proportion of people suffering urethral sloughing ranged from 0%138 to 38%204 with a median of 5%.
Urethral stricture
Six studies involving people undergoing cryotherapy103,114,128,139,154,203 provided information on urethral
stricture that could be used for meta-analysis (Table 16). Meta-analysis of these data showed a similar risk
of stricture following cryotherapy compared with EBRT and this was not statistically significant (the
probability that cryotherapy was superior to EBRT was 0.34). For the comparison with RP, people treated
with cryotherapy showed a statistically significant decrease in risk of stricture (the probability that
cryotherapy was superior to RP was > 0.99). The predicted rate of stricture in the mixed-treatment
comparison model was 1% for cryotherapy, 1% for EBRT and 8% for RP.
Rectal pain and bleeding
Three studies involving people undergoing cryotherapy provided information on rectal pain114,188,203 and two
provided information on rectal bleeding.114,203 Meta-analysis of these data (Tables 17 and 18) showed a
decreased risk of these adverse events following cryotherapy compared with EBRT, but neither reached
statistical significance for rectal pain (the probabilities that cryotherapy was superior to EBRT were 0.89 and 0.94
for rectal pain and bleeding respectively). The predicted rate of rectal pain in the mixed-treatment comparison
model was 3% for cryotherapy and 9% for EBRT. It was not possible to estimate rectal pain/bleeding after RP.
Other adverse events
Data on occurrence of fistula were reported in 13 studies involving people undergoing cryotherapy.52,102,103,
114,129,138,139,154,158,166,188,202,204 The rate of fistula reporting was low and ranged from 0% in eight studies114,129,
138,139,154,166,188,204 to 6% in one.158 The median reported rate of fistula was 0%.
Bladder neck contracture was only reported in one study,204 and the rate of contracture was 11%
(8/71 patients). A single case of bladder spasm was also reported in the same study.
Rates of urinary tract infection were reported in four studies of people undergoing cryotherapy.52,114,124,138
The rate of urinary tract infection ranged from 1%52 to 6%.114
Quality of life
Only one case series of people having cryotherapy reported on quality of life outcomes.124 The data were
insufficient to enable us to assess any difference in this outcome compared with either EBRT or RP.
Further prostate cancer treatment
The need for reintervention within 2 years of initial procedure using further cryotherapy was reported by
six studies of people undergoing primary cryotherapy.114,122,125,129,154,204 The rates of reintervention ranged
from 1% to 15% with a median rate of 9% across the studies.
Within 6 months of initial treatment, Donnelly and colleagues125 reported that 11% of people treated with
cryotherapy received hormonal androgen deprivation therapy and 3% were placed in a watchful waiting
programme. In contrast, Caso and colleagues114 reported the rate of further cancer treatment using any
modality at a median follow-up of 2 years to be 12%.
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Analysis of subgroups
Focal cryotherapy
Of the 19 studies describing the results of primary cryotherapy,52,102,103,114,122,124,125,128,129,138,139,154,158,160,188,202–204,216
six used a focal ablative approach.103,129,138,166,188,202 Given the low number of studies reporting on the use of
focal cryotherapy and the diversity of outcomes reported in each study, no formal subgroup meta-analyses
could be undertaken for most of the outcomes, and therefore a descriptive summary of reported findings
in relation to the overall comparative meta-analysis is given below.
Biochemical failure
Two studies138,188 reporting on the use of focal cryotherapy contributed data for the meta-analysis of our
primary cancer-related outcome, biochemical failure. At 3-year follow-up, rerunning the mixed-treatment
comparison model using the focal studies gave a non-significant numerical increase in biochemical
failure using focal cryotherapy (OR 4.4, 95% CrI 0.5 to 39.5) versus EBRT. A similar result was observed
in the comparison with RP (OR 4.3, 95% CrI 0.35 to 53.5). These findings were consistent with those
estimated using all of the focal and non-focal studies.
Urinary incontinence
Two studies reporting the outcome of focal cryotherapy contributed to the meta-analysis of occurrence of
urinary incontinence at 1 year.138,202 The study by Ward and colleagues202 contributed the majority of
cryotherapy patients reporting on incontinence outcomes (1160 patients). The urinary incontinence rate
from both focal cryotherapy studies was less than 1%, which was lower than that reported in the
non-focal ablation studies (range from 2% to 20%). Rerunning the mixed-treatment comparison model
using the focal studies gave an OR of 0.10 (95% CrI < 0.01 to 2.0) in favour of focal cryotherapy
versus EBRT. Similarly, there was some evidence of a reduction in urinary incontinence rates using focal
cryosurgery versus RP (OR 0.01, 95% CrI < 0.01 to 0.05). There is therefore a suggestion that urinary
incontinence rates may be lower for focal cryotherapy, but caution is needed regarding this interpretation
given the high risk of bias and quantity of the data.
Erectile dysfunction
Three studies reporting the outcomes of focal cryotherapy contributed to the meta-analysis of erectile
dysfunction at 1 year.129,138,202 The rates of erectile dysfunction were 0%,138 11%202 and 40%.129 There was
no evidence of a reduction in erectile dysfunction rates using focal cryosurgery versus RP (OR 0.32,
95% CrI 0.02 to 12.6).
Procedural complications
Studies of the use of focal cryotherapy rarely reported data related to procedural adverse events. Urinary
retention rates were reported in four studies103,138,188,202 and ranged from 1.2%202 to 8%.103 The rate of
urinary retention was consistent with the modelled rate of 4% in Table 15. The number of men with
fistula was reported in all focal cryotherapy studies. Only two cases across the entire cohort of focal
cryotherapy patients were reported, and such a low rate of reported fistula was consistent with the
non-focal cryotherapy studies.
Use of cryotherapy versus active surveillance for people with low-risk
prostate cancers
As described in the methods of the systematic review (see Chapter 3), any comparison with AS
necessitated that the included studies contained low-risk patients only. Five studies reporting the outcome
of cryotherapy met the low-risk disease criteria (described in Chapter 3) for inclusion.103,129,138,160,202 The
studies variably reported comparative outcomes of overall survival, functional outcomes (urinary
incontinence and erectile dysfunction), quality of life and need for further cancer treatment.
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Overall survival
None of the studies involving people undergoing cryotherapy for low-risk disease reported data for overall
survival that could be compared with the included AS studies. Four AS studies reported the proportion
surviving at 4 years as 92%,146 94%,140 96%181 and 99%111 respectively.
Functional outcomes
No data on urinary incontinence were reported in the included studies of people under AS. Three studies
of people with low-risk disease treated with cryotherapy129,138,202 and one of people under AS141 provided
information on erectile dysfunction that could be used for meta-analysis (Table 19). Meta-analysis of these
data showed no statistical evidence of a difference in reported rate of erectile dysfunction at 1 year after
cryotherapy compared with AS (the probability that cryotherapy was superior to AS was 0.41). The
predicted rate of erectile dysfunction in the mixed-treatment comparison model at 1 year for people with
low-risk prostate cancer was 11% for cryotherapy and 5% for AS.
Quality of life
Health status (quality of life) was measured in two studies of people under AS, one using the SF-36199 and
the other measuring anxiety using the State Trait Anxiety Inventory General Anxiety Measure.198 Neither
measure was used in any of the studies where men were treated with cryotherapy, preventing any
comparison (see Appendix 10, Table 88 for full details).
Need for further cancer treatment
Data on outcomes related to further cancer treatment were reported in six studies of people enrolled
in an AS programme.111,134,140,146,181,187 At 1-year follow-up of 2494 people enrolled in an AS programme,
Bul and colleagues111 reported that 21% received a prostate cancer therapy (10% RP, 10% EBRT).
Two studies reported the rate of prostate cancer treatment at 3 years, with rates of 33%187 and 14%.140
Five-year follow-up data were reported in one study,181 with 31% of people initially under AS switching to
a prostate cancer treatment (19% EBRT or hormone therapy, 9% RP, 2% brachytherapy). Finally, after
6 years of follow-up, two studies reported rates of prostate cancer treatment as being 37% (curative aim:
24% RP, 7% EBRT; palliative aim: 5% hormone therapy)134 and 30% (curative aim: 8% RP, 20% EBRT;
palliative aim: 2% hormone therapy).146
Only one of these studies involved UK people.181 The 5-year follow-up data described above may therefore
be the closest representation of treatment implications in the NHS of using a strategy of AS for people
with low-risk prostate cancer, but there must be caution in extrapolating results from a single study at high
risk of bias. The AS protocol in the single UK study consisted of clinical assessment, with DRE and serum
PSA levels taken at 3-month intervals in the first year, 4-month intervals in the second year and 6-month
intervals thereafter. TRUS-guided prostate biopsy was repeated after 18–24 months of AS, and every
2 years thereafter. Treatment modality was selected according to local protocol, clinician judgement and
patient preference.
TABLE 19 Erectile dysfunction at 1 year (AS)
Year Cryotherapy, proportion (95% CrI) AS, proportion (95% CrI)
Cryotherapy vs. AS
OR (95% CrI) p(cryotherapy>AS)
1 0.11 (0.01 to 0.41) 0.05 (< 0.01 to 0.39) 1.51 (0.09 to 615) 0.41
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Summary and conclusions from the evidence of the
comparative effectiveness of cryotherapy
This review considered data from 3995 patients who received cryotherapy across 19 studies (14 case
series,52,102,114,122,124,129,138,139,154,158,166,188,202,204 one RCT125 and four NRCSs103,128,160,203), with most studies
considered to be at high risk of bias. Results should be interpreted cautiously to reflect the very poor
quality of the evidence base and the variation in definition of many of the outcomes. There were limited
published data on long-term efficacy of cryotherapy in achieving lower rates of morbidity and mortality
compared with the standard options of RP and EBRT.
We found conflicting evidence relating to cancer-specific outcomes in the short term when cryotherapy is
compared with either EBRT or surgery. The only finding that reached statistical significance was 1-year
disease-free survival, which was worse for cryotherapy than for either EBRT or RP. However, none of the
other cancer-specific outcomes, such as biochemical failure or overall survival, showed any significant
differences. In fact, there was conflicting evidence relating to overall survival, with cryotherapy having a
numerically better outcome than EBRT, although the difference did not reach statistical significance.
As such, the findings in relation to cancer-specific outcomes are best regarded as inconclusive, and there
is no robust evidence to suggest that mortality or other cancer-specific outcomes are different between
cryotherapy and either EBRT or RP for people treated for localised prostate cancer.
There was evidence that the rate of urinary incontinence at 1 year was lower for people undergoing
cryotherapy than for RP, but the size of the difference decreased with longer follow-up. Similarly, there
was a reduction in erectile dysfunction following cryotherapy at 1 year. There were insufficient data to
draw any conclusions on bowel problems.
There was a general trend for cryotherapy to have fewer procedural complications, apart from urinary
retention. The difference reached statistical significance for stricture when compared with RP and the
findings favoured cryotherapy.
Descriptive subgroup assessment restricted to studies reporting the use of focal cryotherapy was limited,
but suggested that cancer-specific outcomes were at least comparable with those reported by full-gland
cryotherapy studies. Urinary incontinence rates may be lower following focal cryotherapy, but a degree of
caution is needed in light of the poor quality and quantity of the data.
It was not possible to compare the efficacy of cryotherapy with a programme of AS, apart from the rate of
erectile dysfunction at 12 months, which showed no statistically significant difference.
In conclusion, the results of this review and meta-analysis were associated with a large degree of
uncertainty due to the poor study quality and restricted number of studies identified. There was a lack of
use of long-term direct measures of effectiveness and a serious lack of prospective comparative studies.
The rates of short-term adverse events were, in general, favourable towards cryotherapy. The comparative
effectiveness of cryotherapy against either EBRT or RP remains unclear.
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Chapter 5 The comparative effectiveness of
high-intensity focused ultrasound
Included studies
The characteristics of the included studies were described in Chapter 3, and are detailed in Appendix 8 and
summarised here.
There were 4000 enrolled and 3997 analysed patients undergoing HIFU from 21 studies included in the
review.98,99,103,106,107,116,120,127,132,133,142,143,150,159,161,162,173,174,185,191,195 The studies were predominantly case series,
but with one NRCS on HIFU versus cryotherapy versus brachytherapy versus PDT.103
Assessment of effectiveness
A detailed description of all outcomes, including those which were used in meta-analyses, is provided in
Appendix 10.
Cancer-related efficacy outcomes
Biochemical failure
Four studies106,159,162,173 provided data on biochemical failure following HIFU that could be used for
meta-analysis (Table 20). Meta-analysis of these data showed a numerically increased risk of biochemical
failure for HIFU compared with EBRT at 1-year follow-up, which was statistically significant (21% for HIFU
vs. 1.3% for EBRT, with a probability of 0.007 of HIFU being superior to EBRT). However, at 5-year
follow-up, the differences were no longer statistically significant (the probability that HIFU was superior to
EBRT was 0.039 at 5-year follow-up). For the comparison with RP, HIFU showed a numerically increased
risk of biochemical failure at 1 and 5 years. None of the differences were statistically significant (the
probabilities that HIFU was superior to RP were 0.097 and 0.106 for years 1 and 5 respectively). The 5-year
follow-up had the higher number of studies contributing to the meta-analysis, and the predicted rate of
biochemical failure in the mixed-treatment comparison model at 5 years was 34% for HIFU, 13% for EBRT
and 11% for RP. A degree of caution is required in interpreting these findings given that none of the
studies were comparative.
Overall survival
Only two studies162,173 provided data on overall survival following HIFU that could be used for meta-analysis
(Table 21). Meta-analysis of these data showed evidence of improved survival for HIFU compared with
EBRT at 4 years (the probability that HIFU was superior to EBRT was 0.98). The predicted rate of survival in
the mixed-treatment comparison model at 4 years was 99% for HIFU, 91% for EBRT. There were no data
available to estimate survival from the RP studies at 4 years.
Disease-free survival
Five studies107,132,133,161,191 provided data on disease-free survival following HIFU that could be used for
meta-analysis (Table 22). Meta-analysis of these data showed a lower rate of disease-free survival for HIFU
than for EBRT at 1 year and this was statistically significant (the probability that HIFU was superior to EBRT
was < 0.01). There was no evidence of a difference between HIFU and RP at 1 year. Findings for the
3-year follow-up were numerically similar, but the results were no longer statistically significant. The 3-year
follow-up had the higher number of studies contributing to the meta-analysis and the predicted rate of
disease-free survival in the mixed-treatment comparison model at 1 year was 88% for HIFU, 95% for EBRT
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and 90% for RP. As shown in Table 6 (see Chapter 3), the observed differences may reflect a higher-severity
disease profile at baseline in the HIFU studies compared with EBRT.
Adverse effects
Urinary function: urinary incontinence
Four studies116,120,159,174 provided data on urinary incontinence following HIFU that could be used for
meta-analysis (Table 23). Meta-analysis of these data showed a numerically increased risk of incontinence
for HIFU compared with EBRT at 1 year, but this was not statistically significant (the probability that
HIFU was superior to EBRT was 0.18). For the comparison with RP, HIFU showed a statistically significant
decrease in risk of incontinence at 1 year (the probability that HIFU was superior to RP was > 0.99).
By 5 years, the risk of incontinence was numerically larger for HIFU, but was not statistically significant
(the probability that HIFU was superior to RP was 0.38). The predicted rate of incontinence in the
mixed-treatment comparison model at 1 year was 10% for HIFU, 5% for EBRT and 66% for RP.
Sexual function: erectile dysfunction
As described in Chapter 3, Overview of type of outcomes reported, a total of 33 studies provided data
on sexual function.49,98–100,110,113,114,116,117,120,121,124,125,129,138,139,141,143,154,158,159,166,174,184,185,189,191,195,198,202,203,206,207
The time point following intervention when the outcome was assessed and the measure used to quantify
the outcome showed wide variation across the studies. Given the diversity of definitions and types of
data (continuous or dichotomous), it was not possible to collate all the data from individual studies into a form
suitable for meta-analysis. However, two studies185,191 provided information on erectile dysfunction following
HIFU that could be used for meta-analysis (Table 24). Meta-analysis of these data showed a numerical
reduction in rates of erectile dysfunction following HIFU compared with RP at 1 year, but the difference was
not statistically significant (the probability that HIFU was superior to RP was 0.72). The predicted rate of erectile
dysfunction in the mixed-treatment comparison model at 1 year was 23% for HIFU and 33% for RP. There
were no data available to estimate the rate of erectile dysfunction at 1 year in people treated with EBRT.
Bowel function
Bowel function following HIFU was only reported in one study.191 Uchida and colleagues191 reported a
single case of stool incontinence in 72 people.
Procedural complications
Data on short-term adverse events related to the use of HIFU, including dysuria, urinary retention, urethral
sloughing, infection, stricture, bladder neck contracture, bladder spasm, rectal pain/bleeding and fistula,
are presented below. Abstracted data concerning other specific adverse events not included below are
detailed in Appendix 10. Given the variety of definitions and periods of follow-up between studies, a
degree of caution should be used in interpretation of these results.
Dysuria
Three studies98,99,159 provided data on the occurrence of dysuria following HIFU that could be used for
meta-analysis (Table 25). Meta-analysis of these data showed a numerical increase in risk of dysuria
for HIFU compared with EBRT and RP, but this was not statistically significant (the probabilities that HIFU
was superior were 0.29 and 0.16 for EBRT and RP respectively). The predicted rate of dysuria in the
mixed-treatment comparison model was 20% for HIFU, 14% for EBRT and 6% for RP.
Urinary retention
Six studies99,103,127,150,159,185 provided information on urinary retention following HIFU that could be used for
meta-analysis (Table 26). Meta-analysis of these data showed a numerical increase in risk of urinary
retention for HIFU compared with EBRT, but this was not statistically significant (the probability that HIFU
was superior to EBRT was 0.08). The predicted rate of urinary retention in the mixed-treatment comparison
model was 10% for HIFU and 2% for EBRT. There were no data available to estimate the rate of urinary
retention after RP.
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Urethral sloughing
Urethral sloughing was reported by three studies of people undergoing HIFU.99,120,174 The proportion of
people suffering with urethral sloughing ranged from 4%120 to 34%.99
Urethral stricture
Eight studies98,127,143,150,159,174,185,191 provided information on stricture following HIFU that could be used for
meta-analysis (Table 27). Meta-analysis of these data showed a numerical increase in risk of stricture
for HIFU compared with EBRT and this was statistically significant (the probability that HIFU was superior
to EBRT was 0.01). HIFU showed no evidence of a difference in risk of stricture compared with RP (the
probability that HIFU was superior to RP was 0.36). The predicted rate of stricture in the mixed-treatment
comparison model was 8% for HIFU, 1% for EBRT and 8% for RP.
Rectal pain and bleeding
Only one study provided information on rectal pain and rectal bleeding following HIFU.159 Meta-analysis of
the data reporting rectal pain and bleeding (Tables 28 and 29) showed no evidence of a difference in risk
for HIFU compared with EBRT. The predicted rate of rectal pain in the mixed-treatment comparison model
was 11% for HIFU and 9% for EBRT. There were no data available to estimate rectal pain/bleeding
after RP.
Other adverse events
Data on the occurrence of fistula following HIFU were reported in six studies.98,143,150,159,161,185 The rate of
fistula occurrence was low and ranged from 0% in two studies98,143 to 5% in one study.150 The median
reported rate of fistula occurrence was 1%.
Bladder neck contracture was reported in three studies,120,150,185 and the rates of contracture were 0%,150
10%185 and 14%120 respectively. A single case of bladder spasm was reported by Koch and colleagues.150
Rates of urinary infection were reported in nine studies of people undergoing HIFU.99,116,127,142,150,159,161,185,191
The rate of urinary infection ranged from 0.6%161 to 45%.150 The median rate of urinary infection
was 15%.
Quality of life
Two case series of people undergoing HIFU reported on a variety of quality of life outcomes,98,195 but none
of the measures were the same between studies. The data were, therefore, insufficient to inform on any
difference in quality of life following HIFU compared with either EBRT or RP (see Appendix 10, Table 88,
for full details).
Further prostate cancer treatment
The need for reintervention using further HIFU within 2 years of initial procedure was reported in three
studies of people undergoing HIFU.116,161,173 The rates of reintervention were 3%,173 12%161 and 31%116
respectively.
Within 6 months of initial treatment, Pinthus and colleagues173 reported that 1% of patients treated with
HIFU received hormonal androgen deprivation therapy and 7% were placed in an AS programme;
1.5% received RP and 1% EBRT. At 4 years, Misrai and colleagues162 reported that 12% received EBRT,
6% received hormonal androgen deprivation therapy and 1% received RP. In contrast, at 8 years,
Sumitomo and colleagues185 reported that 2% received EBRT, 22% received hormonal androgen
deprivation therapy and 2% received RP.
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Analysis of subgroups
Focal high-intensity focused ultrasound
Of the 21 studies reporting outcomes in people receiving HIFU,98,99,103,106,107,116,120,127,132,133,142,143,150,159,161,162,173,
174,185,191,195 four used a focal HIFU approach.98,99,103,127 Given the low number of studies reporting on the use
of focal HIFU and the diversity of outcomes reported in each study, no formal subgroup meta-analyses
could be undertaken, and therefore a descriptive summary of reported findings in relation to the overall
comparative meta-analysis is given.
Cancer-related efficacy outcomes
No focal HIFU studies reported cancer-related efficacy data (biochemical failure, overall survival and
disease-free survival) that could be compared with non-focal HIFU studies.
Incontinence or erectile dysfunction
No focal HIFU studies reported data on incontinence or erectile dysfunction that could be compared with
non-focal HIFU studies.
Procedural complications
The focal HIFU studies reported data related to procedural adverse events. The dysuria rates were 22%99
and 30%98 in the focal HIFU studies, which were numerically higher than the pooled rate of 20% reported
in Table 25. Urinary retention rates were 2%,99 8%127 and 24%,103 which were broadly similar to the
pooled estimate of 10% in Table 26. Twenty-four per cent of people had urethral sloughing,99 which
was the highest rate across all the included HIFU studies. An infection rate of 17% was reported in two
focal HIFU studies,99,127 which was broadly similar to the median infection rate of all HIFU studies. Only
three cases of stricture were reported across the cohort of focal HIFU patients, and such a low number of
strictures was consistent with the non-focal HIFU studies.
Use of high-intensity focused ultrasound versus active surveillance for
people with low-risk prostate cancer
As described in the methods of the systematic review (see Chapter 3), any comparison with AS necessitated
that the included studies contained low-risk patients only. Two studies of people following HIFU met the
low-risk patient criterion for inclusion.116,162 The studies variably reported comparative outcomes of overall
survival, functional outcomes (urinary incontinence and erectile dysfunction), quality of life and need for
further cancer treatment.
Overall survival
One study162 on people following HIFU reported data for overall survival at 4-year follow-up that could be
compared with the included AS studies (Table 30). Meta-analysis of these data showed a numerical
difference in survival for HIFU compared with AS at 4 years, but was not statistically significant (the
probability that HIFU was superior to AS was 0.84). The predicted rate of survival in the mixed-treatment
comparison model at 4 years was > 99% for HIFU and 95% for AS.
Functional outcomes
No data on urinary incontinence were reported in the included studies of people on AS. One study116 of
people following HIFU and two studies141,198 of people on AS provided information on erectile function that
could be used for meta-analysis (Table 31). Meta-analysis of the data showed no evidence of a difference
in erectile dysfunction at 1 year for HIFU compared with AS (the probability that HIFU was superior to AS
was 0.71). The predicted rate of erectile function in the mixed-treatment comparison model at 1 year was
65% for HIFU and 74% for AS.
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Quality of life
Health status (quality of life) was measured in two studies of people under AS, one using the SF-36199 and
the other measuring anxiety using the State Trait Anxiety Inventory General Anxiety Measure.198 Neither
measure was used in any of the studies in which people were treated with HIFU, preventing any comparison.
Need for further cancer treatment
Data related to the need for further cancer treatment in AS studies were described in Chapter 4 (see Use
of cryotherapy versus active surveillance for people with low-risk prostate cancers).
Summary and conclusions from the evidence of the comparative
effectiveness of high-intensity focused ultrasound
This review considered data from 4000 patients who received HIFU across 21 studies (20 case series,98,99,106,
107,116,120,127,132,133,142,143,150,159,161,162,173,174,185,191,195 one NRCS103), with all studies considered to be at high risk of
bias. Results should, therefore, be interpreted cautiously to reflect the very poor quality of the evidence
base and the variation in definition of many of the outcomes. There were limited published data on the
long-term efficacy of HIFU in achieving lower rates of morbidity and mortality compared with the standard
options of RP and EBRT.
In the short term, there was some evidence that biochemical failure rates increased at 1 year when using
HIFU compared with EBRT, and the difference was statistically significant. However, this was no longer
statistically significant at 5 years. Similar findings were observed with regard to disease-free survival at
1 year, with a worse outcome for HIFU than for EBRT, which was statistically significant. The difference
was no longer significant at 3 years. The biochemical result was in contrast to the overall survival which
suggested that at 4 years HIFU had statistically significantly better survival. The early difference in
biochemical failure may have been a reflection that participants in the EBRT studies in general had
lower-risk prostate cancer at baseline than those in the HIFU studies that reported biochemical failure
rates. There was no evidence of a difference in cancer-specific outcomes for HIFU versus RP.
There were insufficient data on any of urinary incontinence, erectile dysfunction or bowel problems to
draw any robust conclusions, although at 1 year HIFU appeared to have lower incontinence rates than RP,
with the differences statistically significant. However, there were no significant differences at 5 years. The
safety profile for HIFU was generally good, apart from a potential numerical increase in urinary retention
and dysuria, but the differences did not reach statistical significance. However, HIFU appeared to have a
slightly higher incidence of urethral stricture than EBRT, and the difference was statistically significant.
Descriptive subgroup assessment restricted to studies reporting the use of focal HIFU was too limited to
draw any conclusions.
TABLE 31 Erectile function at 1 year (AS)
Outcome HIFU, proportion (95% CrI) AS, proportion (95% CrI)
HIFU vs. AS
OR (95% CrI) p(HIFU>AS)
Erectile function 0.65 (0.13 to 0.96) 0.74 (0.35 to 0.93) 0.66 (0.06 to 5.7) 0.71
TABLE 30 Meta-analysis of overall survival at 4-year follow-up (AS)
Follow-up HIFU, proportion (95% CrI) AS, proportion (95% CrI)
HIFU vs. AS
OR (95% CrI) p(HIFU>AS)
4 years > 0.99 (0.91 to > 0.99) 0.95 (0.80 to 0.99) 8.5 (0.15 to 861) 0.84
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Limited data comparing outcomes in people following HIFU with a programme of AS suggested no
evidence of a difference in either overall survival at 4 years or erectile dysfunction at 1 year.
In conclusion, the results of this review and meta-analysis were associated with a large degree of
uncertainty due to the poor study quality and restricted number of studies identified. There was a lack
of use of long-term direct measures of effectiveness and a lack of prospective comparative studies. The
comparative effectiveness of HIFU against either EBRT or RP remains unclear.
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Chapter 6 The comparative effectiveness
of brachytherapy
Included studies
The characteristics of the included studies were described in Chapter 3, and are detailed in Appendix 8 and
summarised here.
There were 26,129 enrolled and 25,805 analysed patients undergoing brachytherapy from 41 studies
(40 reports) included in the review.36,49,100,101,103,105,108–110,113,117,119,121,123,126,128,130,131,135,136,144,145,149,151,153,156,160,163,
170–172,176,182,184,186,189,203,205–207 The studies were predominantly non-randomised studies: nine on brachytherapy
versus RP,101,108–110,113,121,123,145,149 13 on brachytherapy versus EBRT,105,119,126,135,136,170–172,182,189,205–207 13 on
brachytherapy versus EBRT versus RP,36,100,117,130,131,144,151,153,156,163,176,184,186 one study128 on brachytherapy
versus cryotherapy versus EBRT versus RP, one on brachytherapy versus cryotherapy versus RP,160 one on
brachytherapy versus cryotherapy versus HIFU versus PDT103 and one on brachytherapy versus cryotherapy.203
There were two RCTs on brachytherapy versus RP.49,121
Assessment of effectiveness
A detailed description of all outcomes, including those which were used in meta-analyses, is provided in
Appendix 10.
Cancer-related efficacy outcomes
Biochemical failure
Seven studies49,112,119,135,149,184,206 provided data on biochemical failure following brachytherapy that could be
used for meta-analysis (Table 32). Meta-analysis of these data showed a numerically decreased risk of
biochemical failure for brachytherapy compared with EBRT at 1-, 3- and 5-year follow-up and this was
statistically significant at 5 years (the probability that brachytherapy was superior to EBRT for this outcome
was > 0.99 for 5-year follow-up). For the comparison with RP, brachytherapy showed a numerically
decreased risk of biochemical failure at 1, 3 and 5 years. All of the differences were statistically significant
(the probabilities that brachytherapy was superior to RP for this outcome were 0.99, 0.99 and > 0.99 for
years 1, 3 and 5 respectively). The 5-year time point had a higher number of studies contributing to the
meta-analysis and the predicted rate of biochemical failure in the mixed-treatment comparison model at
5 years was 7% for brachytherapy, 13% for EBRT and 11% for RP.
Overall survival
There were no studies that provided information on overall survival that could be used for meta-analysis.
The largest NRCS with longer-term follow-up144 reported 10-year survival of 81.7% [95% confidence
interval (CI) 78.7% to 84.4%] for brachytherapy, 82.6% (95% CI 79.8% to 85.0%) for EBRT and 88.9%
(95% CI 87.5% to 90.1%) for RP.
Disease-free survival
Twelve studies involving people undergoing brachytherapy36,49,109,119,126,135,136,151,170,171,204,206 provided
information on disease-free survival that could be used for meta-analysis (Table 33). Meta-analysis of these
data showed a higher rate of disease-free survival for people undergoing brachytherapy than for those
treated with EBRT and RP at 1 and 3 years, and this was statistically significant (the probability that
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brachytherapy was superior to EBRT/RP was > 0.99). The 3-year time point had the greater number of studies
contributing to the meta-analysis and the predicted rate of disease-free survival in the mixed-treatment
comparison model at 3 years was 96% for brachytherapy, 95% for EBRT and 90% for RP.
Adverse effects
Urinary function: urinary incontinence
Six studies involving people treated with brachytherapy49,117,121,145,172,184 provided information on urinary
incontinence that could be used for meta-analysis (Table 34). Meta-analysis of these data showed a
numerically increased risk of incontinence for brachytherapy compared with EBRT at 1 year, but this was not
statistically significant (the probability that the outcome favoured brachytherapy was 0.09). For comparison
with RP, brachytherapy showed a statistically significant decrease in risk of incontinence at 1 year (the
probability that brachytherapy was superior to RP was 0.94). By 5 years, the risk of incontinence was still
numerically lower for people treated with brachytherapy and statistically significant (the probability that the
outcome favoured brachytherapy was > 0.99). The predicted rate of incontinence in the mixed-treatment
comparison model at 3 years was 11% for brachytherapy, 10% for EBRT and 28% for RP.
Sexual function: erectile dysfunction
As described in Chapter 3, Overview of type of outcomes reported, a total of 33 studies provided data on
sexual function.49,98–100,110,113,114,116,117,120,121,124,125,129,138,139,141,143,154,158,159,166,174,184,185,189,191,195,198,202,203,206,207 The time
point following intervention when the outcome was assessed and the measure used to quantify the outcome
showed wide variation across the studies. Given the diversity of definitions and types of data (continuous or
dichotomous), it was not possible to collate all the data from individual studies into a form suitable for
meta-analysis. However, four studies involving people treated with brachytherapy113,117,121,184 provided
information on erectile dysfunction that could be used for meta-analysis (Table 35). Meta-analysis of these
data showed a numerically lower rate of erectile dysfunction for people treated with brachytherapy than for
those receiving RP at 1, 3 and 5 years, and the difference was statistically significant at 3 and 5 years (the
probability that brachytherapy was superior to RP was > 0.99 for 3 and 5 years). Only 3-year data were
available for EBRT. Meta-analysis of these data showed a numerically lower rate of erectile dysfunction for
people treated with brachytherapy than for those treated with EBRT at 3 years, and the difference was
statistically significant (the probability that brachytherapy was superior to RP was > 0.99). The predicted rates
of erectile dysfunction in the mixed-treatment comparison model at 3 years were 60% for brachytherapy,
81% for EBRT and 88% for RP.
Bowel function
Disturbance in bowel function among people treated with brachytherapy was rarely measured as an
outcome, and when it was reported, the diversity of definitions used prevented meta-analysis. At 3-year
follow-up, two NRCSs117,184 compared brachytherapy with both EBRT and RP. In one study,184 people treated
with brachytherapy reported a lower rate of moderate or severe bowel problems as measured by the
UCLA-PCI217 at 3-year follow-up (0% vs. 14% and 35% for EBRT and RP respectively). In a second study,117
68% of people treated with brachytherapy reported bowel problems at 3-year follow-up using the Prostate
Cancer Symptom Index.217 The corresponding rates were 75% and 44% for EBRT and RP respectively.
Procedural complications
Data on short-term adverse events related to the use of brachytherapy, including dysuria, urinary retention,
infection, stricture, bladder neck contracture, rectal pain/bleeding, fistula and toxicity, are presented below.
Abstracted data concerning other specific adverse events not included below are detailed inAppendix 10.
Given the variety of definitions and periods of follow-up between studies, a degree of caution should be used
in interpretation of these results.
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Dysuria
Four studies113,121,172,182 provided information on the occurrence of dysuria that could be used for
meta-analysis (Table 36). Meta-analysis of these data showed an increase in risk of dysuria for brachytherapy
compared with EBRT which was not statistically significant (the probability that brachytherapy was superior
was 0.05). There was a statistically significant increase in risk of dysuria for brachytherapy compared with
RP (the probability that brachytherapy was superior was < 0.01). The predicted rates of dysuria in the
mixed-treatment comparison model were 22% for brachytherapy, 14% for EBRT and 6% for RP.
Urinary retention
Four studies involving people undergoing brachytherapy49,182,203,206 provided information on urinary
retention that could be used for meta-analysis (Table 37). Meta-analysis of these data showed a statistically
significant increase in risk of urinary retention among people treated with brachytherapy compared with
EBRT (the probability that brachytherapy was superior to EBRT for this outcome was < 0.01). The predicted
rates of urinary retention in the mixed-treatment comparison model were 9% for brachytherapy and 4%
for EBRT. It was not possible to estimate the rate of urinary retention after RP.
Urethral stricture
Six studies involving people undergoing brachytherapy49,126,128,182,203,206 provided information on urethral
stricture that could be used for meta-analysis (Table 38). Meta-analysis of these data showed a statistically
significant increase in risk of stricture following brachytherapy compared with EBRT (the probability
that brachytherapy was superior to EBRT was < 0.01). For the comparison with RP, people treated
with brachytherapy showed a statistically significant decrease in risk of stricture (the probability that
brachytherapy was superior to RP was > 0.99). The predicted rates of stricture in the mixed-treatment
comparison model were 4% for brachytherapy, 1% for EBRT and 8% for RP.
Rectal pain and bleeding
Four studies involving people undergoing brachytherapy provided information on rectal pain126,172,182,203 and
six provided information on rectal bleeding.113,172,182,203,206,207 Meta-analysis of these data (Tables 39 and 40)
showed a decreased risk of these adverse events following brachytherapy compared with EBRT, and this
was statistically significant for rectal pain (the probability that brachytherapy was superior to EBRT was
> 0.99). The predicted rates of rectal pain in the mixed-treatment comparison model were 5% for
brachytherapy and 9% for EBRT. It was not possible to estimate rectal pain/bleeding after RP.
Toxicity
Five studies involving people undergoing brachytherapy provided information on acute genitourinary
toxicity126,171,182,205,206 and four provided information on acute gastrointestinal toxicity.126,171,182,205
Meta-analysis of these data (Tables 41 and 42) showed a statistically significant increased risk of acute
genitourinary toxicity following brachytherapy compared with EBRT (the probability that brachytherapy was
superior to EBRT was < 0.01). There was a numerical decrease in risk of acute gastrointestinal toxicity
following brachytherapy compared with EBRT which was borderline statistically significant (the probability
that brachytherapy was superior to EBRT was 0.95).
Other adverse events
Data on occurrence of fistula were reported in only one study involving people undergoing brachytherapy203
and the rate of fistula occurrence was 0.3% (27/9985 patients).
Bladder neck contracture was only reported in one study,126 and the rate of contracture was 0.6%
(1/158 patients).
Urinary tract infection data were reported in one study of people undergoing brachytherapy203 and the rate
was 2.4% (237/9985 patients).
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Quality of life
Quality of life was not reported consistently enough across studies to perform a meta-analysis. The most
robust evidence came from a single RCT of brachytherapy versus RP.49 The patients in the study reported
similar significant decreases in some functional and symptom European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire – Core 30 (EORTC-QLQ-C30) scales after 6 months
and 1 year regardless of the treatment, and both groups of patients reported a normal global health after
1 and 5 years.
A similar pattern at 2-year follow-up was observed in the non-randomised study130 that compared people
receiving brachytherapy, RP and EBRT. Health-related quality of life (HRQoL) initially decreased across all the
treatment modalities, and made a partial recovery by 2 years (see Appendix 10, Table 88 for full details).
Further prostate cancer treatment
Within 3 months of initial treatment, Giberti and colleagues49 reported that 2.5% of people treated with
brachytherapy received hormonal androgen deprivation therapy, 2.5% received EBRT and 3% received RP.
In contrast, Pickles and colleagues171 reported a rate of hormonal androgen deprivation therapy at a
follow-up of 5 years to be 5%, compared with 8% for people who initially received EBRT.
Analysis of subgroups
Focal brachytherapy
Of the 39 studies on brachytherapy, only Barret and colleagues103 reported a focal technique and included
12 participants at enrolment and in the final outcome analyses. Given the low number of studies (and
people) reporting on the use of focal brachytherapy, no further data exploration was undertaken.
Use of brachytherapy versus active surveillance for people with low-risk
prostate cancers
As described in the methods of the systematic review (see Chapter 3), any comparison with AS necessitated
that the included studies contained low-risk patients only. Twenty-four studies reporting the outcome of
brachytherapy met the low-risk disease criterion for inclusion.36,49,101,105,109,110,117,119,123,126,135,151,153,156,160,170–172,184,
186,189,205–207 The studies variably reported comparative outcomes of overall survival, functional outcomes
(urinary incontinence and erectile dysfunction), quality of life and need for further cancer treatment.
TABLE 41 Acute genitourinary toxicity
Outcome
Brachytherapy,
proportion (95% CrI)
EBRT, proportion
(95% CrI)
Brachytherapy vs. EBRT
OR (95% CrI) p(brachytherapy> EBRT)
Acute genitourinary
toxicity
0.03
(< 0.01 to 0.09)
0.01
(< 0.01 to 0.03)
2.7
(1.8 to 4.1)
< 0.01
TABLE 42 Acute gastrointestinal toxicity
Outcome
Brachytherapy,
proportion (95% CrI)
EBRT, proportion
(95% CrI)
Brachytherapy vs. EBRT
OR (95% CrI) p(brachytherapy> EBRT)
Acute gastrointestinal
toxicity
< 0.001
(< 0.0001 to 0.004)
0.003
(< 0.001 to 0.01)
0.20
(0.01 to 1.3)
0.95
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Overall survival
None of the studies involving people undergoing brachytherapy for low-risk disease reported data for
overall survival that could be compared with the included AS studies.
Functional outcomes
No data on urinary incontinence were reported in the included studies of people under AS. Three studies
of people with low-risk disease treated with brachytherapy49,172,189 and two of people under AS141,198
provided information on erectile function that could be used for meta-analysis (Table 43). Meta-analysis of
these data showed a numerically lower chance of erectile function at 1 year after brachytherapy than
under AS (the probability that brachytherapy was superior to AS was 0.22). The predicted rates of erectile
function in the mixed-treatment comparison model at 1 year for people with low-risk prostate cancer were
52% for brachytherapy and 74% for AS.
Quality of life
Health status (quality of life) was measured in two studies of people under AS, one using the SF-36199 and
the other measuring anxiety using the State Trait Anxiety Inventory General Anxiety Measure.198 Neither
measure was used in any of the studies in which people were treated with brachytherapy, preventing
any comparison.
Need for further cancer treatment
Data related to the need for further cancer treatment in AS studies were described in Chapter 4 (see Use
of cryotherapy versus active surveillance for people with low-risk prostate cancers).
Summary and conclusions from the evidence of the
comparative effectiveness of brachytherapy
This review considered data from 26,129 patients who received brachytherapy across 41 studies
(two RCTs49,121 and 39 NRCSs36,100,101,103,105,108–110,113,117,119,121,123,126,128,130,131,135,136,144,145,149,151,153,156,160,163,170–172,176,
182,184,186,189,203,205–207), with most studies considered to be at high risk of bias. Results should be interpreted
cautiously to reflect the very poor quality of the evidence base and the variation in definition of many of
the outcomes, but the data for brachytherapy were generally more robust than for other ablative therapies.
There were limited published data on the long-term efficacy of brachytherapy in achieving lower rates of
morbidity and mortality compared with the standard options of RP and EBRT.
In the short term, we found some evidence that the rate of biochemical failure was lower for brachytherapy
than for EBRT or RP at 5-year follow-up. There was also some evidence that disease-free survival was better
for brachytherapy at 3-year follow-up. These findings should be regarded cautiously as the one RCT of
brachytherapy versus RP49 did not identify a numerical difference in either of these outcomes. Nevertheless,
there appeared to be some evidence that cancer-specific outcomes after brachytherapy were at least no
worse than after EBRT or RP.
TABLE 43 Erectile function at 1 year (AS)
Outcome
Brachytherapy,
proportion (95% CrI)
AS, proportion
(95% CrI)
Brachytherapy vs. AS
OR (95% CrI) p(brachytherapy>AS)
Erectile function 0.52 (0.19 to 0.84) 0.74 (0.35 to 0.93) 0.47 (0.05 to 3.5) 0.22
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There was evidence that the rate of urinary incontinence at up to 5 years was lower for people undergoing
brachytherapy than for those receiving RP, but the size of the difference decreased with longer follow-up.
There was also a trend towards lower erectile dysfunction rates for brachytherapy than for EBRT or RP, and
this reached statistical significance at 3-year follow-up. There were insufficient data to draw any
conclusions on bowel problems.
The findings related to procedural complications were mixed. Dysuria rates were higher for brachytherapy
and this reached statistical significance when compared with RP. Urinary retention was also statistically
significantly higher for brachytherapy when compared with EBRT. Stricture rates were higher for
brachytherapy than for EBRT, but were lower when compared with RP. The differences reached statistical
significance for stricture when compared with RP. For rectal pain, there was significant evidence that rates
were lower for brachytherapy than for EBRT. Acute genitourinary toxicity rates were statistically higher for
brachytherapy than for EBRT, but acute gastrointestinal toxicity was lower for brachytherapy, though the
difference was not statistically significant.
It was not possible to compare the efficacy of brachytherapy with a programme of AS apart from the rate
of erectile dysfunction at 12 months; the rate of erectile dysfunction was lower for AS, but this was not
statistically significant.
In conclusion, the results of this review and meta-analysis were associated with a degree of uncertainty
due to the poor quality of studies identified, but the data were generally from higher-quality studies than
the data on other ablative therapies. Although there was a lack of use of long-term direct measures of
effectiveness, there was some evidence that the short-term cancer-related effects were generally better for
brachytherapy. This review found no evidence to suggest that brachytherapy is inferior to the standard
therapies of EBRT or RP, apart from a possible increased risk of dysuria and urinary retention.
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Chapter 7 Effects of other ablative therapies
Included studies
Ablative therapies other than cryotherapy, HIFU and brachytherapy were considered separately and
grouped together under ‘other ablative therapies’. The characteristics of the included studies were
described in Chapter 3, and are detailed in Appendix 8 and summarised here.
Only two studies were included, which enrolled a total of 118 patients. One study155 was a prospective
single-arm case series involving focal laser ablative therapy (n= 12). The intervention involved interstitial
laser ablation [Indigo® OPTIMA laser system (Ethicon Endo-Surgery, Inc., Cincinnati, OH)], which was
delivered to a focal area of the prostate using TRUS guidance assisted by fusion software which linked
cancer areas within the prostate pre-identified by MRI. The ablation process was monitored in real time
using contrast-enhanced ultrasound scan. The participants all had low-risk localised prostate cancer. The
assessment of effectiveness included extended repeat biopsies at 3 and 6 months to assess the presence of
residual cancer, and assessment of urinary [International Prostate Symptom Score (I-PSS)] and erectile
function (IIEF-5 score) at 3 and 6 months.
The other study103 was a prospective NRCS (n= 106) involving four arms: focal brachytherapy (n= 12),
cryotherapy (n= 50), HIFU (n= 21) and vascular-targeted PDT (n= 23). The intervention involved using
laser probes inserted transperineally under TRUS guidance followed by injection of a photoactive substance
(padeliporfin) intravenously. The PDT procedure was set for a 20-minute illumination period whereby the
photoactive substance was activated by laser light. The participants all had low-risk localised prostate
cancer. The assessment of effectiveness included the measurement of perioperative adverse events using
the Clavien–Dindo system, measurement of urinary (I-PSS) and erectile function (IIEF-5 score), and
continence status, at 3, 6 and 12 months.
The characteristics of the included studies and study participants are summarised in Appendix 8.
Assessment of effectiveness
A detailed description of all outcomes, including those which were used in meta-analyses, is provided in
Appendix 10.
Cancer-related efficacy outcomes
Treatment failure
For focal laser ablative therapy,155 33% of patients (4/12) had treatment failure (defined as persistent
cancer on repeat prostate biopsies in treated areas 3–6 months post treatment). One of the four patients
underwent salvage RP.
The study on PDT103 did not measure cancer-related outcomes.
Functional outcomes
For focal laser ablative therapy,155 there was no significant change in urinary or erectile function at 3 and
6 months postoperatively compared with the preoperative status.
For PDT,103 at a median follow-up of 9 months, there was no difference in urinary function nor erectile
function between PDT and the other comparators (HIFU, cryotherapy and focal brachytherapy). However,
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for the intragroup comparison of patients who underwent PDT, erectile dysfunction appeared to be worse
after treatment than prior to treatment (a difference in median scores of 10 on the IIEF-5 score); the
authors did not specify whether or not this result was statistically significant. There was no difference in
urinary function between the pre- and postoperative states in patients who underwent PDT. In terms of
continence, all patients were reportedly continent postoperatively.
Adverse events
For focal laser ablative therapy,155 there were no perioperative complications. Postoperative morbidity was
minimal and self-limiting; this included perineal discomfort (25% of patients), mild haematuria (16.7% of
patients) and haematospermia (16.7% of patients).
For PDT,103 the results for treatment-related complications were not reported separately. However, all of
the reported complications involved patients who underwent either HIFU or cryotherapy; hence it is
assumed that no patients who underwent PDT had any complications.
Summary and conclusions from the evidence of the
comparative effectiveness of laser ablative therapy and
photodynamic therapy
This review considered data from two studies, enrolling 106 patients who were treated with PDT within a
four-arm non-randomised prospective study (n= 23 for PDT arm), and 12 patients who were treated with
focal laser ablative therapy within a single-arm prospective case series. Both studies were considered as
having a high risk of bias. Data were restricted to short-term outcomes, with virtually no data beyond
1 year. As a result, the findings should be interpreted with caution to reflect the very poor quality of the
evidence base. Within these limitations, the review found that focal laser ablative therapy appeared to be
reasonably effective in terms of cancer-related outcomes, with a 6-month treatment failure rate of 33%,
which is comparable with the other ablative therapies. In the short term, the technology appeared to be
associated with a reasonable functional outcome, and a low rate of adverse events. For PDT, data were
restricted to short-term functional and adverse event outcomes. There appeared to be no difference in
urinary and erectile function between PDT and the other ablative therapies (including cryotherapy, HIFU
and focal brachytherapy) following treatment, and the procedure was associated with a low risk of
adverse events.
In conclusion, the results of this review were associated with significant uncertainty due to the quality and
quantity of the evidence base. Data were restricted to short-term outcomes only and there was a lack of
good-quality prospective comparative studies. The comparative effectiveness of the newer ablative
therapies, such as laser ablation and PDT, compared with established therapies remains uncertain.
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Chapter 8 Effectiveness of salvage ablative
therapy following primary external beam radiotherapy
Included studies
The characteristics of the included studies were described in Chapter 3, and are detailed in Appendix 8 and
summarised here.
The review included nine studies120,208–215 which enrolled a total of 400 participants. All nine studies were
single-arm cohort studies. Six were studies of salvage RP,209–211,213–215 two of salvage cryotherapy208,212
and one of salvage HIFU.120 In only three of the studies were data collected prospectively.212,213,215
Assessment of effectiveness
A detailed description of all outcomes, including those which were used in meta-analyses, is provided in
Appendix 11.
Cancer-related efficacy outcomes
Only two studies on salvage ablative therapies reported on cancer-related outcomes,208,212 and both studies
involved salvage cryotherapy. In contrast, all six studies on salvage RP209–211,213–215 reported on cancer-related
outcomes. The data were limited by heterogeneity of outcome definition, different time points of outcome
measurement and different means of reporting (e.g. biochemical control vs. failure).
Biochemical disease-free survival
For salvage cryotherapy, one study208 reported a biochemical disease-free survival (defined as PSA ≤ 2 ng/ml)
ranging from 71% at 1 year to 54% at 4 years. The corresponding figures for salvage RP,215 with
biochemical disease-free survival defined as PSA ≤ 0.1 ng/ml, were 89% at 1 year and 54% at 4 years.
Biochemical control and failure
For salvage cryotherapy, the 2-year biochemical control rate was 51.6–55%, using different definitions
of biochemical control.179,208 For salvage RP, the 2-year biochemical control rate was 76%,213 and the
3-year biochemical control rate was 50%,210,214 with different definitions of biochemical control. One study
provided a 10-year estimate of biochemical failure for salvage RP of 69%.215
Overall survival
For salvage cryotherapy, only one study reported on overall survival,179 with a 2-year overall survival of
93%. For salvage RP, one study reported a 7-year overall survival of 91% (10/11 patients).209
Functional outcomes
Only three studies on salvage ablative therapies reported on functional outcomes: two studies on
salvage cryotherapy179,208 and one on salvage HIFU.120 Six studies of salvage RP reported on functional
outcomes.209–211,213–215 The data were limited by heterogeneity of outcome definition, different time points
of outcome measurement and different means of reporting (e.g. urinary continence vs. incontinence).
Urinary incontinence
For salvage cryotherapy, at a median of 18.6 months follow-up (range 3–54 months), the incontinence
rate was 20%, whereas for salvage HIFU, at 15 months’ follow-up, the incontinence rate was 7%. For
salvage RP, at a median follow up of 18–20 months, the incontinence rate ranged from 25%211 to 72%.213
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The variability in results probably reflected the heterogeneity in outcome definition, which significantly
limits the comparability of the results.
Sexual dysfunction
Using different definitions of sexual dysfunction, the sexual dysfunction rate for salvage cryotherapy212 was
68.8% at 1 year and 51.9% at 2 years. The figures for salvage RP (based on different definitions) were
81% at 1 year215 and 74% at a median of 18 months.213
Quality of life
Only one study on salvage ablative therapy reported on quality of life outcomes; this was Robinson 2006212
on salvage cryotherapy. One study on salvage RP reported on quality of life outcomes.214 The data were
limited by heterogeneity of the different quality of life measures used, different time points of outcome
measurement and different means of reporting (e.g. total score vs. individual component score).
Adverse events
Only three studies on salvage ablative therapies reported on adverse events: two studies on salvage
cryotherapy208,212 and one on salvage HIFU.120 Six studies of salvage RP reported on adverse events.209–211,213–215
For salvage cryotherapy, at a median follow-up of 18.6 months, the incidence of adverse events was relatively
low, ranging from 2% (bladder neck stenosis) to 3% (rectourethral fistula). The corresponding figure for
salvage RP, within a similar period of follow-up, was 4.8–6% (rectovesical fistula) and 3–25% (bladder neck
stenosis or anastomotic stricture). For salvage HIFU, at 15 months follow-up, the incidence of rectourethral
fistula was 6% and that of bladder neck stenosis was 17%. The data were limited by the relatively low
number of patients and low event rates.
Summary and conclusions from the evidence of the
comparative effectiveness of salvage ablative therapy
This review considered data from 400 participants treated with salvage therapy following primary EBRT across
nine studies,120,208–215 all of which were single-arm case series. Six studies involved salvage RP,209–211,213–215 two
involved salvage cryotherapy208,212 and one involved salvage HIFU.120 All of the studies were considered as
having a high risk of bias. Consequently, the findings should be interpreted cautiously to reflect the extremely
poor quality of the evidence base and the heterogeneity of outcome definition, different time points of
outcome measurement and different means of outcome reporting. Data on the long-term effectiveness
of salvage therapy were limited, with the majority of studies reporting on short-term data only.
In the short term, there was no robust evidence that mortality or other cancer-specific outcomes
(biochemical disease-free survival or failure) differed between salvage cryotherapy and salvage RP.
There were no data on cancer-specific outcomes for salvage HIFU.
With regard to functional outcomes, including urinary and sexual dysfunction and quality of life outcomes,
the limited data prevented any valid conclusions from being made.
For adverse event outcomes, therewas a general trend for salvage cryotherapy to have fewer procedure-related
complications, especially for bladder neck stenosis (up to 2% at amedian of 18.6months), in comparison with
salvage HIFU (up to 17%at amedian of 15months) and salvage RP (up to 25%at amedian of 20months).
However, the data limitations render these findings uncertain at best.
In conclusion, the results of this review on salvage therapies were associated with large uncertainty owing
to the quality and quantity of the evidence base. There was a lack of long-term direct measures of
effectiveness and a lack of prospective comparative studies. There was no evidence to suggest that salvage
ablative therapy was either better or worse than salvage RP following primary EBRT for any outcomes.
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Chapter 9 Economic evaluation methods
The objective of this chapter is to present the economic evaluation of ablative therapies for the primarytreatment of localised low-/intermediate-risk prostate cancer compared with AS, RP and EBRT. It was
originally intended that we would also seek to look at these interventions for locally recurrent disease;
however, a lack of effectiveness data, as reported in Chapter 8, has prevented any meaningful modelling.
Description of the care pathways compared
The cost-effectiveness of the different treatments and their subsequent care pathways was assessed using
a modified Markov chain simulation model. This modelling approach allowed us to model the sequence
of events that individual people would follow from their initial treatment until death. It also allowed for
differences in the characteristics of the individual people who might alter their journey through the model
to be incorporated.
The care pathways modelled within the modified Markov chain simulation model were based on care
pathways which were developed in consultation with the study team and the expert panel (Figure 16). The
main study team for this element of the work included two urologists (TL, RP), a health economist (LV) and
two biological modellers (MS, SR). Over a number of meetings, the group mapped out the sequence of
events for people potentially eligible for the interventions under consideration. Additional information
came from our previous models in this area, notably our model comparing robotic with laparoscopic RP,218
reviewed guidelines and expert opinion. These care pathways were then presented to the expert panel and
revised to reflect the comments received.
Figure 16 describes the care pathways that were modelled. As noted above, the purpose of this model was
to compare and contrast different ablative therapies for localised prostate cancer, and to compare and
contrast ablative therapies with comparative whole-gland therapies. Within Figure 16 a number of
different initial managements are specified. In the subsequent modelling (described throughout this
chapter), each of these had different monetary costs both for initial care and ongoing management, and
for treatment of subsequent events (e.g. recurrence) associated with it. In addition, the events that might
be experienced may affect not just length of life but also quality of life. Therefore, quality of life (utility)
weights were also included. Combining these data with information on the probabilities of events
occurring over time enabled cost, patient outcomes and quality-adjusted life-years (QALYs) to be estimated
for hypothetical cohorts of patients undergoing each therapy.
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Outline of the model
The model simulated the health status and treatment of a cohort of individuals. All individuals possessed
two state variables: age and severity of disease. These variables were considered of relevance to the model
given their potential effect on the clinical pathways experienced by patients. Severity was categorised as
low, intermediate or high risk according to established definitions used in the UK NHS.9
Assumptions
Most of the assumptions inherent in the modelling process were derived from definitions and estimations
of the driving parameters (see Estimation of probabilities used within the model). The importance of these
assumptions in determining model output was estimated with elasticity analysis, as described in Estimation
of utilities used within the model.
Process overview and scheduling
The structure of the simulation model is described in the care pathways constructed for all ablative and
comparative therapies for prostate cancer (Figure 16 in general and Figures 17–20). This care pathway
forms the basis of a conceptual model of the processes to be simulated, and consists of three different
elements: states, events and the transitions between them. A state is a stage in the model in which the
patient spends at least one time step. Events are stages in the network that take up less than one time
step. Each individual could therefore undergo one or more events plus a single state in each time step of
the model. Transitions are the probability that an individual passes between different states and events.
The care pathway does not claim to capture every possible patient trajectory (that is, a single route
through the care pathway), as factors connected to the patient and their health-care team may result in
treatment decisions that are unique to their individual circumstances. However, this care pathway was
scrutinised by our expert advisory group and is considered to be definitive for 95% or more of all possible
patient trajectories.
The conceptual model can be conceived as a network or graph. In mathematical terms, a network is
expressed as a set of vertices and a set of edges which connect them. In this context, the vertices were
states and events, and the edges were the transitions. This mathematical framework can be described in
terms of an adjacency matrix for this network, and this adjacency matrix served as the transition matrix to
determine the next event or state experienced in each modelled time step.
Beginning at the initial event of diagnosis, the state of each simulated patient at each time step was
determined by the transition matrix. Within a modelled time step, a patient could also experience one or
more events. Over time the patient could receive different types of therapy, experience different adverse
events or spend time in one of three surveillance states: AS which occurs before primary therapy,
surveillance which occurs after primary therapy and before biochemical failure, and follow-up surveillance
which occurs following biochemical failure and salvage treatment. The simulation ended once all patients
had entered one of the three ‘sink’ states: operative mortality, non-cancer mortality and cancer mortality.
The model employed a 6-month time step. All driving variables were probabilities that were usually
calculated as yearly probabilities (P12m); these were scaled to 6-month probabilities (P6m) thus:
P6m=1−

(1−P12m)
6
12

. (1)
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Model design
Design concepts
The model was a modified Markov chain simulation model, where subsequent status was determined by
current status multiplied by a matrix of transition probabilities. The basic design of a Markov chain model
was altered to permit the state variables (age and severity) to have an impact on driving variables
(transition probabilities).
Stochasticity
Stochasticity was incorporated into the model by simulating probabilities of changes in health status by
sampling random deviates from a uniform distribution in the range of 0–1. Subsequent health status for
each simulated patient trajectory was determined by the value of the random deviate compared with the
cumulative probability of all destination states and events from the current health status. For states,
remaining in the current state and entering the non-cancer-related mortality sink state were always
possible destinations; neither of these options was available for events.
Observation
In each time step, the state of each simulated patient was recorded along with all events experienced during
the time step. Each state and event was assigned a monetary cost. Utilities assigned to each state and event
were converted into QALYs by calculating the product of all utilities experienced in each modelled year and
then summing over the survival of the patient (i.e. the time before entering one of the three sink states).
Initialisation
The model was initialised with 1000 patients. Age of each patient was randomly sampled from a Poisson
distribution with λ= 70 years. Severity for each patient was determined from data in the review of clinical
effectiveness reported earlier [see Chapter 3, Primary review (quantity and quality of included studies)].
Inputs
There were two inputs to the model. The first input was an edge list of possible transitions in the model,
with associated driving variables (transition probabilities). The second input was a vertex list of the
monetary cost and the utility associated with each event or state. The data used for transitions, cost and
utilities are described below (see Estimation of probabilities used within the model, Estimation of costs
used within the model and Estimation of utilities used within the model).
Submodel: side effects
The three side effects of urinary incontinence (UI), erectile dysfunction (ED) and bowel dysfunction (BD) were
each simulated independently with submodels. The side effects submodel was a Markov chain model
dependent on the current state or event of the individual, or the current side effect status of the individual.
Patients undergoing primary treatment had a probability of developing a dysfunction at an initial prevalence A,
and therefore had a probability of maintaining function of 1− prevalence A. In subsequent time steps,
development of a dysfunction or recovery to functionality was determined by a second prevalence, B (Table 44).
Patients in AS did not develop dysfunctions until after active treatment commenced (where their state is
TABLE 44 Transition matrix for the three side effects submodels
To/from Primary treatment AS Dysfunction Function Deceased
Primary treatment 0 0 Prevalence A 1− prevalence A 0
AS 0 1 0 0 0
Dysfunction 0 0 Prevalence B 1− prevalence B 0
Function 0 0 Prevalence B 1− prevalence B 0
Deceased 0 0 0 0 1
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changed to primary treatment by the main model), and so were unable to develop or recover from dysfunctions
prior to this. Patients in one of the three deceased states also remained in their current state (unable to develop
or recover from dysfunctions).
The two prevalences, A and B, allowed for an initial post-treatment prevalence of a side effect that was
different from the long-term prevalence of the side effect; typically, prevalence A was higher than
prevalence B, but this was not always the case.
Characterisation of the risk profile of the simulated cohort
Severity was categorised as low, intermediate and high risk according to the distribution of patients at
each stage, as found in the studies identified in the review of clinical effectiveness described in
Chapters 4–6.
Estimation of probabilities used within the model
This section summarises the parameter values used in the model. All probabilities in the following tables
are given as yearly probabilities for better concordance with the data tables in this report. Probabilities
were converted into 6-monthly estimates prior to use. For most variables parameter ranges were not
available, and point estimates were used throughout rather than a distribution of variables.
All probabilities originating at the same state or event must sum to unity. As some probabilities depend on
the state variables of the patient, it is not always possible in these tables to provide exact parameter values,
and ‘balance’ has been used to denote where the difference between unity and the sum of the other
driving variables for that state or event was used.
Age distribution of cohort being modelled and the probability of death from
causes other than prostate cancer
The age distribution of the cohort was randomly sampled from a Poisson distribution with a λ value of 70.
At any point in the model, there is a risk of death from all causes, including prostate cancer. The
interventions under investigation might alter the prostate cancer-specific component of this mortality but
would not be expected to affect other causes of mortality. Non-cancer mortality was calculated from
age- and sex-specific UK life expectancy and mortality tables for the UK produced by the Office for
National Statistics (ONS).219,220 These data were resolved into a lognormal equation of male age-specific
mortality rates using generalised linear modelling. This equation explained 97% of the variation in the
published data.
Selection of primary treatment or active surveillance on diagnosis
Five separate model runs were conducted using the entire cohort of 1000 simulated patients, one model
run for each of the main treatments (HIFU, cryotherapy, brachytherapy, EBRT and RP). Separate model runs
meant that it was not necessary to use routine data sources to estimate the relative proportions of patients
diagnosed with localised disease receiving each treatment as their primary therapy.
However, routine data sources were required to derive an estimate for parameter values regarding the
proportion of patients receiving adjuvant treatments (e.g. EBRT or hormone therapy), and the proportion
of people who received AS prior to any primary therapy.
Data from the National Cancer Intelligence Network provide information on treatments given to
18,839 diagnosed patients in 2009 (for a further 16,008 the initial treatment strategy was reported as
unknown).221 These data were not available separately for patients in different stages of disease at diagnosis.
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However, the British Association of Urological Surgeons (BAUS) Cancer Registry has published information on
the initial treatment strategies used for patients diagnosed in 2007, and these data are available separately
for various PSA level thresholds (0–5, 6–10, 11–15, 16–20, 21–50, 50+).222 We used a threshold PSA of ≤ 20
as a proxy for localised disease and used both sources to estimate the required parameter values.
In 2009, approximately 5104 patients received AS as their primary treatment strategy following diagnosis.221
This equates to 27.1% of the 18,839 patients for whom primary treatment was known.
The probability of staying in AS rather than moving to a primary therapy was determined from data in the
review of clinical effectiveness described in Chapters 4–6 (Table 45).
Probabilities related to primary treatment
Ablative therapy (including retreatment)
For ablative therapies, some data from the systematic review reported in Chapters 4–6 were available on
the proportion of recipients needing reintervention, although reintervention was often ill-defined and in
some instances may be more likely to be describing salvage treatment using the same intervention as was
used initially. We assumed that a constant rate of 10% of those receiving each ablative therapy would
need reintervention as part of that same primary therapy for localised disease, based on the review of
effectiveness data reported earlier (Table 46).
The probability of operative mortality (as opposed to perioperative mortality, which was parameterised
separately) was considered to be 0.00054% of all operations performed.223 This predominantly reflects the
risk of anaesthesia alone. Additional risks of perioperative death for procedures were modelled separately
as perioperative adverse events.
Radical prostatectomy
As shown in Figures 16 and 20, the model assumes that patients having RP can do so either with or
without a lymph node dissection (lymphadenectomy) as part of this surgery, and that any RP patient
(regardless of lymphadenectomy status) may or may not also receive adjuvant EBRT. However, the model
also assumes that only those receiving radical surgery alongside a lymphadenectomy would receive
adjuvant hormone therapy alongside any adjuvant EBRT received.
TABLE 46 Transition probabilities for ablative therapy
From To HIFU and cryotherapy Source
Ablative therapy Ablative therapy retreatmenta 0.1 See Chapter 5b
Ablative therapy Operative mortality 5.4E-06 Aitkenhead 2005223
Ablative therapy Surveillance 0.899995 Balance
a It was assumed that all patients experiencing retreatment of ablative therapies would then pass on to surveillance with a
probability of 1.
b Median for HIFU reintervention rate given in studies reporting this outcome reported in Chapter 5.
TABLE 45 Transition probabilities for AS
From To All therapies Source
AS Primary therapy 0.271 See Chapter 4
AS AS Balancea
AS Non-cancer mortality Non-cancer mortality ONS
a Non-cancer mortality is approximately 0.008255, so balance is about 0.72.
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For RP patients, we assumed that the probability of pelvic lymphadenectomy during surgery was 0.582.218
Using data from the BAUS 2007 survey for those with a PSA of ≤ 20, we estimated that for patients
receiving RP with a lymphadenectomy, 38.1% would receive the adjuvant EBRT and hormone therapy,
based on the probability of radical surgery being the sole treatment for 61.9% (for those with a PSA of
16–20, that is the highest-risk proportion of the ‘localised’ groups). Of those undergoing a prostatectomy
without lymphadenectomy, we assumed that 33.3% would receive adjuvant EBRT, based on the
probability of radical surgery being the sole treatment for 66.7% of those with a PSA of 11–15 (i.e. the
next highest-risk proportion of the localised groups) (Table 47).222
Brachytherapy and external beam radiotherapy
Patients receiving either brachytherapy or EBRT as their primary treatment could also receive adjuvant
hormone therapy. However, the model did not allow the combination of brachytherapy and EBRT as a
primary treatment. The information from the BAUS survey allowed us to estimate that around 46%
of brachytherapy patients receive adjuvant hormone therapy, based on the fact that brachytherapy was
reported as being provided as the sole treatment in 53.7% of diagnosed patients with a PSA of ≤ 20.
However, using the same method to calculate the frequency with which EBRT was used as an adjuvant
treatment, it was noted that 16% received solely EBRT, thus suggesting that EBRT is rarely provided as the
sole primary treatment for localised disease, and we assumed that adjuvant hormone therapy was provided
to 84% of EBRT patients (Table 48).222
All patients experiencing adjuvant therapies following primary therapy (adjuvant EBRT for radical surgery,
and adjuvant hormonal therapy for radical surgery, brachytherapy and EBRT) pass on to surveillance with a
probability of 1. This means that for these patient subgroups, both operative mortality and non-cancer
mortality are not considered possible within this part of the model.
TABLE 47 Transition probabilities for RP
From To Radical surgery Source
Radical surgery Adjuvant EBRT 0.3333
Radical surgery Operative mortality 5.4E-06
Radical surgery Surveillance 0.666695
Radical surgery: lymph node dissection EBRT and adjuvant HT 0.381
Radical surgery: lymph node dissection Operative mortality 5.4E-06
Radical surgery: lymph node dissection Surveillance 0.618995
HT, hormonal therapy.
TABLE 48 Transition probabilities for brachytherapy and EBRT
From To Brachytherapy Source
Brachytherapy Adjuvant HT 0.463 BAUS 2007222
Brachytherapy Operative mortality 5.4E-06 Aitkenhead 2005223
Brachytherapy Surveillance 0.536995
From To EBRT Source
EBRT Adjuvant HT 0.84
EBRT Surveillance 0.16 BAUS 2007222
HT, hormonal therapy.
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Perioperative adverse events
The systematic review of clinical effectiveness identified studies that had reported information on
perioperative adverse events. Two clinicians (RP and TL) graded each of these adverse events based
on expected severity and subsequent management. This rating system informed the Clavien–Dindo rating
approach.80 An average probability for the occurrence of a perioperative adverse event for each grade was
calculated using the reported information from the review. The model accounted for differences between
the treatments in terms of perioperative adverse events by costing additional days in hospital caused.
Information on additional length of stay in hospital for different Clavien–Dindo ratings was taken from a
study by Prentis and colleagues,224 whereby ratings of < 3 and ≥ 3 resulted in 4 and 15 additional days’
stay respectively (Table 49).
Biochemical recurrence after primary treatment
Recurrence
The probability of recurrence following primary treatment was calculated from patient severity and primary
treatment. The probability of PSA success for 1 year for all five primary treatments was used as input,
categorised further by low-, intermediate- and high-risk groups. These probabilities were converted into
the probability of a recurrence after 6 months. In most cases, the decline in PSA success beyond 1 year
could be explained by assuming a constant rate over time.
Informing the probability of recurrence were data from the systematic review reported in Chapters 4–6.
At each 6-month time step the individual modelled would either continue surveillance without recurrence
or (i) have a local recurrence identified that would lead to further treatment; (ii) have a systemic recurrence
identified that would lead to further treatment; or (iii) die from causes other than prostate cancer.
Although the systematic review of clinical effectiveness reported in Chapters 4–6 provided details of
recurrence, it was not always clear for each intervention whether that recurrence was local or systemic.
Therefore, we used the European Association of Urology (EAU) guidance for RP, which informed
judgements about the likelihood of a recurrence being local or systemic (Table 50).73 This likelihood was
dependent on the time at which a recurrence occurred, with a shorter time frame indicating a higher
likelihood of the recurrence being systemic.
TABLE 49 Probability of perioperative adverse events by Clavien–Dindo score of < 3 or ≥ 3
Primary treatment
Probability of an adverse event
with Clavien–Dindo score of < 3
Probability of an adverse event
with Clavien–Dindo score of ≥ 3 Source
Cryotherapy 0.018 0.04775 See Chapters 4–6
HIFU 0.05 0.05 See Chapters 4–6
Brachytherapy 0.32 0.08575 See Chapters 4–6
EBRT 0.057 0.033 See Chapters 4–6
RP 0.184 0.0325 See Chapters 4–6
TABLE 50 Annual probability that a recurrence, if identified, was localised disease
Recurrence at time point Value Source
Recurrence at ≤ 1 year indicating localised disease 0.07 EAU73
Recurrence at 1–2 years indicating localised disease 0.1 EAU73
Recurrence at > 2 years indicating localised disease 0.61 EAU73
Recurrence at > 3 years indicating localised disease 0.74 EAU73
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For the base-case analysis, the probability of remaining free from recurrence was derived from the
prevalences reported in the meta-analysis reported in Chapters 4–6. Under the assumption of a constant
rate of biochemical failure per year, the raw data from the meta-analysis were converted into yearly
rates by raising the probability of biochemical failure to the nth root, where n was the number of years
that the patients had remained recurrence-free. The assumption that there was a constant rate of
biochemical failure was tested using linear mixed-effects regression modelling. The response was the yearly
estimate of biochemical failure, the predictor was the time point from which the yearly estimate was
derived and the random effect was the treatment type. The intercept was significantly different from zero
(estimate= 0.041, p= 0.0008) but the predictor of time of the estimate was not (estimate= –0.001,
p= 0.4699). This indicated that the assumption of constant rates of biochemical failure over time was
valid. This conversion of the meta-analysis data resulted in the yearly probabilities of remaining free from
recurrence, reported in Table 51.
Alternatively, the data contributing to the values in Table 51 regarding the probability of remaining free
from recurrence were divided into low, intermediate and high risk for each treatment type; these were
assigned to simulated patients with severity state variables of 1, 2 and 3 respectively (Table 52).
These data were combined with the information from the EAU on the link between the time to recurrence
and the probability of that recurrence being local or systemic, to estimate the proportion of the cohort
entering the local and systemic recurrence states respectively (Table 53).
TABLE 52 Yearly probabilities of remaining free from recurrence for each therapy by risk level
Primary therapy Low risk Intermediate risk High risk
Ablative: HIFU 0.989 0.934 0.926
Ablative: cryotherapy 0.740 0.700 0.600
Brachytherapy 0.984 0.970 0.731
EBRT 0.992 0.990 0.908
Radical surgery 0.980 0.920 0.965
TABLE 51 Yearly probabilities of remaining free from recurrence for each therapy
Primary therapy Minimum estimate Median estimate Maximum estimate
Ablative: HIFU 0.994 0.973 0.943
Ablative: cryotherapy 0.923 0.978 0.949
Brachytherapy 0.999a 0.994 0.986
EBRT 0.997 0.992 0.973
Radical surgery 0.996 0.989 0.957
a The minimum estimate was actually unity for this probability, but a more conservative value was used to permit
biochemical failure as an extremely rare event.
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Treatment options following biochemical recurrence
Table 54 shows the yearly transition probabilities for those who move from recurrence to subsequent
events. These data were then converted to 6-monthly rates.
Salvage treatment for localised recurrence
Salvage therapies (including retreatment)
The choice of salvage treatment for localised recurrence may depend on the choice of initial/primary
treatment. For example, patients whose initial treatment was radical surgery could not receive radical
surgery again as a salvage treatment as the prostate would already have been removed during the initial
operation. Therefore, the probability of receiving a specific salvage treatment is conditional on the primary
treatment received. Lacking detailed studies of salvage therapy, for HIFU, cryotherapy and brachytherapy
the retreatment rate of salvage therapy was assumed to be the same as for primary therapy with HIFU
(0.1). For radical surgery and EBRT, the retreatment rate of salvage therapy was assumed to be the average
retreatment rate of primary therapy with HIFU and cryotherapy. The probability of avoiding retreatment
with salvage therapy was the difference between unity and the retreatment rate plus operative mortality.
Table 55 reports the transition probabilities for movements from salvage therapy.
For salvage therapy patients who reach the follow-up surveillance state, Table 56 outlines the probabilities
of the possible options for future movement from this state.
TABLE 53 Transition probabilities for surveillance
From To All therapies Source
Surveillance Non-cancer mortality Non-cancer mortality ONS219
Surveillance Recurrence: local Year 1: 0.07 × recurrence
Year 2: 0.10 × recurrence
Year 3: 0.61 × recurrence
Year 4+: 0.74 × recurrence
See Tables 47 and 52
Surveillance Recurrence: systemic Year 1: 0.93 × recurrence
Year 2: 0.90 × recurrence
Year 3: 0.39 × recurrence
Year 4+: 0.26 × recurrence
See Tables 47 and 52
Surveillance Surveillance Balance
TABLE 54 Transition probabilities for movement from recurrence events
From To All therapies Source
Recurrence: local Salvage therapy 0.958
Recurrence: local Watchful waiting 0.042 BAUS 2007222
Recurrence: systemic HT 0.9703
Recurrence: systemic Watchful waiting 0.0297 BAUS 2007222
HT, hormonal therapy.
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Watchful waiting
From watchful waiting, treatment options for patients become limited to those generally used to treat
metastatic disease. Table 57 reports the transition probabilities from the watchful waiting state to
such treatments.
Treatment for systemic recurrence after primary or salvage treatment
It was assumed that on progression following salvage treatment, or on systemic recurrence following
primary treatment, patients would be treated for advanced disease, with ‘watchful waiting’ being
conducted initially and alternative treatment options (which in clinical practice will depend on individual
patient circumstances) being hormonal therapy and castrate-resistant stage therapies (including
chemotherapy) as well as palliative treatment. Palliative treatment might also involve drug treatment, but
to treat sequelae of the prostate cancer (e.g. bone metastases) rather than the prostate cancer itself.
TABLE 56 Transition probabilities for follow-up surveillance following salvage treatment
From To Radical surgery All other therapies Source
Follow-up surveillance Follow-up surveillance Balance Balance
Follow-up surveillance Non-cancer mortality Non-cancer mortality Non-cancer mortality
Follow-up surveillance Watchful waiting 0.11a 0.0297 See Chapters 4–8
BAUS 2007222
a This is 1 minus the probability of progression-free survival, from salvage data for RP.
TABLE 55 Transition probabilities for movements from salvage therapy
From To
HIFU, cryotherapy,
brachytherapy
Radical surgery
and EBRT Source
Salvage therapy Follow-up surveillance 0.899995 0.907995
Salvage therapy Operative mortality 5.4E-06 5.4E-06 Aitkenhead 2005223
Salvage therapy Salvage therapy retreatmenta 0.1 0.092 Systematic review
datab
a All patients experiencing retreatment with salvage therapies pass on to follow-up surveillance with a probability of 1.
b This is based on retreatment rate following primary treatment with HIFU.
TABLE 57 Transition probabilities from the watchful waiting state
From To All therapies Source
Watchful waiting Castrate-resistant stage 0.335a Tangen 2003225
Watchful waiting HT Balance
Watchful waiting Non-cancer mortality Non-cancer mortality
Watchful waiting Other palliative treatment 0.1 Assumption
Watchful waiting Watchful waiting 0.0297 BAUS 2007222
HT, hormonal therapy.
a Assuming that if 0.77 survived < 5 years, then the failure rate per year can be taken to be 0.77 × (1/5). Similarly,
5–10 years is 0.16 × (1/10), and survival for > 10 years is 0.07 × (1/15). Add all these up to get overall/average failure rate
of 0.335.
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Table 58 shows the yearly transition probabilities for those who move from hormonal therapy,
castrate-resistant disease and other palliative treatments to subsequent care and events.
We used guidelines on the treatment of the disease at this stage to estimate the typical processes of care
at this stage in the care pathway. We assumed that patients at this point would initially receive hormonal
therapy, with the rate of progression to hormone refractory disease taken from available guideline
evidence on treatment for metastatic disease.73 The initial probability of response was estimated at 80%,
with 60% still showing progression-free response at 3 years.73
Overall survival has been separately estimated at a median of 5 years,226 with 7% surviving beyond
10 years.225 Similarly, further review evidence on survival following chemotherapy treatment for advanced
cancer was used to inform the model for castrate-resistant disease. On progression with hormone
therapy, the probability of staying in the castrate-resistant stage for ≥ 1 time step was considered
equivalent to the yearly probability of response to chemotherapy (0.52).226 Palliative treatment was
considered to confer a 6-month survival on average (though cancer mortality could also occur prior to
having any palliative treatment).227
Probability of longer-term adverse events (used in submodels of
adverse events)
Values for the two prevalences (A and B) were calculated from data in the systematic review. For each of
the three adverse events it was assumed that within the first 6 months the rate would differ from any
longer-term trend. Prevalence A was calculated as the median for all sources reporting the prevalence of
the adverse event at a follow-up time of ≤ 6 months. It was assumed that after 6 months, the prevalence
would settle to a constant rate. All data on each adverse event that were reported for a follow-up time
of beyond 6 months were converted to a yearly rate and then the average was taken to calculate
prevalence B. The results are summarised in Table 59.
TABLE 58 Yearly transition probabilities: metastatic disease
From To All therapies Source
HT Castrate-resistant stage 0.335 See Table 57
HT HT Balance
HT Non-cancer mortality Non-cancer mortality
From To All therapies Source
Castrate-resistant stage Cancer mortality 0.2499 See notea
Castrate-resistant stage Castrate-resistant stage 0.52 × balance Shelley 2008226
Castrate-resistant stage Non-cancer mortality Non-cancer mortality
Castrate-resistant stage Other palliative treatment 0.48 × balance Shelley 2008226
From To All therapies Source
Other palliative treatment Cancer mortality 0.2499 See notea
Other palliative treatment Non-cancer mortality Non-cancer mortality
Other palliative treatment Other palliative treatment Balance
HT, hormonal therapy.
a Estimating from a median overall survival (1.37 years), we turned this into a rate of death per year (1/1.37), then
subtracted the probability of going on to palliative care (0.73− 0.48) to get the final probability of 0.2499.
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Estimation of costs used within the model
All costs were estimated based on resource-use inputs and unit costs for the 2011–12 financial year, and
are reported in UK pounds sterling. All resource inputs, unit costs and their sources for each treatment,
associated care pathways and management of events are shown in Appendix 13. With the exception of
costs of radical surgery and palliative treatments, which were taken from the literature, costs included in the
model were estimated using a micro-costing exercise. The data used in this exercise were then subsequently
approved by the external advisory group. Specific costs to the NHS, relevant to the treatments, care
pathways and events, included diagnostic tests and imaging, staff time, equipment (including consumables),
theatre time and capital (for reusable equipment) costs. With the exception of consumables and theatre
time, which were sourced from relevant NHS providers, and capital costs, which were sourced from specific
commercial providers, most unit costs were sourced from NHS reference costs,228 unit costs of health and
social care229 and the NHS Agenda for Change.230 Where costs were not reported in 2011–12 values, they
were inflated by the Hospital and Community Health Sector inflation index.229
All capital costs for each of the treatment pathways were costed using current market prices obtained
from various commercial providers to the NHS. A lower and upper estimate of these prices was provided
by each relevant supplier (as the cost to each NHS provider is dependent on individual contractual
arrangements) to provide a distribution around the market price. These initial outlay costs were annuitised
over the useful working lifespan of the piece of equipment (assumed to be 10 years for all equipment),
applying an annual discount factor of 3.5%231 to account for the opportunity cost of the investment over
time. The equivalent annual cost of each piece of equipment was divided by its estimated number of
uses per annum (from NHS providing units and expert opinion) to give cost-per-use estimates. If capital
equipment was used for procedures other than the treatment in question, the timings of each procedure
were checked for equality in order that a cost-per-use estimate would be valid.
TABLE 59 Prevalences for each side effect, by primary treatment
Side effect Primary treatment Prevalence A Prevalence B
Urinary incontinence Ablative: HIFU 0.116 0.033
Ablative: cryotherapy 0.099 0.041
Brachytherapy 0.332 0.363
EBRT 0.092 0.111
Radical surgery 0.248 0.278
Erectile dysfunction Ablative: HIFU 0.430 0.383
Ablative: cryotherapy 0.807 0.561
Brachytherapy 0.268 0.262
EBRT 0.486 0.406
Radical surgery 0.645 0.706
Bowel disorder Ablative: HIFU 0.010 0.010
Ablative: cryotherapy 0.106 0.061
Brachytherapy 0.055 0.116
EBRT 0.152 0.181
Radical surgery 0.040 0.128
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Treatment costs associated with primary treatments
Table 60 shows the cost estimates used in the model for AS, Table 61 the cost estimates for primary
treatment costs and Table 62 the cost estimates for the follow-up surveillance state.
Active surveillance
As noted above, the costs of AS were estimated using a micro-costing (bottom-up) approach, with
treatment pathways and associated resource inputs being identified by clinical experts within the research
team. The costs of AS were estimated for each of the first 5 years, then annually thereafter, based on the
assumption that there were no changes in the condition of a patient such that they had to leave active
monitoring and be given a different primary radical treatment. In year 1, patients would attend four
nurse-led urology outpatient appointments with PSA tests conducted at each appointment. The unit costs
of non-consultant-led follow-up outpatient appointments were obtained from the NHS reference costs228
and the unit costs for the PSA test were obtained from Ramsay and colleagues (2012).218
TABLE 60 Annual AS costs
Year Resource inputs Value (£) Lower limit (£)a Upper limit (£)a
1 4 nurse-led outpatient appointments
4 PSA tests
1 DRE
1 MDT meeting
442.24 283.68 574.80
2 1 TRUS-guided biopsy
2 nurse-led outpatient appointments
2 PSA tests
1 DRE
368.12 233.84 499.40
3 2 nurse-led outpatient appointments
2 PSA tests
1 DRE
169.12 117.84 228.40
4 1 TRUS-guided biopsy
2 nurse-led outpatient appointments
2 PSA tests
1 DRE
368.12 233.84 499.40
5 2 nurse-led outpatient appointments
2 PSA tests
1 DRE
169.12 117.84 228.40
Annually
thereafter
1 practice nurse appointment
1 PSA test
1 DRE
19.81 14.86 24.76
MDT, multidisciplinary team.
a Upper and lower limits of triangular distribution calculated at ± 25% of the point estimate.
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Following this, at 12 months, a multidisciplinary team (MDT) cancer meeting would take place to review
each patient, the unit cost of which was obtained from the NHS reference costs (cost code CMDT_Oth).228
Patients in year 2 of AS would attend two nurse-led urology outpatient appointments, again with PSA
tests performed at each appointment. In addition, patients would undergo a standard TRUS-guided biopsy,
the unit cost of which was taken from the NHS reference costs228 using the appropriate Healthcare
Resource Group (LB27Z). Year 4 of AS was assumed to be identical to this, and years 3 and 5 were
assumed to be the same with the exception of the TRUS-guided needle biopsy. Patients would also have
an annual DRE for years 1–5. However, we assumed that the costs of this would be minimal and that it
could effectively be included within the cost of the nurse-led outpatient appointment. After the first
5 years, it was assumed that patients would receive an annual PSA test conducted by a practice nurse in a
general practice setting. The unit cost of a practice nurse appointment was taken from the unit costs of
health and social care.229
Radical surgery (with and without lymphadenectomy)
The costs of radical surgery were taken from the recent HTA comparing laparoscopic and robotic RP.218
Given the likelihood of higher future use of robotic compared with laparoscopic surgery (based on clinical
opinion within the research team), it was assumed that all radical surgery within the model would be performed
using robotic surgery. The cost per procedure was based on the assumption that 200 procedures per annum
TABLE 62 Annual surveillance costs
Year Resource inputs Value (£) Lower limit (£)a Upper limit (£)a
1 4 nurse-led outpatient appointments
4 PSA tests
1 DRE
340.40 255.30 425.50
2–5 2 nurse-led outpatient appointments
2 PSA tests
1 DRE
170.20 127.65 212.75
Annually thereafter 1 practice nurse appointment
1 PSA test
19.81 14.86 24.76
a Upper and lower limits of triangular distribution calculated at ± 25% of the point estimate.
TABLE 61 Primary treatment costs
Costs Value (£) Source
Distribution (values used
to define the distribution) (£)a
Radical surgery (with and
without lymphadenectomy)
3848.76 Ramsay218
Cryotherapy 6407.72 Micro costed 4802.61–7986.62
HIFU 4277.98 Micro costed 3208.48–5347.48
Brachytherapy alone 6756.61 Micro costed 5024.95–9121.70
EBRT 2508.58 Micro costed 1881.44–3135.73
Adjuvant and salvage EBRT 2356.46 Micro costed 1767.34–2945.58
Adjuvant hormone therapy 555.00 Micro costed 416.25–693.75
a Upper and lower limits of triangular distribution calculated at ± 25% of the point estimate.
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would be carried out at any providing unit and the cost per procedure was the same regardless of whether or
not a lymphadenectomy had taken place.
External beam radiotherapy
The costs of EBRT by a NHS unit carrying out the IMRT procedure were calculated on the basis of 37 sessions
within a 7-week time frame. A list of staff time by grade and specialty involved in the procedure was
provided by the Newcastle upon Tyne Hospitals NHS Foundation Trust (Edgar Paez, consultant urologist
and Gill Lawrence, Head of Radiotherapy Physics, Northern Centre for Cancer Care, 2013, personal
communication). UK capital costs for a Varian radiotherapy solution incorporating a TrueBeam™ linear
accelerator (Varian Medical Systems, Palo Alto, CA), a treatment planning system, an oncology management
system and associated maintenance costs were obtained from Varian Medical Systems (www.varian.com).
The expected number of uses per annum for linear accelerator equipment was based on 37 fractions per day
based on a 253-day working year, and for the treatment planning and oncology management systems this
was based on 4500 patients per year. These estimates were provided by the Newcastle upon Tyne Hospitals
NHS Foundation Trust (Debbie Bennett, Radiotherapy Service Manager at the Northern Centre for Cancer
Research, 2013, personal communication).
Adjuvant external beam radiotherapy
The costs of adjuvant and salvage EBRT were considered by expert opinion to be the same in terms of the
treatment pathway and associated resource inputs. Furthermore, the expert advisory group advised that the
only difference between this and primary EBRT was the reduced number of fractions that each patient
received, from 37 to 33. Thus, the costs for adjuvant and salvage EBRT were based on the same micro-costing
approach conducted for EBRT, albeit with a reduction in capital cost per patient for the accelerator to allow
for the reduction in fractions and a reduction in radiographer’s time in the delivery of the fractions.
Brachytherapy
The costs of brachytherapy were estimated from a treatment pathway and associated resource inputs being
identified by a NHS unit carrying out the procedure (Newcastle upon Tyne Hospitals NHS Foundation Trust).
This was subsequently checked with the external advisory group. The costs associated with brachytherapy
were calculated on the basis of a two-stage procedure with a 1-night length of stay, and a list of all
resource inputs relevant to the procedure was provided by Newcastle upon Tyne Hospitals NHS Foundation
Trust (Ian Pedley, clinical director/clinical oncologist at the Northern Centre for Cancer Care, and Gill
Lawrence, 2013, personal communication). A list of reusable equipment and consumables used during the
procedure, along with their unit costs [including Isostrand® seeds (Eckert & Ziegler BEBIG GmbH, Berlin,
Germany) and implantation needles] came from Newcastle upon Tyne Hospitals NHS Foundation Trust
(Steve Locks, Consultant Clinical Scientist in Radiotherapy Physics, 2013, personal communication). Clinical
audit showed that between 60 and 110 seeds were used per patient at this centre, with an average of
80 seeds per patient, and between 17 and 46 implantation needles were used per procedure, with an
average of 28 needles used per patient. UK capital costs for the VariSeed™ treatment planning system
(Varian Medical Systems, Palo Alto, CA; equipment version 8.0.2.), ancillary equipment and maintenance
costs were obtained from Eckert & Ziegler BEBIG (www.bebig.eu). The expected number of uses per annum
for this treatment planning system was based on 100 patients per annum, with a range of 25–250 patients.
These figures are based on numbers of patients treated in each UK centre obtained from the UK Prostate
Brachytherapy Advisory Group’s website.232,233
Cryotherapy
The costs of cryotherapy were estimated from the treatment pathway and associated resource inputs being
identified by a NHS unit carrying out the procedure (City Hospitals Sunderland Foundation Trust). This was
subsequently checked by the external advisory group. A list of all resource inputs relevant to the procedure
was provided by City Hospitals Sunderland Foundation Trust (Sue Asterling, urology research nurse; Damien
Greene, consultant urologist; and Mark Kelly, Acting Divisional General Manager – Theatres, 2013, personal
communication). UK capital costs for the Visual-Ice® cryoablation system (Galil Medical, Arden Hills, MN),
ancillary equipment and maintenance costs were obtained from Galil Medical (www.galil-medical.com).
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The expected number of uses per annum for this treatment system was based on an estimate of 200 patients
per annum. Cryotherapy was assumed to require a 2-night length of stay.
High-intensity focused ultrasound
The costs of HIFU were estimated from a NHS unit carrying out the procedure (University College London
Hospitals NHS Foundation Trust). The costs associated with HIFU were calculated on the basis of a focal
procedure with patients returning home on the day of surgery. A list of all resource inputs relevant to
the procedure was provided by University College London Hospitals NHS Foundation Trust (Mark Emberton,
Professor in Interventional Oncology, and Lois Roberts, General Manager, Division of Surgical Specialties,
2013, personal communication). UK capital costs for the Sonablate® 500 HIFU surgical ablation system
(SonaCare Medical, Charlotte, NC) (including maintenance and ancillary costs) were provided by Nuada
Medical Prostate Care. The expected number of uses per annum for this treatment system was based on
200 patients per annum. Although most patients return home the same day the treatment is given, it was
acknowledged that some patients do have an overnight stay in secondary care. We therefore assumed that
20% of patients would have a 1-night length of stay (Mark Emberton, personal communication).
Adjuvant hormone therapy
A proportion of patients who receive either brachytherapy or EBRT as a primary radical treatment
subsequently have adjuvant hormone therapy. It was assumed (based on advice from our expert advisory
group) that these patients would be treated with 3 weeks of cypoterone acetate (Androcur®, Bayer)
(100mg) at a cost of £58.50,234 and two courses, each of 3 months, of the LHRH agonist goserelin
(Zoladex® LA, AstraZeneca) (10.8-mg 3-month injection), at a total cost of £470. It was assumed that
goserelin would be administered by a practice nurse in a primary care setting at a cost of £13.25 per visit.229
Surveillance
The costs of surveillance following primary treatment were estimated using treatment pathways and
associated resource inputs identified by clinical experts within the research team. Costs were estimated for
each of the first 5 years then annually thereafter, based on the assumption that there were no changes in
a patient’s condition nor evidence of biochemical recurrence such that the patient had to leave the
surveillance state. In the first year of surveillance, patients would attend four nurse-led urology outpatient
appointments, with PSA tests conducted in each of these. The unit costs of non-consultant-led follow-up
outpatient appointments were obtained from the NHS reference costs228 and the unit costs for the PSA test
were obtained from Ramsay and colleagues.218 For the second through to the fifth year it was assumed
that patients would attend two nurse-led urology outpatient appointments with PSA testing at each
outpatient appointment. After the first 5 years, it was assumed that patients would receive an annual PSA
test conducted by a practice nurse in a primary care setting. The unit cost of a practice nurse appointment
was taken from the unit costs of health and social care.229 Patients would also have an annual DRE (with
the exception of those who have undergone RP) each year for the first 5 years, but the cost of this was
subsumed in the cost of the nurse-led outpatient appointment.
Treatment costs associated with biochemical recurrence after
primary treatment
Based on elevated PSA levels observed while under surveillance state, biochemical recurrence can entail
two different types of diagnosis event: local recurrence and metastatic recurrence. Table 63 shows the
costs of diagnosing local and metastatic recurrence.
TABLE 63 Costs of diagnosis of local and metastatic recurrences
Diagnosis event Value (£) Lower limit (£)a Upper limit (£)a
Local recurrence 569 392 641
Metastatic recurrence 755 523 873
a Upper and lower limits of triangular distribution calculated at ± 25% of the point estimate.
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Local recurrence
Resource inputs regarding diagnosis of local recurrence were based on expert opinion. It was assumed that
patients would have two consultant-led outpatient appointments: one before diagnostic testing and one
after to discuss further treatment options. Each patient would undergo a MRI scan, which would be
followed by a MDT cancer meeting and a nurse-led urology outpatient appointment.
Metastatic recurrence
It was assumed on the basis of expert opinion that the only difference between diagnosing local and
metastatic recurrence would be that patients with suspected metastasis would also have to undergo a
bone scan.
Costs associated with local progression following treatment for
localised disease
A proportion of the cohort might experience biochemical recurrence following primary radical treatment
for localised prostate cancer. Depending on the primary treatment received, these patients were modelled
to receive any one of the following salvage therapies: ablative therapy, radical surgery, brachytherapy or
EBRT. The cost and utility for salvage therapies was calculated from the combination of the possible
salvage therapies following the primary therapy modelled. Primary radical surgery could be followed
by salvage EBRT or salvage ablative therapy. Primary brachytherapy or EBRT could be followed by salvage
surgery or salvage ablative therapy. Primary ablative therapy could be followed by salvage ablative therapy,
salvage EBRT, salvage brachytherapy or salvage radical surgery. When combining multiple salvage therapies
into an average treatment, the lower limit was taken to be the minimum of the calculated lower limits,
the upper limit to be the maximum of the calculated upper limit and the point estimate to be the mean
of the point estimates. With the exception of salvage EBRT, the costs associated with these salvage
treatments were assumed to be the same as for the primary treatments. The costs of salvage EBRT per
patient, as specified in Table 61, were considered to be lower than those of the primary treatment owing
to a lower number of fractions received (33 sessions over a 6-week time frame). Following salvage therapy,
patients were modelled to enter into a follow-up surveillance state. The costs for this were assumed to be
the same for the first 5 years of the surveillance state in Table 62. Provided the patient’s disease did not
progress, after 5 years patients were modelled to enter into a watchful waiting state, the costs of which
were assumed to be the same as the annual costs after 5 years specified in the surveillance state described
above (see Table 62).
Costs associated with metastatic progression
Patients with metastatic recurrence were modelled initially to receive either hormone therapy or watchful
waiting. Following this, patients could either remain in this state or enter into other states (which in clinical
practice will depend on individual patient circumstances), these being hormonal therapy, castrate-resistant
stage therapies (including chemotherapy) or palliative treatment.
Watchful waiting
The costs of watchful waiting were assumed to be the same as the annual costs after 5 years specified
in the surveillance state described above, that is patients would receive an annual PSA test conducted by a
practice nurse in a primary care setting at a cost of £19.81.
Hormonal therapy
It was assumed (based on advice from our clinical experts in the research team) that these patients would
be treated with 3 weeks of cypoterone acetate (100mg) at a cost of £58.50234 and a 3-month course
of the LHRH agonist goserelin (10.8-mg 3-month injection) at a cost of £235 until the patient either died
or entered into the castrate-resistant stage. It was assumed that goserelin would be administered by a
practice nurse in a primary care setting at a cost of £13.25 per visit.
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Castrate-resistant stage
We assumed that 50% of patients would undergo a first-line docetaxel-based (Taxotere®, Sanofi-Aventis)
chemotherapy regimen (£10,450) and that 70% of these patients would go on to receive a second-line
abiraterone-based (Zytiga®, Janssen) regimen (£24,670) prior to death, as per the assumptions in the
costing template for the NICE abiraterone technical appraisal.235
Other palliative treatment
These costs were taken from Collins and colleagues236 and were estimated to be £4454 per annum.
Summary of costs used in the model
Costs used in the model are all summarised in Table 64.
Costs and utilities used in the submodel of adverse events
Time in each state of dysfunction for all three side effects incurred a cost which was added to the yearly
costs to obtain lifetime totals for each patient. Costs used are listed in Table 65.
TABLE 64 Summary of costs used in the model
State or event Cost (£) Source
Primary therapy events
Ablative therapy: HIFU 4277.98 See Treatment costs associated with primary treatments; Table 61
Ablative therapy:
cryotherapy
6407.72 See Treatment costs associated with primary treatments; Table 61
Brachytherapy 6756.61 See Treatment costs associated with primary treatments; Table 61
EBRT 2508.58 See Treatment costs associated with primary treatments; Table 61
Radical surgery 3848.76 See Treatment costs associated with primary treatments; Table 61
States
AS Year 1: 442.24
Years 2, 4: 368.12
Years 3, 5: 169.12
Years 6+: 19.81
See Treatment costs associated with primary treatments; Table 61
Surveillance Year 1: 340.40
Years 2–5: 170.20
Years 6+: 19.81
See Treatment costs associated with primary treatments; Table 61
Follow-up surveillance (Same as surveillance) See Treatment costs associated with primary treatments
Watchful waiting (Same as surveillance) See Treatment costs associated with primary treatments
Castrate-resistant stage 50% of patients:
10,450.00+
70% of these:
24,670.00
See Costs associated with metastatic progression,
Castrate-resistant stage
Hormonal therapy Cypoterone acetate:
58.50+
Goserelin: 235.00+
Delivery: 13.25
See Costs associated with metastatic progression,
Hormonal therapy
Other palliative treatment 4454.00 Collins236
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TABLE 64 Summary of costs used in the model (continued )
State or event Cost (£) Source
Events
Adjuvant EBRT 2356.46 See Treatment costs associated with primary treatments; Table 61
Adjuvant hormonal
therapy
555.00 See Treatment costs associated with primary treatments; Table 61
Local recurrence 569.00 See Treatment costs associated with biochemical recurrence after
primary treatment, Metastatic recurrence; Table 63
Salvage therapy Brachytherapy: 5342.85
Cryotherapy: 4172.89
EBRT: 4844.82
HIFU: 4705.32
Radical
surgery: 4812.63
See Treatment costs associated with biochemical recurrence after
primary treatment, Costs associated with local progression
following treatment for localised disease
Systemic recurrence 755.00 See Treatment costs associated with biochemical recurrence after
primary treatment, Metastatic recurrence; Table 63
Mortality states
Cancer mortality 0.00 N/A
Non-cancer mortality 0.00 N/A
Operative mortality 0.00 N/A
N/A, not applicable.
TABLE 65 Costs used for adverse events
Side effect Cost (£) Source
UI Self-management (94.8%): 263.59 (per year)
AUS device (5.2%): 3928.00 (implantation)+ 4918.00 (cost of device)
Ramsay 2012218
ED No treatment (43%)
Treatment (57%)
Sildenafil (82.2% of treated): 5.88 (per week)
Alprostadil (15.4% of treated): 11.94 (per week)
Penile prosthesis (2.4% of treated): 2262.00 (implantation)+ 5023.00
(cost of device)
Ramsay 2012218
BD Annual monitoring cost: 368.50
Mean treatment cost: 2352.90
Ara 2009;237 Shimizu 2008238
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Estimation of utilities used within the model
Quality-adjusted life-years are calculated by weighting life-years with utility values, to reflect patients’
preferences for the HRQoL that they experience. There are various methods and tools that can be used to
elicit utility values. In its methods guide,231 NICE recommends the use of the European Quality of Life-5
Dimensions (EQ-5D).
Sources of utility data for patient states and events in the model related to diagnosing and treating
prostate cancer were identified from systematic searches of several databases, including MEDLINE,
EMBASE, NHS Economic Evaluation Database (NHS EED), Health Economic Evaluations Database (HEED)
and the Cost-effectiveness Analysis (CEA) Registry. Search strategy details are available in Appendix 1.
Two reviewers independently screened the titles and abstracts of the studies identified from all searches
and sources. A full paper copy of any study judged to be relevant by either reviewer was obtained where
possible. A total of 306 references were identified. Of these, 56 were selected for potential inclusion in
terms of reporting utility values by any method. An iterative method of study selection was planned to
identify the best evidence regarding utility values:
1. values obtained by the EQ-5D
2. values obtained using other public preference-based weights of HRQoL scores [e.g. Health Utilities
Index, Short Form questionnaire-6 Dimensions (SF-6D)]
3. values obtained by direct preference elicitation methods (e.g. time trade-off, standard gamble).
The final studies used to calculate utilities included in the model are reported in more detail in Appendix 12,
together with a detailed summary of the methods and results for each study. Final utility values used in the
model are specified in the summary results (Table 66).
The availability of data regarding utilities for health states and events included in the model was poor.
For many treatment events there were no available data. Furthermore, where data did exist, there was
heterogeneity in methods used to elicit utilities across all relevant studies. Therefore, utility values used in
the model were calibrated in the model to the EQ-5D by using the value measured using the EQ-5D at
initial diagnosis of prostate cancer.238
Diagnosis events
Where multiple sources of utility values for particular parameters were available, median values from the
literature reviewed were used, which were then calibrated to the EQ-5D. For local recurrence, utility values
were estimated on the basis of values taken from four studies.243,247–249 For systemic recurrence, utility
values were estimated on values taken from two studies.247,250
Primary treatments
For many primary treatment events, such as brachytherapy, cryotherapy, etc., there were no utility data
available. It was assumed that the utility values for these treatment events were the same as that used for
surveillance. This seemed a reasonable assumption as this was estimated to be the same as the utility value
for EBRT.
Where EQ-5D scores were available from one source for multiple time points (as with EBRT),239 the
percentage improvement from baseline to 6 months post intervention was calculated. This was then
calibrated by the EQ-5D value of initial diagnosis. It was assumed that the utility values for adjuvant EBRT
with and without hormone therapy were the same as this. The utility value for RP with lymphadenectomy
was assumed to be the same as that for RP alone owing to the absence of data.
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TABLE 66 Utility values used in the model
Event/treatment Value Source
Diagnosis events
Initial diagnosis 0.9 Shimizu 2008238
Local recurrence 0.63 See Estimation of utilities used within the model, Diagnosis events
Systemic recurrence 0.45 See Estimation of utilities used within the model, Diagnosis events
Primary treatments
Cryotherapy 0.88 See Estimation of utilities used within the model, Primary treatments
HIFU 0.88 See Estimation of utilities used within the model, Primary treatments
Brachytherapy 0.88 See Estimation of utilities used within the model, Primary treatments
EBRT 0.88 Korfage 2005239
Radical surgery with and
without lymphadenectomy
0.60 Stewart 2005240
Adjuvant EBRT with and
without hormone therapy
0.88 See Estimation of utilities used within the model, Primary treatments
Surveillance states
AS 0.87 Zeliadt 2005241
Surveillance 0.88 Krahn 1994242
Follow-up surveillance 0.88 Krahn 1994242
Watchful waiting 0.648 Cowen 1996243
Further cancer treatment
All salvage treatments See Costs associated with local progression following treatment for
localised disease
Brachytherapy 0.88
Cryotherapy 0.81
EBRT 0.79
HIFU 0.81
Radical surgery 0.88
General states
All-cause mortality 0 Value assigned to death in EQ-5D
Hormone therapy 0.8
(range
0.4–0.9)
Bayoumi 2000244
Castrate-resistant stage 0.58 Hummel 2010245
Palliative treatment stage 0.46 Sandblom 2004246
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Further cancer treatment
There were no utility data for any of the salvage treatments included in the model. We therefore estimated
this (for all salvage treatments), taking the average of utility values for local recurrence, 6 weeks post RP
and surveillance at 12 weeks.
General states
For the palliative stage of disease, we used the utility value for people with prostate cancer in the last
4 months of their lives, as reported by Sandblom and colleagues.246
Summary of costs and utilities used in the submodel of adverse events
Time in each state of dysfunction for all three side effects incurred a cost and utility which were
(respectively) added to/multiplied by the yearly costs and utilities to obtain lifetime totals for each patient.
Costs and utilities used are listed in Tables 65 and 67.
Elasticity analysis
The sensitivity of a model parameter is its potential to affect the overall model outcomes. A small change
in a variable to which the model is highly sensitive may have a large impact on model outcomes, whereas
the effect of a variable with a low sensitivity may go unnoticed amid the random noise of a stochastic
model. An elasticity analysis examines the individual sensitivities of each driving variable to a given
outcome, in this case survival, and is sometimes called a sensitivity analysis; however, this term is avoided
here to avoid confusion with sensitivity analyses of the form more commonly reported in economic
evaluations (we note, however, that this approach is consistent with the multiparameter probabilistic
sensitivity analyses typically conduced in economic evaluations, the main difference being in the
representation of results).
In addition to highlighting variables to which the model is most sensitive (and that hence should be the
focus of greater efforts to obtain the best available data), the elasticity analysis also has a role in exploring
the internal consistency of the model (see Model validation). This is because, as a precursor to any attempt
to explore the sensitivity of the model to a change in parameters, we needed first to ensure that the
internal logic of the model was correct.
There is no accepted procedure for testing the elasticity of a stochastic model. Swartzman251 recommends
that a successful method meets the following criteria: (a) it must be clearly defined, straightforward and
specify the number of model runs required; (b) it must account for the effects of interactions between
parameters; (c) it must include information on the variability associated with parameter estimates; and
(d) it must allow interpretation for several output variables. Here we present our protocol for a sensitivity
analysis of a Markov chain simulation model which includes all of these features. We use Latin hypercube
sampling to sample the data range of each input variable, using the restricted pairing technique of Iman
and Conover252 to eliminate correlation between input variables. In addition, the calculation of partial
correlation coefficients for each input variable takes into account the variance in model results caused by
other input variables and calculates the proportion of the variance in the output which is uniquely
accounted for by each input variable.
TABLE 67 Utilities used for adverse events
Side effect Utility Source
UI 0.830 Ramsay 2012218
ED 0.840 Ramsay 2012218
BD 0.720 Hummel 2010245
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An elasticity analysis was performed on each of the nine primary treatment pathways. The pathways for
these nine treatments differ in terms of the primary and subsequent treatments employed; for example, all
ablative therapies follow the same treatment pathway because they share the same options for salvage
treatments, even though some of these treatments may have different frequencies of use with different
primary ablative treatments. The nine treatment pathways considered were:
l radical surgery
l radical surgery with adjuvant radiotherapy
l radical surgery with pelvic lymphadenectomy
l radical surgery with pelvic lymphadenectomy and adjuvant radiotherapy and hormonal therapy
l ablative therapy
l brachytherapy
l brachytherapy with adjuvant hormonal therapy
l EBRT
l EBRT with adjuvant hormonal therapy.
Latin hypercube sampling253 was used to generate sets of parameter values from uniform distributions of
known or estimated ranges. The aim was to provide a range of input values for each variable that could
potentially occur under clinical conditions. In other words, the model would be run a sufficiently large
number of times to encompass the potential range of conditions that occur naturally, rather than simply
worst- and best-case scenarios.254 In this method, sample values of the input parameters were selected by
a randomisation procedure subject to constraints on the extent of correlation of input variables that were
imposed by the modeller. There were insufficient data available to identify the distribution function for
all parameters; furthermore, there were no data available to assess the extent to which each of the life
history parameters was correlated with the others. A uniform distribution was therefore assumed for each
variable, with upper and lower limits derived from the literature, and variables were also assumed to be
independent of each other. This approach will lead to an overestimate of the size of the likely universe of
possible values that each life history parameter could take. This is because, firstly, it is likely to lead to the
selection of values for parameters that are near the extremes of their distributions more frequently than
would be expected in reality. Secondly, the assumption of non-independence between the life history
variables will lead to variable pairs being selected in the model that are unlikely to occur in the field
(e.g. high mortality and high fecundity). On the other hand, it also ensures that all potential values
(within the known range of observed behaviours for each variable) are sampled. In other words, although
we know that the hyperspace of possible values for each parameter in the model will be larger than
reality, we know that reality lies somewhere in that space and not outside it.
There is a trade-off to consider when choosing the number of simulations to perform in a sensitivity
analysis. In assessing the effects of individual parameters on model output, it is critical not only to be able
to accept the alternative hypothesis of an effect with confidence (i.e. significance, α), but also to have
sufficient confidence in the predictions to avoid mistakenly rejecting the null hypothesis (i.e. power, 1− β).
The power of a statistical test is reliant on the effect size looked for (that is, the posited difference
between the sampled test statistic and the true test statistic) and the number of samples.255 Thus, the
number of input parameter sets generated by the Latin hypercube sampling can be chosen to achieve
the required criteria for significance and power (i.e. minimise type I and type II errors).
In an ideal world, millions of replicates would be performed, producing high statistical power and,
therefore, high confidence in the results. On the other hand, computer run-time dictates the maximum
number of replicates possible, as does the capacity of statistical programs to analyse the data. With a Latin
hypercube sampling procedure, there is a maximum of (n!k−1) parameter sets, where n is the number of
simulations and k is the number of variables. Iman and Helton (1985)256 suggest n> 4/3k as a minimum
number of simulations; however, this number was reached from experience with their models, and is not
necessarily a portable rule.
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Therefore, to investigate the effect of number of simulations on the elasticity analysis, a heuristic approach
was used. The Latin hypercube sampling procedure was used to generate 250 sets of the driving variables
in the model. The restricted pairing technique of Iman and Conover (1982)252 was used, rejecting
parameter sets with significant correlations. The model was then run 250 times, once for each parameter
set. Each model run consisted of a cohort of 1000 patients. Another 250 sets of input parameters were
then generated using the Latin hypercube sampling procedure and the model was run again. This process
was repeated to 250,000 model runs (i.e. 1000 replicates × 250 sets of random driving variables). Each
replicate used the same random seeds to generate probabilities, to maximise the variation caused by
changing the parameter values and minimise the variation caused by random noise. The life history outputs
generated by each parameter set were recorded.
Partial correlation coefficients were calculated between the sets of driving variables and each of the output
variables. Partial correlation coefficients represent the proportion of the correlation coefficient that is due
only to the predictor, having removed variation caused by interactions with the other variables in the
model. Significant partial correlation coefficients therefore indicated which parameter values had a
significant effect on the output variable. Significant partial correlation coefficients were ranked in order
of their F-value, and their sign (positive or negative) was recorded. The power of the partial correlation
coefficients was calculated exactly using the method of Cohen and Cohen.257
Data analysis
Each state and event in the model had a cost and a utility associated with it. For a state, the cost and
utility were incurred in each time step of the model in which the simulated patient remained in the state;
for some states there was an additional cost when the state was first entered. For an event, the cost and
utility were incurred during any time step of the model in which the simulated patient experienced the
event. The sum of the cost in each year and the product of the utilities in each year were summed over
the lifetime of the simulated patient to compute total cost and QALY for that individual.
In all cases, costs and utilities were drawn from a triangular distribution with the listed value as the peak
value, and ± 25% used as the minimum and maximum values (utilities were truncated at zero and unity
respectively). A triangular distribution was chosen as it makes minimal assumptions about the spread
of values within the distribution while still acknowledging the presence of a peak around the calculated
cost, utility or other estimated outcome. The model compared alternative treatments for localised prostate
cancer by simulating for each treatment pathway the following outcomes.
Economic outputs
The economic outputs of the model included:
l Total costs per patient over the patient lifetime. These data tended to be highly skewed as some
patients survived in the model for a long time but also experienced a number of very high-cost events.
These were then summarised at a population level to produce average total cost over the patient
lifetime for each initial treatment.
l Total QALYs of each patient. As noted earlier, this was calculated by summing the yearly products
of the within-year utilities for each state and event. QALYs also tended to have a highly skewed
distribution as some patients experienced an early death or experienced events that greatly reduced the
amount of QALYs they could gain. These were then summarised at a population level to produce
average QALYs for each initial treatment.
l Incremental mean costs.
l Incremental mean QALYs.
l Incremental cost per QALY gained.
l Net monetary benefits.
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Within the base-case analysis, we adopted a NHS perspective and discounted costs and QALYs at the
recommended 3.5% discount rate.231 All costs and QALYs are for a lifetime time horizon and all monetary
values are expressed in 2011–12 prices.
The base-case analysis has assumed that biochemical recurrence does not differ across the procedures,
which is consistent with the evidence in the review of effectiveness presented in Chapters 4–7. However,
an alternative analysis where biochemical recurrence varies according to the results of the meta-analysis of
clinical effectiveness is also reported.
Sensitivity analysis
We addressed uncertainty by conducting probabilistic sensitivity analyses and deterministic (e.g. one-way)
sensitivity analyses. The probabilistic sensitivity analysis involved running 1000 iterations of the model for
each intervention considered for each analysis. These data were then used to prepare cost-effectiveness
plots and cost-effectiveness acceptability curves.258 These curves provide an estimate of the likelihood that
an intervention would be considered cost-effective at different threshold values for society’s willingness to
pay for either a recurrence avoided or a day at usual activities.
The following deterministic sensitivity analyses were considered. A new intervention, AS, was introduced as
an alternative to initial active therapy for localised prostate disease. In effect, this is a policy of delayed and
selective treatment, which might be a viable option where disease is unlikely to become symptomatic over
the expected lifetime of the individual or where the expected harms (in terms of side effects) would be
worse than any symptoms currently experienced. This analysis was facilitated because it was assumed in
the base-case analysis that, for each active treatment, a period of AS would take place for approximately
20% of people. In the modelling, this means that approximately 20% of the model runs for each active
treatment involved AS. These data have been used to construct an additional comparator, AS, to allow
cost-effectiveness analysis to be explored.
Model validation
Internal consistency checks
With respect to face validity the structure of the model and all data inputs were scrutinised by the research
team and the external advisory group to ensure that the model structure suitably reflected the decision
problem addressed and that data inputs and methods to assemble these inputs seemed plausible.
The elasticity analysis provided a further computational validity in that it explored the importance of model
transitions. This provided a check on the mathematical logic of the model and allowed the modelling code
to be tested for errors. Counterintuitive results became the focus of further investigation. Further,
sensitivity analysis (not reported) was used to explore whether or not data had been incorporated correctly.
External validity
Alternative models comparing the cost-effectiveness of these interventions are not available and so this
approach was not available to check external validity. However, the results of the model were checked
with experts to assess their face validity. The model was also used to produce outputs that could be
compared with data not used in the model (because it was not reported in sufficiently disaggregated form
to be incorporated into the model).
Any issues with the internal or external validity of the model or its outputs were resolved prior to producing
the final results reported in the next chapter.
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Chapter 10 Economic evaluation results
Elasticity analysis
An illustration of the elasticity analysis output can be found in Figure 21. It is evident that all edges which lead
to non-cancer mortality reduced the number of cancer-related deaths (coloured dark grey), whereas those
which lead an individual closer to the cancer mortality sink state increased the number of cancer-related
deaths (coloured black). These results are to be expected; what is informative from the elasticity analysis is
that these driving variables are the ones that have the largest impact on the predicted costs and output for
each initial treatment. From this we can identify for which variables it might be most important to obtain
good data in order to estimate outcomes for each intervention and differences between interventions.
For all nine treatment pathways under consideration, the same processes appeared in the ‘top three’
(Table 68). A diagrammatic illustration of the elasticity analysis for ablative therapies is shown in Figure 21.
The output under consideration was the proportion of individuals dying of cancer-related mortality. In this
figure, transitions (edges) coloured dark grey indicate those processes which decreased the mortality from
cancer; those coloured black increased the mortality from cancer. Edges coloured light grey had no
significant impact on this output. The thickness of the edges indicates the relative importance of that process
in cancer-related mortality.
Table 68 and Figure 21 show variables that drive decreases in cancer mortality, which were the probabilities
of patients succumbing to non-cancer mortality during the watchful waiting, castrate-resistant and
other palliative treatment states and the probability of patients proceeding to active monitoring before
undergoing primary treatment. Variables driving any increases in cancer mortality were the probabilities
of patients suffering cancer mortality during the castrate-resistant and palliative care stages, and the
probability of patients proceeding to watchful waiting from diagnosis, and bypassing primary
treatment altogether.
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TABLE 68 Top three processes increasing and decreasing cancer mortality in all nine treatment pathways.
The processes are listed in descending order for each pathway
Treatment Pathway
Top Three processes decreasing
cancer mortality
Top Three processes increasing
cancer mortality
From To From To
Ablative therapy Castrate-resistant
stage
Non-cancer
mortality
Diagnosis Watchful waiting
Watchful waiting Non-cancer
mortality
Castrate-resistant
stage
Cancer mortality
Diagnosis Active monitoring Other palliative
treatment
Cancer mortality
Brachytherapy Castrate-resistant
stage
Non-cancer
mortality
Diagnosis Watchful waiting
Watchful waiting Non-cancer
mortality
Castrate-resistant
stage
Cancer mortality
Diagnosis Active monitoring Other palliative
treatment
Cancer mortality
Brachytherapy with adjuvant
hormonal therapy
Watchful waiting Non-cancer
mortality
Diagnosis Watchful waiting
Castrate-resistant
stage
Non-cancer
mortality
Castrate-resistant
stage
Cancer mortality
Other
palliative treatment
Non-cancer
mortality
Other palliative
treatment
Cancer mortality
EBRT Castrate-resistant
stage
Non-cancer
mortality
Castrate-resistant
stage
Cancer mortality
Watchful waiting Non-cancer
mortality
Diagnosis Watchful waiting
Other palliative
treatment
Non-cancer
mortality
Other palliative
treatment
Cancer mortality
EBRT with adjuvant hormonal
therapy
Watchful waiting Non-cancer
mortality
Other palliative
treatment
Cancer mortality
Castrate-resistant
stage
Non-cancer
mortality
Castrate-resistant
stage
Cancer mortality
Other
palliative treatment
Non-cancer
mortality
Diagnosis Watchful waiting
Radical surgery Castrate-resistant
stage
Non-cancer
mortality
Diagnosis Watchful waiting
Watchful waiting Non-cancer
mortality
Castrate-resistant
stage
Cancer mortality
Diagnosis Active monitoring Other palliative
treatment
Cancer mortality
Radical surgery with adjuvant
radiotherapy
Castrate-resistant
stage
Non-cancer
mortality
Diagnosis Watchful waiting
Watchful waiting Non-cancer
mortality
Castrate-resistant
stage
Cancer mortality
Diagnosis Active monitoring Other palliative
treatment
Cancer mortality
continued
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Incremental cost-effectiveness
Base-case analysis: equal risk of biochemical recurrence
When making the assumption that biochemical recurrence is equivalent, the choice between interventions
is driven by three factors: (i) the cost of the interventions; (ii) perioperative complications; and (iii) the
impact of long-term complications. Table 69 shows the incremental cost-effectiveness analysis for
the comparison of the different interventions. These data are derived from the Monte Carlo simulations.
As this table illustrates, HIFU is, on average, less costly per patient and results in more QALYs than any
of the other interventions. However, this analysis is potentially misleading as it does not display the
imprecision surrounding estimates of costs, QALYs and cost-effectiveness. This imprecision can be
portrayed by plotting the costs and QALYs for each intervention (Figure 22) and, as was described in
Chapter 9, these data can be displayed as cost-effectiveness acceptability curves (Figure 23).
TABLE 68 Top three processes increasing and decreasing cancer mortality in all nine treatment pathways.
The processes are listed in descending order for each pathway (continued )
Treatment Pathway
Top Three processes decreasing
cancer mortality
Top Three processes increasing
cancer mortality
From To From To
Radical surgery with
pelvic lymphadenectomy
Castrate-resistant
stage
Non-cancer
mortality
Diagnosis Watchful waiting
Watchful waiting Non-cancer
mortality
Castrate-resistant
stage
Cancer mortality
Diagnosis Active monitoring Other palliative
treatment
Cancer mortality
Radical surgery with pelvic
lymphadenectomy and
adjuvant radiotherapy and
hormonal therapy
Watchful waiting Non-cancer
mortality
Diagnosis Watchful waiting
Other palliative
treatment
Non-cancer
mortality
Other palliative
treatment
Cancer mortality
Castrate-resistant
stage
Non-cancer
mortality
Castrate-resistant
stage
Cancer mortality
TABLE 69 Base-case analysis: equal biochemical recurrence (probabilistic analysis)
Intervention QALYs Cost (£) Incremental cost per QALY (£)
EBRT 3.69 19,363
HIFU 3.86 19,860 2915
Cryotherapy 3.78 23,010 Dominateda
Brachytherapy 3.75 24,456 Dominated
RP 3.44 26,507 Dominated
a Intervention is more costly but less effective than an intervention that is less costly.
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As Figure 22 illustrates, there is a wide variation in cost and QALYs for each intervention. For all
interventions, the majority of individuals in the Monte Carlo simulation have relatively modest QALYs (< 5)
but with considerably more variation in cost, which reflects the varying intensities of care that they receive
over time. However, a small number of individuals for each intervention experience very low cumulative
costs and considerably more QALYs, reflecting the possibility that some prostate cancers will not
necessarily be problematic and might require considerably less care.
Figure 23 shows that should society not be willing to pay anything for an additional QALY, the
intervention most likely to be cost-effective is EBRT, with an approximately 50% likelihood of being
considered cost-effective. HIFU is more likely to be more costly than EBRT but provides more QALYs,
hence as society’s willingness to pay for a QALY increases, the likelihood that HIFU would be considered
cost-effective also increases. Thus, at threshold values for society’s willingness to pay for a QALY that
might be considered worthwhile – for example, between £20,000 and £30,000 per QALY231 – there is a
70% likelihood that HIFU would be considered cost-effective. Over the same range, the other interventions
(RP, cryotherapy and brachytherapy) have a very low likelihood of being considered cost-effective. It should
be noted, however, that, as Figure 22 illustrates, the interventions are in fact similar and the results shown
in Figure 23 are driven by small differences in costs and QALYs.
Alternative analysis using the results from the meta-analysis for
biochemical recurrence
As an alternative to the base-case analysis, the results in this subsection assume that the results of the
meta-analysis of biochemical recurrence are the most appropriate to use in the model. Table 70 shows that
the rank ordering of interventions has now changed and that EBRT is now the least costly and least
effective intervention, but with HIFU dominating the other treatments. In this analysis, HIFU is associated
with an incremental cost per QALY that is beyond the threshold level generally considered acceptable for
society.231 However, these average data are very sensitive to the skewed data and do not illustrate the
precision surrounding the estimates.
Figure 24 shows the plots of costs and QALYs for each intervention and these are broadly similar to the
plots shown in Figure 22. Likewise, the cost-effectiveness acceptability curve for this analysis (Figure 25)
shows a broadly similar pattern to that shown in Figure 23. Again, HIFU is most likely to be considered
cost-effective at the threshold values for willingness to pay for a QALY that society might be willing to pay.
However, the same caveats as noted above also apply.
TABLE 70 Incremental cost-effectiveness when estimates of biochemical recurrence come from the meta-analysis
(probabilistic analysis)
Intervention QALYs Cost (£) Incremental cost per QALY (£)
EBRT 3.99 11,250
HIFU 4.04 15,648 85,762
Brachytherapy 3.94 18,782 Dominateda
RP 3.60 22,461 Dominated
Cryotherapy 3.39 29,954 Dominated
a Intervention is more costly but less effective than an intervention that is less costly.
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FIGURE 25 Cost-effectiveness acceptability curves when risk of biochemical recurrence is based on the results of the
meta-analysis.
0 5 10 15
Effectiveness (QALYs)
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
160,000
180,000
200,000
St
ra
te
g
y 
co
st
 (
£) Brachy
Cryo
EBRT
HIFU
RP
FIGURE 24 Plots of costs and QALYs for each intervention when risk of biochemical recurrence is based on the
results of the meta-analysis.
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Sensitivity analyses
As there are considerable uncertainties within the data used in the model, analyses have been conducted
where parameters have been changed to plausible extreme values. The results of these analyses for both
probabilistic and deterministic results are shown in Table 71. Of note in the sensitivity analyses is the
reduction in the likelihood that HIFU would be considered cost-effective compared with the base-case
analysis and the analysis using the data from the meta-analysis. This helps illustrate the degree of
uncertainty surrounding some of the data inputs to the model.
In one sensitivity analysis we attempted to construct a new comparator, ‘active surveillance’. The
introduction of an AS option was, on average, less costly and more effective than the immediate use
of an active treatment. However, although interesting, these data need to be treated exceptionally
cautiously and hence they are not further reported.
TABLE 71 Summary of sensitivity analyses results
Sensitivity
analysis Intervention QALYs Cost (£)
Incremental
cost per
QALY (£)
Probability of cost-effectiveness for
different threshold values for society’s
willingness to pay for a QALY (%)
£10,000 £20,000 £30,000 £50,000
Base-case model:
equal biochemical
recurrence
EBRT 3.69 19,363 55 18 16 13
HIFU 3.86 19,860 2915 36 75 76 78
Cryotherapy 3.78 23,010 Dominateda 0 0 0 0
Brachytherapy 3.75 24,456 Dominated 0 2 3 5
RP 3.44 26,507 Dominated 8 6 5 5
Biochemical
recurrence based on
meta-analyses data
EBRT 3.99 11,250 65 25 22 18
HIFU 4.04 15,648 85,762 28 59 58 57
Brachytherapy 3.94 18,782 Dominateda 1 4 6 9
RP 3.60 22,461 Dominated 4 3 3 3
Cryotherapy 3.39 29,954 Dominated 3 9 11 13
Parameters set at a
plausible best case
EBRT 4.02 10,861 51 16 13 12
HIFU 4.22 11,670 4020 43 71 70 70
Brachytherapy 4.01 17,882 Dominateda 0 1 2 3
RP 3.75 17,521 Dominated 3 4 4 4
Cryotherapy 3.42 30,764 Dominated 2 7 10 12
Parameters set at a
plausible worst case
EBRT 3.72 19,550 54 22 19 17
HIFU 3.92 19,692 690 22 60 61 60
Brachytherapy 3.41 31,003 Dominateda 3 6 6 9
RP 3.03 34,322 Dominated 14 4 4 4
Cryotherapy 3.33 31,651 Dominated 6 9 10 10
a Intervention is more costly but less effective than an intervention that is less costly.
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Summary
The economic evaluation suggests that HIFU might be the intervention that is most likely to be considered
cost-effective when assessed against threshold values for a cost per QALY that society might be willing to
pay. There is marked uncertainty within the analyses as plausible extremes would suggest that EBRT may
also be most likely to be considered cost-effective in some circumstances. Over the limited range of
analyses, cryotherapy, brachytherapy and RP were unlikely to be viewed as cost-effective over the
threshold values considered. It is, however, important to note that given the uncertainties surrounding
parameter estimates and the similarities in costs and QALYs estimated, as illustrated by Figure 22, it is not
impossible that plausible combinations of data inputs could be identified that could make these
interventions appear cost-effective.
Thus, the results presented here are unlikely to be sufficient to form recommendations to change practice,
but they do indicate that further robust studies around HIFU and EBRT as treatment options for localised
prostate cancer may be useful.
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Chapter 11 Discussion
Clinical effectiveness and harms
Primary ablative therapy
Statement of principal findings
The systematic review assessed the evidence for the clinical effectiveness and cost-effectiveness of ablative
therapies in comparison with standard interventions for the management of localised prostate cancer,
in a comprehensive and robust manner. Meta-analysis of studies was performed whenever the data
allowed for it, which, unfortunately, was not often, with the majority of studies suffering from clinical and
methodological heterogeneity. A total of 34,159 patients who underwent ablative therapy were included
across 76 studies.36,49,52,98–103,105–110,113,114,116,117,119–133,135,136,138,139,142–145,149–151,153–156,158–163,166,170–174,176,182,184–186,188,189,
191,195,202–207 Brachytherapy accounted for 76.5% of patients, with all brachytherapy studies being either
NRCSs (39/41 studies)36,100,101,103,105,108–110,113,117,119,121,123,126,128,130,131,135,136,144,145,149,151,153,156,160,163,170–172,176,182,184,186,
189,203,205–207 or RCTs (2/41 studies).49,121 As such, the evidence base for brachytherapy is inherently more
reliable. In contrast, for non-brachytherapy ablative therapies, the majority of studies (35/40) were
case series.52,98,99,102,106,107,114,116,120,122,124,127,129,132,133,138,139,142,143,150,154,155,158,159,161,162,166,173,174,185,188,191,195,202,204
The majority of included ablative studies involved total gland ablation. For the newer development of
focal ablative therapy (incorporating hemigland, nerve-sparing or focal ablation), 10 studies were
included,52,98,99,103,127,129,138,166,188,202 recruiting a total of 1525 patients; more than 90% of these patients
underwent focal cryotherapy. The majority of these studies (9/10) were case series.52,98,99,127,129,138,166,188,202
Clinical effectiveness and harms of ablative therapies (whole-gland or
non-focal intention)
For cryotherapy and HIFU, the evidence relating to cancer-specific outcomes, such as biochemical
recurrence or survival, was limited by the lack of long-term follow-up data and by contradictory findings.
There were some observed differences in biochemical recurrence in the short-term favouring EBRT over
HIFU, but these differences were lost in the longer term beyond 1 year, and probably reflect clinical
heterogeneity between the studies, whereby patients in the EBRT studies, in general, had lower-risk
prostate cancer at baseline than those in the HIFU studies. At best, the review found no robust evidence
to suggest that mortality or other cancer-specific outcomes were significantly different between either
cryotherapy or HIFU, versus either EBRT or RP, for people treated for localised prostate cancer. In terms of
functional outcomes, both cryotherapy and HIFU appeared to have a better rate of urinary incontinence
at 1 year than RP, but this apparent benefit was lost in the longer term. There were insufficient data to
comment on ED. Cryotherapy was associated with fewer short-term adverse effects or periprocedural
complications than either RP or EBRT, whereas HIFU, although it appeared to have a reasonable safety
profile, was associated with a slightly higher urethral stricture rate than EBRT.
The data concerning brachytherapy were more robust and reliable than for either cryotherapy or HIFU.
There was some evidence that cancer-specific outcomes following brachytherapy were no worse than those
following either EBRT or RP, at least in the short term. It was quite encouraging to note that brachytherapy
appeared to be associated with better functional outcomes, with lower incontinence and ED rates in the
medium term (up to 5 years) than either EBRT or RP. However, brachytherapy carried a higher risk of some
adverse effects, especially dysuria, urinary retention, genitourinary toxicity and urethral stricture.
Apart from cryotherapy, HIFU and brachytherapy, only two other ablative therapies were identified in the
review, namely focal laser ablative therapy and vascular-targeted PDT. Data were too scarce (the total
number of patients included in studies for these two procedures was 35) for any definitive conclusions to
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be made, apart from the observation that there was no evidence to suggest that the procedures were not
safe or were not associated with a low risk of adverse events.
Clinical effectiveness and harms of focal ablative therapy (hemigland,
nerve-sparing or focal ablation)
The evidence for focal ablative therapy, although limited, was largely obtained from studies involving focal
cryotherapy. This suggested that cancer-specific outcomes for focal cryotherapy were at least comparable
with those observed in full-gland cryotherapy studies. There was a suggestion that urinary incontinence
rates may be lower following focal cryotherapy than following whole-gland cryotherapy, but this assertion
may be unreliable owing to the poor quality and quantity of data. For focal HIFU, no comparative data were
available to make any judgements regarding most effectiveness outcomes, apart from adverse events, for
which there did not appear to be any significant difference between focal and whole-gland HIFU.
Clinical effectiveness and harms of ablative therapies versus active
surveillance for low-risk localised disease
For low-risk localised prostate cancer, there is an increasing trend towards adopting AS as a viable
management option in current clinical practice. As such, comparative evidence involving ablative therapies
versus AS for low-risk localised disease is potentially important, especially for focal ablative therapies.
Subgroup analysis from the review found that there was no evidence of any significant difference in any of
the outcomes, including cancer-specific, functional and adverse event outcomes, between any of the focal
ablative therapies and AS, although data were scarce, with significant heterogeneity of outcome definition
and measurement.
In summary, the results of this review and meta-analysis regarding clinical effectiveness and harms were
associated with a considerable degree of uncertainty owing to the poor quality of studies identified. There
was a lack of data on long-term direct measures of effectiveness, and a lack of prospective comparative
studies, which considerably limited the quality of the evidence synthesised from the review.
Salvage ablative therapy
Statement of principal findings
This review included data from 400 participants who were treated with salvage therapy following primary
EBRT across nine studies.120,208–215 All studies were single-arm case series, which severely limits the reliability
and strength of the conclusions. Six studies involved salvage RP,209–211,213–215 whereas two involved salvage
cryotherapy,208,212 and one salvage HIFU.120 In the majority of studies (six out of nine120,208–211,214), data were
not collected prospectively, and were restricted to short-term outcomes only. As such, all of the studies
were considered as having a high risk of bias. With those limitations in mind, there was no robust evidence
that mortality or other cancer-specific outcomes (i.e. biochemical disease-free survival or failure) differed
between salvage cryotherapy and salvage RP in the short term. There were no data on cancer-specific
outcomes for salvage HIFU. With regard to functional and quality of life outcomes, the paucity of data
prevented any definitive conclusions from being made. In terms of adverse event outcomes, salvage
cryotherapy appeared to be associated with fewer periprocedural complications (especially for bladder neck
stenosis) than salvage HIFU or salvage RP, but there was a high level of uncertainty with this observation.
In summary, the findings for salvage ablative therapy were associated with significant uncertainty on
account of the very limited quality and quantity of the evidence base. There was a lack of long-term direct
measures of effectiveness and a lack of prospective comparative studies. Data on the long-term
effectiveness of salvage therapy were limited, with the majority of studies reporting on short-term data
only. In addition, the evidence base was seriously marred by heterogeneity of outcome definition, different
time points of outcome measurement and different means of outcome measurement and reporting.
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Cost-effectiveness of primary ablative therapies
Statement of principal findings
The first stage of the economic analysis was an elasticity analysis. The elasticity analysis helped identify which
transition probabilities were the principal determinants of survival. This analysis was conducted for each
intervention and showed that many of the principal determinants of survival were related to the characteristics
of the initial cancer and many of the probabilities of outcomes following recurrence. Of moderate importance
was the performance of individual therapies in preventing or delaying recurrence. In the economic evaluation
that compared alternative interventions, the probabilities of events following recurrence were generally the
same for all interventions and hence their effect on estimates of cost-effectiveness would be entirely caused
by differences in recurrence rates between interventions.
With respect to the economic evaluation itself, the results of this analysis suggest that HIFU might be the
intervention that is most likely to be considered cost-effective when assessed against threshold values for a
cost per QALY that society might be willing to pay.231 There is marked uncertainty within the analyses as
plausible extremes would suggest that EBRT may also be most likely to be considered cost-effective in some
circumstances. Over the limited range of analyses, cryotherapy, brachytherapy and RP were unlikely to be
viewed as cost-effective over the threshold values for society’s willingness to pay for a QALY that were
considered. It is, however, important to note that given the uncertainties surrounding parameter estimates
and the similarities in costs and QALYs estimated (as illustrated by Figure 22), it is quite possible that plausible
combinations of data inputs could be identified that could make these interventions appear cost-effective.
Thus, the results presented here are unlikely to be sufficient to form recommendations to change practice,
but they do indicate that further robust studies around the relative effectiveness and cost-effectiveness of
HIFU and EBRT as treatment options for localised prostate cancer may be most useful.
Strengths and limitations of the assessment
Clinical effectiveness
The main strength of the study is the systematic approach taken to review the literature. Exhaustive
systematic searches were made of the major electronic databases. All potentially relevant studies were
reviewed for eligibility. The risk of bias of included comparative studies and quality assessment of included
case series were assessed using the best available tools. To prevent any biases caused by selective data
abstraction, all outcomes were predetermined by both expert panel and patient focus group consensus.
Any data were extracted using standard forms. Despite these efforts it is possible that some relevant data
remained hidden as a result of non-publication.
In total, 121 reports were included.36,49,52,98–215 Although this number of studies seems impressive, not every
study contributed data to each outcome. Furthermore, differences in reporting between studies also
limited the opportunities for robust meta-analysis. Given the limited evidence base, the CrIs around many
of the estimates of differences were wide and included differences that would be clinically important but
could favour any of the therapies under investigation. Another major limitation resulted from the majority
of comparisons using case series, with few head-to-head comparisons of ablative therapies against current
practice. The estimates were therefore generated using indirect comparisons. Like all analyses, they
require assumptions to be made that may or may not be reasonable. In the context of this analysis, an
important assumption is that the studies in each meta-analysis were representative of a similar population
(i.e. the clinical and demographic characteristics of the people were similar across studies). Data in Table 2
demonstrated that the assumption had broad face validity, but that there were some differences, such as a
slight increase in the average clinical stage for people in the EBRT study. Accordingly, the results should be
interpreted with a large degree of caution.
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A further methodological limitation that frustrated pooled analysis was the use of differing definitions and
measures of functional outcomes for urinary, erectile and bowel dysfunction. The variety of different ways
of measuring dysfunction reduced the ability to narratively compare data or to conduct a comprehensive
meta-analysis. Although in part the difficulty is reflected by changing measurement methodology over
time, it will remain a problem until consensus on important outcome measurements in this clinical area can
be agreed. Initiatives such as the UK Medical Research Council- and European Union-funded Core
Outcome Measures in Effectiveness Trials (COMET) or Consensus-based Standards for the Selection of
Health Measurement Instruments (COSMIN) may be useful in this context. Such initiatives help patients,
clinicians and researchers to develop a standardised set of outcomes that should be measured and
reported as a minimum in all clinical trials of a specific condition, thereby making it easier to contrast and
synthesise the results of trials.
Identifying outcomes that can be used to compare ablative therapies with both AS and RP or EBRT was
challenging. Long-term survival is a key outcome that could be used consistently across studies, but it
is limited because differences are unlikely to be observed for at least 10–15 years, and few of the ablative
studies had such length of follow-up. Dysfunctional and quality of life outcomes can be used for
comparison, but were limited for the reasons given previously. Need for further (systemic) treatment may
also be used to contrast all therapies, but again this was rarely reported in the studies. All of these issues
contributed to the review providing little information on the comparative effectiveness of AS and
active treatment.
Cost-effectiveness
The cost-effectiveness analysis shares the strengths and limitations of the review of effectiveness, as the
estimates derived from the review of effectiveness were important input parameters into the economic
model. The data on relative effectiveness are, however, only one component of the estimation of
cost-effectiveness. Rigorous attempts were made to develop a model of the disease and care pathways for
localised prostate cancer. Within an elasticity analysis, the importance of individual probability parameters
was explored to help prevent the distorted assembly of data and focus the research effort on the assembly
of data inputs into the model on the most important elements. Computationally, the elasticity analysis is
very demanding and in this analysis the focus was on survival. A similar elasticity analysis could, however,
have been performed for other key outcomes, but both total costs and QALYs are closely related to
survival and hence might not provide further information of sufficient value to warrant the additional costs
of conducting the research. What would, however, be of value would be to consider the elasticity analysis
in a comparative analysis of different therapies, as many of the probabilities identified in the elasticity
analysis as being important are, or are assumed to be, the same between treatments.
The rigorous attempts to assemble other data inputs have reduced some of the uncertainties that are
faced. The probabilistic sensitivity analysis that was performed attempted to explore the imprecision
around model outputs. Largely this was accomplished by using triangular distributions. Ordinarily, such an
approach would not be recommended, but the use of alternative distributions would have required an
additional set of assumptions, given the lack of data, to define the distribution. Therefore, in this analysis
we have assumed a simpler triangular distribution.
The assembly of data on costs of interventions was based on an intensive micro-costing exercise, and other
cost data were derived so as to be most applicable to this decision-making context. The assembly of data
on health state utilities was likewise systematic and focused on identifying the most applicable data for
the decision problem. Nevertheless, the extant data were, in places, sparse or not well suited to the study
and necessitated a number of strong assumptions to be made. Among these are the utilities that would
be applicable during the recovery phase. Within the model, these were derived based on expert advice and
consideration of data for related events. It is questionable how accurate these assumptions actually are.
Ideally, an exercise to systematically derive empirical estimates of relevant health state utilities would
be undertaken.
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A further limitation imposed by the nature of the clinical evidence is the limited data that are available to
explore clinical uncertainties. Three distinct clinical questions have not been addressed. These are: (i) what
is the role of AS as opposed to immediate treatment with an active therapy?; (ii) are focal therapies more
cost-effective than whole-gland ablative therapies?; and (iii) what is the optimal form of salvage therapy?
With respect to (i), some exploratory analysis around the value of AS was performed. The results of this
analysis appeared to suggest that AS would be associated with a substantial survival benefit. However,
given the structure of the model and the data used, these results were judged to be unreliable as it was
felt that given the data available, AS was essentially just adding a delay in the development of the disease.
With respect to (ii), we would expect little difference in the costs of focal compared with whole-gland
ablation, and some gains in QALYs and reductions in costs if the probabilities of incontinence were
avoided. However, the impact on costs and QALYs of ‘early’ reoperation and of difference in recurrence
rates in the medium and long term are unknown. For the third clinical question that remained
unanswered, regarding which is the best salvage therapy, the model structure was designed to be able to
address this but too few data were available to populate the model. These three clinical questions remain
options for further primary research.
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Chapter 12 Conclusions
Implications for health care
The increasing incidence of low- and medium-risk localised prostate cancer indicates that demand for
treatment interventions which are less aggressive than the established radical treatments will likely increase
over the next decade in the UK. Such interventions include ablative therapy, which appears to be the ideal
intervention because, unlike AS, it actively treats cancer while being minimally invasive and potentially
organ-sparing, unlike either RP or EBRT. This review was tasked with assessing the evidence base regarding
the clinical effectiveness and cost-effectiveness of ablative therapy for people with localised prostate cancer
in the NHS.
For primary ablative therapy, neither cryotherapy nor HIFU had sufficiently robust data to enable any
definitive conclusions to be made in regard to their clinical effectiveness, harms or cost-effectiveness in
comparison with RP, EBRT or AS. The data on brachytherapy were more robust, although there were some
limitations which resulted in some uncertainties surrounding the estimates. Nevertheless, there was
some evidence that cancer-specific outcomes in the short term were either better than or equivalent to
those of either EBRT or RP, with comparable adverse effect profiles apart from a possible increased risk of
dysuria and urinary retention. The findings on focal ablative therapy were mostly derived from data on
focal cryotherapy, which suggested that cancer-specific outcomes were at least comparable with those of
full-gland cryotherapy, and there was a suggestion that UI outcome may be better following focal
cryotherapy than whole-gland cryotherapy. In terms of the economic analysis, the findings suggest that
of all the ablative interventions, HIFU is the most likely to be considered cost-effective when assessed
against threshold values for a cost per QALY that society might be willing to pay. However, marked
uncertainties within the analyses, and the lack of reliable estimates of its clinical effectiveness and harms,
mean that the cost-effective advantage needs to be interpreted cautiously. At best, the data highlight that
this modality might be a good target for further robust primary research.
For salvage ablative therapy following primary EBRT, a lack of reliable and robust data prevented any
meaningful conclusions from being made, in comparison with salvage RP.
The findings from the review indicate that there is insufficient evidence to form any clear recommendations
on the use of ablative therapies which either influence or change current clinical practice.
Implications for research
The main gaps in the evidence base are the lack of direct comparative studies of ablative therapies, the
role of focal ablative therapies and the lack of longer-term data on cancer control, such as overall and
cancer-specific mortality. To investigate if the evidence base will improve, we conducted a search for
ongoing studies. We found the following ongoing studies as of 3 October 2013.
Brachytherapy
Five case series of focal brachytherapy;259–263 four case series of whole-gland brachytherapy;264–267 one RCT
of brachytherapy versus EBRT;268 one RCT of brachytherapy versus RP;269 and one RCT of brachytherapy
versus radiotherapy versus RP versus AS;270 and one NRCS of RP versus EBRT versus brachytherapy versus
AS versus cryotherapy.271
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
Cryotherapy
Two case series of focal cryotherapy;272,273 one case series of whole-gland cryotherapy;274 one case series of
whole-gland salvage cryotherapy,275 one NRCS of cryotherapy versus RP versus radiotherapy;276 and one
case series of focal salvage cryotherapy and HIFU.277
High-intensity focused ultrasound
Three case series of focal HIFU278–280 and one case series of whole-gland HIFU.281
Other ablative therapies
One case series of focal laser ablation;282 one case series of whole-gland laser ablation;283 one case series
of whole-gland PDT;284 and one RCT of focal PDT versus AS.285 In addition, we identified two case series of
cyberknife;286,287 one RCT of hemi versus total irreversible electroporation [Nanoknife® (AngioDynamics,
Latham, NY)] ablation;288 one case series of focal irreversible electroporation;289 one case series of
irreversible electroporation 30 days prior to prostatectomy;290 and one case series of transurethral
ultrasound ablation291 and one case series of hypofractionated radiosurgery.292
In general, the ongoing studies clearly illustrate that the evidence base for ablative therapies is following
an upwards trajectory, and, in particular, the evidence for focal ablative therapies is likely to increase in
quantity. However, it is also clear that the quality of the evidence base will not be substantially improved
given that the majority of the ongoing studies are case series. Research efforts in the use of ablative
therapies in the management of prostate cancer should now be concentrated on the performance of more
rigorous, high-quality studies. Lessons from our systematic review lead us to the following areas in which
further research would be important:
1. HIFU and brachytherapy seem the most promising newer interventions but they lack high-quality
evaluation. Such evaluation should ideally be by multicentre RCT with long-term follow-up, and would
include predefined assessment of cancer-specific, dysfunction and HRQoL measures. Such studies
should incorporate economic evaluations and also inform economic modelling.
2. The role of focal therapies in the management of people with localised prostate cancer should be
investigated. It may be desirable to incorporate the focal approach into the design described above. It is
noted, however, that use of focal therapies is dependent on prior precise localisation of the cancer for
which the technology remains developmental.
3. AS is an increasingly used strategy for people with localised prostate cancer that is deemed to be at low
initial risk of spread. The results of ongoing studies are required to assess its safety, acceptability to
people with prostate cancer and cost-effectiveness.
4. Agreed definitions of outcomes in urology and agreed measures for recording them are urgently
needed. Partnership between governing bodies and international initiatives such as COSMIN and
COMET may be desirable.
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Appendix 1 Search strategy
Ablative therapies for prostate cancer: clinical effectiveness
Database: EMBASE (1974 to week 13, 2013), Ovid MEDLINE(R) (1946 to
March week 3, 2013), Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations (29 March 2013)
Ovid multifile search URL: https://shibboleth.ovid.com/
Search strategy
1. Prostatic Neoplasms/ use mesz
2. exp prostate cancer/ use oemez
3. (prostat$ adj3 (neoplasm$ or cancer or carcinoma or tumo?r$ or malignan$)).tw.
4. or/1-3
5. ablation techniques/ use mesz
6. ablation therapy/ use oemez
7. (ablation or ablative).ti.
8. brachytherapy/
9. interstitial radiation/ use oemez
10. brachytherap$.tw.
11. (seed$ adj3 implant$).tw.
12. ((interstitial or intracavit$ or implant$ or surface) adj3 radio$).tw
13. cryosurgery/
14. (cryotherap$ or cryoablat$ or cryosurg$).tw.
15. exp High-Intensity Focused Ultrasound Ablation/ use mesz
16. high intensity focused ultrasound/ use oemez
17. (hifu or “high intensity focused ultrasound”).tw.
18. Photochemotherapy/ use mesz
19. photodynamic therapy/ use oemez
20. (photodynamic adj3 (therap$ or treat$)).tw.
21. (photosensitiv$ or phototherm$).tw.
22. exp Light Coagulation/
23. (laser adj3 (photocoagulat$ or coagulat$ or therap$ or treat$)).tw.
24. laser surgery/
25. laser coagulation/ use oemez
26. (laser adj3 (ablat$ or interstitial tumo?r)).tw.
27. radiofrequency interstitial tumo?r ablat$.tw.
28. rita.tw.
29. catheter ablation/
30. ((focal or focus$) adj3 (therap$ or treat$)).tw.
31. hemi?ablat$.tw.
32. or/5-31
33. 4 and 32
34. (external beam adj3 (radiotherapy or radiation)).tw.
35. ebrt.tw.
36. Radiotherapy, Conformal/ use mesz
37. external beam radiotherapy/ use oemez
38. ((active or expectant or conservative) adj3 (management or surveillance or treatment)).tw.
39. watchful waiting.tw.
40. Watchful Waiting/
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41. conservative treatment/ use oemez
42. or/34-41
43. 4 and 42
44. exp clinical trial/ use oemez
45. randomized controlled trial.pt.
46. controlled clinical trial.pt.
47. randomization/ use oemez
48. randomi?ed.ab.
49. randomly.ab.
50. trial.ab.
51. groups.ab.
52. or/44-51
53. (exp animals/ or nonhuman/) not humans/
54. 52 not 53
55. 33 and 54
56. 43 and 54
57. 55 or 56
58. comparative study/ use mesz
59. controlled study/ use oemez
60. (compare$ or compara$).tw. use oemez
61. or/58-60
62. 61 and (33 or 43)
63. 62 not 53
64. 63 not 57
65. limit 64 to english
66. follow-up studies/ use mesz
67. time factors/ use mesz
68. Treatment outcome/ use oemez
69. major clinical study/ use oemez
70. survival rate/
71. (chang$ or evaluat$ or reviewed or baseline).tw.
72. (prospective$ or retrospective$).tw. use mesz
73. (cohort$ or case series).tw. use mesz
74. or/66-73
75. case report/ use oemez
76. case reports.pt.
77. 74 not (75 or 76)
78. 77 not 53
79. 33 and 78
80. 4 and (38 or 39 or 40 or 41)
81. 80 and 78
82. 79 or 81
83. 82 not (57 or 65)
84. limit 83 to english
85. 57 or 65 or 84
86. 85 not conference abstract.pt.
87. 86 not (letter or editorial or review or comment or note or short survey).pt.
88. remove duplicates from 87
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Science Citation Index (1970 to 1 April 2013)
Bioscience Information Service (1956 to 1 April 2013)
ISI Web of Knowledge URL: http://wok.mimas.ac.uk/
Search strategy
# 1 (TS=(prostat* NEAR/3 (neoplasm* or cancer or carcinoma or tumour* or tumor* or malignan*))
# 2 (TS=(ablation or abalative))
# 3 (TS=brachytherap*)
# 4 (TS=(seed NEAR/3 implant*))
# 5 (TS=((interstitial or intracavit* or implant* or surface) NEAR/3 radio*))
# 6 (TS=(cryotherap* or cryoablat* or cryosurg*))
# 7 (TS=(hifu or “high intensity focused ultrasound”))
# 8 (TS=photochemotherap*)
# 9 (TS=(photodynamic NEAR/3 (therap* or treat*)))
# 10 (TS=(photosensitiv* or phototherm*))
# 11 (TS=light coagulat*)
# 12 (TS=(laser NEAR/3 (ablat* or interstitial)))
# 13 (TS=rita)
# 14 (TS=(“radiofrequency interstitial” NEAR/2 ablat*))
# 15 (TS=catheter ablat*)
# 16 (TS=((focal or focus*) NEAR/3 (therap* or treat*)))
# 17 (TS= (hemi ablat* or hemiablat*))
# 18 (#2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #15 or #16 or #17)
# 19 (#1 and #18)
# 20 (TS= (“external beam” NEAR/3 (radiotherap* or radiation)))
# 21 (TS=watchful waiting)
# 22 (TS=((active or expectant or conservative) NEAR/3 (management or surveillance or treatment)))
# 23 (#20 or #21 or #22)
# 24 (#1 and #23)
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# 25 (#19 or #24)
# 26 (TS=(randomized or randomised))
# 27 (TS=randomly)
# 28 (#25 and (#26 or #27))
# 29 (TS=control group*)
# 30 (TS=control arm*)
# 31 (TS=comparative)
# 32 (TS=trial)
# 33 (#25 and (#29 or #30 or #31 or #32)) AND Language=(English)
# 34 (#19 not (#28 or #33)) AND Language=(English)
# 35 (#34 and su=oncology) AND Language=(English)
# 36 (#35 OR #33 OR #28 ) AND Document Types=(Article)
The Cochrane Library issue 3, 2013 (CENTRAL, Cochrane Database of
Systematic Reviews, Database of Abstracts of Reviews of Effects,
Health Technology Assessment Database, NHS EED)
URL: www3.interscience.wiley.com/
Search strategy
#1 MeSH descriptor Prostatic Neoplasms, this term only
#2 (prostat* NEAR/3 (neoplasm* or cancer or carcinoma or tumor* or tumour* or malignan*)):ti,ab,kw
#3 (#1 OR #2)
#4 MeSH descriptor Ablation Techniques, this term only
#5 MeSH descriptor Brachytherapy, this term only
#6 MeSH descriptor Cryosurgery, this term only
#7 MeSH descriptor High-Intensity Focused Ultrasound Ablation explode all trees
#8 MeSH descriptor Photochemotherapy, this term only
#9 MeSH descriptor Light Coagulation explode all trees
#10 MeSH descriptor Laser Therapy, this term only
#11 MeSH descriptor Catheter Ablation, this term only
#12 MeSH descriptor Radiotherapy, Conformal, this term only
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#13 MeSH descriptor Watchful Waiting, this term only
#14 (ablation or ablative):ti,ab,kw
#15 (brachytherap*):ti,ab,kw or (seed* NEAR/3 implant*):ti,ab,kw or (cryotherap*):ti,ab,kw or (cryosurg*):
ti,ab,kw or (cryoablat*):ti,ab,kw
#16 (radio* NEAR/3 (interstitial or intracavit* or implant* or surface)):ti,ab,kw 225 edit delete
#17 (hifu):ti,ab,kw or “high intensity focused ultrasound”:
#18 (photosensitiv*):ti,ab,kw or (phototherm*):ti,ab,kw or (photodynamic NEAR/3 (therap* or treat*)):ti,
ab,kw
#19 (rita):ti,ab,kw or “radiofrequency interstitial”:ti,ab,kw
#20 (hemiablat*):ti,ab,kw or (hemi ablat*):ti,ab,kw or (focal NEAR/3 (therap* or treat*)):ti,ab,kw or (focus*
NEAR/3 (therap* or treat*)):ti,ab,kw
#21 (laser near/3 (ablat* or interstitial or therap*)):ti,ab,kw or (laser near/3 (photocoagulat* or coagulat*
or treat*)):ti,ab,kw
#22 “external beam” near/3 (radiotherap* or radiation):ti,ab,kw or (ebrt):ti,ab,kw
#23 (watchful waiting):ti,ab,kw or (active near/3 (management or surveillance or treatment)):ti,ab,kw or
(expectant near/3 (management or surveillance or treatment)):ti,ab,kw or (conservative near/3
(management or surveillance or treatment)):ti,ab,kw
#24 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #15 OR #16 OR #17 OR
#18 OR #19 OR #20 OR #21 OR #22 OR #23)
#25 (#3 AND #24)
Scopus (1 April 2013)
URL: www.scopus.com/home.url
Search strategy
(“prostate cancer”)) AND ((TITLE-ABS-KEY(prostatectomy OR radation OR surveillance OR salvage) AND
DOCTYPE(ip)) OR (TITLE-ABS-KEY(ablation OR brachytherapy OR cryotherapy OR hifu OR laser OR pdt)
AND DOCTYPE(ip))) AND (LIMIT-TO(PUBYEAR, 2013) OR LIMIT-TO(PUBYEAR, 2012)) AND (LIMIT-TO
(LANGUAGE, “English”))
Health Technology Assessment/Database of Abstracts of Reviews of Effects
(September 2012)
Centre for Reviews and Dissemination URL: http://nhscrd.york.ac.uk/welcome.htm
Search strategy
1. MeSH DESCRIPTOR Prostatic Neoplasms
2. MeSH DESCRIPTOR Ablation Techniques
3. MeSH DESCRIPTOR cryosurgery EXPLODE ALL TREES
4. MeSH DESCRIPTOR High-Intensity Focused Ultrasound Ablation EXPLODE ALL TREES
5. MeSH DESCRIPTOR brachytherapy
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6. MeSH DESCRIPTOR photochemotherapy EXPLODE ALL
7. MeSH DESCRIPTOR light coagulation EXPLODE ALL TREES
8. MeSH DESCRIPTOR Laser Therapy
9. MeSH DESCRIPTOR Catheter Ablation
10. MeSH DESCRIPTOR Radiotherapy, Conformal
11. MeSH DESCRIPTOR Watchful Waiting
12. (ebrt) OR (hifu) OR (rita)
13. (external beam) OR (hemiablat &or hemi ablat*) OR (ablat*)
14. (focal) OR (focus*)
15. (expectant) OR (conservative) OR (active)
16. (photosentitiv*) OR (phototherm*) OR (photodynamic)
17. (radiofrequency) OR (radiotherapy)
18. #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
OR #16 OR #17
19. #1 AND #18
ClinicalTrials.gov (September 2012)
URL: http://clinicaltrials.gov/ct/gui/c/r
Search strategy
Condition=prostatic neoplasms
Interventions=brachytherapy or cryotherapy or cryoablation or cryosurgery or ablation or focal or focus* or
hifu or high intensity focussed ultrasound or photo* or laser or coagulation
Current Controlled Trials (September 2012)
URL: www.controlled-trials.com/
Search strategy
Prostat% cancer
International Clinical Trials Registry Platform (ICTRP) (September 2012)
World Health Organization URL: www.who.int/ictrp/en/
Search strategy
Condition=prostat* cancer
Intervention= brachy* or cryo* or ablation or focal or focus* or hifu or photo* or coagulation
Additional searches for salvage prostatectomy after external
beam radiotherapy
EMBASE (1980 to week 13, 2013), Ovid MEDLINE(R) (1946 to March week 3,
2013), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
(29 March 2013)
Ovid multifile search URL: https://shibboleth.ovid.com/
Search strategy
1. exp prostatic neoplasms/su use mesz
2. exp prostate cancer/su use emez
3. or/1-2
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4. prostatic neoplasms/ use mesz
5. exp prostate cancer/ use emez
6. (cancer adj3 (prostate or prostatic)).tw.
7. (carcinoma adj3 (prostate or prostatic)).tw.
8. (neoplas$ adj3 (prostate or prostatic)).tw.
9. (malignan$ adj3 (prostate or prostatic)).tw.
10. or/4-9
11. prostatectomy/
12. (radical adj5 prostatectom$).tw.
13. surgical procedures,operative/ use mesz
14. surgery/ use emez
15. su.fs.
16. (surgery or surgical or surgeon$).tw.
17. (resect $ or operation$ or operate$).tw.
18. or/11-17
19. 10 and 18
20. 3 or 19
21. salvage therapy/
22. (salvage adj5 prostat$).tw.
23. 21 or 22
24. 20 and 23
25. Neoplasm Recurrence, Local/su use mesz
26. Tumor Recurrence/su use emez
27. 10 and (25 or 26)
28. 24 or 27
29. exp clinical trial/ use emez
30. randomized controlled trial.pt.
31. controlled clinical trial.pt.
32. randomization/ use emez
33. randomi?ed.ab.
34. placebo.ab.
35. drug therapy.fs.
36. randomly.ab.
37. trial.ab.
38. groups.ab.
39. or/29-38
40. comparative study/ use mesz
41. follow-up studies/ use mesz
42. time factors/ use mesz
43. Treatment outcome/ use emez
44. major clinical study/ use emez
45. controlled study/ use emez
46. clinical trial/ use emez
47. (preoperat$ or pre operat$).mp. use mesz
48. (chang$ or evaluat$ or reviewed or baseline).tw.
49. (prospective$ or retrospective$).tw. use mesz
50. (cohort$ or case series).tw. use mesz
51. (compare$ or compara$).tw. use emez
52. case report/ use emez
53. case reports.pt.
54. or/39-51 (1)
55. 54 not (52 or 53)
56. 28 and 55
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57. (exp animals/ or nonhuman/) not humans/
58. 56 not 57
59. 58 not (conference abstract or letter or editorial or review or comment or note or short
60. limit 59 to english language
61. remove duplicates from 60
The Cochrane Library issue 3, 2013 (CENTRAL, CDSR, DARE, HTA Database,
NHS EED)
URL: www3.interscience.wiley.com/
Search strategy
#1 MeSH descriptor: [Prostatic Neoplasms]
#2 ((prostate or prostatic) near/3 cancer):ti,ab,kw
#3 ((prostate or prostatic) near/3 carcinoma):ti,ab,kw
#4 ((prostate or prostatic) near/3 neoplas*):ti,ab,kw
#5 ((prostate or prostatic) near/3 malignan*):ti,ab,kw
#6 #1 or #2 or #3 or #4 or #5 4014
#7 MeSH descriptor: [Prostatectomy] explode all trees
#8 (radical near/5 prostatectom$) .:ti,ab,kw
#9 #7 or #8
#10 #6 and #9
#11 MeSH descriptor: [Salvage Therapy] explode all trees
#12 salvage near/5 prostat*
#13 #11 or #12
#14 #10 and #13
Ablation therapies for prostate cancer: quality of life
EMBASE (1980 to week 13, 2013), Ovid MEDLINE(R) (1946 to March week 3,
2013), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
(1 April 2013)
Ovid multifile search URL: https://shibboleth.ovid.com/
Search strategy
1. quality of life/
2. quality adjusted life year/
3. “Value of Life”/ use mesz
4. health status indicators/ use mesz
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5. health status/ use emez
6. sickness impact profile/ use mesz
7. disability evaluation/ use mesz
8. disability/ use emez
9. activities of daily living/ use mesz
10. exp daily life activity/ use emez
11. cost utility analysis/ use emez
12. rating scale/
13. questionnaires/
14. (quality adj1 life).tw.
15. quality adjusted life.tw.
16. disability adjusted life.tw.
17. (qaly? or qald? or qale? or qtime? or daly?).tw.
18. (euroqol or euro qol or eq5d or eq 5d).tw.
19. (hql or hqol or h qol or hrqol or hr qol).tw.
20. (hye or hyes).tw
21. health$ year$ equivalent$.tw.
22. (hui or hui1 or hui2 or hui3).tw.
23. (health adj3 (utilit$ or disutili$)).tw.
24. (health adj3 (state or status)).tw.
25. (sf36 or sf 36 or short form 36 or shortform 36).tw.
26. (sf6 or sf 6 or short form 6 or shortform 6).tw.
27. (sf12 or sf 12 or short form 12 or shortform 12).tw.
28. (sf16 or sf 16 or short form 16 or shortform 16).tw.
29. (sf20 or sf 20 or short form 20 or shortform 20).tw.
30. willingness to pay.tw
31. standard gamble.tw.
32. trade off.tw.
33. conjoint analys?s.tw.
34. discrete choice.tw.
35. or/1-34
36. (case report or editorial or letter).pt.
37. case report/
38. Prostatic Neoplasms/ use mesz
39. exp prostate cancer/ use emez
40. (prostat$ adj3 (neoplasm$ or cancer or carcinoma or tumo?r$ or malignan$)).tw. (186141)
41. or/38-40
42. ablation techniques/ use mesz
43. ablation therapy/ use emez
44. (ablation or ablative).ti.
45. brachytherapy/
46. interstitial radiation/ use emez
47. brachytherap$.tw.
48. (seed$ adj3 implant$).tw.
49. ((interstitial or intracavit$ or implant$ or surface) adj3 radio$).tw.
50. cryosurgery/
51. (cryotherap$ or cryoablat$ or cryosurg$).tw.
52. exp High-Intensity Focused Ultrasound Ablation/ use mesz
53. high intensity focused ultrasound/ use emez
54. (hifu or “high intensity focused ultrasound”).tw.
55. Photochemotherapy/ use mesz
56. photodynamic therapy/ use emez
57. (photodynamic adj3 (therap$ or treat$)).tw.
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58. (photosensitiv$ or phototherm$).tw.
59. exp Light Coagulation/
60. (laser adj3 (photocoagulat$ or coagulat$ or therap$ or treat$)).tw.
61. laser surgery/
62. laser coagulation/ use emez
63. (laser adj3 (ablat$ or interstitial tumo?r)).tw.
64. radiofrequency interstitial tumo?r ablat$.tw.
65. rita.tw.
66. catheter ablation/
67. ((focal or focus$) adj3 (therap$ or treat$)).tw.
68. hemi?ablat$.tw.
69. or/42-68
70. 41 and 69
71. (external beam adj3 (radiotherapy or radiation)).tw.
72. ebrt.tw
73. Radiotherapy, Conformal/ use mesz
74. external beam radiotherapy/ use emez
75. ((active or expectant or conservative) adj3 (management or surveillance or treatment)).tw.
76. watchful waiting.tw
77. Watchful Waiting/
78. conservative treatment/ use emez
79. or/71-78
80. 41 and 79
81. 70 or 80
82. 35 and 81
83. 82 not (36 or 37)
84. remove duplicates from 83
85. limit 84 to english language
Science Citation Index (1995 to 2 April 2013)
ISI Web of Knowledge URL: http://wok.mimas.ac.uk/
Search strategy
# 1 (TS=(prostat* NEAR/3 (neoplasm* or cancer or carcinoma or tumour* or tumor* or malignan*)))
# 2 (TS=(ablation or abalative))
# 3 (TS=brachytherap*)
# 4 (TS=(seed NEAR/3 implant*))
# 5 (TS=((interstitial or intracavit* or implant* or surface) NEAR/3 radio*))
# 6 (TS=(cryotherap* or cryoablat* or cryosurg*))
# 7 (TS=(hifu or “high intensity focused ultrasound”))
# 8 (TS=photochemotherap*)
# 9 (TS=(photodynamic NEAR/3 (therap* or treat*)))
# 10 (TS=(photosensitiv* or phototherm*))
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# 11 (TS=light coagulat*)
# 12 (TS=(laser NEAR/3 (ablat* or interstitial)))
# 13 (TS=rita)
# 14 (TS=(“radiofrequency interstitial” NEAR/2 ablat*))
# 15 (TS=catheter ablat*)
# 16 (TS=((focal or focus*) NEAR/3 (therap* or treat*)))
# 17 (TS= (hemi ablat* or hemiablat*))
# 18 (#2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #15 or #16 or #17)
# 19 (#1 and #18)
# 20 (TS= (“external beam” NEAR/3 (radiotherap* or radiation)))
# 21 (TS=watchful waiting)
# 22 (TS=((active or expectant or conservative) NEAR/3 (management or surveillance or treatment)))
# 23 (#20 or #21 or #22)
# 24 (#1 and #23)
# 25 (#19 or #24)
# 26 (TS=quality of life)
# 27 (TS=quality adjusted life)
# 28 (TS=disability adjusted life)
# 29 (TS= (qaly* OR qald* OR qale* OR qtime* OR daly))
# 30 (TS=(hql OR hqol OR h qol OR hrqol OR hr qol))
# 31 (TS=(euroqol* OR euro qol* OR eq5d OR eq 5d))
# 32 (TS=health* year* equivalent*)
# 33 (TS=(hye OR hyes OR hui OR hui1 OR hui2 OR hui3))
# 34 (TS=(health utilit* OR disutilit*)
# 35 (TS=willingness to pay)
# 36 (TS= conjoint analys*)
# 37 (TS=trade off)
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# 38 (TS=discrete choice.)
# 39 (TS=standard gamble)
# 40 (#26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39)
#41 #25 AND #40 AND Language=(English) AND Document Types=(Article)
Cost-effectiveness Analysis Registry, September 2012
URL: https://research.tufts-nemc.org/cear4/default.asp
Search strategy
Prostate cancer or prostatic cancer
Ablation therapies for prostate cancer: economic evaluations
NHS Economic Evaluation Database, September 2012
Centre for Reviews and Dissemination URL: http://nhscrd.york.ac.uk/welcome.htm
Search strategy
1. MeSH DESCRIPTOR Prostatic Neoplasms
2. MeSH DESCRIPTOR Ablation Techniques
3. MeSH DESCRIPTOR cryosurgery EXPLODE ALL TREES
4. MeSH DESCRIPTOR High-Intensity Focused Ultrasound Ablation EXPLODE ALL TREES
5. MeSH DESCRIPTOR brachytherapy
6. MeSH DESCRIPTOR photochemotherapy EXPLODE ALL
7. MeSH DESCRIPTOR light coagulation EXPLODE ALL TREES
8. MeSH DESCRIPTOR Laser Therapy
9. MeSH DESCRIPTOR Catheter Ablation
10. MeSH DESCRIPTOR Radiotherapy, Conformal
11. MeSH DESCRIPTOR Watchful Waiting
12. (ebrt) OR (hifu) OR (rita)
13. (external beam) OR (hemiablat &or hemi ablat*) OR (ablat*)
14. (focal) OR (focus*)
15. (expectant) OR (conservative) OR (active)
16. (photosentitiv*) OR (phototherm*) OR (photodynamic)
17. (radiofrequency) OR (radiotherapy)
18. #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
OR #16 OR #17
19. #1 AND #18
IDEAS, September 2012
Research Papers in Economics (RePEc) URL: http://ideas.repec.org/
Search strategy
(prostate | prostatic) + cancer
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Websites consulted
Agency for Healthcare Research and Quality (URL: www.ahrq.gov/).
American Society of Clinical Oncology (URL: www.asco.org).
American Urological Association (URL: www.auanet.org/).
Australian Safety and Efficacy Register of New Interventional Procedures (URL: www.surgeons.org/
for-health-professionals/audits-and-surgical-research/asernip-s).
Belgian Health Care Knowledge Centre (KCE) (URL: https://kce.fgov.be/).
BAUS (URL: www.baus.org.uk/).
Canadian Agency for Drugs and Technologies in Health (URL: www.cadth.ca/).
Cancer Research UK (URL: http://info.cancerresearchuk.org/cancerstats/).
European Association of Urology (URL: www.uroweb.org/).
French National Authority for Health (HAS) (URL: www.has-sante.fr/).
Health Information and Quality Authority (URL: www.hiqa.ie/).
Institute for Clinical and Economic Review (URL: www.icer-review.org/).
Institute for Quality and Efficiency in Health Care (URL: www.iqwig.de/).
Medical Services Advisory Committee, Australia (URL: http://www.msac.gov.au/).
National Comprehensive Cancer Network (URL: www.nccn.org/index.asp).
National Institute for Health and Care Excellence (URL: www.nice.org.uk/).
NHS Quality Improvement Scotland (URL: www.healthcareimprovementscotland.org/).
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Appendix 2 Data extraction form
Data Extraction Form 
 
Ablative therapy for people with localised prostate cancer: systematic review and economic 
modelling evaluation 
 
Reviewer ID:                          Data extraction date:  
Study ID (Author, year):                                                                      Language if non-English:    
 
Publication status: full-text papers / conference abstract / personal communication / other unpublished reports (specify) 
 
Study IDs of any linked reports:  
 
Reporting Institution: 
 
Hospital(s):  
 
Study design 
Aim of the study: 
 
Study design: 
 
         RCT                Non-randomised comparative study                  Registry report                Case series (ablative only)        
 
                  
Prospective/ Retrospective/ Unclear/ Not reported 
                                          
For non-RCTs and case series, was patients recruitment consecutive: Yes /No / not reported 
 
 
 
     
Intervention :  
 
 
Comparator :  
 
For comparative studies, patients in the groups were recruited during the same period/different period/not reported 
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 Number of study centres: Single centre / multicentre n=        / not reported 
 
Setting: hospital / other:                                                                           Country: 
 
Study start – end dates:                                                     Duration of study: 
 
 
 
Length of follow-up:  
 
Source of funding:  
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Patients 
Inclusion criteria: 
 
Exclusion criteria:  
 
 
 
Baseline Patient Characteristics  
                               Intervention:  
 
Comparator:  
 
Total 
Number of patients enrolled    
Number randomised (RCTs only)  
 
   
Withdrew/lost to follow-up, with 
reasons  
 
   
Number analysed    
Age (Mean/median, SD/range) 
 
   
BMI  (Mean/median, SD/range) 
 
   
Co-morbidities, including previous 
abdominal or pelvic surgery, previous 
pelvic radiotherapy, n/N (%):  
 
 
 
 
 
   
Disease severity 
PSA level, ng/ml, n, mean(SD) /  
median (range); if categorical, 
specify n, mean(SD) /  median 
(range) for each category 
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   Clinical stage     T1, n 
                          T2, n 
                          T3, n  
                          T4, n 
 
Staging method: (e.g. digital rectal 
examination, MRI) 
   
Biopsy Gleason Score ≤  6, n 
7, n 
8-10, n 
   
Prostate size, ml, mean (SD) / 
median (range) 
 
   
Erectile dysfunction, n/N (%), specify 
measure and whether validated or not: 
   
 
Intervention(s) 
 
Definition of focal therapy 
 
Yes            No 
 
If yes, 
 
Tissues preservation                                       Subtotal                                                        Partial 
 
Nerve sparing prostate ablation                      Posterior hockey stick                                  Hyperfocal 
 
Hemiablation                                                 Targeted focal therapy                                   
 
Anterior hockey stick ablation                         Zonal ablation                                               Other.................................... 
 
                                                                                                                                   
 
Cryotherapy  
 
Name, Manufacturer and Model of the equipment: 
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HIFU 
 
Name, Manufacturer and Model of the equipment: 
 
 
PDT 
 
Name, Manufacturer and Model of the equipment: 
 
 
RITA 
 
Name, Manufacturer and Model of the equipment: 
 
Laser ablation 
 
Name, Manufacturer and Model of the equipment: 
 
 
Brachytherapy 
 
Radiation source: Iodine          Palladium          Caesium 
 
Low dose rate (permanent seeds) 
 
High dose rate (temporary seeds) 
 
Dose:  
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Comparator 
Prostatectomy 
 
Yes                                             No 
 
If yes, 
 
Open n/N (%): 
Laparoscopic n/N (%): 
Robot-assisted n/N (%): 
Type of prostatectomy not specified    
 
Active surveillance  
Number of assessments:  
Definition of failure: 
 
 
 
 
 
 
 
EBRT 
 
Name, Manufacturer and Model of the equipment: 
 
Dose: 
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Efficacy outcomes  
 Timing  Intervention:  
 
Comparator:  
Disease free survival, n/N (%)    
Overall survival n/N (%)    
Biochemical disease-free status - - - 
    PSA control n/N (%)      
    PSA level ng/ml    
Positive biopsy on follow up n/N (%)    
Re-intervention rates n/N (%)    
Functional outcomes 
n/N (%), mean (SD)/median (range) 
score 
Timing Intervention: Comparator: 
Sexual (penile erection) function 
(validated score or as defined by trialists) 
 
International Index of Erectile            
Dysfunction 
 
Other measure: 
 
 
 
   
Urinary continence (validated score, or 
as defined by trialists) 
 
<1 thin pad per day 
 
Other measure: 
 
 
   
Faecal continence (validated score, or 
as defined by trialists) 
 
ICIQ-BS 
Other measure: 
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Other complications: 
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Adverse effects 
 Timing Intervention: Comparator: 
Urethral sloughing n/N (%)    
Recto-urethral fistula formation n/N 
(%) 
   
Urethral stricture formation n/N (%)    
Acute urinary retention n/N (%)    
Dysuria n/N (%)    
Pelvic pain n/N (%)    
Rectal injury n/N (%)    
Perioperative death n/N (%)    
Others    
Quality of life outcomes 
Mean (SD)/median (range) score 
(per category if applicable)  
Timing Intervention: 
 
Comparator: 
 
Generic QoL measure: 
 
 
 
 
Disease specific QoL 
measure: 
 
 
 
 
Other validated measure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Procedural outcomes 
 Intervention: Comparator: 
Procedure time (min), reported as 
mean/median 
  
Nature of anaesthetic (e.g. general, local)   
Length of hospital stay (days), reported as 
mean/median 
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Procedures done in the centre each year, 
mean (SD) / median (range) 
  
Surgeon competence (as reported by the 
trialists) 
  
Abandonment n/N (%)   
Conclusion as reported by the authors of the study 
 
 
 
 
 
Additional information and comments 
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Appendix 3 Cochrane risk-of-bias form for
randomised controlled trials
Ablative therapy for people with localised prostate cancer:
systematic review and economic modelling evaluation
Study ID Reviewer ID Date
Domain Supporting quote Reviewer’s judgement
Selection bias
Random sequence generationi
Allocation concealmentii
Performance bias
Blinding of participants and personneliii
Outcome 1:
Blinding of participants and personneliii
Outcome 2:
Blinding of participants and personneliii
Outcome 3:
Blinding of participants and personneliii
Outcome 4:
Detection bias
Blinding of outcome assessmentiv
Outcome 1:
Blinding of outcome assessmentiv
Outcome 2:
Blinding of outcome assessmentiv
Outcome 3:
Blinding of outcome assessmentiv
Outcome 4:
Attrition bias
Incomplete outcome datav
Outcome 1:
Incomplete outcome datav
Outcome 2:
Incomplete outcome datav
Outcome 3:
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Study ID Reviewer ID Date
Incomplete outcome datav
Outcome 4:
Reporting bias
Selective reportingvi
Other bias
Other sources of biasvii
i Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether or
not it should produce comparable groups.
ii Describe the method used to conceal the allocation sequence in sufficient detail to determine whether or not
intervention allocations could have been foreseen in advance of, or during, enrolment.
iii Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a
participant received. Provide any information relating to whether or not the intended blinding was effective.
iv Describe all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant
received. Provide any information relating to whether or not the intended blinding was effective.
v Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis.
State whether or not attrition and exclusions were reported, the numbers in each intervention group (compared with
total randomised participants), reasons for attrition/exclusions where reported, and any reinclusions in analyses
performed by the review authors.
vi State how the possibility of selective outcome reporting was examined by the review authors, and what was found.
vii State any important concerns about bias not addressed in the other domains in the tool. If particular questions/entries
were pre-specified in the review’s protocol, responses should be provided for each question/entry.
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Appendix 4 Cochrane risk-of-bias form for
non-randomised controlled studies
Cochrane risk-of-bias table (non-randomised studies)
Ablative therapy for people with localised prostate cancer: systematic
review and economic modelling evaluation
Assessor initial: Date evaluated:
Study ID:
Item Judgementa
Description (quote from paper,
or describe key information)
1. Sequence generation
2. Allocation concealment
3a. Confounding Outcome 1
(Efficacy)
Confounders
balancedb,c
PSA score balanced at
baseline
Difference between risk
group (D’Amico definition)
3b. Confounding Outcome 2
(Functional outcomes)
Confounders
balancedb,c
Erectile function Pre-op status
Age
Urinary function Pre-op status
Age
Bowel function Pre-op status
Age
3c. Confounding Outcome 3 (Quality of life) Confounders
balancedc,d
Age
4a. Blinding? Outcome 1
(Efficacy outcomes)
4b. Blinding? Outcome 2
(Erectile function)
Outcome 2
(Urinary function)
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Item Judgementa
Description (quote from paper,
or describe key information)
Outcome 2
(Bowel function)
4d. Blinding? Outcome 3
(Quality of life)
5a. Incomplete
outcome data
addressed?
Outcome 1
(Efficacy outcomes)
5b. Incomplete
outcome data
addressed?
Outcome 2
(Erectile function)
Outcome 2
(Urinary function)
Outcome 2
(Bowel function)
5c. Incomplete
outcome data
addressed?
Outcome 3
(Quality of life)
6a. Free of
selective
reporting?
Outcome 1
(Efficacy outcomes)
6b. Free of
selective
reporting?
Outcome 2
(Erectile function)
Outcome 2
(Urinary function)
Outcome 2
(Bowel function)
6c. Free of
selective
reporting?
Outcome 3
(Quality of life)
7. Free of other bias?
8. A priori protocol?e
9. A priori analysis plan?f
a Some items on low/high risk/unclear scale (single-line border), some on yes/no/unclear scale (dashed border). For all
items, record ‘unclear’ if inadequate reporting prevents a judgement being made.
b Confounders listed by order of importance (high to low importance) based on list of confounders considered important
at the outset and defined in the protocol for the review.
Low risk:
2 balanced= low risk
1 balanced, 1 unclear= low risk
High risk:
2 unbalanced= high risk
1 unbalanced, 1 unclear= high risk
Unclear:
2 unclear= unclear
- - - - - - - - -
-- --
-- --
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c Note, if confounders are unbalanced but adjusted for in the analysis, the imbalance is no longer a serious concern for
risk of bias.
d For quality of life outcomes where only one confounder was considered relevant, the following decision rules
were applied:
Low risk:
1 balanced= low risk
High risk:
1 unbalanced= high risk
Unclear:
1 unclear= unclear
e Did the researchers write a protocol defining the study population, intervention and comparator, primary and other
outcomes, data collection methods, etc., in advance of starting the study?
f Did the researchers have an analysis plan defining the primary and other outcomes, statistical methods, subgroup
analyses, etc., in advance of starting the study?
General decision rules
Where a paper does not report details of confounders/other source of bias this should be judged
as unclear.
Where a paper does not report considered outcome this should be judged as not applicable.
Allocation concealment should be judged as high risk of bias if groups are allocated by factors such as
surgeon decision, patient preference. Allocation by hospital/institution= low risk. Where no details are
given, judge as unclear.
Absence of blinding is likely to have low risk of bias for perioperative and efficacy outcomes.
Free of other bias: default is low risk unless there is a fundamental flaw with the study (e.g. inadequate
follow-up time for dysfunction outcomes, data not presented for learning curve effects if these are likely to
influence outcomes).
Judging overall direction of bias for individual outcomes: if confounding is judged unbalanced, outcome
should be judged as high risk of bias.
Further guidance:
Refer to tables 13.2.a and b in Reeves BC, Deeks J, Higgins JP, Wells GA on behalf of the Cochrane
Non-Randomised Studies Methods Group. Chapter 13: Including non-randomized studies. In Higgins JP,
Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011). Cochrane; 2011. URL: www.cochrane-handbook.org (accessed March 2011).
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Appendix 5 Quality assessment form for
case series
Checklist of quality assessment of non-randomised studies
Ablative therapy for people with localised prostate cancer: systematic
review and economic modelling evaluation
Assessor initial: Date evaluated:
Study ID:
Criteria Yes No Unclear Comments
1. Were participants a representative sample selected from a relevant patient
population, e.g. randomly selected from those seeking treatment despite age,
duration of disease, primary or secondary disease, and severity of disease?
2. Were the inclusion/exclusion criteria of participants clearly described?
3. Were participants entering the study at a similar point in their disease
progression, i.e. severity of disease?
4. Was selection of patients consecutive?
5. Was data collection undertaken prospectively?
6. Were the groups comparable on demographic characteristics and clinical features? N/A N/A N/A N/A
7. Was the intervention (and comparison) clearly defined?
8. Was the intervention undertaken by someone experienced at performing the
procedure?1
9. Were the staff, place and facilities where the patients were treated appropriate for
performing the procedure? (e.g. access to back-up facilities in hospital or special clinic)
10. Were any of the important outcomes considered?
11. Were objective (valid and reliable) outcome measures used?
12. Was the assessment of main outcomes blind? N/A N/A N/A N/A
13. Was follow-up long enough (≥ 1 year) to detect important effects on outcomes
of interest?
14. Was information provided on non-respondents, dropouts?2
15. Were the withdrawals/dropouts similar in characteristics to those who completed
the study and therefore unlikely to cause bias?3
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Criteria Yes No Unclear Comments
16. Was length of follow-up similar between comparison groups? N/A N/A N/A N/A
17. Were the important prognostic factors identified, e.g. age, disease severity,
pre-operative status?4
18. Were the analyses adjusted for confounding factors? N/A N/A N/A N/A
N/A, not applicable.
Note
1. ‘Yes’ if the practitioner received training on conducting the procedure before or conducted same kind of procedure
before, i.e. no learning curve.
2. ‘No’ if participants were from those whose follow-up records were available (retrospective).
3. ‘Yes’ if no withdrawal/dropout; ‘no’ if dropout rate ≥ 30% or differential dropout, e.g. those having most severe disease
died during follow-up but the death was not due to treatment; no description of those lost.
4. ‘Yes’ if two or more than two factors were identified.
The same form was adapted to assess the quality of case series by excluding questions 6, 12, 16 and 18.
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Appendix 9 Detailed risk-of-bias and quality
assessment
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TABLE 75 Risk-of-bias assessment: RCTs and non-randomised comparative studies (primary review)
Study ID
Sequence
generation
Allocation
concealment
Confounding Blinding
Efficacy
Erectile
function
Urinary
function
Bowel
function QoL Efficacy
Erectile
function
Urinary
function
Bowel
function QoL
a
Crook 2011
121
? ? ? ? ?
a
Donnelly 2010
125
? ? ✓
a
Giberti 2009
49
✓ ? ✓ ✓ ✓ ✓ ✓
a
Paulson 1982a
168
? ? ✓
Alemozaffar 2011
100
✗ ✗ ✗ ✗
Arvold 2011
101
✗ ✗ ✗ ✓
Barret 2013
103
✗ ✗ ✓ ? ✗ ✓ ? ?
Beyer 2000
105
✗ ✗ ✗ ✓
Boettcher 2012
108
✗ ✗ ✗ ? ✗ ?
Borchers 2004
109
✗ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✗ ✗ ✗
Bradley 2004
110
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Buron 2007
113
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Chen 2009
117
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Coen 2012
119
✗ ✗ ✓ ✓
Crook 2011
121
✗ ✗ ✗ ✓ ✓ ✗ ✗ ✗
D’Amico 1998
36
✗ ✗ ✗ ✓
D’Amico 2003
123
✗ ✗ ✗ ✓
Eade 2008
126
✗ ✗ ✗ ✗ ✗ ✗ ✓ ✓ ✓ ?
Elliott 2007
128
✗ ✗
Ferrer 2008
130
✗ ✗ ? ✓ ✓ ✓ ✗ ✗ ✗ ✗ ✗
Frank 2007
131
✗ ✗ ? ? ? ? ? ✗ ✗ ✗ ✗
Goldner 2012a
135
✗ ✗ ✓ ✓
Goldner 2012b
136
✗ ✗ ✗ ✓
Kibel 2012
144
✗ ✗ ✓ ✓
Kirschner-Hermans
2008
145
✗ ✗ ✗ ✓ ✗ ✗
Kobuke 2009
149
✗ ✗ ✗ ✗ ✓ ✗ ✓ ✓ ✗ ✗ ✗ ✗
Kupelian 2004
151
✗ ✗ ✗ ✓
Lee 2001
153
✗ ✗ ✓ ✓ ✗ ✗
Litwin 2004
156
✗ ✗ ✓ ? ✗
Malcolm 2010
160
✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Mohamed 2012
163
✗ ✗ ✗ ✗ ✗ ✗
Pe 2009
170
✗ ✗ ✗ ✓
Pickles 2010
171
✗ ✗ ✗ ✓
Pinkawa 2009
172
✗ ✗ ✓ ✓ ✗ ✓ ✗ ✗ ✗ ✗
Reeve 2012
176
✗ ✗ ✓ ? ✗ ✗
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Incomplete outcome data Free of selective reporting
Other
biasEfficacy
Erectile
function
Urinary
function
Bowel
function QoL Efficacy
Erectile
function
Urinary
function
Bowel
function QoL
✗ ✗ ✗ ✗ ✗ ✗ ✗
✓ ✓ ?
? ? ? ? ? ? ? ? ? ? ?
✗ ? ✗
✓ ? ?
? ? ?
? ? ? ✗ ✗ ✗ ✗
✗ ✗ ?
✓ ✓ ✗ ✗ ?
✓ ✗ ✗ ✗ ✗ ✓ ✗ ✗ ✗ ✗ ✗
✓ ✓ ✓ ✓ ? ? ? ? ?
? ? ? ? ? ? ?
✓ ✓ ✓ ? ? ? ?
✓ ✓ ?
? ? ? ? ? ? ✗
✓ ? ?
✗ ? ?
✓ ✓ ✓ ✓ ? ? ? ? ?
✓
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ?
✓ ✓ ✓ ✓ ✗ ✗ ✗ ✗ ?
? ? ?
? ? ?
✓ ✓ ✗
? ✗ ? ? ?
? ? ? ? ? ? ? ? ? ? ✗
? ? ✗
✓ ✓ ✓ ✓ ?
✗ ✗ ✓
✗ ✗ ✗ ✗ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✗
? ? ?
✓ ? ?
✗ ✗ ✗ ✗ ? ? ? ? ?
✗ ✗ ✓ ✓ ✗ ?
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TABLE 75 Risk-of-bias assessment: RCTs and non-randomised comparative studies (primary review) (continued )
Study ID
Sequence
generation
Allocation
concealment
Confounding Blinding
Efficacy
Erectile
function
Urinary
function
Bowel
function QoL Efficacy
Erectile
function
Urinary
function
Bowel
function QoL
Shah 2012
182
✗ ✗ ? ? ? ✓ ? ?
Smith 2009
184
✗ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✗ ✗ ✗
Talcott 2003
186
✗ ✗ ✓ ✓ ✓ ✗ ✗ ✗
Tsui 2005
189
✗ ✗ ✗ ✓ ✗ ✓ ✓ ✗ ✗ ✗
van den Bergh
2012
198
✗ ✗ ✗ ✗ ✗
Williams 2012
203
✗ ✗ ✓ ✓ ? ? ? ?
Wong 2009
205
✗ ✗ ✓ ✓
Zelefsky 1999
206
✗ ✗ ✓ ✗ ✓ ✓ ✓ ✗ ✓ ✓
Zelefsky 2011
207
✗ ✗ ✗ ✗ ✓ ✗
QoL, quality of life.
a Randomised controlled studies.
Incomplete outcome data Free of selective reporting
Other
biasEfficacy
Erectile
function
Urinary
function
Bowel
function QoL Efficacy
Erectile
function
Urinary
function
Bowel
function QoL
✓ ✓ ✓ ✓ ✓ ?
✓ ✓ ✓ ✓ ✓ ? ? ? ? ? ?
✓ ✓ ✓ ✓ ✓ ✓ ✗
? ? ? ? ? ? ? ? ?
✗ ? ?
✓ ✓ ? ✓ ✓ ? ✓
? ✓ ?
? ? ? ? ? ? ? ? ?
? ? ? ? ?
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TABLE 76 Quality assessment: case series (primary review)
Study ID
Spectrum
representative
Description of
eligibility criteria
Similarity in
disease
severity
Consecutive
patient
selection
Prospective
data
collection
Clear definition
of intervention
Ahmed 201198 ✓ ✓ ✓ ? ✓ ✓
Ahmed 201299 ✓ ✓ ✓ ? ✓ ✓
Bahn 2002102 ✓ ✓ ✓ ✓ ✗ ✓
Bellardita 2013104 ✓ ✓ ✓ ? ? ✓
Blana 2009106 ✓ ✓ ✓ ✓ ✗ ✗
Blana 2012107 ✓ ✓ ✓ ✓ ✗ ✗
Bul 2013111 ✓ ✓ ✓ ? ✓ ✓
Caso 2012114 ✓ ? ✓ ✓ ✓ ✓
Chaussy 2003116 ✓ ✓ ✓ ? ? ✓
Colombel 2006120 ✓ ✗ ? ? ? ✗
Cytron 2003122 ✓ ? ✓ ✓ ? ✓
Donnelly 2002124 ✓ ✓ ✗ ✓ ✓ ✓
El Fegoun 2011127 ✓ ✓ ✓ ? ✗ ✓
Ellis 2007129 ✓ ✓ ✓ ✓ ? ✓
Ganzer 2008132 ✓ ✓ ✓ ? ? ✓
Ganzer 2011133 ✓ ✓ ✓ ✓ ✗ ✓
Godtman 2013134 ✓ ? ? ? ✓ ?
Hale 2013138 ✓ ✓ ✓ ? ? ✓
Han 2003139 ✓ ? ✓ ? ✓ ✓
Hardie 2005140 ✓ ✓ ✓ ? ✓ ✓
Hilton 2012141 ✓ ✓ ✓ ? ✓ ✓
Hubosky 200752 ✓ ✓ ✓ ✓ ✓ ✓
Illing 2006142 ✓ ✓ ✓ ? ? ✓
Inoue 2011143 ✓ ✓ ✓ ✓ ✓ ✓
Klotz 2010146 ✓ ✓ ✓ ? ✓ ✓
Koch 2007150 ✓ ✓ ? ? ✓ ✓
Lian 2011154 ✓ ✓ ✓ ✓ ✗ ✓
Lidner 2009155 ✓ ✓ ✓ ? ✓ ✓
Mack 1997158 ✓ ✗ ✓ ? ? ✓
Maestroni 2008159 ✓ ✗ ✗ ? ? ✓
Mearini 2009161 ✓ ✓ ✗ ✓ ✓ ✓
Misrai 2008162 ✓ ✓ ✗ ? ✗ ✓
Onik 2008166 ✓ ? ✓ ? ? ✓
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Procedure
carried out by
experienced
doctor
Adequate and
appropriate
facilities
Important
outcomes
considered
Objective
(valid and
reliable)
outcome
measures
Adequate
follow-up
period
Information
on dropouts
Dropouts
similar to
completers
Pre-operative
identification of
prognostic
factors
? ? ✓ ✓ ✓ ✓ ✓ ✓
? ? ✓ ✓ ✓ ✓ ? ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✗ ✓ ? ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ✓ ? ✓
? ? ✓ ✓ ✓ ? ? ✓
? ? ✓ ✓ ✓ ✗ ? ?
? ? ✓ ✓ ✓ ✗ ✗ ?
? ? ✓ ✓ ✓ ? ✗ ✓
? ? ✓ ✓ ✓ ✓ ✓ ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ✗ ✓ ✓
? ? ✓ ✓ ✓ ✓ ? ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ✓ ? ✓
? ? ✓ ✓ ✓ ✓ ? ✓
? ? ✓ ? ✓ ? ? ✓
? ? ✓ ✓ ✓ ✓ ✓ ✓
? ? ✓ ✓ ✓ ✓ ✓ ✓
? ? ✓ ✓ ✓ ✓ ✓ ✓
? ? ✓ ✓ ✗ ✓ ✓ ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ? ? ✓
? ? ✓ ✓ ✗ ✓ ✓ ?
? ? ✓ ✓ ✗ ✗ ? ✓
? ? ✓ ✓ ✗ ✓ ✓ ✓
? ? ✓ ✓ ✓ ✓ ? ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ✗ ? ✓
continued
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
365
TABLE 76 Quality assessment: case series (primary review) (continued )
Study ID
Spectrum
representative
Description of
eligibility criteria
Similarity in
disease
severity
Consecutive
patient
selection
Prospective
data
collection
Clear definition
of intervention
Pinthus 2012173 ✓ ✓ ✗ ✓ ✗ ✓
Poissonnier 2007174 ✓ ✓ ✓ ✓ ✓ ✓
Selvadurai 2013181 ✓ ✓ ✓ ? ✓ ✓
Sumitomo 2010185 ✓ ✓ ✓ ? ✗ ✓
Tosoian 2011187 ✓ ✓ ✓ ? ✓ ✓
Truesdale 2010188 ✓ ✓ ✓ ✗ ✗ ✓
Uchida 2005191 ✓ ✓ ? ✓ ✓ ✓
Uchida 2009195 ✓ ✓ ✓ ✓ ? ✓
Vasarainen 2012199 ✓ ✓ ✓ ? ✓ ✓
Ward 2012202 ✓ ✓ ✓ ✗ ✓ ?
Wong 1997204 ✓ ? ✓ ? ? ✓
TABLE 77 Quality assessment: case series (salvage review)
Study ID
Spectrum
representative
Description of
eligibility criteria
Similarity in
disease
severity
Consecutive
patient
selection
Prospective
data
collection
Clear definition
of intervention
Chin 2001208 ✓ ✓ ? ? ? ✓
Colombel 2006120 ✓ ✓ ? ? ? ✓
Darras 2006209 ✓ ✓ ? ? ? ✓
Gheiler 1998210 ✓ ✓ ? ? ✗ ✓
Neerhut 1988211 ✓ ✓ ? ? ? ✓
Robinson 2006212 ? ✓ ? ? ✓ ✓
Seabra 2009213 ✓ ✓ ? ? ✓ ✗
Tefilli 1998214 ✓ ✓ ✗ ? ✗ ✗
van der Poel
2008215
? ✓ ? ? ? ✓
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Procedure
carried out by
experienced
doctor
Adequate and
appropriate
facilities
Important
outcomes
considered
Objective
(valid and
reliable)
outcome
measures
Adequate
follow-up
period
Information
on dropouts
Dropouts
similar to
completers
Pre-operative
identification of
prognostic
factors
? ? ✓ ✓ ✓ ✓ ? ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ✓ ✓ ✓
? ? ✓ ✓ ✓ ✓ ? ✓
? ? ✓ ✓ ✓ ✓ ✗ ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ✓ ✓ ✓ ✓ ✓
? ? ✓ ✓ ✓ ? ? ✓
? ? ✓ ✓ ✓ ✓ ✗ ✓
? ? ✓ ✓ ✓ ✗ ✗ ✓
? ? ✓ ? ✓ ? ? ✓
Procedure
carried out by
experienced
doctor
Adequate and
appropriate
facilities
Important
outcomes
considered
Objective
(valid and
reliable)
outcome
measures
Adequate
follow-up
period
Information
on dropouts
Dropouts
similar to
completers
Pre-operative
identification of
prognostic
factors
? ? ✓ ✓ ✓ ✗ ? ✓
? ? ✓ ✓ ✓ ✗ ? ✓
? ? ✓ ? ✓ ✗ ? ✓
? ? ✓ ? ✓ ✓ ✗ ✓
? ? ✓ ? ✓ ✗ ? ✓
? ? ✓ ✓ ✓ ✓ ? ✓
? ? ✓ ? ✓ ✗ ? ✓
? ? ✓ ? ✓ ✓ ✓ ✓
? ? ✓ ? ✓ ✗ ? ✓
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Appendix 10 Data tables of the primary review
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TABLE 78 Cancer-related efficacy outcomes
Study ID Timeline Outcome
BT CRYO
N n % N n %
Prostate cancer specific mortality (PCSM)
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
2 years PCSM
Bul 2013,111
van den Bergh
2010197
2.8 years PCSM
Tosoian 2011187 Median
2.7 years
PCSM
Hardie 2005140 Median
3.5 years
(42 months)
PCSM
D’Amico 2003123 Median
3.9 years (BT)
and 4.2 years
(RP)
PCSM 196 0 0
Misrai 2008162 Mean 3.9 (range
1–6.8) years
PCSM
Arvold 2011101 Median
3.6 (range
1.8–5.9) years
PCSM 5902 29 0.57
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
4 years PCSM
Pinthus 2012173 4 years PCSM
Selvadurai 2013181 4 years PCSM
Donnelly 2010,125
Robinson 2009179
5 years PCSM 117 5 4.3
Pickles 2010171 67–68 months PCSM 139 1 0.72
Kibel 2012144 Median
5.6 years (IQR
43–96 months)
PCSM 1680 12 0.7
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
6 years PCSM
Inoue 2011143 7 years PCSM
Selvadurai 2013181 8 years PCSM
Uchida 2009195 Median 8 years PCSM
Kibel 2012144 10 years PCSM (unadjusted) 1680 2.4 (95% CI
0.6 to 4.2)
Kibel 2012144 10 years PCSM (adjusted) 1680 2.3 (95% CI
2 to 2.6)
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HIFU AS EBRT RP
N n % N n % N n % N n %
450 0 0
2494 0 0
769 0 0
80 0 0
322 0 0
119 0 0
2937 15 0.51
450 1 0.22
402 0 0
471 1 0.21
114 5 4.4
139 1 0.72
2264 94 4.2 6485 76 1.2
450 3 0.67
137 0 0
471 2 0.42
517 0 0
2264 6.1 (95% CI
4.7 to 7.5)
6485 2.2 (95% CI
1.6 to 2.8)
2264 2.9 (95% CI
2.6 to 3.3)
6485 1.8 (95% CI
1.6 to 2.1)
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
10 years PCSM
Godtman 2013134 12.7 years PCSM
Mack 1997158 3–16 years PCSM 66 18 27
Overall survival (OS)
Lian 2011154 Postoperative OS 102 102 100
Barret 2013103 Median 9 (IQR
6–15) months
OS 12 12 100 50 50 100
Bul 2013,111 van
den Bergh 2010197
Median 1.2 (IQR
1.0–1.6) years
OS
Bul 2013,111 van
den Bergh 2010197
2 years OSa
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
2 years OSa
Selvadurai 2013181 2 years OSa
Tosoian 2011187 2.7 years OS
Hardie 2005140 3.5 years OS
Misrai 2008162 Mean 3.9 (range
1–6.8) years
OS
Bul 2013,111 van
den Bergh 2010197
4 years OSa
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
4 years OSa
Pinthus 2012173 4 years OS
Donnelly 2002124 5 years OS 73 68 93.2
Donnelly 2010,125
Robinson 2009179
5 years OS 117 108 92.3
Selvadurai 2013181 5 years OSa
Shah 2012,182
Vicini 2011201
5 years OS:a
African American
36 97
Shah 2012,182
Vicini 2011201
5 years OS:a white 504 92.8
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HIFU AS EBRT RP
N n % N n % N n % N n %
450 5 1.1
439 1 0.2
21 21 100
2494 2476 99.3
2494 97.1
450 86.4
471 99 (95% CI
98 to 100)
769 755 98.2
80 75 94
119 118 99.1
2494 86.5
450 92.7
402 401 99.7
114 103 90.4
471 96 (95% CI
95 to 98)
12 86.3
469 83.3
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
6 years OSa
Selvadurai 2013181 6 years OS
Inoue 2011143 7 years OS
Coen 2012119 8 years OS 141 96
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
8 years OSa
Godtman 2013134 10 years OSa
Kibel 2012144 10 years OSa (unadjusted) 1680 59.8 (95% CI
52.2 to 66.5)
Kibel 2012144 10 years OSa (adjusted) 1680 81.7 (95% CI
78.7 to 84.4)
Kibel 2012144 10 years OS 1680 1481 88.1
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
10 years OSa
El Fegoun 2011127 Median 10.6
(range
7.5–11.1) years
OS
Klotz 2010146
(Klotz 2005,148
Klotz 2012,147
Loblaw 2010157)
12 years OSa
Mack 1997158 3–16 years OS 66 38 57.6
Biochemical failure/recurrence or clinical failure
Lian 2011154 3 months Biochemical failure
(PSA ≥ 0.5 ng/ml)
102 8 7.8
Coen 2012119 1 year Biochemical failurea
(Phoenix definition)
141 0.7
Donnelly 2010,125
Robinson 2009179
1 year Cumulative incidence
of failurea (updated
Trifecta definition
with biochemical
failure defined as PSA
nadir+ 2 ng/ml)
117 3.4
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HIFU AS EBRT RP
N n % N n % N n % N n %
450 84.3
471 444 94.3
137 132 96.4
141 93
450 77.2
439 81.1
2264 63.2 (95% CI
60 to 66.1)
6485 87 (95% CI
85.5 to 88.3)
2264 82.6 (95% CI
79.8 to 85)
6485 88.9 (95% CI
87.5 to 90.1)
2264 1674 73.9 6485 6018 92.8
450 68 (95% CI
62 to 74)
12 10 83
450 55.8
141 1.4
114 1.7
continued
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
375
TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Donnelly 2010,125
Robinson 2009179
1 year Cumulative incidence
of failurea (original
Trifecta definition
with failure defined as
radiological evidence
of disease or
biochemical failure
2 PSA rises and final
PSA value >1 ng/ml
or initiation of
secondary treatment)
117 7
Kobuke 2009149 1 year Biochemical
recurrence (PSA
> 0.2 ng/ml)
36 0 0
Maestroni 2008159 1 year Treatment failure
(ASTRO criterion: PSA
rise in 3 consecutive
samples)
Pinthus 2012173 1 year Biochemical failure
(Stuttgart definition:
nadir+ 1.2 ng/ml
‘at call’)
Pinthus 2012173 1 year Biochemical failure
(Horwitz definition:
2 consecutive
increases of at
least 0.5 ng/ml,
backdated)
Polascik 2007,175
Caso 2012,114
Caso 2012115
Median
1.5 years (range
3 months–
3.5 years)
PSA failure (PSA
≥ 0.5 ng/ml)
50 5 10
Coen 2012119 2 years Biochemical failurea
(Phoenix definition)
141 2.04
Donnelly 2010,125
Robinson 2009179
2 years Cumulative incidence
of failurea (updated
Trifecta definition
with failure defined
as biochemical
failure: PSA
nadir+ 2 ng/ml)
117 12.1
Donnelly 2010,125
Robinson 2009179
2 years Cumulative incidence
of failurea (original
Trifecta definition
with failure defined as
radiological evidence
of disease or
biochemical failure
2 PSA rises and final
PSA value >1 ng/ml
or initiation of
secondary treatment)
117 18.8
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N n % N n % N n % N n %
114 1
37 3 8.1
25 4 16
402 33 8.2
402 89 22.1
141 2.2
114 8.9
114 12.5
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Pinthus 2012173 2 years Biochemical failure
(Stuttgart definition:
nadir+ 1.2 ng/ml
‘at call’)
Pinthus 2012173 2 years Biochemical failure
(Horwitz definition:
2 consecutive
increases of at least
0.5 ng/ml, backdated)
Truesdale 2010,188
Lambert 2007152
Median 2 (range
0–7.25) years
Biochemical failure
(Phoenix criterion:
PSA nadir+ 2 ng/ml)
77 21 27.3
Zelefsky 1999206 Median
1.7 years (BT)
and 2.1 years
(EBRT)
PSA relapse
(3 successive PSA
elevations from the
post-treatment nadir)
145 12 8
Hale 2013138 2.5 years Biochemical failure
(PSA nadir+0.5ng/ml)
26 3 12
Coen 2012119 3 years Biochemical failurea
(Phoenix definition)
141 2.1
Donnelly 2010,125
Robinson 2009179
3 years Cumulative incidence
of failurea (Trifecta
with biochemical
failure defined as PSA
nadir+ 2 ng/ml)
117 17.1
Donnelly 2010,125
Robinson 2009179
3 years Cumulative incidence
of failurea [Trifecta with
failure defined as
radiological evidence
of disease or
biochemical failure
and final PSA values
(2 PSA rises and final
PSA value > 1 ng/ml),
or initiation of
secondary treatment]
117 23.9
Smith 2009184 3 years Disease recurrence
or spread
58 0 0
Misrai 2008162 Mean 3.9 (range
1–6.8) years
Biochemical
recurrence (ASTRO
definition:
nadir+ 2 ng/ml)
Pinthus 2012173 4 years Biochemical failure
(Stuttgart definition:
nadir+ 1.2 ng/ml
‘at call’)
Pinthus 2012173 4 years Biochemical failure
(Horwitz definition:
2 consecutive
increases of at least
0.5 ng/ml, backdated)
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N n % N n % N n % N n %
402 67 16.7
402 99 24.6
137 11 8
141 2.8
114 13.2
114 23.7
123 2 2 981 64 7
119 53 44.5
402 81 20.1
402 99 24.6
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Blana 2009106 Median
4.7 years
Clinical failure
(positive prostate
biopsy, initiation of
secondary prostate
cancer therapy,
radiographic evidence
of prostate cancer
metastases or prostate
cancer-related death)
Burdick 2009,112
Ciezki 2004,118
Vassil 2010,200
Kibel 2012,144
Nepple 2013165
Median 4.5
(range 2–10.25)
years
Biochemical failure
(RP: PSA > 0.3 ng/ml
on one reading; BT
and EBRT: PSA level
> 2 ng/ml)
127 14 11
Coen 2012119 5 years Biochemical failurea
(Phoenix definition)
141 6.4
Donnelly 2010,125
Robinson 2009179
5 years Cumulative incidence
of failurea (Trifecta
with biochemical
failure defined as
PSA nadir+ 2 ng/ml)
117 23.9
Giberti 200949 5 years Biochemical failure
(RP: 2 consecutive
PSA increases
≥ 0.2 ng/ml; BT: PSA
nadir+≥ 2 ng/ml,
independent of the
serum concentration
of nadir)
85 7 8.3
Goldner 2012a135 5 years Biochemical evidence
of disease rate
(Phoenix definition:
absolute nadir+
2 ng/ml rise or in case
of the start of
hormonal therapy,
owing to rising PSA):
low risk
667 30 4
Paulson 1982168 5 years Treatment failure
(positive acid
phosphatase
elevation)
Inoue 2011143 7 years PSA failure (Phoenix
criterion, PSA
nadir+> 2 ng/ml)
El Fegoun 2011127 Median 10.6
(range 7.5–11.1)
years
Treatment failure
(positive biopsy
irrespective of side
and/or need for
salvage therapy for a
positive biopsy or
when PSA increased
above pretreatment
levels)
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N n % N n % N n % N n %
285 71 25
268 50 19 310 98 32
141 5.7
114 23.7
89 8 9
252 31 12.3
41 3 7.3 56 2 3.6
137 11 8
12 5 41.7
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Biochemical disease-free survival
Eade 2008126 6 months Freedom from
biochemical failurea
(failure defined as
PSA nadir+ 2 ng/ml)
158 100
Giberti 200949 6 months Biochemical
disease-free survival
ratea
100 99.5
Saliken 1999,180
Donnelly 2002,124
Robinson 1999,177
Robinson 2002178
6 months PSA control
(undetectable PSA
< 0.3 ng/ml)
71 53 75
Ward 2012202 6 months Biochemical
disease-free survivala
(ASTRO definition)
1160 84.2
Cytron 2003122 9 months PSA nadir ≤ 0.5 ng/ml 22 16 72.7
Cytron 2003122 9 months PSA nadir ≤ 1 ng/ml 22 17 77.3
Mearini 2009161 10 months Biochemical
disease-free survivala
(Phoenix criterion:
post-treatment PSA
nadir+ 2 ng/ml)
Wong 2009205 10 months Biochemical no
evidence of diseasea
(PSA < 2 ng/ml above
the nadir with no
backdating): IMRT
225 100
Blana 2012107 1 year Biochemical
disease-free survival
ratea (Phoenix
definition)
Cytron 2003122 1 year PSA nadir ≤ 0.5 ng/ml 14 9 64.3
D’Amico 2003123 1 year PSA failure-free
survivala (BT:
3 consecutive
increments; RP:
> 0.2 ng/ml
post operation)
196 100
Eade 2008126 1 year Freedom from
biochemical failurea
(failure defined as
PSA nadir+ 2 ng/ml)
158 100
Ellis 2007129 Median 12
(range 3–36)
months
Biochemical
disease-free survivala
(ASTRO criteria)
51 41 80.4
Ganzer 2011133 1 year Biochemical
disease-free survivala
(Phoenix definition)
Giberti 200949 1 year Biochemical
disease-free survival
ratea
100 95.9
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N n % N n % N n % N n %
216 100
100 100
160 84.4
314 98.5
356 97.4
322 97.1
216 100
804 96.5
100 98.2
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Goldner 2012a135 1 year Actuarial biochemical
no evidence of
disease ratea (Phoenix
definition: absolute
nadir+ 2 ng/ml rise or
in case of the start of
hormonal therapy,
due to rising PSA):
EBRT 70Gy, low risk
667 98.9
Goldner 2012a135 1 year Actuarial biochemical
no evidence of
disease ratea (Phoenix
definition: absolute
nadir+ 2 ng/ml rise or
in case of the start of
hormonal therapy,
due to rising PSA):
EBRT 74Gy, low risk
Goldner 2012b136 1 year Actuarial biochemical
no evidence of
disease ratea (Phoenix
definition: absolute
nadir+ 2 ng/ml rise or
in case of the start of
hormonal therapy,
due to rising PSA):
intermediate risk
601 98.1
Han 2003139 1 year PSA control (PSA
< 0.4 ng/ml)
89 66 74
Hubosky 200752 1 year Cumulative
biochemical
disease-free survivala
(ASTRO definition)
81 94
Kupelian 2004151 1 year Biochemical
relapse-free survivala
[ASTRO definition:
3 consecutive rising
PSA levels after
a nadir (EBRT, BT);
2 consecutive
detectable PSA levels
(> 0.2 ng/ml) (RP)]:
EBRT < 72Gy
950 99
Pe 2009170 1 year Biochemical failure-
free ratea (PSA failure
defined by Phoenix
criterion: PSA
nadir+≥ 2 ng/ml)
171 100
Pickles 2010171 1 year Biochemical
non-evidence of
diseasea
139 100
Saliken 1999,180
Donnelly 2002124
1 year PSA control
(undetectable PSA
< 0.3 ng/ml)
64 43 67
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N n % N n % N n % N n %
82 100
170 99.4
289 97.5
484 94 1034 92
189 100
139 98.5
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Sumitomo 2010185 1 year Disease-free survival
ratea (Phoenix
definition: PSA
nadir+ 2 ng/ml)
Sumitomo 2010185 1 year Disease-free survival
ratea (Phoenix
definition: PSA
nadir+ 2 ng/ml)
HIFU+ TURP
Uchida 2005191 1 year Biochemical disease-
free survivala
(ASTRO criterion)
Vassil 2010,200
Burdick 2009,112
Ciezki 2004,118
Kibel 2012,144
Nepple 2013165
1 year Biochemical
recurrence-free
survivala [failure
defined as
nadir+ 2 ng/ml
(BT and RT); PSA
≥ 0.4 ng/ml (RP)]:
Laparoscopic RP
256 100
Vassil 2010,200
Burdick 2009,112
Ciezki 2004,118
Kibel 2012,144
Nepple 2013165
1 year Biochemical
recurrence-free
survivala [failure
defined as
nadir+ 2 ng/ml
(BT and RT); PSA
≥ 0.4 ng/ml (RP)]:
Retropubic RP
Ward 2012202 1 year Biochemical disease-
free survivala
(ASTRO definition)
1160 80.7
Zelefsky 1999206 1 year Actuarial PSA
relapse-free survivala
145 96.2
Mearini 2009161 1.25 years Biochemical
disease-free survivala
(Phoenix criterion:
post-treatment PSA
nadir+ 2 ng/ml)
Saliken 1999,180
Donnelly 2002124
1.5 years PSA control
(undetectable PSA
< 0.3 ng/ml)
43 40 93
Giberti 200949 2 years Biochemical disease-
free survival ratea
100 95
Uchida 2005191 2 years Biochemical disease-
free survivala
(ASTRO definition)
Borchers 2004109 2.3 years PSA relapse-free
survival (patients with
a decrease in serum
PSA level < 0.1 ng/ml)
52 44 85
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N n % N n % N n % N n %
65 87.7
64 93.8
60 78
305 100 64 92.8
354 94
137 99.6
160 79.9
100 93.6
60 76
42 40 96
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Mearini 2009161 2.5 years Biochemical
disease-free survivala
(Phoenix definition:
post-treatment PSA
nadir+ 2 ng/ml)
Blana 2012107 3 years Biochemical disease-
free survival ratea
(Phoenix definition)
D’Amico 2003123 3 years PSA failure-free
survivala [BT: ASTRO
criterion (3 consecutive
PSA increments) RP:
>0.2 ng/ml post
operation was
considered as
detectable]
196 100
Eade 2008126 3 years Freedom from
biochemical failurea
(failure defined as
PSA nadir+ 2 ng/ml)
158 99.5
Ganzer 2011133 3 years Biochemical
disease-free survivala
(Phoenix definition)
Giberti 200949 3 years Biochemical disease-
free survival ratea
100 93.6
Goldner 2012a135 3 years Actuarial biochemical
no evidence of
disease ratea (Phoenix
definition: absolute
nadir+ 2 ng/ml rise or
in case of the start of
hormonal therapy,
due to rising PSA):
EBRT 70Gy, low risk
667 96.3
Goldner 2012a135 3 years Actuarial biochemical
no evidence of
disease ratea (Phoenix
definition: absolute
nadir+ 2 ng/ml rise or
in case of the start of
hormonal therapy,
due to rising PSA):
EBRT 74Gy, low risk
Goldner 2012b136 3 years Actuarial biochemical
no evidence of
disease ratea (Phoenix
definition: absolute
nadir+ 2 ng/ml rise or
in case of the start of
hormonal therapy,
due to rising PSA):
intermediate risk
601 85.9
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N n % N n % N n % N n %
160 71.9
356 91.7
322 94.3
216 99.5
804 87
100 92.7
82 94.7
170 95.9
289 90
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Kupelian 2004151 3 years Biochemical
relapse-free survivala
[ASTRO definition:
3 consecutive rising
PSA levels after a
nadir (EBRT, BT);
2 consecutive
detectable PSA levels
(> 0.2 ng/ml)
(RP)]< 72Gy
950 92
Pe 2009170 3 years Biochemical failure-
free ratea (PSA failure
defined by Phoenix
criterion: PSA
nadir+≥ 2 ng/ml)
171 96.1
Pickles 2010171 3 years Biochemical non-
evidence of diseasea
139 97
Sumitomo 2010185 3 years Disease-free survival
ratea (Phoenix
definition: PSA
nadir+ 2 ng/ml)
Sumitomo 2010185 3 years Disease-free survival
ratea (Phoenix
definition: PSA
nadir+ 2 ng/ml):
HIFU+ TURP
Vassil 2010,200
Burdick 2009,112
Ciezki 2004,118
Kibel 2012,144
Nepple 2013165
3 years Biochemical
recurrence-free
survivala [failure
defined as
nadir+ 2 ng/ml
(BT and RT); PSA
≥ 0.4 ng/ml (RP)]:
laparoscopic RP
256 91.4
Vassil 2010,200
Burdick 2009,112
Ciezki 2004,118
Kibel 2012,144
Nepple 2013165
3 years Biochemical
recurrence-free
survivala [failure
defined as
nadir+ 2 ng/ml
(BT and RT); PSA
≥ 0.4 ng/ml (RP)]:
retropubic RP
Ward 2012202 3 years Biochemical disease-
free survivala
(ASTRO definition)
1160 75.7
Zelefsky 1999206 3 years Actuarial PSA
relapse-free
survivala
145 86.4
Ganzer 2008132 3.3 years Disease-free survival
ratesa (disease-free
status defined as PSA
nadir ≤ 0.2 ng/ml)
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N n % N n % N n % N n %
484 62 1034 85
189 98.5
139 94
65 70.6
64 83.7
305 94.3 64 63.1
354 84.4
137 90.5
66 95
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Mearini 2009161 3.3 years Biochemical disease-
free survivala (Phoenix
definition of failure:
post-treatment PSA
nadir+ 2 ng/ml)
Wong 2009205 3.3 years Biochemical no
evidence of diseasea
(ASTRO – Phoenix
definition: PSA
nadir+< 2 ng/ml
with no backdating):
IMRT
225 94.1
Eade 2008126 3.5 years Freedom from
biochemical failurea
(failure defined as
PSA nadir+ 2 ng/ml)
158 20.9
Onik 2008166 Median 4 (range
2–8.75) years
PSA stability rate
(ASTRO definition)
21 20 95
Pe 2009170 4 years Biochemical failure-
free ratea (Phoenix
definition:
nadir+≥ 2 ng/ml)a
171 96.1
Pickles 2010171 4 years Biochemical
non-evidence
of diseasea
139 96.5
Pinthus 2012173 4 years Biochemical failure-
free ratea (Stuttgart
definition:
nadir+ 1.2 ng/ml
‘at call’)
Beyer 2000105 5 years Failure-free survivala
(failure defined as
rising PSA at the time
of analysis)
695 71
Blana 2012107 5 years Biochemical disease-
free survival ratea
(Phoenix definition)
D’Amico 2003123 5 years PSA failure-free
survivala [BT: ASTRO
criterion (3 consecutive
increments) RP:
>0.2 ng/ml post
operation was
considered as
detectable]
196 97.8
Ganzer 2008132 5 years Disease-free survival
ratesa (disease-free
status defined as PSA
nadir ≤ 0.2 ng/ml)
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N n % N n % N n % N n %
160 71.9
314 93.1
216 20.8
189 97
139 88.1
402 68
1527 69
356 84.7
322 92.3
66 94.9
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Ganzer 2011133 5 years Biochemical disease-
free survivala
(Phoenix definition)
Giberti 200949 5 years Biochemical disease-
free survival ratea
100 91.4
Goldner 2012a135 5 years Actuarial biochemical
no evidence of disease
ratea (Phoenix
definition: absolute
nadir+2ng/ml rise or
in case of the start of
hormonal therapy,
due to rising PSA):
EBRT 70Gy, low risk
667 93
Goldner 2012a135 5 years Actuarial biochemical
no evidence of
disease ratea (Phoenix
definition: absolute
nadir+ 2 ng/ml rise or
in case of the start of
hormonal therapy,
due to rising PSA):
EBRT 74Gy, low risk
Goldner 2012b136 5 years Actuarial biochemical
no evidence of
disease ratea (Phoenix
definition: absolute
nadir+ 2 ng/ml rise or
in case of the start of
hormonal therapy,
due to rising PSA):
intermediate risk
601 78
Kupelian 2004151 5 years Biochemical
relapse-free survivala
[ASTRO definition:
3 consecutive rising
PSA levels after a
nadir (EBRT, BT);
2 consecutive
detectable PSA levels
(> 0.2 ng/ml) (RP)]:
EBRT< 72Gy
950 83
Misrai 2008162 5 years Biochemical disease-
free survival ratea
(ASTRO criteria: a rise
in PSA of 2 ng/ml or
more above the
nadir PSA)
Pe 2009170 5 years Biochemical failure-
free ratea (PSA failure
defined by Phoenix
criterion: PSA
nadir+≥2ng/ml)
171 96.1
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N n % N n % N n % N n %
804 80
100 91
82 84
170 91
289 74
484 51 1034 81
119 30
189 94.8
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Pickles 2010171 5 years Biochemical
non-evidence
of diseasea
139 95.2
Shah 2012,182
Vicini 2011201
5 years Disease-free survivala
(absence of local
recurrence, disease or
death secondary to
prostate cancer):
African American
36 84.8
Shah 2012,182
Vicini 2011201
5 years Disease-free survivala
(absence of local
recurrence, disease or
death secondary to
prostate cancer): white
504 90.7
Sumitomo 2010185 5 years Disease-free survival
ratea (Phoenix
definition: PSA
nadir+ 2 ng/ml): HIFU
Sumitomo 2010185 5 years Disease-free survival
ratea (Phoenix
definition: PSA
nadir+ 2 ng/ml):
HIFU+ TURP
Vassil 2010,200
Burdick 2009,112
Ciezki 2004,118
Kibel 2012,144
Nepple 2013165
5 years Biochemical
recurrence-free
survivala [failure
defined as
nadir+ 2 ng/ml
(BT and RT); PSA
≥ 0.4 ng/ml (RP)]:
laparoscopic RP
256 89.5
Vassil 2010,200
Burdick 2009,112
Ciezki 2004,118
Kibel 2012,144
Nepple 2013165
5 years Biochemical
recurrence-free
survivala [failure
defined as
nadir+ 2 ng/ml
(BT and RT); PSA
≥ 0.4 ng/ml (RP)]:
retropubic RP
Wong 2009205 5 years Biochemical no
evidence of diseasea
(ASTRO – Phoenix
definition: PSA
nadir+< 2 ng/ml
with no backdating):
IMRT
225 94
Zelefsky 1999206 5 years Actuarial PSA
relapse-free survivala
145 82
Giberti 200949 6 years Biochemical disease-
free survival ratea
85 91.7
Mack 1997158 Mean 8.5 (range
6–18) years
No evidence
of disease
66 25 37.9
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
396
HIFU AS EBRT RP
N n % N n % N n % N n %
139 84.7
12 82
469 77.4
65 61.3
64 75.2
305 85.7 64 60.2
354 79.9
314 87
137 88
89 91
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Chaussy 2003116 10 years PSA stability ratea
(ASTRO criterion):
HIFU
Reintervention
Ahmed 201299 After 6 months Reintervention
Ahmed 201198 6–12 months Reintervention
Donnelly 2010,125
Robinson 2009179
Within 6 months Reintervention 117 14 12
Koch 2007150 Within 6 months Reintervention:
two treatments
Koch 2007150 Within 6 months Reintervention:
three treatments
Lindner 2009155 6 months Reintervention
Cytron 2003122 9 months
(unclear)
Reintervention 22 1 4.5
Chaussy 2003116 Mean 10.9
(range 2.9–26.9)
months
Reintervention:
HIFU+ TURP
Ellis 2007129 Mean 15.2
(SD 7.4) months
Reintervention 60 11 18
Chaussy 2003116 Mean 18 (range
3–46.3) months
Reintervention: HIFU
Chaussy 2003116 Reintervention: all
patients (HIFU
and HIFU+ TURP)
Mearini 2009161 Median 2 years
(range 11.8–40.8
months)
Reintervention
Pinthus 2012173 Median 24
(range 6–48)
months
Reintervention
Caso 2012,114
Caso 2012,115
Polascik 2007175
Median 2.3
(range 1–3.4)
years
Reintervention 97 4 4.1
Lian 2011154 Median 2.5
years (range
9–56 months)
Reintervention 102 1 1
Wong 1997204 2.5 years Reintervention 83 12 14.5
Inoue 2011143 Median 3 years
(range
12–84 months)
Reintervention
Onik 2008166 Median 4.2 years
(range 24–105
months)
Reintervention 21 1 4.8
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HIFU AS EBRT RP
N n % N n % N n % N n %
96 84.2
41 4 10
19 1 5.3
N/A N/A N/A
20 10 50
20 2 10
175 7
96 24
271 31
163 20 12.3
402 12 3
137 15 10.9
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Blana 2009106 Median 4.7
(range 2–10.9)
years
Reintervention
Poissonnier 2007174 5 years Reintervention and
watchful waiting
Bahn 2002102 Median
5.43 years
Reintervention 75 32 42.7
Donnelly 2002,124
Saliken 1999180
Median 5 years
(range
35–85 months)
Reintervention:
two treatments
76 10 13.1
Donnelly 2002,124
Saliken 1999180
Median 5 years
(range
35–85 months)
Reintervention:
three treatments
76 1 1.3
El Fegoun 2011127 Median 10.6
(range 7.5–11.1)
years
Reintervention
Moved to other treatments
Giberti 200949 3 months Additional treatments 85 7 8.3
Ahmed 201299 After 6 months Moved to AS
Ahmed 201198 6–12 months Moved to AS
Donnelly 2010,125
Robinson 2009179
Within 6 months Moved to
other treatments
117 16 13.7
Donnelly 2010,125
Robinson 2009179
Within 6 months Moved to other
treatments: CRYO
N/A N/A N/A
Donnelly 2010,125
Robinson 2009179
Within 6 months Moved to other
treatments:
hormone therapy
117 13 11.1
Donnelly 2010,125
Robinson 2009179
Within 6 months Moved to other
treatments:
watchful waiting
117 3 2.6
Maestroni 2008159 After 6 months Moved to other
treatments:
hormone therapy
Bul 2013,111 van
den Bergh 2010197
1.6 years Moved to
other treatments
Bul 2013,111 van
den Bergh 2010197
1.6 years Moved to other
treatments: RP
Bul 2013,111 van
den Bergh 2010197
1.6 years Moved to other
treatments:
radiotherapy
Bul 2013,111 van
den Bergh 2010197
1.6 years Moved to other
treatments:
hormone therapy
Bul 2013,111 van
den Bergh 2010197
1.6 years Moved to other
treatments: HIFU
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HIFU AS EBRT RP
N n % N n % N n % N n %
285 43 15.1
227 12 5.3
12 1 8.3
89 8 9
41 5 12
19 1 5.3
114 32 28.1
114 9 7.9
114 16 14
114 7 6.1
25 4 16
2494 527 21.1
2494 253 10.1
2494 238 9.5
2494 8 0.32
2494 4 0.16
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Bul 2013,111 van
den Bergh 2010197
1.6 years Moved to other
treatments: unknown
Pinthus 2012173 Median 2 years
(range
6–48 months)
Moved to other
treatments: RP
Pinthus 2012173 Median 2 years
(range
6–48 months)
Moved to other
treatments:
radiotherapy
Pinthus 2012173 Median 2 years
(range
6–48 months)
Moved to other
treatments:
hormone therapy
Pinthus 2012173 Median 2 years
(range
6–48 months)
Moved to other
treatments: AS
Pinthus 2012173 Median 2 years
(range
6–48 months)
Moved to
other treatments
Caso 2012,114
Caso 2012,115
Polascik 2007175
Median 2.3
(range 1–3.4)
years
Moved to
other treatments
97 12 12.3
Caso 2012,114
Caso 2012,115
Polascik 2007175
Median 2.3
(range 1–3.4)
years
Moved to other
treatments:
radiotherapy
97 3 3.1
Caso 2012,114
Caso 2012,115
Polascik 2007175
Median 2.3
(range 1–3.4)
years
Moved to other
treatments:
hormone therapy
97 2 2.1
Caso 2012,114
Caso 2012,115
Polascik 2007175
Median 2.3
(range 1–3.4)
years
Moved to other
treatments:
watchful waiting
97 1 1
Caso 2012,114
Caso 2012,115
Polascik 2007175
Median 2.3
(range 1–3.4)
years
Moved to other
treatments:
chemotherapy
97 1 1
Mearini 2009161 Median 2 years
(range 11.8–40.8
months)
Moved to other
treatments:
radiotherapy
Tosoian 2011187 Median 2.7
(range 0.01–15.0)
years
Moved to
other treatments
Hardie 2005140 Median 3.5 years
(range
1–116 months)
Moved to
other treatments
Misrai 2008162 Median 3.8
(range 1–6.8)
years
Moved to
other treatments
Misrai 2008162 Median 3.8
(range 1–6.8)
years
Moved to other
treatments:
radiotherapy
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HIFU AS EBRT RP
N n % N n % N n % N n %
2494 28 1.12
402 6 1.5
402 4 1
402 4 1
402 7 1.7
402 28 7
163 2 1.2
769 255 33.2
80 11 14
119 22 18.5
119 14 11.8
continued
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
403
TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Misrai 2008162 Median 3.8
(range 1–6.8)
years
Moved to other
treatments:
hormone therapy
Misrai 2008162 Median 3.8
(range 1–6.8)
years
Moved to other
treatments: RP
Blana 2009106 Median 4.7
(range 2–10.9)
years
Moved to other
treatments:
hormone therapy
Blana 2009106 Median 4.7
(range 2–10.9)
years
Moved to other
treatments:
radiotherapy
Poissonnier 2007174 5 years Moved to other
treatments:
radiotherapy
Poissonnier 2007174 5 years Moved to other
treatments:
hormone therapy
Poissonnier 2007174 5 years Moved to other
treatments:
EBRT+ hormone
therapy
Pickles 2010171 5 years Moved to other
treatments: hormone
therapy
(actuarial use)
139 7 5
Selvadurai 2013,181
van As 2008196
Median
5.7 years
Moved to
other treatments
Selvadurai 2013,181
van As 2008196
Median
5.7 years
Moved to other
treatments:
EBRT+ hormone
therapy
Selvadurai 2013,181
van As 2008196
Median
5.7 years
Moved to other
treatments: RP
Selvadurai 2013,181
van As 2008196
Median
5.7 years
Moved to other
treatments: BT
Selvadurai 2013,181
van As 2008196
Median
5.7 years
Moved to other
treatments: HIFU
Selvadurai 2013,181
van As 2008196
Median
5.7 years
Moved to other
treatments:
hormone therapy
Godtman 2013134 Median 6 (range
0.08–15.1) years
Moved to
other treatments
Godtman 2013134 Median 6 (range
0.08–15.1) years
Moved to other
treatments: RP
Godtman 2013134 Median 6 (range
0.08–15.1) years
Moved to other
treatments:
radiotherapy
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HIFU AS EBRT RP
N n % N n % N n % N n %
119 7 5.9
119 1 0.8
285 15 5.2
285 7 2.5
227 12 5.3
227 3 1.3
227 4 1.8
139 11 8
471 148 31.4
471 91 19.3
471 43 9.1
471 10 2.1
471 1 0.2
471 3 0.6
439 162 37
439 106 24.1
439 32 7.3
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TABLE 78 Cancer-related efficacy outcomes (continued )
Study ID Timeline Outcome
BT CRYO
N n % N n %
Godtman 2013134 Median 6 (range
0.08–15.1) years
Moved to other
treatments:
hormone therapy
Klotz 2010,146
Klotz 2005,148
Klotz 2012,147
Loblaw 2010157
Median 6.8
(range 1–13)
years
Moved to
other treatments
Klotz 2010,146
Klotz 2005,148
Klotz 2012,147
Loblaw 2010157
Median 6.8
(range 1–13)
years
Moved to other
treatments: RP
Klotz 2010,146
Klotz 2005,148
Klotz 2012,147
Loblaw 2010157
Median 6.8
(range 1–13)
years
Moved to other
treatments:
radiotherapy
Klotz 2010,146
Klotz 2005,148
Klotz 2012,147
Loblaw 2010157
Median 6.8
(range 1–13)
years
Moved to other
treatments:
hormone therapy
Sumitomo 2010185 12–93 months Moved to other
treatments:
hormone therapy
Sumitomo 2010185 12–93 months Moved to other
treatments:
radiotherapy
Sumitomo 2010185 12–93 months Moved to other
treatments:
radiohormonal
therapy
Sumitomo 2010185 12–93 months Moved to other
treatments:
chemotherapy
Sumitomo 2010185 12–93 months Moved to other
treatments: RP
Mack 1997158 Mean 8.5 years Moved to other
treatments:
radiotherapy
66 20 30
Mack 1997158 Mean 8.5 years Moved to other
treatments:
hormone therapy
66 27 41
El Fegoun 2011127 Median 10.6
(range 7.5–11.1)
years
Moved to other
treatments:
hormone therapy
ASTRO, American Society for Radiation Oncology; BT, brachytherapy; CRYO, cryotherapy; IQR, interquartile range;
N/A, not applicable; N/R, not reported; OS, overall survival; PCSM, prostate cancer-specific mortality; RT, radiotherapy;
SD, standard deviation; TURP, transurethral resection of the prostate.
a The percentages are Kaplan–Meier estimates, and thus the numbers at risk at each time point rather than N would be
required to calculate n.
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
406
HIFU AS EBRT RP
N n % N n % N n % N n %
439 24 5.5
450 135 30
450 35 7.7
450 90 20
450 10 2.3
129 28 21.7
129 2 1.5
129 1 0.8
129 1 0.8
129 3 2.3
12 4 33.3
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TABLE 78a All efficacy outcomes: laser
Study ID Timeline Outcome N n %
Lindner 2009155 6 months Reintervention 12 1 8.3
TABLE 78b All efficacy outcomes: PDT
Study ID Timeline Outcome N n %
Barret 2013103 Median follow-up
9 (IQR 6–15) months
23 23 100
IQR, interquartile range.
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
408
TA
B
LE
79
U
ri
n
ar
y
fu
n
ct
io
n
d
ic
h
o
to
m
o
u
s
o
u
tc
o
m
es
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
U
ri
n
ar
y
co
n
ti
n
en
ce
A
hm
ed
20
12
99
6
m
on
th
s
U
rin
ar
y
co
nt
in
en
ce
(p
ad
fr
ee
an
d
no
le
ak
)/U
C
LA
EP
IC
41
37
90
.2
A
hm
ed
20
11
98
6
m
on
th
s
U
rin
ar
y
co
nt
in
en
ce
(p
ad
fr
ee
an
d
no
le
ak
)
20
19
95
A
hm
ed
20
12
99
12
m
on
th
s
U
rin
ar
y
co
nt
in
en
ce
(p
ad
fr
ee
an
d
no
le
ak
)/U
C
LA
EP
IC
41
38
92
.7
Bo
rc
he
rs
20
04
10
9
1
ye
ar
U
rin
ar
y
co
nt
in
en
ce
:
EO
RT
C
-Q
LQ
-P
R3
0
52
13
42
62
U
ri
n
ar
y
in
co
n
ti
n
en
ce
(U
I)
Ba
hn
20
02
10
2
6
m
on
th
s
(a
ve
ra
ge
)
A
ny
le
ak
ag
e
(e
ve
n
a
dr
op
of
ur
in
e)
(d
ef
in
iti
on
2)
53
3
23
4.
3
El
lis
20
07
12
9
6
m
on
th
s
(m
or
e
or
eq
ua
l)
M
ea
n
fo
llo
w
-u
p
15
.2
(S
D
7.
4)
m
on
th
s
U
Id
ef
in
ed
as
dr
op
of
ur
in
e
at
an
y
tim
e
60
2
3.
3
G
ib
er
ti
20
09
49
6
m
on
th
s
U
I
10
0
0
0
10
0
16
16
M
oh
am
m
ed
20
12
,1
64
Sh
ah
20
12
,1
82
V
ic
in
i2
01
12
01
6
m
on
th
s
(w
ith
in
3–
6
m
on
th
s)
U
I:
al
lp
at
ie
nt
s
54
0
45
8.
3
21
90
18
8
8.
6
Bo
rc
he
rs
20
04
10
9
1
ye
ar
N
ew
ly
de
ve
lo
pe
d
(U
I)
(E
O
RT
C
-Q
LQ
-P
R3
0)
52
N
R
40
42
N
R
20
C
as
o
20
12
,1
14
C
as
o
20
12
,1
15
Po
la
sc
ik
20
07
17
5
W
ith
in
1
ye
ar
A
ll
in
co
nt
in
en
ce
10
6
22
20
.8
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
409
TA
B
LE
79
U
ri
n
ar
y
fu
n
ct
io
n
d
ic
h
o
to
m
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
H
an
20
03
13
9
1
ye
ar
fo
llo
w
-u
p
(r
ep
or
te
d
as
po
st
op
er
at
iv
e)
A
ll
in
co
nt
in
en
ce
10
4
8
7.
7
K
irs
ch
ne
r-
H
er
m
an
ns
20
08
14
5
1
ye
ar
U
I(
IC
Sm
al
e)
33
17
52
61
40
66
H
ub
os
ky
20
07
52
1.
1-
ye
ar
m
ea
n
fo
llo
w
-u
p
(r
an
ge
1–
32
,
m
ed
ia
n
11
m
on
th
s)
In
co
nt
in
en
ce
de
fin
ed
as
re
qu
ire
d
pa
ds
be
ca
us
e
of
le
ak
in
g
ur
in
e
89
2
2
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
16
m
on
th
s
(R
T:
ra
ng
e
12
–
21
m
on
th
s;
BT
:
ra
ng
e
12
–
24
m
on
th
s)
M
od
er
at
e/
bi
g
pr
ob
le
m
fr
om
dr
ip
pi
ng
or
le
ak
in
g
ur
in
e
(E
PI
C
)
52
6
12
52
3
6
W
ar
d
20
12
20
2
1
ye
ar
U
I(
us
e
of
an
y
pa
ds
)
11
60
8
0.
7
H
al
e
20
13
13
8
M
ea
n
1.
6
ye
ar
s
(r
an
ge
2–
52
m
on
th
s)
U
I(
us
e
of
an
y
pa
ds
)
26
0
0
U
ch
id
a
20
05
19
1
M
ed
ia
n
1.
7
ye
ar
s
(r
an
ge
2–
24
m
on
th
s)
U
Ig
ra
de
1
D
ef
in
ed
by
Ja
pa
ne
se
ve
rs
io
n
of
N
at
io
na
lC
an
ce
r
In
st
itu
te
-
C
om
m
on
To
xi
ci
ty
C
rit
er
ia
ve
rs
io
n
2.
0
72
1
1.
4
Bu
ro
n
20
07
11
3
2
ye
ar
s
U
I:
EO
RT
C
-Q
LQ
-P
R2
5
30
8
39
12
.7
12
7
25
19
.7
Re
ev
e
20
12
17
6
2
ye
ar
s
U
I
41
13
31
.7
16
9
67
39
.6
72
32
44
.4
W
ill
ia
m
s
20
12
20
3
2
ye
ar
s
(w
ith
in
5
ye
ar
s)
U
I
A
ss
es
se
d
us
in
g
se
lf-
as
se
ss
m
en
t
w
ith
va
lid
at
ed
in
st
ru
m
en
ts
99
85
11
16
11
.2
94
3
18
2
19
.3
Li
an
20
11
15
4
M
ed
ia
n
2.
5
ye
ar
s
(r
an
ge
9–
56
m
on
th
s)
U
Ir
eq
ui
rin
g
1–
2
pa
ds
pe
r
da
y
10
2
4
3.
9
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
410
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
C
he
n
20
09
11
7
3
ye
ar
s
U
I(
PC
SI
)
78
16
20
.5
15
4
46
30
11
2
60
53
.6
Sm
ith
20
09
18
4
3
ye
ar
s
U
I(
us
e
of
an
y
pa
ds
)
58
3
5.
4
12
3
3
2.
7
98
1
11
1
12
.3
O
ni
k
20
08
16
6
M
ed
ia
n
4.
2
ye
ar
s
(r
an
ge
24
–
10
5
m
on
th
s)
,
re
po
rt
ed
as
po
st
op
er
at
iv
e
U
I
21
0
0
C
ol
om
be
l2
00
61
20
5
ye
ar
s
U
Ig
ra
de
1
24
2
23
9.
5
C
ro
ok
20
11
12
1
5
ye
ar
s
A
ny
ur
in
ar
y
le
ak
ag
e
(E
PI
C
)
10
1
14
13
.9
67
27
40
.3
D
on
ne
lly
20
02
12
4
W
ith
in
5
ye
ar
s
U
I
76
1
1.
3
G
ib
er
ti
20
09
49
5
ye
ar
s
U
I
10
0
0
0
10
0
0
0
El
Fe
go
un
20
11
12
7
M
ed
ia
n
10
.6
(r
an
ge
7.
5–
11
.1
)
ye
ar
s
U
I(
us
e
of
an
y
pa
ds
)
12
0
0
U
ri
n
ar
y
fu
n
ct
io
n
A
hm
ed
20
11
98
6
m
on
th
s
A
ny
LU
TS
(I-
PS
S
or
di
na
ls
um
)
20
20
10
0
Bo
et
tc
he
r
20
12
10
8
6
m
on
th
s
U
rg
en
cy
fr
eq
ue
nc
y
fr
om
O
A
B
se
ve
rit
y
sc
al
e
33
14
42
.4
66
10
15
.2
G
ib
er
ti
20
09
49
6
m
on
th
s
Irr
ita
tiv
e
sy
m
pt
om
s
10
0
68
68
10
0
4
4
K
oc
h
20
07
15
0
6
m
on
th
s
U
rin
ar
y
dy
sf
un
ct
io
n,
I-P
SS
(m
ild
:
<
8;
m
od
er
at
e:
8–
19
;
se
ve
re
:
20
–
35
)
D
ec
re
as
e
in
sc
or
e
19
12
63
.2
K
oc
h
20
07
15
0
6
m
on
th
s
U
rin
ar
y
dy
sf
un
ct
io
n,
I-P
SS
(m
ild
:
<
8;
m
od
er
at
e:
8–
19
;
se
ve
re
:
20
–
35
)
N
o
ch
an
ge
in
sc
or
e
19
2
10
.5
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
411
TA
B
LE
79
U
ri
n
ar
y
fu
n
ct
io
n
d
ic
h
o
to
m
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
K
oc
h
20
07
15
0
6
m
on
th
s
U
rin
ar
y
dy
sf
un
ct
io
n,
I-P
SS
(m
ild
:
<
8;
m
od
er
at
e:
8–
19
;
se
ve
re
:
20
–
35
)
In
cr
ea
se
in
sc
or
e
19
5
26
.3
Po
is
so
nn
ie
r
20
07
17
4
6
m
on
th
s
U
rg
en
cy
22
7
12
5
Sh
ah
20
12
,1
82
V
ic
in
i2
01
1,
20
1
M
oh
am
m
ed
20
12
16
4
3–
6
m
on
th
s
Fr
eq
ue
nc
y/
ur
ge
nc
y:
al
lp
at
ie
nt
s
54
0
29
5
54
.6
21
90
88
3
40
.3
Ts
ui
20
05
18
9
6
m
on
th
s
U
rin
ar
y
sy
m
pt
om
s
(m
ed
ia
n
I-P
SS
>
ba
se
lin
e)
86
67
77
.9
N
/R
N
/R
N
/R
Ts
ui
20
05
18
9
6
m
on
th
s
U
rin
ar
y
sy
m
pt
om
s
(R
TO
G
>
0)
N
/R
N
/R
N
/R
76
4
5.
3
A
hm
ed
20
11
98
1
ye
ar
A
ny
LU
TS
(I-
PS
S
or
di
na
ls
um
)
20
20
10
0
Bo
et
tc
he
r
20
12
10
8
1
ye
ar
U
rg
en
cy
fr
eq
ue
nc
y
fr
om
O
A
B
se
ve
rit
y
sc
al
e
33
11
33
.5
66
8
12
.1
C
as
o
20
12
,1
14
C
as
o
20
12
,1
15
Po
la
sc
ik
20
07
17
5
1
ye
ar
W
or
se
ni
ng
LU
TS
(u
rg
en
cy
)
10
6
8
7.
5
C
as
o
20
12
,1
14
C
as
o
20
12
,1
15
Po
la
sc
ik
20
07
17
5
1
ye
ar
Sp
la
ye
d
st
re
am
10
6
2
1.
8
K
irs
ch
ne
r-
H
er
m
an
ns
20
08
14
5
1
ye
ar
LU
TS
(IC
Sm
al
e)
33
29
88
61
49
80
K
irs
ch
ne
r-
H
er
m
an
ns
20
08
14
5
1
ye
ar
Bo
th
er
so
m
e
LU
TS
(‘q
ui
te
a
pr
ob
le
m
’
or
‘a
se
rio
us
pr
ob
le
m
’)
(IC
Sm
al
e)
33
10
30
61
7
11
K
irs
ch
ne
r-
H
er
m
an
ns
20
08
14
5
1
ye
ar
U
rg
en
cy
(IC
Sm
al
e)
33
29
88
61
39
64
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
412
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
K
irs
ch
ne
r-
H
er
m
an
ns
20
08
14
5
1
ye
ar
Bo
th
er
so
m
e
ur
ge
nc
y
(‘q
ui
te
a
pr
ob
le
m
’
or
‘a
se
rio
us
pr
ob
le
m
’)
(IC
Sm
al
e)
33
7
21
61
1
2
Bo
et
tc
he
r
20
12
10
8
2
ye
ar
s
U
rg
en
cy
fr
eq
ue
nc
y:
O
A
B
se
ve
rit
y
sc
al
e
33
12
36
.6
66
8
12
.1
Bu
ro
n
20
07
11
3
2
ye
ar
s
U
rin
ar
y
ur
ge
nc
y:
EO
RT
C
-Q
LQ
-P
R2
5
30
8
76
24
.7
12
7
14
11
Bu
ro
n
20
07
11
3
2
ye
ar
s
D
iu
rn
al
ur
in
ar
y
fr
eq
ue
nc
y:
EO
RT
C
-Q
LQ
-P
R2
5
30
8
74
24
12
7
8
6.
3
Bu
ro
n
20
07
11
3
2
ye
ar
s
N
oc
tu
rn
al
ur
in
ar
y
fr
eq
ue
nc
y:
EO
RT
C
-Q
LQ
-P
R2
5
30
8
62
20
.1
12
7
7.
4
5.
8
Bo
et
tc
he
r
20
12
10
8
3
ye
ar
s
U
rg
en
cy
fr
eq
ue
nc
y:
O
A
B
se
ve
rit
y
sc
al
e
33
10
30
66
7
11
C
he
n
20
09
11
7
3
ye
ar
s
U
rin
ar
y
ob
st
ru
ct
io
n/
irr
ita
tio
n
75
27
36
15
2
10
1
66
.4
10
7
53
49
.5
C
ro
ok
20
11
12
1
5
ye
ar
s
W
ea
k
st
re
am
an
d
in
co
m
pl
et
e
em
pt
yi
ng
(E
PI
C
)
10
1
39
38
.6
67
21
31
.3
G
ib
er
ti
20
09
49
5
ye
ar
s
Irr
ita
tiv
e
sy
m
pt
om
s
10
0
0
0
10
0
0
0
In
ou
e
20
11
14
3
7
ye
ar
s
U
rg
en
cy
in
vo
id
in
g
13
7
15
11
In
ou
e
20
11
14
3
7
ye
ar
s
D
iff
ic
ul
t
vo
id
in
g
13
7
30
22
BT
,
br
ac
hy
th
er
ap
y;
C
RY
O
,
cr
yo
th
er
ap
y;
EO
RT
C
-Q
LQ
-P
R2
5,
Eu
ro
pe
an
O
rg
an
is
at
io
n
fo
r
Re
se
ar
ch
an
d
Tr
ea
tm
en
t
of
C
an
ce
r
Q
ua
lit
y
of
Li
fe
Q
ue
st
io
nn
ai
re
–
Pr
os
ta
te
-2
5
ite
m
s;
EO
RT
C
-Q
LQ
-P
R3
0,
Eu
ro
pe
an
O
rg
an
is
at
io
n
fo
r
Re
se
ar
ch
an
d
Tr
ea
tm
en
t
of
C
an
ce
r
Q
ua
lit
y
of
Li
fe
Q
ue
st
io
nn
ai
re
–
Pr
os
ta
te
-3
0
ite
m
s;
EP
IC
,
Ex
pa
nd
ed
Pr
os
ta
te
C
an
ce
r
In
de
x
C
om
po
si
te
;
IC
Sm
al
e,
In
te
rn
at
io
na
lC
on
tin
en
ce
So
ci
et
y-
m
al
e
qu
es
tio
nn
ai
re
;
LU
TS
,
lo
w
er
ur
in
ar
y
tr
ac
t
sy
m
pt
om
s;
N
/R
,
no
t
re
po
rt
ed
;
N
R,
nu
m
be
r
at
ris
k
(d
ef
in
ed
as
nu
m
be
r
w
ho
w
er
e
co
nt
in
en
t
pr
io
r
to
tr
ea
tm
en
t)
;
O
A
B,
ov
er
ac
tiv
e
bl
ad
de
r;
PC
SI
,
Pr
os
ta
te
C
an
ce
r
Sy
m
pt
om
In
de
x;
RT
,
ra
di
ot
he
ra
py
;
SD
,
st
an
da
rd
de
vi
at
io
n;
U
C
LA
EP
IC
,
U
ni
ve
rs
ity
of
C
al
ifo
rn
ia
,
Lo
s
A
ng
el
es
Ex
pa
nd
ed
Pr
os
ta
te
C
an
ce
r
In
de
x
C
om
po
si
te
.
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
413
TA
B
LE
80
U
ri
n
ar
y
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
U
I
Tr
ue
sd
al
e
20
10
,1
88
La
m
be
rt
20
07
15
2
6
m
on
th
s
M
ea
n
(S
D
)
U
IA
U
A
Sy
m
pt
om
In
de
x
sc
or
e
30
8.
9
(7
.3
)
Ta
lc
ot
t
20
03
18
6
1
ye
ar
M
ea
n
(S
D
)
U
Is
ym
pt
om
in
de
x
(u
rin
ar
y,
bo
w
el
an
d
se
xu
al
fu
nc
tio
n
sc
al
e)
80
4.
6
(1
1.
1)
18
2
9.
2
(1
5.
8)
12
9
23
.9
(2
3.
5)
Tr
ue
sd
al
e
20
10
,1
88
La
m
be
rt
20
07
15
2
1
ye
ar
M
ea
n
(S
D
)
U
IA
U
A
Sy
m
pt
om
In
de
x
sc
or
e
54
7.
6
(6
.3
)
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
RT
:
ra
ng
e
12
–
21
m
on
th
s;
BT
:
ra
ng
e
12
–
24
m
on
th
s
M
ea
n,
m
ed
ia
n
(r
an
ge
)
U
Is
co
re
(E
PI
C
)
52
90
,
10
0
(8
3
–
10
0)
52
90
,
10
0
(9
0–
10
0)
Ta
lc
ot
t
20
03
18
6
2
ye
ar
s
M
ea
n
(S
D
)
U
Is
ym
pt
om
in
de
x
(u
rin
ar
y,
bo
w
el
an
d
se
xu
al
fu
nc
tio
n
sc
al
e)
80
7.
5
(1
5.
1)
18
2
8.
5
(1
5.
7)
12
9
23
.4
(2
3.
9)
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
3
ye
ar
s
M
ea
n
U
IE
PI
C
do
m
ai
n-
sp
ec
ifi
c
15
5
88
.7
10
0
89
.7
10
9
N
/R
Fr
an
k
20
07
13
1
3.
5
ye
ar
s
(B
T)
;
4.
7
ye
ar
s
(E
BR
T)
;
4
ye
ar
s
(R
P)
M
ea
n
(S
D
)
U
I(
EP
IC
)
74
85
.9
(2
3)
13
5
85
.5
(1
8.
9)
23
4
73
.4
(2
5.
1)
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
414
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
U
ri
n
ar
y
b
o
th
er
K
ob
uk
e
20
09
14
9
6
m
on
th
s
U
rin
ar
y
bo
th
er
(U
C
LA
-P
C
I)
36
77
.1
37
86
.6
M
oh
am
ed
20
12
16
3
6
m
on
th
s
M
ea
n
(S
D
)
U
rin
ar
y
bo
th
er
(A
U
A
Sy
m
pt
om
In
de
x)
24
0
2.
26
(1
.1
2)
48
3
1.
84
(0
.9
)
14
6
1.
99
(1
.0
8)
K
ob
uk
e
20
09
14
9
1
ye
ar
U
rin
ar
y
bo
th
er
(U
C
LA
-P
C
I)
36
86
.6
37
87
.8
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
RT
:
ra
ng
e
12
–
21
m
on
th
s;
BT
:
ra
ng
e
12
–
24
m
on
th
s
M
ea
n,
m
ed
ia
n
(IQ
R)
U
rin
ar
y
bo
th
er
(E
PI
C
)
52
82
,
89
(6
8
–
10
0)
52
88
,
93
(8
3–
96
)
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
RT
:
ra
ng
e
12
–
21
m
on
th
s;
BT
:
ra
ng
e
12
–
24
m
on
th
s
M
ea
n,
m
ed
ia
n
(IQ
R)
U
Ib
ot
he
r
(E
PI
C
)
52
86
,
10
0
(9
4
–
10
0)
52
92
,
10
0
(1
00
–
10
0)
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
RT
:
ra
ng
e
12
–
21
m
on
th
s;
BT
:
ra
ng
e
12
–
24
m
on
th
s
M
ea
n,
m
ed
ia
n
(IQ
R)
U
rin
ar
y
ob
st
ru
ct
iv
e/
irr
ita
tiv
e
bo
th
er
(E
PI
C
)
52
82
,
87
(6
6
–
10
0)
52
87
,
90
(8
0–
10
0)
Sm
ith
20
09
18
4
3
ye
ar
s
M
ea
n
(S
D
)
U
rin
ar
y
bo
th
er
Lo
ng
-f
or
m
U
C
LA
-P
C
I:
RP
ne
rv
e
sp
ar
in
g
58
84
.4
(2
4.
6)
12
3
81
.4
(2
7.
6)
49
4
84
.8
(2
3.
5)
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
415
TA
B
LE
80
U
ri
n
ar
y
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
Sm
ith
20
09
18
4
3
ye
ar
s
M
ea
n
(S
D
)
U
rin
ar
y
bo
th
er
(L
on
g-
fo
rm
U
C
LA
-P
C
I):
RP
no
n-
ne
rv
e
sp
ar
in
g
47
6
83
.1
(2
5.
3)
Fr
an
k
20
07
13
1
M
ed
ia
n
3.
5
ye
ar
s
(B
T)
,m
ed
ia
n
4.
7
ye
ar
s
(E
BR
T)
,
m
ed
ia
n
4
ye
ar
s
(R
P)
M
ea
n
(S
D
)
U
rin
ar
y
bo
th
er
(E
PI
C
do
m
ai
n
sp
ec
ifi
c)
74
78
(1
9.
6)
13
5
80
.4
(1
8)
23
4
83
.2
(1
6.
1)
U
ri
n
ar
y
fu
n
ct
io
n
EP
IC
do
m
ai
n
ur
in
ar
y
fu
nc
tio
n
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
6
m
on
th
s
M
ea
n
(S
E)
U
rin
ar
y
fu
nc
tio
n
do
m
ai
n
(E
PI
C
)
24
7
89
.5
(0
.9
)
18
0
96
.1
(0
.7
)
11
8
83
.2
(1
.5
)
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
1
ye
ar
M
ea
n
(S
E)
U
rin
ar
y
do
m
ai
n
(E
PI
C
)
25
5
92
.6
(0
.8
)
18
4
94
.7
(0
.8
)
12
1
88
.5
(1
.2
)
A
hm
ed
20
12
99
1
ye
ar
M
ed
ia
n
(IQ
R)
U
rin
ar
y
fu
nc
tio
n
do
m
ai
n
(E
PI
C
)
41
10
0
(9
2.
5,
10
0)
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
(R
T:
ra
ng
e
12
–
21
m
on
th
s;
BT
:
ra
ng
e
12
–
24
m
on
th
s)
M
ea
n,
m
ed
ia
n
(r
an
ge
)
U
rin
ar
y
fu
nc
tio
n
(E
PI
C
)
52
91
,
10
0
(8
9
–
10
0)
52
94
,
10
0
(9
4–
10
0)
Fr
an
k
20
07
13
1
M
ed
ia
n
3.
5
ye
ar
s
(B
T)
,
m
ed
ia
n
4.
7
ye
ar
s
(E
BR
T)
,
m
ed
ia
n
4
ye
ar
s
(R
P)
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
do
m
ai
n
(E
PI
C
)
74
85
.8
(2
4.
3)
13
5
90
.1
(1
5.
3)
23
4
83
.7
(1
5.
8)
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
416
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
Fr
an
k
20
07
13
1
M
ed
ia
n
3.
5
ye
ar
s
(B
T)
,m
ed
ia
n
4.
7
ye
ar
s
(E
BR
T)
,
m
ed
ia
n
4
ye
ar
s
(R
P)
M
ea
n
(S
D
)
U
rin
ar
y
irr
ita
tio
n
do
m
ai
n
(E
PI
C
)
74
79
.9
(1
9)
13
5
85
.2
(1
2.
8)
23
4
89
.9
(1
1.
6)
C
ro
ok
20
11
12
1
M
ed
ia
n
5.
2
ye
ar
s
fo
llo
w
-u
p
M
ea
n
(S
D
)
U
rin
ar
y
do
m
ai
n
(E
PI
C
):
al
lp
ar
tic
ip
an
ts
10
1
91
.8
2
(8
.5
3)
67
88
.1
5
(1
1.
47
)
C
ro
ok
20
11
12
1
M
ed
ia
n
5.
2
ye
ar
s
fo
llo
w
-u
p
M
ea
n
(S
D
)
U
rin
ar
y
do
m
ai
n
(E
PI
C
):
RC
T
pa
tie
nt
s
15
93
.3
7
(3
.3
6)
15
82
.8
7
(1
2.
05
)
C
ro
ok
20
11
12
1
M
ed
ia
n
5.
2
ye
ar
s
fo
llo
w
-u
p
M
ea
n
(S
D
)
U
rin
ar
y
do
m
ai
n
(E
PI
C
):
N
RC
S
pa
tie
nt
s
86
91
.5
4
(9
.1
6)
52
89
.8
3
(1
0.
86
)
I-P
SS
ur
in
ar
y
fu
nc
tio
n
G
ib
er
ti
20
09
49
6
m
on
th
s
M
ea
n
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
85
15
.2
89
4.
9
K
ob
uk
e
20
09
14
9
6
m
on
th
s
M
ea
n
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
36
12
37
8.
4
Li
nd
ne
r
20
09
15
5
6
m
on
th
s
M
ea
n
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
M
ae
st
ro
ni
20
08
15
9
6
m
on
th
s
M
ea
n
(r
an
ge
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
25
5.
2
(1
–
14
)
M
ea
rin
i2
00
91
61
6
m
on
th
s
M
ed
ia
n
(r
an
ge
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
16
0
7
(5
–
12
)
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
417
TA
B
LE
80
U
ri
n
ar
y
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
Sh
oj
i2
01
0,
18
3
U
ch
id
a
20
09
19
5
6
m
on
th
s
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
32
6
9.
28
(6
.3
8)
Su
m
ito
m
o
20
10
18
5
6
m
on
th
s
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
:
H
IF
U
50
13
.6
(3
.6
)
Su
m
ito
m
o
20
10
18
5
6
m
on
th
s
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
:
H
IF
U
+
TU
RP
60
7.
7
(2
.9
)
Ts
ui
20
05
18
9
6
m
on
th
s
M
ed
ia
n
(r
an
ge
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
80
10
(1
–
32
)
A
hm
ed
20
12
99
1
ye
ar
M
ed
ia
n
(IQ
R)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
41
7
(3
–
12
)
G
ib
er
ti
20
09
49
1
ye
ar
M
ea
n
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
85
10
.1
89
4.
7
K
ob
uk
e
20
09
14
9
1
ye
ar
M
ea
n
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
36
9.
8
37
8.
7
Le
e
20
01
15
3
1
ye
ar
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
44
10
.4
(7
.3
)
23
8.
5
(5
.4
)
23
5.
5
(3
.7
)
Sh
oj
i2
01
0,
18
3
U
ch
id
a
20
09
19
5
1
ye
ar
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
32
6
8.
34
(7
.1
4)
Su
m
ito
m
o
20
10
18
5
1
ye
ar
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
:
H
IF
U
50
14
.1
(3
.3
)
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
418
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
Su
m
ito
m
o
20
10
18
5
1
ye
ar
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
:
H
IF
U
+
TU
RP
60
8
(3
.4
)
Ts
ui
20
05
18
9
1
ye
ar
M
ed
ia
n
(r
an
ge
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
75
7
(0
–
23
)
U
ch
id
a
20
05
19
1
1
ye
ar
M
ea
n
U
rin
ar
y
sy
m
pt
om
ch
an
ge
sc
or
e
(I-
PS
S)
24
9.
1
C
ha
us
sy
20
03
11
6
M
ea
n
1.
6
(S
D
1)
ye
ar
s
(r
an
ge
3–
46
.3
m
on
th
s)
:
H
IF
U
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
:
H
IF
U
96
8.
91
(1
0.
89
)
C
ha
us
sy
20
03
11
6
M
ea
n
10
.9
(S
D
6.
2)
m
on
th
s
(r
an
ge
2.
9–
26
.9
m
on
th
s)
:
H
IF
U
+
TU
RP
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
:
H
IF
U
+
TU
RP
17
5
3.
37
(3
.2
1)
C
as
o
20
12
,1
14
C
as
o
20
12
,1
15
Po
la
sc
ik
20
07
17
5
2
ye
ar
s
M
ed
ia
n
(r
an
ge
)
I-P
SS
58
6
(2
–
10
)
Sh
oj
i2
01
0,
18
3
U
ch
id
a
20
09
19
5
2
ye
ar
s
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
32
6
8.
8
(7
.7
6)
Su
m
ito
m
o
20
10
18
5
2
ye
ar
s
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
:
H
IF
U
50
14
.9
(3
.6
)
Su
m
ito
m
o
20
10
18
5
2
ye
ar
s
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
:
H
IF
U
+
TU
RP
60
7.
9
(3
.2
)
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
419
TA
B
LE
80
U
ri
n
ar
y
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
Ts
ui
20
05
18
9
2
ye
ar
s
M
ed
ia
n
(r
an
ge
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
41
5.
5
(0
–
25
)
Ts
ui
20
05
18
9
3
ye
ar
s
M
ed
ia
n
(r
an
ge
)
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
21
4
(1
–
19
)
G
ib
er
ti
20
09
49
5
ye
ar
s
M
ea
n
U
rin
ar
y
fu
nc
tio
n
(I-
PS
S)
85
5.
1
89
4.
7
El
Fe
go
un
20
11
12
7
M
ed
ia
n
10
.6
(r
an
ge
7.
5–
11
.1
)
ye
ar
s
M
ea
n,
m
ed
ia
n
(r
an
ge
)
I-P
SS
sc
or
e
12
5.
5,
6
(1
–
12
)
O
th
er
Bo
et
tc
he
r
20
12
10
8
6
m
on
th
s
O
A
B
se
ve
rit
y
sc
al
e
(1
–
5)
U
rg
en
ce
sc
or
e
33
2.
57
66
1.
72
G
ib
er
ti
20
09
49
6
m
on
th
s
M
ea
n
ur
in
ar
y
sy
m
pt
om
s
EO
RT
C
-Q
LQ
-P
R2
5
85
36
89
17
H
ub
os
ky
20
07
52
6
m
on
th
s
A
U
A
Sy
m
pt
om
In
de
x
46
6.
43
H
ub
os
ky
20
07
52
6
m
on
th
s
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I)
46
74
H
ub
os
ky
20
07
52
6
m
on
th
s
%
ba
se
lin
e
sc
or
e,
ur
in
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
op
en
RP
12
2
92
46
99
13
5
80
H
ub
os
ky
20
07
52
6
m
on
th
s
%
ba
se
lin
e
sc
or
e,
ur
in
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
ro
bo
tic
RP
12
2
92
46
99
13
5
69
K
ob
uk
e
20
09
14
9
6
m
on
th
s
M
ea
n
ur
in
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I)
36
87
.5
37
78
.2
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
6
m
on
th
s
M
ea
n
ur
in
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I)
11
2
90
.2
10
9
83
.5
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
420
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
Sm
ith
20
09
18
4
6
m
on
th
s
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
ne
rv
e
sp
ar
in
g
58
93
.5
(1
4.
3)
12
3
92
.6
(1
5.
2)
49
4
85
.5
(1
7)
Sm
ith
20
09
18
4
6
m
on
th
s
M
ea
n
(S
D
)
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
no
n-
ne
rv
e
sp
ar
in
g
58
93
.5
(1
4.
3)
12
3
92
.6
(1
5.
2)
47
6
83
.3
(1
9.
2)
Bo
et
tc
he
r
20
12
10
8
1
ye
ar
O
A
B
se
ve
rit
y
sc
al
e
(1
–
5)
U
rg
en
cy
sc
or
e
33
2.
56
66
1.
85
G
ib
er
ti
20
09
49
1
ye
ar
M
ea
n
ur
in
ar
y
sy
m
pt
om
s
sc
or
e
(E
O
RT
C
-Q
LQ
-P
R2
5)
85
15
89
10
H
ub
os
ky
20
07
52
1
ye
ar
U
rin
ar
y
fu
nc
tio
n
(A
U
A
Sy
m
pt
om
In
de
x)
35
7.
6
M
oh
am
ed
20
12
16
3
1
ye
ar
M
ea
n
(S
D
)
U
rin
ar
y
dy
sf
un
ct
io
n
(A
U
A
Sy
m
pt
om
In
de
x)
24
0
2.
36
(0
.9
9)
48
3
1.
85
(0
.8
)
14
6
1.
17
(0
.8
5)
M
oh
am
ed
20
12
16
3
1
ye
ar
M
ea
n
(S
D
)
U
rin
ar
y
lim
ita
tio
n
(A
U
A
Sy
m
pt
om
In
de
x)
24
0
1.
52
(0
.9
9)
48
3
1.
24
(0
.5
8)
14
6
1.
37
(0
.7
4)
H
ub
os
ky
20
07
52
1
ye
ar
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I)
35
87
.6
M
al
co
lm
20
10
16
0
1
ye
ar
%
ba
se
lin
e
sc
or
e
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
op
en
RP
12
2
84
.6
81
98
.6
13
5
70
.3
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
421
TA
B
LE
80
U
ri
n
ar
y
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
M
al
co
lm
20
10
16
0
1
ye
ar
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
ro
bo
tic
RP
44
7
68
.1
K
ob
uk
e
20
09
14
9
1
ye
ar
M
ea
n
ur
in
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I)
36
83
.7
37
66
.1
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
1
ye
ar
M
ea
n
ur
in
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I)
11
2
88
.7
10
5
88
.4
Ta
lc
ot
t
20
03
18
6
1
ye
ar
M
ea
n
(S
D
)
U
rin
ar
y
ob
st
ru
ct
io
n/
irr
ita
tio
n
sy
m
pt
om
in
de
x
(u
rin
ar
y,
bo
w
el
an
d
se
xu
al
fu
nc
tio
n
sc
al
e)
80
19
.3
(1
2.
8)
18
2
13
(1
5.
2)
12
9
19
.3
(1
2.
8)
H
ub
os
ky
20
07
52
1.
5
ye
ar
s
U
rin
ar
y
fu
nc
tio
n
(A
U
A
Sy
m
pt
om
In
de
x)
25
7.
4
H
ub
os
ky
20
07
52
1.
5
ye
ar
s
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I)
25
90
.4
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
1.
5
ye
ar
s
M
ea
n
ur
in
ar
y
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
11
1
91
.6
10
0
90
.2
Bo
et
tc
he
r
20
12
10
8
2
ye
ar
s
O
A
B
se
ve
rit
y
sc
al
e
(1
–
5)
U
rg
en
cy
sc
or
e
33
2.
57
66
1.
7
H
ub
os
ky
20
07
52
2
ye
ar
s
U
rin
ar
y
fu
nc
tio
n
(A
U
A
Sy
m
pt
om
In
de
x)
11
7.
1
H
ub
os
ky
20
07
52
2
ye
ar
s
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I)
11
88
.4
M
al
co
lm
20
10
16
0
2
ye
ar
s
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
op
en
RP
12
2
81
.0
81
94
.9
13
5
74
.8
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
422
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
M
al
co
lm
20
10
16
0
2
ye
ar
s
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
ro
bo
tic
RP
47
70
.0
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
2
ye
ar
s
M
ea
n
ur
in
ar
y
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
10
8
90
.6
10
6
89
.6
Ta
lc
ot
t
20
03
18
6
2
ye
ar
s
M
ea
n
(S
D
)
U
rin
ar
y
ob
st
ru
ct
io
n/
irr
ita
tio
n
sy
m
pt
om
in
de
x
(u
rin
ar
y,
bo
w
el
an
d
se
xu
al
fu
nc
tio
n
sc
al
e)
80
18
.8
(1
3.
1)
18
2
12
.1
(1
5.
3)
12
9
18
.8
(1
3.
1)
Bo
et
tc
he
r
20
12
10
8
3
ye
ar
s
O
A
B
se
ve
rit
y
sc
al
e
(1
–
5)
U
rg
en
cy
sc
or
e
33
2.
18
66
1.
85
M
al
co
lm
20
10
16
0
3
ye
ar
s
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
op
en
RP
12
2
79
.2
81
10
5.
1
13
5
73
.9
M
al
co
lm
20
10
16
0
3
ye
ar
s
U
rin
ar
y
fu
nc
tio
n
(U
C
LA
-P
C
I):
ro
bo
tic
RP
44
7
71
.8
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
3
ye
ar
s
M
ea
n
ur
in
ar
y
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
10
5
93
10
5
88
.6
G
ib
er
ti
20
09
49
5
ye
ar
s
M
ea
n
ur
in
ar
y
sy
m
pt
om
s
sc
or
e
(E
O
RT
C
-Q
LQ
-P
R2
5)
85
17
89
10
A
U
A
,
A
m
er
ic
an
U
ro
lo
gi
ca
lA
ss
oc
ia
tio
n;
BT
,
br
ac
hy
th
er
ap
y;
C
RY
O
,
cr
yo
th
er
ap
y;
EO
RT
C
-Q
LQ
-P
R2
5,
Eu
ro
pe
an
O
rg
an
is
at
io
n
fo
r
Re
se
ar
ch
an
d
Tr
ea
tm
en
t
of
C
an
ce
r
Q
ua
lit
y
of
Li
fe
Q
ue
st
io
nn
ai
re
–
Pr
os
ta
te
-2
5
ite
m
s;
EP
IC
,
Ex
pa
nd
ed
Pr
os
ta
te
C
an
ce
r
In
de
x
C
om
po
si
te
;
IQ
R,
in
te
rq
ua
rt
ile
ra
ng
e;
O
A
B,
ov
er
ac
tiv
e
bl
ad
de
r;
RT
,
ra
di
ot
he
ra
py
;
SD
,
st
an
da
rd
de
vi
at
io
n;
SE
,
st
an
da
rd
er
ro
r.
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
423
TA
B
LE
80
a
U
ri
n
ar
y
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
:
PD
T
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
n
Sc
o
re
Ba
rr
et
20
13
10
3
1
ye
ar
M
ed
ia
n
(IQ
R)
ur
in
ar
y
fu
nc
tio
n
sc
or
e
(I-
PS
S)
23
6
(3
–
10
)
Ba
rr
et
20
13
10
3
1
ye
ar
M
ed
ia
n
(IQ
R)
ur
in
ar
y
fu
nc
tio
n
sc
or
e
(I-
PS
S)
23
IQ
R,
in
te
rq
ua
rt
ile
ra
ng
e.
TA
B
LE
81
B
o
w
el
fu
n
ct
io
n
d
ic
h
o
to
m
o
u
s
o
u
tc
o
m
es
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
B
o
w
el
b
o
th
er
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
6
m
on
th
s
M
od
er
at
e
or
bi
g
pr
ob
le
m
bo
w
el
bo
th
er
(U
C
LA
-P
C
I)
11
1
8
7.
3
10
9
17
15
.6
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
1
ye
ar
M
od
er
at
e
or
bi
g
pr
ob
le
m
bo
w
el
bo
th
er
(U
C
LA
-P
C
I)
11
0
5
4.
6
10
5
18
17
.1
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
EB
RT
:
ra
ng
e
12
–
21
m
on
th
s
BT
:
ra
ng
e
12
–
24
m
on
th
s
M
ea
n
bo
w
el
fu
nc
tio
n
sc
or
e
(E
PI
C
)
52
1
2.
0
52
6
12
.0
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
2
ye
ar
s
M
od
er
at
e
or
bi
g
pr
ob
le
m
bo
w
el
bo
th
er
(U
C
LA
-P
C
I)
10
2
6
5.
9
10
1
15
15
.0
C
he
n
20
09
11
7
3
ye
ar
s
Bo
w
el
pr
ob
le
m
s
(P
C
SI
)
72
49
68
.0
14
0
10
5
75
.0
10
0
44
44
.0
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
3
ye
ar
s
M
od
er
at
e
or
bi
g
pr
ob
le
m
bo
w
el
bo
th
er
(U
C
LA
-P
C
I)
98
7
7.
2
97
10
10
.3
Sm
ith
20
09
18
4
3
ye
ar
s
M
od
er
at
e
or
bi
g
pr
ob
le
m
bo
w
el
bo
th
er
(U
C
LA
-P
C
I)
58
0
0.
0
12
3
16
14
.5
98
1
32
3.
5
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
424
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
B
o
w
el
sy
m
p
to
m
s
Ts
ui
20
05
18
9
6
m
on
th
s
Bo
w
el
sy
m
pt
om
s
(R
TO
G
)
55
6
11
64
8
12
.5
Ts
ui
20
05
18
9
1
ye
ar
Bo
w
el
sy
m
pt
om
s
(R
TO
G
)
61
2
3.
3
76
12
.1
Ts
ui
20
05
18
9
2
ye
ar
s
Bo
w
el
sy
m
pt
om
s
(R
TO
G
)
42
3
7.
1
76
14
.9
Ts
ui
20
05
18
9
3
ye
ar
s
Bo
w
el
sy
m
pt
om
s
(R
TO
G
)
21
4
19
.0
76
4.
5
Fa
ec
al
co
n
ti
n
en
ce
Sh
ah
20
12
,1
82
M
oh
am
m
ed
20
12
,1
64
V
ic
in
i2
01
12
01
M
ed
ia
n
fo
llo
w
-u
p
of
4.
8
ye
ar
s
G
ra
de
≥
2
re
ct
al
in
co
nt
in
en
ce
(N
C
I-C
TC
A
E
v3
.0
)
41
7
1
0.
3
10
39
31
3.
0
Sh
ah
20
12
,1
82
M
oh
am
m
ed
20
12
,1
64
V
ic
in
i2
01
12
01
M
ed
ia
n
fo
llo
w
-u
p
af
te
r
6
m
on
th
s:
4.
8
ye
ar
s
G
ra
de
≥
3
re
ct
al
in
co
nt
in
en
ce
(N
C
I-C
TC
A
E
v3
.0
)
41
7
0
0.
0
10
39
4
0.
4
Bo
rc
he
rs
20
04
10
9
1
ye
ar
St
oo
li
nc
on
tin
en
ce
(K
el
le
y
qu
es
tio
nn
ai
re
an
d
EO
RT
C
-
Q
LQ
-C
30
)
52
20
.0
42
4.
0
U
ch
id
a
20
05
19
1
M
ed
ia
n
1.
2
ye
ar
s
(r
an
ge
2–
24
m
on
th
s)
G
ra
de
1
st
oo
li
nc
on
tin
en
ce
(J
ap
an
es
e
N
C
I-C
TC
A
E
v2
.0
)
72
1
1.
0
Bu
ro
n
20
07
11
3
2
ye
ar
s
Fa
ec
al
in
co
nt
in
en
ce
(E
O
RT
C
-
Q
LQ
-P
R2
5)
20
0
18
8.
9
52
1
2.
0
BT
,
br
ac
hy
th
er
ap
y;
C
RY
O
,
cr
yo
th
er
ap
y;
EO
RT
C
-Q
LQ
-P
R2
5,
Eu
ro
pe
an
O
rg
an
is
at
io
n
fo
r
Re
se
ar
ch
an
d
Tr
ea
tm
en
t
of
C
an
ce
r
Q
ua
lit
y
of
Li
fe
Q
ue
st
io
nn
ai
re
–
Pr
os
ta
te
-2
5
ite
m
s;
EP
IC
,
Ex
pa
nd
ed
Pr
os
ta
te
C
an
ce
r
In
de
x
C
om
po
si
te
;
N
C
I-C
TC
A
E
v3
.0
,
N
at
io
na
lC
an
ce
r
In
st
itu
te
C
om
m
on
Te
rm
in
ol
og
y
C
rit
er
ia
fo
r
A
dv
er
se
Ev
en
ts
ve
rs
io
n
3.
0;
PC
SI
,
Pr
os
ta
te
C
an
ce
r
Sy
m
pt
om
In
de
x.
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
425
TA
B
LE
82
B
o
w
el
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
B
o
w
el
fu
n
ct
io
n
(E
PI
C
)
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
6
m
on
th
s
M
ea
n
(S
E)
bo
w
el
fu
nc
tio
n
sc
or
e
(E
PI
C
)
24
7
95
.2
(0
.6
)
18
0
93
.9
(1
.0
)
11
8
96
.8
(0
.9
)
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
1
ye
ar
M
ea
n
(S
E)
bo
w
el
fu
nc
tio
n
sc
or
e
(E
PI
C
)
25
5
96
.8
(0
.6
)
18
4
94
.6
(0
.8
)
12
1
97
.4
(0
.9
)
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
RT
:
ra
ng
e
12
–
21
m
on
th
s
BT
:
ra
ng
e
12
–
24
m
on
th
s
M
ea
n,
m
ed
ia
n
(IQ
R)
bo
w
el
fu
nc
tio
n
sc
or
e
(E
PI
C
)
52
93
.0
,
96
.0
(9
2.
0–
10
0.
0)
52
89
.0
,
82
.0
(9
2.
0–
96
.0
)
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
2
ye
ar
s
M
ea
n
(S
E)
bo
w
el
fu
nc
tio
n
sc
or
e
(E
PI
C
)
24
0
97
.9
(0
.3
)
17
9
94
.5
(0
.9
)
12
2
97
.9
(0
.7
)
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
3
ye
ar
s
M
ea
n
bo
w
el
fu
nc
tio
n
sc
or
e
(E
PI
C
)
15
5
96
.8
10
0
94
.6
10
9
N
/R
Fr
an
k
20
07
13
1
BT
:
3.
5
ye
ar
s;
EB
RT
:
4.
7
ye
ar
s;
RP
:
4
ye
ar
s
M
ea
n
(S
D
)
bo
w
el
fu
nc
tio
n
sc
or
e
(E
PI
C
)
74
89
.4
(1
1.
5)
13
5
85
.8
(1
4.
2)
23
4
93
.0
(9
.0
)
C
ro
ok
20
11
12
1
M
ed
ia
n
5.
2
ye
ar
s
M
ea
n
(S
D
)
bo
w
el
do
m
ai
n
sc
or
e
(E
PI
C
)
10
1
93
.0
(1
1.
6)
67
94
.4
(8
.9
)
B
o
w
el
fu
n
ct
io
n
(U
C
LA
-P
C
I)
H
ub
os
ky
20
07
52
6
m
on
th
s
M
ea
n
bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
46
77
.0
K
ob
uk
e
20
09
14
9
6
m
on
th
s
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
36
90
.7
37
90
.5
Li
tw
in
20
04
15
6
6
m
on
th
s
M
ea
n
(S
E)
bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
20
9
79
(2
.1
)
99
75
(2
.2
)
12
76
84
(1
.2
)
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
426
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
M
al
co
lm
20
12
16
0
6
m
on
th
s
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
12
2
85
.0
81
82
.0
O
pe
n:
13
5
Ro
bo
tic
:
44
7
O
pe
n:
89
.0
Ro
bo
tic
:
90
.0
D
on
ne
lly
20
10
,1
25
Ro
bi
ns
on
20
09
17
9
6
m
on
th
s
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
11
2
80
.0
10
9
87
.5
H
ub
os
ky
20
07
52
1
ye
ar
M
ea
n
bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
35
92
.8
K
ob
uk
e
20
09
14
9
1
ye
ar
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
36
86
.1
37
92
.1
Li
tw
in
20
04
15
6
1
ye
ar
M
ea
n
(S
E)
bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
20
9
78
.0
(2
.3
)
99
76
.0
(2
.3
)
12
76
85
.0
(1
.3
)
M
al
co
lm
20
12
16
0
1
ye
ar
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
12
2
87
.0
81
91
.0
O
pe
n:
13
5
Ro
bo
tic
:
44
7
O
pe
n:
89
.0
Ro
bo
tic
:
91
.0
D
on
ne
lly
20
10
,1
25
Ro
bi
ns
on
20
09
17
9
1
ye
ar
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
11
2
84
.3
10
5
89
.8
H
ub
os
ky
20
07
52
2
ye
ar
s
M
ea
n
bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
11
86
.0
Li
tw
in
20
04
15
6
2
ye
ar
s
M
ea
n
(S
E)
bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
20
9
80
.0
(3
.3
)
99
78
.0
(2
.8
)
12
76
84
.0
(1
.4
)
M
al
co
lm
20
12
16
0
2
ye
ar
s
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
12
2
92
.0
81
90
.0
O
pe
n:
13
5
Ro
bo
tic
:
44
7
O
pe
n:
90
.0
Ro
bo
tic
:
89
.0
D
on
ne
lly
20
10
,1
25
Ro
bi
ns
on
20
09
17
9
2
ye
ar
s
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
10
8
85
.2
10
6
89
.0
M
al
co
lm
20
12
16
0
3
ye
ar
s
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
12
2
90
.0
81
90
.0
O
pe
n:
13
5
Ro
bo
tic
:
44
7
O
pe
n:
88
.0
Ro
bo
tic
:
90
.0
D
on
ne
lly
20
10
,1
25
Ro
bi
ns
on
20
09
17
9
3
ye
ar
s
Bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
10
5
88
.1
10
5
84
.1
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
427
TA
B
LE
82
B
o
w
el
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
Sm
ith
20
09
18
4
3
ye
ar
s
M
ea
n
(S
D
)
bo
w
el
fu
nc
tio
n
sc
or
e
(U
C
LA
-P
C
I)
58
88
.8
(1
1.
5)
84
.5
(1
5.
8)
N
er
ve
sp
ar
in
g:
49
4
N
on
-n
er
ve
sp
ar
in
g:
47
6
N
er
ve
sp
ar
in
g:
88
.1
(1
3.
9)
N
on
-n
er
ve
sp
ar
in
g:
88
.5
(1
2.
3)
B
o
w
el
b
o
th
er
(E
PI
C
)
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
RT
:
ra
ng
e
12
–
21
m
on
th
s
BT
:
ra
ng
e
12
–
24
m
on
th
s
M
ea
n,
m
ed
ia
n
(IQ
R)
bo
w
el
bo
th
er
sc
or
e
(E
PI
C
)
52
93
.0
,
10
0.
0
(9
3.
0–
10
0.
0)
52
87
.0
,
79
.0
(9
6.
0–
10
0.
0)
Fr
an
k
20
07
13
1
BT
:
m
ed
ia
n
3.
5
ye
ar
s
EB
RT
:
m
ed
ia
n
4.
7
ye
ar
s
RP
:
m
ed
ia
n
4
ye
ar
s
M
ea
n
(S
D
)
bo
w
el
bo
th
er
sc
or
e
(E
PI
C
)
74
86
.4
(1
6.
8)
13
5
85
.1
(1
9.
8)
23
4
94
.6
(1
0.
4)
B
o
w
el
b
o
th
er
(E
O
R
TC
-Q
LQ
-P
R
25
)
G
ib
er
ti
20
09
49
6
m
on
th
s
M
ea
n
bo
w
el
sy
m
pt
om
s
sc
or
e
(E
O
RT
C
-Q
LQ
-P
R2
5)
85
6.
0
89
3.
0
G
ib
er
ti
20
09
49
1
ye
ar
M
ea
n
bo
w
el
sy
m
pt
om
s
sc
or
e
(E
O
RT
C
-Q
LQ
-P
R2
5)
85
4.
0
89
2.
0
G
ib
er
ti
20
09
49
5
ye
ar
s
M
ea
n
bo
w
el
sy
m
pt
om
s
sc
or
e
(E
O
RT
C
-Q
LQ
-P
R2
5)
85
5.
0
89
2.
0
B
o
w
el
b
o
th
er
(S
ym
p
to
m
In
d
ex
)
Ta
lc
ot
t
20
03
18
6
1
ye
ar
M
ea
n
(S
D
)
bo
w
el
pr
ob
le
m
s
sc
or
e
(S
ym
pt
om
In
de
x)
80
7.
2
(7
.1
)
18
2
9.
8
(9
.8
)
12
9
4.
4
(5
.9
)
Ta
lc
ot
t
20
03
18
6
2
ye
ar
s
M
ea
n
(S
D
)
bo
w
el
pr
ob
le
m
s
sc
or
e
(S
ym
pt
om
In
de
x)
80
7.
2
(8
.5
)
18
2
8.
9
(9
.4
)
12
9
4.
8
(6
.0
)
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
428
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
B
o
w
el
b
o
th
er
(U
C
LA
-P
C
I)
H
ub
os
ky
20
07
52
6
m
on
th
s
M
ea
n
bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
46
73
.0
K
ob
uk
e
20
09
14
9
6
m
on
th
s
Bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
36
88
.8
37
92
.1
Li
tw
in
20
04
15
6
6
m
on
th
s
M
ea
n
(S
E)
bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
20
9
75
.0
(3
.0
)
99
70
.0
(3
.1
)
12
76
84
.0
(1
.8
)
M
al
co
lm
20
12
16
0
6
m
on
th
s
Bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
12
2
86
.0
81
89
.0
O
pe
n:
13
5
Ro
bo
tic
:
44
7
O
pe
n:
94
.0
Ro
bo
tic
:
94
.0
H
ub
os
ky
20
07
52
1
ye
ar
M
ea
n
bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
35
80
.0
K
ob
uk
e
20
09
14
9
1
ye
ar
Bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
36
85
.3
37
92
.6
Li
tw
in
20
04
15
6
1
ye
ar
M
ea
n
(S
E)
bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
20
9
78
.0
(3
.2
)
99
72
.0
(3
.2
)
12
76
84
.0
(1
.8
)
M
al
co
lm
20
12
16
0
1
ye
ar
Bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
12
2
99
.0
81
92
.0
O
pe
n:
13
5
Ro
bo
tic
:
44
7
O
pe
n:
91
.0
Ro
bo
tic
:
94
.0
H
ub
os
ky
20
07
52
2
ye
ar
s
M
ea
n
bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
11
66
.0
Li
tw
in
20
04
15
6
2
ye
ar
s
M
ea
n
(S
E)
bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
20
9
80
.0
(4
.7
)
99
73
.0
(3
.9
)
12
76
83
.0
(2
.0
)
M
al
co
lm
20
12
16
0
2
ye
ar
s
Bo
w
el
bo
th
er
sc
or
e
(U
C
LA
-P
C
I)
12
2
89
.0
81
93
.0
O
pe
n:
13
5
Ro
bo
tic
:
44
7
O
pe
n:
94
.0
Ro
bo
tic
:
91
.0
Sm
ith
20
09
18
4
3
ye
ar
s
M
ea
n
(S
D
)
M
od
er
at
e
or
bi
g
bo
w
el
pr
ob
le
m
s
(U
C
LA
-P
C
I)
58
91
.1
(1
4.
6)
12
3
79
.8
(2
8.
2)
N
er
ve
sp
ar
in
g:
49
4
N
on
-n
er
ve
sp
ar
in
g:
47
6
N
er
ve
sp
ar
in
g:
90
.0
(2
0.
9)
N
on
-n
er
ve
sp
ar
in
g:
90
.5
(1
8.
7)
BT
,
br
ac
hy
th
er
ap
y;
C
RY
O
,
cr
yo
th
er
ap
y;
EO
RT
C
-Q
LQ
-P
R2
5,
Eu
ro
pe
an
O
rg
an
is
at
io
n
fo
r
Re
se
ar
ch
an
d
Tr
ea
tm
en
t
of
C
an
ce
r
Q
ua
lit
y
of
Li
fe
Q
ue
st
io
nn
ai
re
–
Pr
os
ta
te
-2
5
ite
m
s;
EP
IC
,
Ex
pa
nd
ed
Pr
os
ta
te
C
an
ce
r
In
de
x
C
om
po
si
te
;
IQ
R,
in
te
rq
ua
rt
ile
ra
ng
e;
N
/R
,
no
t
re
po
rt
ed
;
RT
,
ra
di
ot
he
ra
py
;
SD
,
st
an
da
rd
de
vi
at
io
n;
SE
,
st
an
da
rd
er
ro
r.
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
429
TA
B
LE
83
Se
xu
al
fu
n
ct
io
n
d
ic
h
o
to
m
o
u
s
o
u
tc
o
m
es
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
A
S
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
Er
ec
ti
le
d
ys
fu
n
ct
io
n
(E
D
)
Bu
ro
n
20
07
11
3
6
m
on
th
s
ED
(o
nl
y
fo
r
se
xu
al
ly
ac
tiv
e
pa
tie
nt
s)
(E
O
RT
C
-Q
LQ
-P
R2
5)
30
8
12
2
39
.6
12
7
63
49
.6
El
lis
20
07
12
9
6
m
on
th
s
ED
/im
po
te
nc
e
60
22
36
.7
K
oc
h
20
07
15
0
6
m
on
th
s
N
ew
on
se
t
se
ve
re
ED
(II
EF
<
8)
20
4
20
El
lis
20
07
12
9
1
ye
ar
ED
/im
po
te
nc
e
60
24
40
H
an
20
03
13
9
1
ye
ar
ED
/im
po
te
nc
e
10
4
83
79
.8
Su
m
ito
m
o
20
10
18
5
1
ye
ar
ED
(II
EF
–
5
>
7)
12
9
36
27
.9
W
ar
d
20
12
20
2
1
ye
ar
N
ew
-o
ns
et
ED
11
60
12
2
10
.5
U
ch
id
a
20
05
19
1
1.
2
ye
ar
s
ED
gr
ad
e
3
72
12
16
.7
H
ilt
on
20
12
14
1
1–
1.
5
ye
ar
s
Se
xu
al
ac
tiv
ity
:
in
ac
tiv
e
42
7
64
15
Bu
ro
n
20
07
11
3
1.
5
ye
ar
s
ED
(o
nl
y
fo
r
se
xu
al
ly
ac
tiv
e
pa
tie
nt
s)
(E
O
RT
C
-Q
LQ
-P
R2
5)
30
8
85
27
.6
12
7
42
33
.1
Po
la
sc
ik
20
07
,1
75
C
as
o
20
12
,1
14
C
as
o
20
12
11
5
M
ed
ia
n
1.
5
ye
ar
s
(ra
ng
e
3–
43
m
on
th
s)
ED
/im
po
te
nc
e
50
3
6
H
al
e
20
13
13
8
M
ea
n
1.
6
ye
ar
s
(r
an
ge
2–
52
m
on
th
s)
Im
po
te
nc
e
26
0
0
A
le
m
oz
af
fa
r
20
11
10
0
2
ye
ar
s
ED
(E
xp
an
de
d
Pr
os
ta
te
C
an
ce
r
In
de
x
C
om
po
si
te
,
EP
IC
-2
6)
24
7
14
0
57
22
9
14
5
63
51
1
33
4
65
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
430
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
A
S
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
A
le
m
oz
af
fa
r
20
13
10
0
2
ye
ar
s
ED
:
of
th
os
e
po
te
nt
pr
io
r
to
tr
ea
tm
en
t
(E
PI
C
-2
6)
15
8
59
37
12
1
51
42
41
4
24
8
60
Sh
oj
i2
01
0,
18
3
U
ch
id
a
20
09
19
5
M
ed
ia
n
2
ye
ar
s
(r
an
ge
2–
88
m
on
th
s)
ED
51
7
33
6.
4
W
ill
ia
m
s
20
12
20
3
W
ith
in
2
ye
ar
s
ED
as
se
ss
ed
us
in
g
se
lf-
as
se
ss
m
en
t
w
ith
va
lid
at
ed
in
st
ru
m
en
ts
99
85
21
02
21
.1
94
3
33
1
35
.1
Ze
le
fs
ky
19
99
20
6
BT
:
m
ed
ia
n
2
ye
ar
s
(r
an
ge
12
–
10
9
m
on
th
s)
EB
RT
:
m
ed
ia
n
3
ye
ar
s
(r
an
ge
6–
10
3
m
on
th
s)
14
5
28
19
.3
13
7
32
23
.4
Po
is
so
nn
ie
r
20
07
17
4
M
ea
n
2.
3
ye
ar
s
(S
D
20
,
ra
ng
e
12
–
10
7
m
on
th
s)
Im
po
te
nc
e
(a
pa
tie
nt
is
un
ab
le
to
pe
ne
tr
at
e
hi
s
pa
rt
ne
r
w
ith
ou
t
ph
ar
m
ac
ol
og
ic
al
su
pp
or
t)
22
7
24
10
.6
Li
an
20
11
15
4
M
ed
ia
n
2.
5
ye
ar
s
(r
an
ge
9–
56
m
on
th
s)
ED
/im
po
te
nc
e
(II
EF
)
10
2
25
24
.5
C
he
n
20
09
11
7
3
ye
ar
s
Se
xu
al
dy
sf
un
ct
io
n
(P
C
SI
):
in
te
rm
ed
ia
te
an
d
po
or
75
61
81
.3
15
0
14
0
93
.3
10
5
10
1
96
In
ou
e
20
11
14
3
M
ed
ia
n
3
(r
an
ge
1–
7)
ye
ar
s
ED
(II
EF
)
(d
ef
in
ed
as
a
sc
or
e
of
≤
7
fo
r
pa
tie
nt
s
w
ho
ha
d
a
pr
et
re
at
m
en
t
IIE
F-
5
sc
or
e
of
>
7)
13
7
22
16
.1
Sm
ith
20
09
18
4
3
ye
ar
s
Im
po
te
nc
e
(d
ef
in
ed
as
be
in
g
un
ab
le
to
ob
ta
in
an
er
ec
tio
n
su
ff
ic
ie
nt
fo
r
se
xu
al
in
te
rc
ou
rs
e)
(U
C
LA
-P
C
I)
58
20
36
.4
12
3
72
67
.9
98
1
69
5
77
.4
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
431
TA
B
LE
83
Se
xu
al
fu
n
ct
io
n
d
ic
h
o
to
m
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
A
S
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
O
ni
k
20
08
16
6
M
ea
n
4.
2
(r
an
ge
2–
8.
8)
ye
ar
s
ED
/im
po
te
nc
e
21
4
19
C
ro
ok
20
11
12
1
5
ye
ar
s
Q
ua
lit
y
of
er
ec
tio
ns
(E
PI
C
)
N
on
e
at
al
l+
no
t
fir
m
en
ou
gh
fo
r
an
y
se
xu
al
ac
tiv
ity
+
fir
m
en
ou
gh
fo
r
m
as
tu
rb
at
io
n
an
d
fo
re
pl
ay
on
ly
99
49
49
.5
67
47
70
M
ac
k
19
97
15
8
M
ea
n
8.
5
ye
ar
s
ED
/im
po
te
nc
e
66
6
9
Po
te
n
cy
A
hm
ed
20
12
99
6
m
on
th
s
Er
ec
tio
ns
sa
tis
fa
ct
or
y
fo
r
pe
ne
tr
at
io
n
(II
EF
)
41
29
70
.7
G
ib
er
ti
20
09
49
6
m
on
th
s
G
oo
d
er
ec
til
e
fu
nc
tio
n
(m
ea
n
IIE
F
sc
or
e
of
>
22
)
10
0
49
49
10
0
36
36
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
6
m
on
th
s
A
ss
is
te
d
an
d
un
as
si
st
ed
in
te
rc
ou
rs
e
(U
C
LA
-P
C
I)
51
5
9.
8
56
24
42
.9
Ts
ui
20
05
18
9
6
m
on
th
s
Po
te
nc
y
(o
nc
ol
og
is
t’
s
de
sc
rip
tio
n)
86
23
26
.7
76
11
14
.5
M
ae
st
ro
ni
20
08
15
9
6–
12
m
on
th
s
N
um
be
r
po
te
nt
(II
EF
-5
:
hi
gh
er
ec
til
e
de
fic
it
sc
or
e
of
6–
10
25
0
0
va
n
de
n
Be
rg
h
20
12
19
8
6
m
on
th
s
‘Y
es
’
re
sp
on
se
to
th
e
qu
es
tio
n
‘W
er
e
yo
u
se
xu
al
ly
ac
tiv
e
(e
.g
.
m
as
tu
rb
at
io
n,
se
xu
al
in
te
rc
ou
rs
e)
du
rin
g
th
e
la
st
2
w
ee
ks
?’
10
7
73
68
29
11
37
8
3
35
A
hm
ed
20
12
99
1
ye
ar
Er
ec
tio
ns
sa
tis
fa
ct
or
y
fo
r
pe
ne
tr
at
io
n
(II
EF
)
41
31
75
.6
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
432
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
A
S
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
A
hm
ed
20
11
98
1
ye
ar
Er
ec
tio
ns
sa
tis
fa
ct
or
y
fo
r
pe
ne
tr
at
io
n
(II
EF
)
20
19
95
G
ib
er
ti
20
09
49
1
ye
ar
G
oo
d
er
ec
til
e
fu
nc
tio
n
(m
ea
n
IIE
F
sc
or
e
of
>
22
)
10
0
66
66
10
0
61
61
H
ilt
on
20
12
14
1
1–
1.
5
ye
ar
s
Se
xu
al
ac
tiv
ity
:
in
te
rc
ou
rs
e
42
7
33
0
77
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
1
ye
ar
A
ss
is
te
d
an
d
un
as
si
st
ed
in
te
rc
ou
rs
e
(U
C
LA
-P
C
I)
51
9
17
.7
54
24
44
.4
Ts
ui
20
05
18
9
1
ye
ar
Po
te
nc
y
(o
nc
ol
og
is
t’
s
de
sc
rip
tio
n)
86
23
26
.7
76
11
14
.5
va
n
de
n
Be
rg
h
20
12
19
8
1
ye
ar
‘Y
es
’
re
sp
on
se
to
th
e
qu
es
tio
n
‘W
er
e
yo
u
se
xu
al
ly
ac
tiv
e
(e
.g
.
m
as
tu
rb
at
io
n,
se
xu
al
in
te
rc
ou
rs
e)
du
rin
g
th
e
la
st
2
w
ee
ks
?’
58
38
65
31
11
36
9
3
36
Pi
nk
aw
a
20
09
17
2
M
ea
n
1.
3
ye
ar
s
(r
an
ge
12
–
21
m
on
th
s)
Er
ec
tio
ns
su
ff
ic
ie
nt
fo
r
se
xu
al
in
te
rc
ou
rs
e
(E
PI
C
)
52
35
67
52
32
61
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
1.
5
ye
ar
s
A
ss
is
te
d
an
d
un
as
si
st
ed
in
te
rc
ou
rs
e
(U
C
LA
-P
C
I)
51
9
17
.7
48
23
47
.9
Ts
ui
20
05
18
9
1.
5
ye
ar
s
Po
te
nc
y
(o
nc
ol
og
is
t’
s
de
sc
rip
tio
n)
86
21
24
.4
76
9
11
.8
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
2
ye
ar
s
A
ss
is
te
d
an
d
un
as
si
st
ed
in
te
rc
ou
rs
e
(U
C
LA
-P
C
I)
47
10
21
.3
51
21
41
.2
Ts
ui
20
05
18
9
2
ye
ar
s
Po
te
nc
y
(o
nc
ol
og
is
t’
s
de
sc
rip
tio
n)
86
24
27
.9
76
11
14
.5
Po
is
so
nn
ie
r
20
07
17
4
M
ea
n
2.
3
ye
ar
s
(S
D
20
,
ra
ng
e
12
–
10
7
m
on
th
s)
Po
te
nc
y
im
pl
ie
s
a
pa
tie
nt
is
ab
le
to
pe
ne
tr
at
e
hi
s
pa
rt
ne
r
w
ith
ou
t
ph
ar
m
ac
ol
og
ic
al
su
pp
or
t
22
7
43
18
.9
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
433
TA
B
LE
83
Se
xu
al
fu
n
ct
io
n
d
ic
h
o
to
m
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
B
T
C
R
Y
O
H
IF
U
A
S
EB
R
T
R
P
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
N
n
%
Li
an
20
11
15
4
M
ed
ia
n
2.
5
ye
ar
s
(r
an
ge
9–
56
m
on
th
s)
Er
ec
til
e
fu
nc
tio
n/
po
te
nc
y
(II
EF
)
10
2
14
13
.7
C
he
n
20
09
11
7
3
ye
ar
s
Se
xu
al
fu
nc
tio
n
(P
C
SI
):
no
rm
al
75
14
19
15
0
12
8
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
3
ye
ar
s
A
ss
is
te
d
an
d
un
as
si
st
ed
in
te
rc
ou
rs
e
(U
C
LA
-P
C
I)
45
10
22
.2
50
18
36
Ts
ui
20
05
18
9
3
ye
ar
s
Po
te
nc
y
(o
nc
ol
og
is
t’
s
de
sc
rip
tio
n)
86
9
10
.5
76
9
11
.8
C
ol
om
be
l2
00
61
20
5
ye
ar
s
Po
te
nc
y
(II
EF
)
24
2
73
30
C
ro
ok
20
11
12
1
5
ye
ar
s
Q
ua
lit
y
of
er
ec
tio
ns
(E
PI
C
)
en
ou
gh
fo
r
in
te
rc
ou
rs
e
99
51
51
.2
2
67
20
30
.0
8
D
on
ne
lly
20
02
12
4
5
ye
ar
s
Re
su
m
pt
io
n
of
se
xu
al
ac
tiv
ity
am
on
g
th
e
pa
tie
nt
s
ca
pa
bl
e
of
un
as
si
st
ed
in
te
rc
ou
rs
e
76
18
23
.7
G
ib
er
ti
20
09
49
5
ye
ar
s
G
oo
d
er
ec
til
e
fu
nc
tio
n
(m
ea
n
IIE
F
sc
or
e
of
>
22
)
10
0
58
58
10
0
58
58
Ze
le
fs
ky
20
11
20
7
M
ed
ia
n
6.
4
(r
an
ge
1–
11
)
ye
ar
s
Th
e
ab
ili
ty
to
ac
hi
ev
e
an
er
ec
tio
n
su
ff
ic
ie
nt
fo
r
se
xu
al
in
te
rc
ou
rs
e
44
8
12
3
27
.5
28
1
81
28
.8
BT
,
br
ac
hy
th
er
ap
y;
C
RY
O
,
cr
yo
th
er
ap
y;
EO
RT
C
-Q
LQ
-P
R2
5,
Eu
ro
pe
an
O
rg
an
is
at
io
n
fo
r
Re
se
ar
ch
an
d
Tr
ea
tm
en
t
of
C
an
ce
r
Q
ua
lit
y
of
Li
fe
Q
ue
st
io
nn
ai
re
–
Pr
os
ta
te
-2
5
ite
m
s;
EP
IC
-2
6,
Ex
pa
nd
ed
Pr
os
ta
te
C
an
ce
r
In
de
x
C
om
po
si
te
-2
6
ite
m
s;
PC
SI
,
Pr
os
ta
te
C
an
ce
r
Sy
m
pt
om
In
de
x;
SD
,
st
an
da
rd
de
vi
at
io
n.
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
434
TA
B
LE
84
Se
xu
al
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
La
se
r
A
S
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
Er
ec
ti
le
d
ys
fu
n
ct
io
n
IIE
F
A
hm
ed
20
11
98
6
m
on
th
s
M
ea
n
er
ec
til
e
fu
nc
tio
n
do
m
ai
n
(II
EF
-1
5)
20
21
.7
A
hm
ed
20
11
98
6
m
on
th
s
M
ea
n
or
ga
sm
ic
fu
nc
tio
n
do
m
ai
n
(II
EF
-1
5)
20
7.
1
A
hm
ed
20
11
98
6
m
on
th
s
M
ea
n
se
xu
al
de
si
re
do
m
ai
n
(II
EF
-1
5)
20
6.
9
A
hm
ed
20
11
98
6
m
on
th
s
M
ea
n
in
te
rc
ou
rs
e
sa
tis
fa
ct
io
n
do
m
ai
n
(II
EF
-1
5)
20
8.
5
A
hm
ed
20
11
98
6
m
on
th
s
M
ea
n
ov
er
al
ls
at
is
fa
ct
io
n
do
m
ai
n
(II
EF
-1
5)
20
7.
4
Li
nd
ne
r
20
09
15
5
6
m
on
th
s
IIE
F
12
23
.1
M
ae
st
ro
ni
20
08
15
9
6
m
on
th
s
M
ea
n
IIE
F-
5
3
2.
75
M
ea
rin
i2
00
91
61
6
m
on
th
s
IIE
F,
m
ed
ia
n
(r
an
ge
)
16
0
12
(6
–
20
)
Sh
oj
i2
01
0,
18
3
U
ch
id
a
20
09
19
5
6
m
on
th
s
M
ea
n
(S
D
)
IIE
F
(n
on
-n
eo
ad
ju
va
nt
th
er
ap
y
pa
tie
nt
s)
11
2
4
(2
.6
5)
Tr
ue
sd
al
e
20
10
,1
88
La
m
be
rt
20
07
15
2
6
m
on
th
s
M
ea
n
(S
D
)
er
ec
til
e
dy
sf
un
ct
io
n/
im
po
te
nc
e
23
33
(2
0.
9)
A
hm
ed
20
11
98
1
ye
ar
M
ea
n
er
ec
til
e
fu
nc
tio
n
do
m
ai
n
(II
EF
-1
5)
20
21
.8
A
hm
ed
20
11
98
1
ye
ar
M
ea
n
in
te
rc
ou
rs
e
sa
tis
fa
ct
io
n
do
m
ai
n
(II
EF
-1
5)
20
7.
6
A
hm
ed
20
11
98
1
ye
ar
M
ea
n
or
ga
sm
ic
fu
nc
tio
n
do
m
ai
n
(II
EF
-1
5)
20
7.
1
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
435
TA
B
LE
84
Se
xu
al
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
La
se
r
A
S
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
A
hm
ed
20
11
98
1
ye
ar
M
ea
n
se
xu
al
de
si
re
do
m
ai
n
(II
EF
-1
5)
20
7
A
hm
ed
20
11
98
1
ye
ar
M
ea
n
ov
er
al
ls
at
is
fa
ct
io
n
do
m
ai
n
(II
EF
-1
5)
20
7
A
hm
ed
20
12
99
1
ye
ar
M
ed
ia
n
(IQ
R)
se
xu
al
fu
nc
tio
n
(II
EF
-1
5)
41
47 (2
9.
5–
63
.3
)
A
hm
ed
20
12
99
1
ye
ar
M
ed
ia
n
(IQ
R)
er
ec
til
e
fu
nc
tio
n
do
m
ai
n
(II
EF
-1
5)
41
21 (1
0.
3–
27
.3
)
A
hm
ed
20
12
99
1
ye
ar
M
ed
ia
n
(IQ
R)
in
te
rc
ou
rs
e
sa
tis
fa
ct
io
n
do
m
ai
n
(II
EF
-1
5)
41
8
(0
–
11
)
A
hm
ed
20
12
99
1
ye
ar
M
ed
ia
n
(IQ
R)
or
ga
sm
ic
fu
nc
tio
n
do
m
ai
n
(II
EF
-1
5)
41
7
(5
–
8.
5)
A
hm
ed
20
12
99
1
ye
ar
M
ed
ia
n
(IQ
R)
se
xu
al
de
si
re
do
m
ai
n
(II
EF
-1
5)
41
7
(5
–
8)
A
hm
ed
20
12
99
1
ye
ar
M
ed
ia
n
(IQ
R)
ov
er
al
l
sa
tis
fa
ct
io
n
do
m
ai
n
(II
EF
-1
5)
41
8
(8
–
9)
Ba
rr
et
20
13
10
3
1
ye
ar
M
ed
ia
n
(IQ
R)
se
xu
al
fu
nc
tio
n
(II
EF
-5
)
12
14
(8
–
24
)
50
14
(8
–
25
)
21
14
(8
–
25
)
Sh
oj
i2
01
0,
18
3
U
ch
id
a
20
09
19
5
1
ye
ar
M
ea
n
(S
D
)
IIE
F
(n
on
-n
eo
ad
ju
va
nt
th
er
ap
y
pa
tie
nt
s)
11
2
6.
36
(5
.3
7)
Tr
ue
sd
al
e
20
10
,1
88
La
m
be
rt
20
07
15
2
1
ye
ar
M
ea
n
(S
D
)
ED
51
34
(2
2.
6)
V
as
ar
ai
ne
n
20
12
19
9
1
ye
ar
M
ea
n
(IQ
R)
er
ec
til
e
fu
nc
tio
n
(II
EF
-5
)
48
19
.5
(1
0–
29
)
Sh
oj
i2
01
0,
18
3
U
ch
id
a
20
09
19
5
2
ye
ar
s
M
ea
n
(S
D
)
IIE
F
(n
on
-n
eo
ad
ju
va
nt
th
er
ap
y
pa
tie
nt
s)
11
2
4.
4
(5
.0
8)
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
436
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
La
se
r
A
S
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
SH
IM
H
ilt
on
20
12
14
1
1–
1.
5
ye
ar
s
M
ea
n
(9
5%
C
I)
17
.7
(1
6.
9
to
18
.5
)
C
as
o
20
12
,1
14
C
as
o
20
12
,1
15
Po
la
sc
ik
20
07
17
5
2
ye
ar
s
M
ed
ia
n
(r
an
ge
)
58
2
(1
–
6)
EP
IC
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
6
m
on
th
s
M
ea
n
(S
E)
se
xu
al
do
m
ai
n
24
7
47
.1
(1
.7
)
18
0
45
.5
(2
)
11
8
23
.7
(1
.6
)
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
1
ye
ar
M
ea
n
(S
E)
se
xu
al
do
m
ai
n
25
5
50
.5
(1
.6
)
18
4
44
.1
(1
.9
)
12
1
33
.8
(2
.1
)
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
RT
:
ra
ng
e
12
–
21
m
on
th
s
BT
:
ra
ng
e
12
–
24
m
on
th
s
M
ea
n
se
xu
al
fu
nc
tio
n
52
61
52
60
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
2
ye
ar
s
M
ea
n
(S
E)
se
xu
al
do
m
ai
n
24
0
49
.8
(1
.6
)
17
9
43
.5
(1
.9
)
12
2
33
.1
(2
.1
)
Fe
rr
er
20
08
,1
30
Pa
rd
o
20
10
,1
67
G
ue
de
a
20
09
13
7
3
ye
ar
s
M
ea
n
se
xu
al
do
m
ai
n
15
5
46
10
0
43
.5
N
/R
N
/R c
on
tin
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
437
TA
B
LE
84
Se
xu
al
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
La
se
r
A
S
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
Fr
an
k
20
07
13
1
BT
:
m
ed
ia
n
3.
5
ye
ar
s
EB
RT
:
m
ed
ia
n
4.
7
ye
ar
s
RP
:
m
ed
ia
n
4
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
fu
nc
tio
n
74
37
.8
(2
7.
2)
13
5
28
(2
7.
9)
23
4
25
.1
(2
4.
5)
C
ro
ok
20
11
12
1
M
ed
ia
n
5.
2
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
do
m
ai
n:
al
lp
at
ie
nt
s
10
1
52
.5
4
(2
4.
06
)
67
39
.2
2
(2
5.
35
)
C
ro
ok
20
11
12
1
M
ed
ia
n
5.
2
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
do
m
ai
n:
ra
nd
om
is
ed
pa
tie
nt
s
15
61
.1
(2
5.
72
)
15
38
.5
4
(2
8.
86
)
C
ro
ok
20
11
12
1
M
ed
ia
n
5.
2
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
do
m
ai
n:
N
RC
S
pa
tie
nt
s
84
50
.9
1
(2
3.
55
)
52
39
.4
3
(2
4.
44
)
EO
RT
C
-Q
LQ
-P
R2
5
G
ib
er
ti
20
09
49
6
m
on
th
s
M
ea
n
se
xu
al
fu
nc
tio
n
do
m
ai
n
85
10
89
9
G
ib
er
ti
20
09
49
6
m
on
th
s
M
ea
n
se
xu
al
ac
tiv
ity
do
m
ai
n
85
11
89
10
G
ib
er
ti
20
09
49
1
ye
ar
M
ea
n
se
xu
al
fu
nc
tio
n
do
m
ai
n
85
7
89
7
G
ib
er
ti
20
09
49
1
ye
ar
M
ea
n
se
xu
al
ac
tiv
ity
do
m
ai
n
85
8
89
8
G
ib
er
ti
20
09
49
2
ye
ar
s
M
ea
n
se
xu
al
fu
nc
tio
n
do
m
ai
n
85
8
89
7
G
ib
er
ti
20
09
49
2
ye
ar
s
M
ea
n
se
xu
al
ac
tiv
ity
do
m
ai
n
85
8
89
8
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
438
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
La
se
r
A
S
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
U
C
LA
-P
C
Is
co
re
H
ub
os
ky
20
07
52
6
m
on
th
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n
46
5.
7
K
ob
uk
e
20
09
14
9
6
m
on
th
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n
36
33
.2
37
5.
5
M
al
co
lm
20
10
16
0
6
m
on
th
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n:
op
en
RP
12
2
49
.3
81
19
.2
13
5
27
.4
M
al
co
lm
20
10
16
0
6
m
on
th
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n:
ro
bo
tic
RP
44
7
24
.1
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
6
m
on
th
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n
11
2
36
10
9
10
.4
H
ub
os
ky
20
07
52
1
ye
ar
Se
xu
al
fu
nc
tio
n
do
m
ai
n
35
5.
2
K
ob
uk
e
20
09
14
9
1
ye
ar
Se
xu
al
fu
nc
tio
n
do
m
ai
n
(U
C
LA
-P
C
I)
36
38
.3
37
9.
5
M
al
co
lm
20
10
16
0
1
ye
ar
Se
xu
al
fu
nc
tio
n
do
m
ai
n:
op
en
RP
12
2
45
.4
81
18
.0
13
5
31
.8
M
al
co
lm
20
10
16
0
1
ye
ar
Se
xu
al
fu
nc
tio
n:
ro
bo
tic
RP
44
7
29
.2
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
1
ye
ar
Se
xu
al
fu
nc
tio
n
do
m
ai
n
11
2
35
.8
10
5
13
.5
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
1.
5
ye
ar
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n
11
1
38
.6
10
0
16
.3
M
al
co
lm
20
10
16
0
2
ye
ar
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n:
op
en
RP
12
2
47
.4
81
21
.6
13
5
34
.0
M
al
co
lm
20
10
16
0
2
ye
ar
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n:
ro
bo
tic
RP
44
7
32
.9
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
2
ye
ar
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n
10
8
38
.3
10
6
13
.9
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
439
TA
B
LE
84
Se
xu
al
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
La
se
r
A
S
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
M
al
co
lm
20
10
16
0
3
ye
ar
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n:
op
en
RP
12
2
46
.7
81
16
.2
13
5
35
.5
M
al
co
lm
20
10
16
0
3
ye
ar
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n:
ro
bo
tic
RP
12
2
73
81
27
44
7
33
.6
Ro
bi
ns
on
20
09
,1
79
D
on
ne
lly
20
10
12
5
3
ye
ar
s
Se
xu
al
fu
nc
tio
n
do
m
ai
n
10
5
16
10
5
36
.7
Sm
ith
20
09
18
4
3
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
fu
nc
tio
n
do
m
ai
n:
ne
rv
e
sp
ar
in
g
58
54
(2
5.
7)
12
3
32
(2
9)
49
4
34
.7
(2
7.
7)
Sm
ith
20
09
18
4
3
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
fu
nc
tio
n
do
m
ai
n:
no
n-
ne
rv
e
sp
ar
in
g
58
54
(2
5.
7)
12
3
32
(2
9)
47
6
22
(2
3.
6)
O
th
er
M
oh
am
ed
20
12
16
3
6
m
on
th
s
M
ea
n
(S
D
)
SA
Q
:
se
xu
al
dy
sf
un
ct
io
n
24
0
2.
86
(1
.0
7)
48
3
2.
84
(1
.0
2)
14
6
2.
93
(0
.7
3)
Ta
lc
ot
t
20
03
18
6
1
ye
ar
M
ea
n
(S
D
)
se
xu
al
fu
nc
tio
n
sy
m
pt
om
in
de
x
(u
rin
ar
y,
bo
w
el
an
d
se
xu
al
fu
nc
tio
n
sc
al
e)
80
42
.4
(3
5.
6)
18
2
65
.8
(3
2)
12
9
73
.7
(2
5.
4)
Ta
lc
ot
t
20
03
18
6
2
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
fu
nc
tio
n
sy
m
pt
om
in
de
x
(u
rin
ar
y,
bo
w
el
an
d
se
xu
al
fu
nc
tio
n
sc
al
e)
80
45
(3
3.
1)
18
2
69
.2
(3
2.
3)
12
9
68
.5
(2
7.
4)
Se
xu
al
b
o
th
er
U
C
LA
-P
C
Is
co
re
H
ub
os
ky
20
07
52
6
m
on
th
s
Se
xu
al
bo
th
er
46
16
.0
K
ob
uk
e
20
09
14
9
6
m
on
th
s
Se
xu
al
bo
th
er
36
71
.2
37
50
.9
M
al
co
lm
20
10
16
0
6
m
on
th
s
Se
xu
al
bo
th
er
:
op
en
RP
12
2
56
.0
81
48
.0
13
5
24
.1
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
440
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
La
se
r
A
S
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
M
al
co
lm
20
10
16
0
6
m
on
th
s
Se
xu
al
bo
th
er
(U
C
LA
-P
C
I):
ro
bo
tic
RP
44
7
35
.3
H
ub
os
ky
20
07
52
1
ye
ar
Se
xu
al
bo
th
er
35
21
.8
K
ob
uk
e
20
09
14
9
1
ye
ar
Se
xu
al
bo
th
er
36
76
.1
37
62
.7
M
al
co
lm
20
10
16
0
1
ye
ar
Se
xu
al
bo
th
er
:
op
en
RP
12
2
50
.4
81
47
.2
13
5
34
.4
M
al
co
lm
20
10
16
0
1
ye
ar
Se
xu
al
bo
th
er
:
ro
bo
tic
RP
44
7
39
.5
M
al
co
lm
20
10
16
0
2
ye
ar
s
Se
xu
al
bo
th
er
:
op
en
RP
12
2
62
.4
81
48
.8
13
5
44
.7
M
al
co
lm
20
10
16
0
2
ye
ar
s
Se
xu
al
bo
th
er
:
ro
bo
tic
RP
44
7
40
.3
M
al
co
lm
20
10
16
0
3
ye
ar
s
Se
xu
al
bo
th
er
:
op
en
RP
12
2
68
81
40
13
5
49
.9
M
al
co
lm
20
10
16
0
3
ye
ar
s
Se
xu
al
bo
th
er
:
ro
bo
tic
RP
44
7
37
.8
Sm
ith
20
09
18
4
3
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
bo
th
er
(U
C
LA
-P
C
I):
ne
rv
e
sp
ar
in
g
58
66
.8
(3
2.
7)
12
3
57
.6
(4
1.
9)
49
4
34
.7
(2
7.
7)
Sm
ith
20
09
18
4
3
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
bo
th
er
(U
C
LA
-P
C
I):
no
n-
ne
rv
e
sp
ar
in
g
58
66
.8
(3
2.
7)
12
3
57
.6
(4
1.
9)
47
6
52
.2
(3
9.
7)
SA
Q
M
oh
am
ed
20
12
16
3
6
m
on
th
s
M
ea
n
(S
D
)
SA
Q
:
se
xu
al
bo
th
er
24
0
2.
67
(1
.2
5)
48
3
2.
53
(1
.2
1)
14
6
3.
35
(1
.1
6)
co
nt
in
ue
d
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
441
TA
B
LE
84
Se
xu
al
fu
n
ct
io
n
co
n
ti
n
u
o
u
s
o
u
tc
o
m
es
(c
o
n
ti
n
u
ed
)
St
u
d
y
ID
Ti
m
el
in
e
O
u
tc
o
m
e
as
re
p
o
rt
ed
/d
ef
in
ed
B
T
C
R
Y
O
H
IF
U
La
se
r
A
S
EB
R
T
R
P
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
n
Sc
o
re
EP
IC
Pi
nk
aw
a
20
09
17
2
M
ed
ia
n
1.
3
ye
ar
s
RT
:
ra
ng
e
12
–
21
m
on
th
s
BT
:
ra
ng
e
12
–
24
m
on
th
s
M
ea
n
se
xu
al
fu
nc
tio
n
sc
or
e
52
61
52
60
Fr
an
k
20
07
13
1
BT
:
m
ed
ia
n
3.
5
ye
ar
s
EB
RT
:
m
ed
ia
n
4.
7
ye
ar
s
RP
:
m
ed
ia
n
4
ye
ar
s
M
ea
n
(S
D
)
se
xu
al
bo
th
er
74
49
.4
(3
1.
9)
13
5
50
.2
(3
6.
7)
23
4
44
.7
(3
1.
8)
BT
,
br
ac
hy
th
er
ap
y;
C
RY
O
,
cr
yo
th
er
ap
y;
EO
RT
C
-Q
LQ
-P
R2
5,
Eu
ro
pe
an
O
rg
an
is
at
io
n
fo
r
Re
se
ar
ch
an
d
Tr
ea
tm
en
t
of
C
an
ce
r
Q
ua
lit
y
of
Li
fe
Q
ue
st
io
nn
ai
re
–
Pr
os
ta
te
-2
5
ite
m
s;
EP
IC
,
Ex
pa
nd
ed
Pr
os
ta
te
C
an
ce
r
In
de
x
C
om
po
si
te
;
IIE
F,
In
te
rn
at
io
na
lI
nd
ex
of
Er
ec
til
e
Fu
nc
tio
n;
N
/R
,
no
t
re
po
rt
ed
;
RT
,
ra
di
ot
he
ra
py
;
SA
Q
,
se
xu
al
ad
ju
st
m
en
t
qu
es
tio
nn
ai
re
;
SD
,
st
an
da
rd
de
vi
at
io
n;
SE
,
st
an
da
rd
er
ro
r;
SH
IM
,
Se
xu
al
H
ea
lth
In
ve
nt
or
y
fo
r
M
en
.
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
442
TABLE 84a Sexual function continuous outcomes: laser
Study ID Timeline Outcome as reported/defined n Score
Lindner 2009155 6 months Mean IIEF-15 12 23.1
TABLE 84b Sexual function continuous outcomes: PDT
Study ID Timeline Outcome as reported/defined n Score
Barret 2013103 1 year Median (IQR) sexual function (IIEF-5) 23 13 (7–25)
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TABLE 88 Summary of outcomes of the primary review: quality of life
Study ID Time
BT CRYO HIFU AS EBRT RP
n Score n Score n Score n Score SD n Score n Score
EORTC-QLQ-PR25
Giberti 200949 1 year 85 9.0 89 9.0
Giberti 200949 5 years 85 8.0 89 8.0
EORTC-QLQ-C30 score
Global health
Borchers 2004109 1 year 66.0 70.0
Giberti 200949 1 year 85 81.0 89 78.0
Kirschner-
Hermanns 2008145
1 year 61.0 70.0
Giberti 200949 5 years 85 82.0 89 78.0
Emotional functioning
Borchers 2004109 1 year 76.0 78.0
Giberti 200949 1 year 85 84.0 89 86.0
Kirschner-
Hermanns 2008145
1 year 33 66.0 61 83.0
Robinson 2009179 1 year 88.3 86.8
Robinson 2009179 2 years 87.3 86.3
Robinson 2009179 3 years 87.3 87.3
Giberti 200949 5 years 85 82.0 89 84.0
Physical function
Borchers 2004109 1 year 90.0 91.0
Giberti 200949 1 year 85 90.0 89 86.0
Robinson 2009179 1 year 96.3 96.3
Robinson 2009179 2 years 90.0 96.6
Robinson 2009179 3 years 90.9 96.5
Giberti 200949 5 years 85 94.0 89 90.0
Role function
Borchers 2004109 1 year 90.0 87.0
Giberti 200949 1 year 85 93.0 89 90.0
Robinson 2009179 1 year 98.7 94.4
Robinson 2009179 2 years 95.7 89.5
Robinson 2009179 3 years 92.0 91.4
Giberti 200949 5 years 85 94.0 89 90.0
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TABLE 88 Summary of outcomes of the primary review: quality of life (continued )
Study ID Time
BT CRYO HIFU AS EBRT RP
n Score n Score n Score n Score SD n Score n Score
Cognitive function
Borchers 2004109 1 year 86.0 86.0
Giberti 200949 1 year 85 88.0 89 90.0
Robinson 2009179 1 year 83.6 86.6
Robinson 2009179 2 years 84.3 88.2
Robinson 2009179 3 years 83.4 87.0
Giberti 200949 5 years 85 88.0 89 90.0
Social function
Borchers 2004109 1 year 77.0 74.0
Giberti 200949 1 year 85 93.0 89 89.0
Robinson 2009179 1 year 87.6 89.1
Robinson 2009179 2 years 87.5 87.0
Robinson 2009179 3 years 87.5 88.0
Giberti 200949 5 years 85 94.0 89 89.0
Sexual function
Borchers 2004109 1 year 53.0 42.0
Health function
Robinson 2009179 1 year 76.9 81.1
Robinson 2009179 2 years 78.3 81.3
Robinson 2009179 3 years 80.9 80.3
Fatigue score
Giberti 200949 1 year 85 19.0 89 18.0
Robinson 2009179 1 year 21.3 14.0
Robinson 2009179 2 years 20.1 12.8
Robinson 2009179 3 years 20.1 13.4
Giberti 200949 5 years 85 18.0 89 18.0
Nausea and vomiting
Giberti 200949 1 year 85 2.0 89 1.0
Robinson 2009179 1 year 1.2 1.2
Robinson 2009179 2 years 1.4 1.4
Robinson 2009179 3 years 1.0 1.0
Giberti 200949 5 years 85 1.0 89 1.0
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TABLE 88 Summary of outcomes of the primary review: quality of life (continued )
Study ID Time
BT CRYO HIFU AS EBRT RP
n Score n Score n Score n Score SD n Score n Score
Pain score
Giberti 200949 1 year 85 8.0 89 9.0
Robinson 2009179 1 year 11.4 7.2
Robinson 2009179 2 years 15.0 6.6
Robinson 2009179 3 years 10.1 7.9
Giberti 200949 5 years 85 8.0 89 9.0
Dyspnoea score
Giberti 200949 1 year 85 10.0 89 8.0
Giberti 200949 5 years 85 11.0 89 8.0
Insomnia score
Giberti 200949 1 year 85 20.0 89 23.0
Giberti 200949 5 years 85 20.0 89 22.0
Appetite loss score
Giberti 200949 1 year 85 4.0 89 4.0
Giberti 200949 5 years 85 4.0 89 3.0
Constipation score
Giberti 200949 1 year 85 1.0 89 4.0
Giberti 200949 5 years 85 0.0 89 3.0
Diarrhoea score
Giberti 200949 1 year 85 8.0 89 6.0
Giberti 200949 5 years 85 6.0 89 5.0
Financial problems score
Giberti 200949 1 year 85 2.0 89 3.0
Giberti 200949 5 years 85 2.0 89 3.0
EPIC
Hormonal domain
Crook 2011121 5 years 101 93.5 67 90.0
Hormonal function score
Ferrer 2008130,137,167 1 year 255 95.5 184 92.9 121 93.3
Pinkawa 2009172 2 years 52 92.0 52 91.0
Ferrer 2008130,137,167 2 years 240 95.5 179 93.7 122 93.7
Ferrer 2008130,137,167 3 years 155 93.5 100 90.7 109 N/R
Hormonal bother score
Pinkawa 2009172 2 years 52 92.0 52 87.0
Patient satisfaction score
Crook 2011121 5 years 101 93.6 67 76.9
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TABLE 88 Summary of outcomes of the primary review: quality of life (continued )
Study ID Time
BT CRYO HIFU AS EBRT RP
n Score n Score n Score n Score SD n Score n Score
FACT-G
Composite score
Ahmed 201299 1 year 41 102.0
Ahmed 201198 1 year 20 101.3
Ferrer 2008130,137,167 1 year 255 81.1 184 80.6 121 79.8
Lee 2001153 1 year 44 102.2 23 101.0 23 101.9
Uchida 2009183,195 1 year 326 92.6
Uchida 2005191 1 year 29 46.2
Ferrer 2008130,137,167 2 years 240 82.5 179 77.5 122 76.6
Uchida 2009183,195 2 years 326 93.5
Physical
Ferrer 2008130,137,167 1 year 255 27.2 184 26.7 121 26.1
Uchida 2009183,195 1 year 326 26.9
Lee 2001153 1 year 44 25.3 23 25.1 23 26.3
Ferrer 2008130,137,167 2 years 240 26.7 179 26.1 122 25.9
Uchida 2009183,195 2 years 326 26.3
Functional
Ferrer 2008130,137,167 1 year 255 17.2 184 16.7 121 17.2
Uchida 2009183,195 1 year 326 22.9
Lee 2001153 1 year 44 24.1 23 23.2 23 23.3
Ferrer 2008130,137,167 2 years 240 16.6 179 16.3 122 15.8
Uchida 2009183,195 2 years 326 23.4
Emotional
Ferrer 2008130,137,167 1 year 255 20.1 184 20.4 121 19.6
Uchida 2009183,195 1 year 326 22.9
Lee 2001153 1 year 44 22.3 23 21.9 23 21.7
Ferrer 2008130,137,167 2 years 240 19.7 179 20.0 122 19.6
Uchida 2009183,195 2 years 326 23.4
Social/family
Ferrer 2008130,137,167 1 year 255 18.5 184 17.7 121 17.7
Uchida 2009183,195 1 year 326 25.9
Lee 2001153 1 year 44 22.7 23 23.1 23 22.8
Ferrer 2008130,137,167 2 years 240 17.1 179 16.6 122 16.3
Uchida 2009183,195 2 years 326 25.3
Doctor/patient relationship
Lee 2001153 1 year 44 7.8 23 7.7 23 7.7
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TABLE 88 Summary of outcomes of the primary review: quality of life (continued )
Study ID Time
BT CRYO HIFU AS EBRT RP
n Score n Score n Score n Score SD n Score n Score
FACT-P
Composite score
Ahmed 201299 1 year 41 145.3
Ahmed 201198 1 year 20 144.2
Ferrer 2008130,137,167 1 year 255 39.5 184 38.7 121 37.9
Donnelly
2002124,177,178,180
1 year 75 135.8
Lee 2001153 1 year 44 138.5 23 136.9 23 140.4
Uchida 2009183,195 1 year 326 37.2
Ferrer 2008130,137,167 2 years 240 38.9 179 37.5 122 37.2
Donnelly
2002124,177,178,180
2 years 75 140.0
Uchida 2009183,195 2 years 326 35.9
Donnelly
2002124,177,178,180
3 years 75 138.9
Physical well-being
Ahmed 201198 1 year 20 27.2
Donnelly
2002124,177,178,180
1 year 75 26.1
Donnelly
2002124,177,178,180
2 years 75 27.0
Donnelly
2002124,177,178,180
3 years 75 26.2
Social/family well-being
Ahmed 201198 1 year 20 26.2
Donnelly
2002124,177,178,180
1 year 75 23.4
Donnelly
2002124,177,178,180
2 years 75 23.1
Donnelly
2002124,177,178,180
3 years 75 21.7
Emotional well-being
Ahmed 201198 1 year 20 22.6
Donnelly
2002124,177,178,180
1 year 75 17.9
Donnelly
2002124,177,178,180
2 years 75 18.3
Donnelly
2002124,177,178,180
3 years 75 18.1
continued
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
463
TABLE 88 Summary of outcomes of the primary review: quality of life (continued )
Study ID Time
BT CRYO HIFU AS EBRT RP
n Score n Score n Score n Score SD n Score n Score
Functional well-being
Ahmed 201198 1 year 20 25.5
Donnelly
2002124,177,178,180
1 year 75 24.1
Donnelly
2002124,177,178,180
2 years 75 25.0
Donnelly
2002124,177,178,180
3 years 75 24.7
Doctor relationship
Donnelly
2002124,177,178,180
1 year 75 7.4
Donnelly
2002124,177,178,180
2 years 75 7.4
Donnelly
2002124,177,178,180
3 years 75 7.5
Additional concerns (total)
Donnelly
2002124,177,178,180
1 year 75 37.2
Donnelly
2002124,177,178,180
2 years 75 37.6
Donnelly
2002124,177,178,180
3 years 75 37.2
FACT-P Trial Outcome Index
Ahmed 201299 1 year 41 97.5
Prostate cancer subscale
Ahmed 201198 1 year 20 43.2
Lee 2001153 1 year 44 36.3 23 35.8 23 38.6
SF-12
Mental component
van den Bergh
2012198
1 year 70 54.8 67 55.3
Crook 2011121 5 years 101 44.7 67 43.2
Physical component
van den Bergh
2012198
1 year 70 47.3 67 51.2
Crook 2011121 5 years 101 55.9 67 55.4
SF-36
Physical component summary
Ferrer 2008130,137,167 1 year 255 52.2 184 50.9 121 52.5
Ferrer 2008130,137,167 2 years 240 50.9 179 49.2 122 50.6
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TABLE 88 Summary of outcomes of the primary review: quality of life (continued )
Study ID Time
BT CRYO HIFU AS EBRT RP
n Score n Score n Score n Score SD n Score n Score
Physical function
Ferrer 2008130,137,167 1 year 255 91.9 184 89.9 121 91.2
Kobuke 2009149 1 year 36 87.9 37 93.5
Ferrer 2008130,137,167 2 years 240 88.8 179 85.1 122 85.7
Role physical
Ferrer 2008130,137,167 1 year 255 96.3 184 94.4 121 93.1
Kobuke 2009149 1 year 36 84.6 37 88.0
Ferrer 2008130,137,167 2 years 240 93.1 179 91.2 122 89.6
Bodily pain
Ferrer 2008130,137,167 1 year 255 87.9 184 84.2 121 86.5
Kobuke 2009149 1 year 36 81.8 37 88.7
Ferrer 2008130,137,167 2 years 240 85.9 179 81.6 122 82.1
General health
Ferrer 2008130,137,167 1 year 255 72.8 184 71.6 121 70.8
Kobuke 2009149 1 year 36 57.3 37 67.7
Ferrer 2008130,137,167 2 years 240 69.3 179 67.9 122 68.8
Mental component summary
Ferrer 2008130,137,167 1 year 255 56.5 184 56.3 121 55.3
Ferrer 2008130,137,167 2 years 240 56.3 179 56.3 122 54.9
Vitality
Ferrer 2008130,137,167 1 year 255 85.8 184 83.3 121 85.3
Kobuke 2009149 1 year 36 66.5 37 74.8
Ferrer 2008130,137,167 2 years 240 83.0 179 81.0 122 80.0
Social function
Ferrer 2008130,137,167 1 year 255 98.0 184 96.9 121 96.0
Kobuke 2009149 1 year 36 84.2 37 91.6
Ferrer 2008130,137,167 2 years 240 98.0 179 96.5 122 95.8
Mental health
Ferrer 2008130,137,167 1 year 255 88.1 184 87.5 121 87.0
Kobuke 2009149 1 year 36 75.7 37 82.3
Ferrer 2008130,137,167 2 years 240 87.0 179 85.9 122 83.6
Role emotional
Ferrer 2008130,137,167 1 year 255 96.3 184 96.6 121 94.6
Kobuke 2009149 1 year 36 83.9 37 88.5
Ferrer 2008130,137,167 2 years 240 94.6 179 94.9 122 93.8
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TABLE 88 Summary of outcomes of the primary review: quality of life (continued )
Study ID Time
BT CRYO HIFU AS EBRT RP
n Score n Score n Score n Score SD n Score n Score
I-PSS-QoL
Ahmed 201299 1 year 41 1.0
Ahmed 201198 1 year 20 1.0
Quality of life index
Uchida 2009183,195 1 year 326 2.2
Uchida 2009183,195 2 years 326 2.3
Trial outcome index
Lee 2001153 1 year 44 85.8 23 84.1 23 88.2
CES-D
van den Bergh
2012198
1 year 129 5.4 70.0 67 7.3
STAI general anxiety measure
van den Bergh
2012198
1 year 129 34.8 70.0 67 32.0
RAND-36
Physical functioning
Vasarainen 2012199 1 year 75 90.0 12.9
Role physical
Vasarainen 2012199 1 year 75 89.0 25.7
Role emotional
Vasarainen 2012199 1 year 75 88.0 29.0
Vitality
Vasarainen 2012199 1 year 75 76.0 16.0
Mental health
Vasarainen 2012199 1 year 75 81.0 14.1
Social functioning
Vasarainen 2012199 1 year 75 93.0 14.0
Body pain
Vasarainen 2012199 1 year 75 87.0 18.7
General health
Vasarainen 2012199 1 year 75 65.0 16.3
BT, brachytherapy; CES-D, Center for Epidemiologic Studies Depression scale; CRYO, cryotherapy; EORTC-QLQ-PR25,
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Prostate-25 items;
EPIC, Expanded Prostate Cancer Index Composite; FACT-G, Functional Assessment of Cancer Therapy – General;
FACT-P, Functional Assessment of Cancer Therapy – Prostate; I-PSS-QoL, I-PSS – quality of life; SD, standard deviation;
SF-12, Short Form questionnaire-12 items; STAI, State–Trait Anxiety Inventory.
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TABLE 89 Summary of outcomes of the primary review: quality of life (change score from baseline)
Study ID Time Outcome as reported/defined
BT RP
n
Change
score n
Change
score
EORTC-QLQ-C30 score
Buron 2007113 1 year Global health change score from baseline 194 −0.6 60 4.3
Buron 2007113 2 years Global health change score from baseline 200 0.8 52 7.7
Buron 2007113 1 year Emotional functioning change score
from baseline
194 7 60 8.5
Buron 2007113 2 years Emotional functioning change score
from baseline
200 9.3 52 12.1
BT, brachytherapy.
TABLE 90 Summary of outcomes of the primary review: quality of life (change score between intervention groups)
Study ID Time Outcome as reported/defined n Change score (range)
AUA-SS
Bradley 2004110 2 years Total score difference between intervention groups BT= 102
RP= 60
−3.32 (−6.67 to 0.03)
AUA-SS, American Urological Association Score; BT, brachytherapy.
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Appendix 11 Data tables of the salvage review
TABLE 91 Summary of outcomes of the salvage review: efficacy
Study ID Time
Outcome as
reported/defined
Salvage CRYO Salvage RP
N n % N n %
Biochemical disease-free survival
aChin 2001208 1 year PSA ≤ 2 ng/ml 118 71.0
van der Poel 2008
215
1 year PSA ≤ 0.1 ng/ml 32 89.0
aChin 2001208 2 years PSA ≤ 2 ng/ml 118 61.0
avan der Poel 2008215 2 years PSA ≤ 0.1 ng/ml 32 79.0
aChin 2001208 3 years PSA ≤ 2 ng/ml 118 55.0
avan der Poel 2008215 3 years PSA ≤ 0.1 ng/ml 32 61.0
aChin 2001208 4 years PSA ≤ 2 ng/ml 118 54.0
avan der Poel 2008215 4 years PSA ≤ 0.1 ng/ml 32 54.0
avan der Poel 2008215 5 years PSA ≤ 0.1 ng/ml 32 48.0
avan der Poel 2008215 6 years PSA ≤ 0.1 ng/ml 32 37.0
avan der Poel 2008215 7 years PSA ≤ 0.1 ng/ml 32 30.0
avan der Poel 2008215 8 years PSA ≤ 0.1 ng/ml 32 18.0
avan der Poel 2008215 9 years PSA ≤ 0.1 ng/ml 32 12.0
avan der Poel 2008215 10 years PSA ≤ 0.1 ng/ml 32 12.0
avan der Poel 2008215 11 years PSA ≤ 0.1 ng/ml 32 12.0
avan der Poel 2008215 12 years PSA ≤ 0.1 ng/ml 32 12.0
avan der Poel 2008215 13 years PSA ≤ 0.1 ng/ml 32 12.0
Biochemical failure
van der Poel 2008215 10 years PSA > 0.1 ng/ml 32 22 69.0
Biochemical control
Robinson 2006212 1 year PSA < 0.3 ng/ml 39 25 64.1
Chin 2001208 2 years PSA ≤ 2 ng/ml 118 65 55.0
Robinson 2006212 2 years PSA < 0.3 ng/ml 31 16 51.6
Seabra 2009213 2 years PSA < 0.2 ng/ml 38 29 76.0
Gheiler 1998210 3 years PSA ≤ 4 ng/ml 30 15 50.0
Tefilli 1998214 3 years PSA < 0.4 ng/ml 24 12 50.0
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TABLE 91 Summary of outcomes of the salvage review: efficacy (continued )
Study ID Time
Outcome as
reported/defined
Salvage CRYO Salvage RP
N n % N n %
Overall survival
Robinson 2006212 2 years Overall survival 46 43 93
Darras 2006209 7 years Overall survival 11 10 91.0
Cancer-specific death
Neerhut 1998211 2 years Cancer-specific death 16 0 0.0
Robinson 2006212 2 years Cancer-specific death 46 1 2.0
Gheiler 1998210 3 years Cancer-specific death 30 0 0.0
van der Poel 2008215 5 years Cancer-specific death 32 0 0.0
Darras 2006209 7 years Cancer-specific death 11 1 9.0
van der Poel 2008215 10 years Cancer-specific death 32 2 6.0
Reintervention
Chin 2001208 2 years Repeat cryoablation 118 7 6.0
Robinson 2006212 2 years Androgen deprivation therapy 46 7 15.2
Darras 2006209 3 years Antiandrogen monotherapy 11 1 9.0
Darras 2006209 3 years Hormonal therapy and
chemotherapy
11 3 27.0
CRYO, cryotherapy.
a Data were abstracted from Kaplan–Meier curves using Engauge Digitizer version 4.1 (http://digitizer.sourceforge.net/).
The numbers at risk at each time point rather than N would be required to calculate n.
TABLE 92 Summary of outcomes of the salvage review: functional (dichotomous data)
Study ID Time
Outcome as
reported/defined
Salvage CRYO Salvage HIFU Salvage RP
N n % N n % N n %
Bowel function
Robinson 2006212 12 months Moderate or big
problem with
sexual function
39 13 32.3
Robinson 2006212 24 months Moderate or big
problem with
sexual function
31 9 29.0
Sexual dysfunction
12 months
Robinson 2006212 12 months Moderate or big
problem with
sexual function
39 27 68.8
van der Poel
2008215
12 months Erections
insufficient
for coitus
32 26 81.0
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TABLE 92 Summary of outcomes of the salvage review: functional (dichotomous data) (continued )
Study ID Time
Outcome as
reported/defined
Salvage CRYO Salvage HIFU Salvage RP
N n % N n % N n %
24 months
Robinson 2006212 24 months Moderate or big
problem with
sexual function
31 16 51.9
Seabra 2009213 Median 18 (range
1–36) months
ED (undefined) 42 31 74.0
Sexual function
Robinson 2006212 24 months Unassisted intercourse 46 1 2.0
Tefilli 1998214 37 months Sexually potent
without any kind
of treatment
24 1 4.2
Urinary continence
van der Poel
2008215
12 months Continent (no pads) 32 14 44.0
Gheiler 1998210 36.1 months Continent (no pads) 30 15 50.0
Darras 2006209 Mean 6.9, median
5.2 years (range
27–158 months)
Complete continence
(no pads)
11 5 45.0
Urinary incontinence
12 months
Colombel 2006120 15 months Incontinence 71 5 7.0
24 months
Chin 2001208 Median 18.6 (range
3–54) months
Incontinence 118 24 20.0
Neerhut 1998211 Median 20 (range
3–39) months
Persistent
incontinence
16 4 25.0
Seabra 2009213 Median 18 (range
1–36) months
Incontinence
(≥ 2 pads/day)
42 30 72.0
36 months
Gheiler 1998210 36.1 months Incontinence
(use of pads)
30 15 50.0
Tefilli 1998214 Mean 37 months Complete
incontinence
21 9 42.9
84 months
Darras 2006209 Mean 6.9, median
5.2 years (range
27–158 months)
Incontinence 11 6 55.0
Urinary function
Robinson 2006212 12 months Moderate or big
problem with
urinary function
39 6 14.6
Robinson 2006212 24 months Moderate or big
problem with
urinary function
31 3 9.7
CRYO, cryotherapy.
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TABLE 93 Summary of outcomes of the salvage review: functional (continuous data)
Study ID Outcome as reported/defined Time
Salvage CRYO Salvage HIFU Salvage RP
n Score n Score n Score
Bowel function
Robinson 2006212 UCLA-PCI bowel function score 12 months 39 86.0
Robinson 2006212 UCLA-PCI bowel function score 24 months 31 82.0
Sexual function
Robinson 2006212 UCLA-PCI sexual function score 12 months 39 6.0
Robinson 2006212 UCLA-PCI sexual function score 24 months 31 8.0
Urinary function
Robinson 2006212 UCLA-PCI urinary function score 12 months 39 55.0
Robinson 2006212 UCLA-PCI urinary function score 24 months 31 58.0
CRYO, cryotherapy.
TABLE 94 Summary of outcomes of the salvage review: adverse events
Study ID Time
Outcome as
reported/defined
Salvage CRYO Salvage HIFU Salvage RP
N n % N n % N n %
Anastomotic stricture/urethral and bladder neck strictures
van der Poel
2008215
1 year Urethral and bladder
neck strictures
32 1 3.0
Neerhut 1998211 Median 20 (range
3–39) months
Anastomotic stricture 16 4 25.0
Darras 2006209 Mean 6.9, median
5.2 years (range
27–158 months)
Anastomotic stricture 11 2 18.0
Bladder neck contracture, bladder neck stenosis
Colombel 2006120 15 months Bladder neck stenosis 71 12 17.0
Gheiler 1998210 36.1 months Bladder neck
contracture
30 5 17.0
Chin 2001208 Median 18.6 (range
3–54) months
Bladder neck
contracture
118 2 2.0
Darras 2006209 Mean 6.9, median
5.2 years (range
27–158 months)
Bladder neck
contracture
11 2 18.0
Operative death
Neerhut 1988211 Median 20 (range
3–39) months
Operative death 16 0 0.0
Debris sloughing
Chin 2001208 Median 18.6 (range
3–54) months
Debris sloughing 118 6 5.0
Deep-vein thrombosis
Gheiler 1998210 36.1 months Deep-vein
thrombosis
30 1 3.0
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TABLE 94 Summary of outcomes of the salvage review: adverse events (continued )
Study ID Time
Outcome as
reported/defined
Salvage CRYO Salvage HIFU Salvage RP
N n % N n % N n %
Grade 3 rectal complaints
van der Poel
2008215
> 1 year Grade 3 rectal
complaints
32 1 3.0
Grade 4 rectal complaints
van der Poel
2008215
> 1 year Grade 4 rectal
complaints
32 1 3.0
Mild acute tubular necrosis
Neerhut 1988211 Median 20 (range
3–39) months
Mild acute
tubular necrosis
16 1 6.0
Prolonged leakage of urine from the anastomotic site
Neerhut 1988211 Median 20 (range
3–39) months
Prolonged leakage of
urine from the
anastomotic site
16 3 19.0
Prolonged postoperative ileus
Gheiler 1998210 36.1 months Prolonged
postoperative ileus
30 1 3.0
Rectourethral fistula, rectovesical fistula
Colombel 2006120 15 months Rectourethral fistula 71 4 6.0
Seabra 2009213 Median 18 (range
1–36) months
Rectovesical fistula 42 2 4.8
Chin 2001208 Median 18.6 (range
3–54) months
Rectourethral fistula 118 4 3.0
Neerhut 1988211 Median 20 (range
3–39) months
Rectovesical fistula 16 1 6.0
Gheiler 1998210 36.1 months Rectovesical fistula 30 1 3.0
Rectal injury
Neerhut 1988211 Median 20 (range
3–39) months
Rectal injury 16 3 19.0
Vesico-urethral fistula beyond external sphincter
Chin 2001208 Median 18.6 (range
3–54) months
Vesico-urethral fistula
beyond external
sphincter
118 1 1.0
Ureteral fistula
Gheiler 1998210 36.1 months Ureteral fistula 30 1 3.0
Ureteral transection
Neerhut 1988211 Median 20 (range
3–39) months
Ureteral transection 16 1 6.0
Uretero–vesical junction stricture and hydronephrosis
Neerhut 1988211 Median 20 (range
3–39) months
Uretero–vesical
junction stricture
and hydronephrosis
16 1 6.0
CRYO, cryotherapy.
DOI: 10.3310/hta19490 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 49
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Ramsay et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
473
TABLE 95 Summary of outcomes of the salvage review: quality of life
Study ID Time Outcome as reported/defined
Salvage CRYO Salvage RP
n Score SD n Score SD
EORTC-QLQ-PR25
Robinson 2006212 12 months Cognitive function score 39 90.0
Robinson 2006212 24 months Cognitive function score 31 89.0
Robinson 2006212 12 months Emotional function score 39 87.0
Robinson 2006212 24 months Emotional function score 31 89.0
Robinson 2006212 12 months Fatigue score 39 17.0
Robinson 2006212 24 months Fatigue score 31 17.0
Robinson 2006212 12 months Health function score 39 78.0
Robinson 2006212 24 months Health function score 31 82.0
Robinson 2006212 12 months Nausea/vomiting score 39 4.0
Robinson 2006212 24 months Nausea/vomiting score 31 2.0
Robinson 2006212 12 months Pain score 39 17.0
Robinson 2006212 24 months Pain score 31 13.0
Robinson 2006212 12 months Physical function score 39 95.0
Robinson 2006212 24 months Physical function score 31 96.0
Robinson 2006212 12 months Role function score 39 94.0
Robinson 2006212 24 months Role function score 31 98.0
Robinson 2006212 12 months Social function score 39 85.0
Robinson 2006212 24 months Social function score 31 89.0
FACT-G
Tefilli 1998214 37 months Physical well-being 24 21.9 5.0
Tefilli 1998214 37 months Social/family well-being 24 22.6 3.6
Tefilli 1998214 37 months Emotional well-being 24 16.4 2.9
Tefilli 1998214 37 months Functional well-being 24 20.7 5.0
Tefilli 1998214 37 months Relationship with doctor 24 7.0 1.3
Tefilli 1998214 37 months FACT-G total 24 88.7 14.2
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TABLE 95 Summary of outcomes of the salvage review: quality of life (continued )
Study ID Time Outcome as reported/defined
Salvage CRYO Salvage RP
n Score SD n Score SD
FACT-P
Tefilli 1998214 37 months FACT-P 24 33.3 6.4
FAIT-U
Tefilli 1998214 37 months FAIT-U 24 24.0 9.6
FACT-Total
Tefilli 1998214 37 months FACT-G total+ FACT-P 24 122.0 19.2
Tefilli 1998214 37 months FACT-G total+ FAIT-U 24 112.7 20.5
TOI-P
Tefilli 1998214 37 months TOI-P= PWB+ FWB+ FACT-P 24 75.8 14.7
TOI-U
Tefilli 1998214 37 months TOI-U= PWB+ FWB+ FAIT-U 24 66.6 16.6
CRYO, cryotherapy; EORTC-QLQ-PR25, European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire – Prostate-25 items; FACT-G, Functional Assessment of Cancer Therapy – General; FACT-P, Functional
Assessment of Cancer Therapy – Prostate; FAIT-U, Functional Assessment of Incontinence Therapy; FWB, functional
well-being; PWB, physical well-being; SD, standard deviation; TOI-P, Trial Outcome Index using FACT-P; TOI-U, Trial
Outcome Index using FAIT-U.
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Appendix 12 Utility table
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Appendix 13 Detailed breakdown of costs
TABLE 96 Intensity-modulated radiotherapy
IMRT Resource description Resource use per patient
Time
(hours)
Hourly
rate (£)
Cost per
patient (£)
1 Patient referred to clinical oncology
outpatient appointment
Consultant-led
outpatient appointment
159 159
2 Scheduling Radiographer – band 6 0.4 18.49 4.62
Appointment Administrator – band 2 0.4 9.37 2.34
3 Imaging
CT scanner CT scan 92
Radiographer – band 5 0.3 14.72 4.91
Radiographer – band 6 0.3 18.49 6.16
MRI scanner MRI scan 199
Radiographer – band 5 0.5 14.72 7.36
Radiographer – band 6 0.5 18.49 9.25
4 Pre-planning preparation
Data preparation Dosimetrist – band 5 0.4 14.72 3.68
Volume and organ at
risk definition
Dosimetrist – band 7 0.75 22.17 16.63
5 Plan development
and administration
Dosimetrist – band 6 2 18.49 36.98
6 Plan data checking Dosimetrist – band 6 0.75 18.49 13.87
7 Plan acceptance Consultant clinical
oncologist
0.5 157 78.5
8 Patient-specific QA
Plan transfer to phantom Physicist – band 7 0.5 22.17 11.09
Measurement on
linear accelerator
Physicist – band 7 0.6 22.17 14.63
Analysis of results Physicist – band 7 0.5 22.17 11.09
Independent MU calculation Dosimetrist – band 6 0.3 18.49 6.16
9 Final preparation of data Radiographer – band 6 0.4 18.49 4.62
Linear accelerator-based
preparation
Radiographer – band 6 0.16 18.49 3.08
Radiographer – band 6 0.16 18.49 3.08
10 Initial verification session Radiographer – band 6 0.5 18.49 9.25
Radiographer – band 5 0.5 14.72 7.36
Course of treatment –
37 treatments
11 Patient set up Radiographer – band 5 3.1 14.72 45.63
Radiographer – band 6 3.1 18.49 57.32
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TABLE 96 Intensity-modulated radiotherapy (continued )
IMRT Resource description Resource use per patient
Time
(hours)
Hourly
rate (£)
Cost per
patient (£)
12 Imaging of patient Radiographer – band 6 3.1 18.49 57.32
Radiographer – band 6 3.1 18.49 57.32
13 Image analysis Radiographer – band 6 3.1 18.49 57.32
Radiographer – band 6 3.1 18.49 57.32
14 Treatment delivery Radiographer – band 5 3.1 14.72 45.63
Radiographer – band 6 3.1 18.49 57.32
15 Offline image analysis Radiographer – band 6 3.1 18.49 57.32
16 Treatment outpatient clinics Follow-up outpatient
appointments
3 per
course
113 339
17 Treatment administration over
course of treatment
Radiographer – band 6 2.5 18.49 46.23
18 Completion of course
administration
Administrator – band 3 0.16 10.88 1.74
Administrator – band 2 0.4 9.37 3.75
19 Capital costs
OMS per course 6.66
OMS maintenance contract per course 1.86
TPS per course 14.39
TPS maintenance contract per course 1.65
Linear accelerator per course 852.85
Linear accelerator
maintenance contract
per course 43.29
Total 2508.58
CT, computerised tomography; MU, monitor unit; OMS, oncology management system; QA, quality assessment;
TPS, treatment planning system.
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TABLE 97 Intensity-modulated radiotherapy: adjuvant+ salvage
IMRT:
adjuvant+
salvage Resource description
Resource use
per patient
Time
(hours)
Hourly
rate (£)
Cost per
patient (£)
1 Patient referred to clinical
oncology outpatient appointment
Consultant-led
outpatient appointment
159 159
2 Scheduling Radiographer – band 6 0.4 18.49 4.62
Appointment Administrator – band 2 0.4 9.37 2.34
3 Imaging
CT scanner CT scan 92
Radiographer – band 5 0.3 14.72 4.91
Radiographer – band 6 0.3 18.49 6.16
MRI scanner MRI scan 199
Radiographer – band 5 0.5 14.72 7.36
Radiographer – band 6 0.5 18.49 9.25
4 Pre-planning preparation
Data preparation Dosimetrist – band 5 0.4 14.72 3.68
Volume and organ at
risk definition
Dosimetrist – band 7 0.75 22.17 16.63
5 Plan development and
administration
Dosimetrist – band 6 2 18.49 36.98
6 Plan data checking Dosimetrist – band 6 0.75 18.49 13.87
7 Plan acceptance Consultant
clinical oncologist
0.5 157 78.5
8 Patient-specific QA
Plan transfer to phantom Physicist – band 7 0.5 22.17 11.09
Measurement on linear
accelerator
Physicist – band 7 0.6 22.17 14.63
Analysis of results Physicist – band 7 0.5 22.17 11.09
Independent MU calculation Dosimetrist – band 6 0.3 18.49 6.16
9 Final preparation of data Radiographer – band 6 0.4 18.49 4.62
Linear accelerator-based
preparation
Radiographer – band 6 0.16 18.49 3.08
Radiographer – band 6 0.16 18.49 3.08
10 Initial verification session Radiographer – band 6 0.5 18.49 9.25
Radiographer – band 5 0.5 14.72 7.36
Course of treatment –
33 treatments
11 Patient set up Radiographer – band 5 2.75 14.72 40.48
Radiographer – band 6 2.75 18.49 50.85
12 Imaging of patient Radiographer – band 6 2.75 18.49 50.85
Radiographer – band 6 2.75 18.49 50.85
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TABLE 97 Intensity-modulated radiotherapy: adjuvant+ salvage (continued )
IMRT:
adjuvant+
salvage Resource description
Resource use
per patient
Time
(hours)
Hourly
rate (£)
Cost per
patient (£)
13 Image analysis Radiographer – band 6 2.75 18.49 50.85
Radiographer – band 6 2.75 18.49 50.85
14 Treatment delivery Radiographer – band 5 2.75 14.72 40.48
Radiographer – band 6 2.75 18.49 50.85
15 Offline image analysis Radiographer – band 6 2.75 18.49 50.85
16 Treatment outpatient clinics Follow-up outpatient
appointments
3 per course 113 339
17 Treatment administration over
course of treatment
Radiographer – band 6 2.5 18.49 46.23
18 Completion of course
administration
Administrator – band 3 0.16 10.88 1.74
Administrator – band 2 0.4 9.37 3.75
19 Capital costs
OMS per course 6.66
OMS maintenance contract per course 1.86
TPS per course 14.39
TPS maintenance contract per course 1.65
Linear accelerator per course 761
Linear accelerator
maintenance contract
per course 38.61
Total 2356.46
CT, computerised tomography; OMS, oncology management system; QA, quality assessment; TPS, treatment
planning system.
TABLE 98 Brachytherapy
Brachytherapy Resource description Resource use per patient
Time
(hours)
Hourly
rate (£)
Cost per
patient (£)
1 Pre treatment
Clinical oncologist
outpatient appointment
Clinical oncologist outpatient clinic 159
Urinary flow study and
transrectal ultrasound
Urology outpatient clinic – nurse led 104
2 Planning session. Formal
theatre volume study – day
case
Theatre session 258
Urologist 1 172 172
Oncologist 1 157 157
Physicist – band 8a 2 26.44 52.88
3 Prostate brachytherapy
plan created
Consultant urologist 0.4 172 43
Physicist – band 8a 0.4 26.44 6.61
Physicist – band 8a 2 26.44 52.88
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TABLE 98 Brachytherapy (continued )
Brachytherapy Resource description Resource use per patient
Time
(hours)
Hourly
rate (£)
Cost per
patient (£)
4 Implantation procedure 2 × brachytherapy physicist
technicians – band 7
2 22.17 44.34
I-125 seeds (Eckert and Ziegler BEBIG
GmbH, Berlin)
3088
Needles: £402 per box of 50, and
28 per patient
225
Brachyballoon 44.5
Brachydrape 15.5
Brachy grid 78
18Fr three-way catheters 6.34
Theatre session 516
Urologist 2 172 344
Oncologist 2 157 314
2 ×medical physicist brachytherapy
technicians – band 7
4 22.17 88.68
Radiographer – band 7 2 22.17 44.34
5 Postimplant MRI and
CT scan
1-night length of stay 321
CT scan 92
Radiographer – band 6 0.5 18.49 9.25
MRI scan 199
Radiographer – band 6 0.5 18.49 9.25
6 Quality assessment
post implant
Dosimetrist – band 6 0.5 18.49 9.245
Physicist – band 8a 1 26.44 26.44
Consultant oncologist 0.4 157 39.25
Physicist – band 8a 0.4 26.44 6.61
7 Outpatient follow-up Outpatient clinical 6 weeks
following implant
94
PSA test 6.56
8 Capital costs Ultrasound scanner 106.18
Ultrasound probe
Isocord® needle rack (Eckert and
Ziegler BEBIG GmbH, Berlin)
Isostrand® cutting fixture (Eckert and
Ziegler BEBIG GmbH, Berlin)
TPS (VariSeed™ 8.0.2 TPS)
VariSeed™ module image
fusion/coregistration
Electrometer
Chamber
TPS maintenance cost 23.76
Total 6756.615
CT, computerised tomography; TPS, treatment planning system.
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TABLE 99 Cryotherapy
Cryotherapy
Resource
description
Resource use
per patient Cost item required
Time
(hours)
Hourly
rate (£)
Cost per
patient (£)
1 Pre treatment Consultant-led
urology outpatient
Outpatient appointment 129
Nurse-led urology
outpatient
47
Bowel preparation Sodium picosulphate
(Picolax®, Ferring
Pharmaceuticals) – two
sachets
3.39
2 Procedure Prostate ice rods Prostate ice rods 4000
Argon × 2 Argon × 2 87
Helium×1 Helium×1 234
Leg bag × 1 Leg bag × 1 6
Suprapubic catheter Suprapubic catheter 13.21
Suture Suture 2.5
Dressings × 3 Dressings × 3 3.5
Sensor wire Sensor wire 20
Bladder syringe Bladder syringe 0.6
Catheter bag Catheter bag 1.25
Brachyballoon Brachyballoon 35
Methylene Methylene 14
Saline bag Saline bag 2.5
Camera drape Camera drape 2.49
Cystoscopy tray Cysto tray 4.15
Urology tray Urology tray 6.08
12° lens 12° lens 3.95
Consultant
oncologist
Consultant oncologist
(1.5 hours)
1.5 157 235.5
Theatre session 904.7
3 Post procedure Length of stay:
2 nights
2 nights, £250 per night 500
4 Post discharge District nurse visit 38
Consultant-led
urology outpatient
94
5 Capital costs Cryo machine
(200 patients)
19.48
Total 6407.3
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TABLE 100 High-intensity focused ultrasound
HIFU Resource description Resource use per patient Time (hours) Hourly rate (£)
Cost per
patient (£)
1 Staff costs Consultant urologist (international
trainer and expert)
3 150 450
Senior registrar (in theatre) 3 40 120
Specialist registrar (ward review) 0.5 40 20
Senior house officer (ward review) 0.5 30 15
Clinical nurse specialist (teach
CISC, remove SPC)
1 30 30
2 Theatre costs HIFU 2 895.6275 1791.26
Cystoscopy and SPC insertion 0.25 895.6275 223.91
3 Ward stay costs Length of stay 1 night based on
20% of patients
78.56
4 Consumables costs Swabs
Mepore® dressing (MoInlycke
Health Care Limited, Bedfordshire)
Urethral and suprapubic catheter
Suprapubic trocar
50-ml syringe
Catheter bag
Leg bag
Flip-flow valve
Self-catheterisation
catheter supplies
HIFU water
HIFU compressed gas
Total consumables costs 200
5 Capital costs Maintenance costs 1 454.6690625 454.67
Cost of Visual-Ice®
cryoablation system
199
% overheads 288.34
6 Imaging costs MRI 199 199
Radiographer – band 6 0.5 18.49 9.24
TRUS 199 199
Total 4277.98
CISC, clean, intermittent self-catheterisation; SPC, suprapubic catheter.
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